<SEC-DOCUMENT>0001628280-21-021747.txt : 20211104
<SEC-HEADER>0001628280-21-021747.hdr.sgml : 20211104
<ACCEPTANCE-DATETIME>20211104160004
ACCESSION NUMBER:		0001628280-21-021747
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211104
DATE AS OF CHANGE:		20211104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		211379767

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>crdf-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:9c181793-10cf-46b3-9b0e-d8b69a1f5f61,g:a6a36519-15ad-476d-ae18-99a2aa63eb87,d:3eee0da1123f4c6a852a858aeb9c6ca6--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:crdf="http://www.cardiffoncology.com/20210930" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>crdf-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80L2ZyYWc6MjhiNDQxOGFmMjYxNGE5MzhiNDIyMDRkOTQwYmMwM2EvdGFibGU6ZTg4YmM4YjEyMmE3NGRjN2I0ODcwNzlmNzA2MzY0MzYvdGFibGVyYW5nZTplODhiYzhiMTIyYTc0ZGM3YjQ4NzA3OWY3MDYzNjQzNl80LTEtMS0xLTY2NTU_35e930ed-40cf-479e-b0a7-def921c866bf">0001213037</ix:nonNumeric><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80L2ZyYWc6MjhiNDQxOGFmMjYxNGE5MzhiNDIyMDRkOTQwYmMwM2EvdGFibGU6ZTg4YmM4YjEyMmE3NGRjN2I0ODcwNzlmNzA2MzY0MzYvdGFibGVyYW5nZTplODhiYzhiMTIyYTc0ZGM3YjQ4NzA3OWY3MDYzNjQzNl83LTEtMS0xLTY2NTU_84e4d94a-f07d-4152-8b93-a5d19c2be0ac">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80L2ZyYWc6MjhiNDQxOGFmMjYxNGE5MzhiNDIyMDRkOTQwYmMwM2EvdGFibGU6ZTg4YmM4YjEyMmE3NGRjN2I0ODcwNzlmNzA2MzY0MzYvdGFibGVyYW5nZTplODhiYzhiMTIyYTc0ZGM3YjQ4NzA3OWY3MDYzNjQzNl84LTEtMS0xLTY2NTU_b98ee63b-cbec-4550-87c1-98460223acbb">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80L2ZyYWc6MjhiNDQxOGFmMjYxNGE5MzhiNDIyMDRkOTQwYmMwM2EvdGFibGU6ZTg4YmM4YjEyMmE3NGRjN2I0ODcwNzlmNzA2MzY0MzYvdGFibGVyYW5nZTplODhiYzhiMTIyYTc0ZGM3YjQ4NzA3OWY3MDYzNjQzNl8xMi0xLTEtMS02NjU1_93267302-deba-440f-b6ff-638ebbdc7c15">2021</ix:nonNumeric><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80L2ZyYWc6MjhiNDQxOGFmMjYxNGE5MzhiNDIyMDRkOTQwYmMwM2EvdGFibGU6ZTg4YmM4YjEyMmE3NGRjN2I0ODcwNzlmNzA2MzY0MzYvdGFibGVyYW5nZTplODhiYzhiMTIyYTc0ZGM3YjQ4NzA3OWY3MDYzNjQzNl8xMy0xLTEtMS02NjU1_3cb94fc3-287e-4c8b-9e38-1525b4ca4f5b">Q3</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="crdf-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i687be38fd69743e5adc911fcb3916233_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5536a0b2fc2740479fff4987362a1f5e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8176bd16da194dae836e30659930f9a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0d1b29ac93e4d80933267bf7ecf68b5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee5016562f414703bd929a2aa895f388_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie19a2c1f7f0b479188b45d6f374dbc81_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia35d15a9dfb646fcbffcffbb9d8262b1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8da7726f257f43acb1bea9b40eef263e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cf61f0afd274f019119b3ea148e5dd3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcfb466ee9f44377b4e807b87d71fd6a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c1a472218714bdea2c26e2f2f2bc0a7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17d10d73626940a1bfac19a0e15cf9bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6ed485db45c4a5f8022e1d59b12bf4d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice871a4562a84cd4b52a4356d2cb860e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb627674086848deba17572418728d83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5d058c8bebe4a3a9d2336d08237e91c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ca2109088ac4793a57a5fce35eb3903_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10e530a8190d4a178d02e013246439d8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5c1a7cba4434a29a666db82f58a89f0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7083bc457c04ea7b4169c892901eaf8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i205895823e59424a919b3d93617d9f2c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i482f9e2b8aa14c00bc8e55d73914ccd7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7880684c50674dbb8cfd7f810fc1727a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eefd6a8f9ad4956b669740bb2b8c353_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a0df33fbbec49a5a57d580b1dcf380b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd12c54fcda54b7ebf4612de0f518a99_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71acb7a4b79649b297dc1e8c8c73d504_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e8063e7fb6749e0af8bd1ecebda0314_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib30b6ac5d0cd4c369a9097268eb12984_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24420ff79ce74c9b9b895204b192740b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3282128780c4055854a3cc8fbe4a2e0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41602febb1074927adedec6da8eb37fe_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2465b36c344b4703902f0880f5e52116_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b018ac82a04fb590b1485d91230d8d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ca563e0d06f4599a46a722d3581dd74_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15e882bdfea4fdf952e43b08bc2429b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350d28ef78674e3eab8458411c7fcc81_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf1c65b7a7224893adb36ad9e8cbe745_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5336d0a252e4aeb98ca683a43ba06b0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5824d16b9ba441788705b462bc177803_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33e4526f7e164ab8b705c8f15dd1b690_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia14d6cd1be5f488284a0548acc13b622_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i402f50ca14e9498daade666a2aba16c6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic553804c0eaf41af8f0aea771674f3de_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56cfeedf0a7846a480b68514e6ec597c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i583e90cffdc74283ad12fcd0e679a613_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7fb9b1347f54faaa7e69ff2ccf6a961_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33912183705e412b83ed2cef39eddc1c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic25a7e642c104708a790b647db5d1ded_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7086816a72204fa58a1df8fa6c35a63a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied522f508b844f94be0b94767cf40167_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d4805fa04ec446eab0d6af2de913c7c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e23d0997d94ed9a6bbb2f8fc1ee85e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib94e5739ad98459497e72c9a6bc0ad84_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83bc7c42c1824b15a08376355aa11ba3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aa726d5321245c1a96ba3990871ca22_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf57c9859a8a4e38b67c19c2be236a90_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i631d652218464d15843c3a80ff37978c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i953e77c8d38e45e6974947b84da4f172_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c0e2ceae22248b4a0ebd0aa20fa60c6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff0a01a8a61a458184bb5efcbdd6cdae_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98824144f8e24c5cad08193a1247420c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd2c102f2b6845ce95560b93eba83063_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i451d0811b3544bcc912debf2a8ede85a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd86fa1857349e7b73861b629a3a124_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49c8e30388454e01b1713f33c031e81a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac2c0c6030c476080cddc898da2fdbe_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaebc49a046040e29e5e4565fd900bcb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63aaf8a8792b4035ba42f8b374bd567e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c0e65a2de674c8a814d4c385ed678a6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5a2c6673bb34fcfaba41b7f80484177_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i110b9bf586124339b177542a41284804_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18b0e382e0084fe29c322a52a6d9fb60_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28dd1563898f43d9b46b76dc77925f8e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i449d2f3eb8d0492f8052bba28b62b75d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic80c59f86e5f4a4186743622863a59c7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2636d69182a44bceacd8ee49296aa242_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib95b420a99f04c7ea8d5bc830d3e1aba_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i205347e8f5484902aba963f9ad58ff6a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f820ff8f6c24d05b3ffd3339f0dcfc9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e7e9d9d6bd7457098d60b651db0d39f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb79d8dc23ad4047a11793096554a73c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfabfd86abc84c9d8332a7d6522f0b05_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d9ab8d6d1f3471aada01b6d9a78f35d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefd2c993874045f0903171fafd6a6737_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b12865eb164c1b8daa72971befc365_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7223f8f5e4b7451fac6e9a53f511b618_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb8b40a3759d4dd8bdff04839d6af29e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60b2d2a3f17d4b329211ee5e90f04d9c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6b51a15c074437984b0293d4935aae9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i793b333bdcf34df8a736118d629cb3b7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8768b38297214afab61b468bbf429f52_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a7ab6cbc6374029b4bffd3ec9b17e0c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie26a981245d5493394cff84a3e0e6e70_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i775faff3942e4e5db3e5bd022093d60f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81e14a5109df413e81014c0b81871037_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51efe940143345028a304e5a815b9230_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if45c6805e8814c47933df9000082c117_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i057b4c0f72d44fdb8719e1f993ada81b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41cb574ec6224df9954670aecbbdd57c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17ac44632d4944509820a9395d78c529_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55b121d890664785a96f2abd68d7743a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4778f546e098429f8ad5e7ca4beac4b6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cd4aae3ff4246df84edcf2ab4da4c2b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5afbd3931f114b889cf2b6d1fcba9d91_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i472a131094f2474fb3218a9b6bc0594c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4544f5428574ef481cdcbd193499f68_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bc75745225b41fda9b79e00c8ab8c58_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21f389c33c2b4cb0969bd99011bcb8db_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie73becd6b06646ffad08290d5060d468_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c421333d9e842cd938364a79a347e01_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4871ed60f064988846d5339b4cefb37_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ab1f91262aa4961bfa27744b525f31a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a924190f51c43a6b7d3270fde532fa2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f837af10c4e49b681e48bb6553d03bb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc20b1e7fdcf4fb4b59ce226be19d676_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cac633b9fd54f2a99fe41969f58f594_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie508430c486f4b33b819c76634f5166c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2272875d1e6040bbbc4cb41775efc0c5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcadbd307c7048f089ba63bc4e00d913_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab14befe92264008986e1a141957af7d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ffd53bdfd4d459c8b703013a42d0264_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia92b222fd62f45f2b838481f5c639808_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if41d19fc393f4c7c97eb7bcda789a9d9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id79faeb4f57d4754840ae281b5c51f1c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec2c0b1298ef43bd8a6cf6425715b928_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic693b77303c24a2a99b2842d76d72241_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81b0c6cd52a849caa99be52f924b86e2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a9858e566ca4451af2bd491f1fdcdad_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i065815c78e2d4c5cb9a8ed1ec7b1f4db_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddf531bc123047f2adcdb4ad64487d5d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ce0447ee3b24f7b8e5c636200fa056d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00578720dda04f5e803f8dd40e53c600_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3c645e1dbc2452aa3d3d3e63a2097ab_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib90db4c568644361b2954142f5e9ef53_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f802e75c98e40ab9791dea64340ce78_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b041904ffe4c919883330668092c9b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica2abb6ba5634bf2bf4bf896d7c9258c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ffcbb6630ed443ea2e088b433bc9ce4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bc267f79c2a489989a67cdc20d3a3c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e6e261cb9904caaadea9698ea51a5af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0222ae72231f44db9f7d8ea289ba7e70_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85d1e68d697c4ef0aff6b17bcd0598d3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb4ce146f5434b44a3a5c1272c9610ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86124e9d3ce549fb84e7bdc9a8ebe5d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i813279dffe5742cdb683aadf13c65b58_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a78ea25d06f4f24a1e99abe072332f0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62c3a0c6662345618211a584192ca26a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib20f35230bce4c59b8a12b5a5680b915_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31763bf591274c6bb305e9bff5fff3d0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e4bc90bddda41caa182ab326e680cfd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96238e9478424ff983eea316b3b6d48c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15293ce702ad4f1994f5e08e17c540fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81df56d144dd4aef8aa1484cbced739d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie267b2ad37e64532bdf3ce1ab2728c95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e08014d936d49259c36229cca64a87f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c2c267750ac4a1f8c2d127cc7cb6594_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>crdf:lease</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ieb7822e6be894e0796c8f0e8eac7e29a_D20220101-20270228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2027-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4c82a6d8fc4a50b3c355ad46b5663c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i2c7f42dfef2c4958ba29b2e28bb9b35d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27c1821fc9ab463284b24faa6a39aeca_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81c4317e30404c12b737872399063ecb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id32688583be64531a4c3b6f8dda463e1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i870cb7768ebe4cd9a47cae43d43fa560_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22ae9743fe9e485bb2f97b84bd14ef48_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93a076cf959748b68d0895f7a702037c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i577dc0d878144b149b1dd7752563c6fe_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1e8bf7f73344b78ab04d1ba7ddea8a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2f22ed10e3b4e019378ae1db12695ed_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebfd4c8685c349cca9ac74c079a51df8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a2fc422184c4397bfd8fde6fbfdd4f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb2a438ab8374c9284bc780389cd9e66_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b6a8197ab2846cf8242cf259266a02c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39e92eec12814d63b23dec15ee3a82e2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i951a79658a174acdabb183cc6c576e38_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44d179594bba4e1dad1a989df3916c06_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c42cef5a93d477d8d01cdeb0d9a6497_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f4bdbe2cd9a4216b241d6c0f58f92af_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd0cbb07f2c48e9809d2340ba480ed4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec5f94b33da24052af9749b10b28f208_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i429dafc4192b4a51aac45b680a2ebe82_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i918a2f804e04472a831f145c622bff4c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ec0a3e52eaa44bfbbe255b9105dd595_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia67d1806a46a419689781a32baf40aff_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd65b030d4494709b2f9be0748ec2b5f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crdf:InducementGrantStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e1d4f2076ee4dce9307fbd38c110992_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf797ce4852460992cc81f91f71ee21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i419dd88bc1ef4b699ca582afa2243156_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i967f68e7c70142858d962d262e96d5a5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53d86dcdd30e4e97a88db626c3ce171f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e7dd4c9b04a4f348fa618cc15a91b23_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7086b0baa05e4031aa8f4f411b551b42_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id64a71bd7b9f42509949a24fc02bdde8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id69610f358d94455a4cc69212cec3ba1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8110c72e246c4d70b73aed2bc0bde2d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7451a3efe7274af285d44ebc3dd77d40_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eff0db6959b461584bc397787961a0d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e88f2da585d4200bcee660bbd23922a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38a9fc7a1cf3406fa656608bfd2022aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90efb04788c94a62b210da8a40d1537a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9421b674007949588bce3135aff1f1ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6585aa9e614148a98914993084f4d834_I20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crdf:NorvianoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide58ed83af2b4d2ebaccb755576f716c_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18a95e66b28b495995cc5b43de061428_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23b7b762231f4268ada27fef1b3fbde1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d5c6bcbeb3143e6819f6adceffa7b49_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7613ce60f5ae411799a4b34ca529c402_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16cbd98a78db40d8a92555d8d4608ec6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItMTctMS0xLTY2NTU_59530542-f04c-47ab-b223-2db7c69d1645 id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItNS0xLTEtNjY1NQ_7234ddc5-b679-4fc0-a393-e948e7d69e05 id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItOS0xLTEtNjY1NQ_1b881f8f-1dfb-4cc2-a134-d47449a4a1f3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk4_21f0155c-d8e7-41c8-8d42-1264084126c7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtNy0xLTEtNjY1NQ_f2aa8f4b-04f8-4b63-911b-932ff2860817 id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtOS0xLTEtNjY1NQ_bce4f6d3-de3c-4401-99d8-dad63b036878 id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMS0xLTEtNjY1NQ_2cb15daf-5623-463f-b164-40c2c32e26af id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMy0xLTEtNjY1NQ_0c21b0be-0a08-4608-bbad-fb219c020305 id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMTctMS0xLTY2NTU_250d4afb-d517-49b4-ae52-055936d7d7c9 id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtNS0xLTEtNjY1NQ_c480c886-f66a-4315-9261-61b886b3ff94" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk3_c69ce9de-335f-478e-9ba5-d6131c0a2877" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xODU3_058e1437-8cc9-4c73-b36a-c0b7e3345011">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6MmVjNTE5YmNkN2JhNGY5ZjhmZjg2NGFlNjVmN2ZlZGQvdGFibGVyYW5nZToyZWM1MTliY2Q3YmE0ZjlmOGZmODY0YWU2NWY3ZmVkZF8wLTAtMS0xLTY2NTU_a4d08a35-c022-4c63-964c-88567387e542">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT UNDER SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xMzc_2e226bb8-a66b-478f-bd6f-b53a53ad1530">September 30, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Y2IyNjVmZTFiYTM1NDA2OWI0OTIxYmFkMGE4ZDY4ZDYvdGFibGVyYW5nZTpjYjI2NWZlMWJhMzU0MDY5YjQ5MjFiYWQwYThkNjhkNl8wLTAtMS0xLTY2NTU_dbf12117-20aa-4811-acc8-223ef2d34019">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT UNDER SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xODU4_95e69c3d-1d62-4bed-9e52-1151b8c97465">001-35558</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xODYw_a6fea90d-3dab-45be-bfc7-a382ebc77eea">CARDIFF ONCOLOGY,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact Name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:48.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV8wLTAtMS0xLTY2NTU_59cea0bd-a396-4539-9eb3-3a9c057d68b3">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV8wLTItMS0xLTY2NTU_7eb565f3-3326-4242-a262-842b16ed3a49">27-2004382</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV8zLTAtMS0xLTY2NTUvdGV4dHJlZ2lvbjpmY2M4YTA2NjExYWQ0ZTkyYTQ4ZTI5YzBjNWVhZGU1NV80_f83a65da-4a02-4d52-a3c4-ed8b7cbab764">11055 Flintkote Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV8zLTAtMS0xLTY2NTUvdGV4dHJlZ2lvbjpmY2M4YTA2NjExYWQ0ZTkyYTQ4ZTI5YzBjNWVhZGU1NV84_6c3b65dd-df83-420d-8471-483c0e68c104">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV8zLTAtMS0xLTY2NTUvdGV4dHJlZ2lvbjpmY2M4YTA2NjExYWQ0ZTkyYTQ4ZTI5YzBjNWVhZGU1NV8xMg_6652b31a-acea-4f60-a364-79d536049546">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV8zLTItMS0xLTY2NTU_8c929af1-7c6e-4a32-9acf-7c9a2e4e88d0">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV82LTAtMS0xLTY2NTUvdGV4dHJlZ2lvbjo4N2ZjODIyODY5NjI0MGZhYTNhYTMwMDM4YmMzOGEzZl81_17a836f3-0ac5-44b7-89b5-8c018675c8cf">858</ix:nonNumeric>) <ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV82LTAtMS0xLTY2NTUvdGV4dHJlZ2lvbjo4N2ZjODIyODY5NjI0MGZhYTNhYTMwMDM4YmMzOGEzZl85_297bc75a-5631-4be6-9519-4902f86a3444">952-7570</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:31.862%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.725%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading&#160;Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6MDc5NGY2ZWVlNmYzNDE1YjgzMTQ4OGViNGJlYmQyZmMvdGFibGVyYW5nZTowNzk0ZjZlZWU2ZjM0MTViODMxNDg4ZWI0YmViZDJmY18xLTAtMS0xLTY2NTU_84a1b293-306b-497f-822a-e97f2d971a66">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6MDc5NGY2ZWVlNmYzNDE1YjgzMTQ4OGViNGJlYmQyZmMvdGFibGVyYW5nZTowNzk0ZjZlZWU2ZjM0MTViODMxNDg4ZWI0YmViZDJmY18xLTItMS0xLTY2NTU_4ecf7ff0-8f34-4737-957b-8cbf90dde446">CRDF</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the issuer (1)&#160;filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xODYx_e4164388-1830-494b-b619-4accc003166f">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xODU1_aae23b33-d0de-4aa2-89a2-a3186953a1cf">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:17.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.999%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Y2Q3NmM2NGQwYjdhNGMyZmE0OGIyZWM5NTkzYWU4NDgvdGFibGVyYW5nZTpjZDc2YzY0ZDBiN2E0YzJmYTQ4YjJlYzk1OTNhZTg0OF8wLTQtMS0xLTY2NTUvdGV4dHJlZ2lvbjo0NjI1YzdjYTdmNjQ0ZDY5OGUwMmFmODU3MmM4ODk5ZV80_74f4852d-8d1c-433e-a855-667e36234d79">Non-accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company&#160;<ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Y2Q3NmM2NGQwYjdhNGMyZmE0OGIyZWM5NTkzYWU4NDgvdGFibGVyYW5nZTpjZDc2YzY0ZDBiN2E0YzJmYTQ4YjJlYzk1OTNhZTg0OF8wLTYtMS0xLTY2NTUvdGV4dHJlZ2lvbjpmODA5ZWIxNzg0MGM0YTBhYmRjN2FhNjg5NTYyYWVmM18zMA_c5bb16a9-91a1-4ab5-93b0-7bf60ec64584">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Y2Q3NmM2NGQwYjdhNGMyZmE0OGIyZWM5NTkzYWU4NDgvdGFibGVyYW5nZTpjZDc2YzY0ZDBiN2E0YzJmYTQ4YjJlYzk1OTNhZTg0OF8wLTgtMS0xLTY2NTUvdGV4dHJlZ2lvbjpjN2EzNDk2YjFlNjc0ZTQ3OGRkMGQzYzE1ZjAwYzFmNF8yOA_2b65cad5-1266-4ea7-beb4-d3dcf595afa1">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xODU2_898ce5cf-4f23-4fd6-894e-750e74c097de">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;29, 2021, the issuer had <ix:nonFraction unitRef="shares" contextRef="i687be38fd69743e5adc911fcb3916233_I20211029" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xODA1_8dbd1e72-0b4d-47d2-9edc-4501dcb0c75c">39,552,129</ix:nonFraction> shares of Common Stock issued and outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_10">PART&#160;I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_13">Item 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_13">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_16">Condensed Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_16">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_19">Condensed Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_19">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_22">Condensed Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_22">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_25">Condensed Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_25">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_31">Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_31">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_37">Notes to Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_37">11</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_73">Item 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_73">20</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_94">Item 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_94">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_91">27</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_97">Item 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_97">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_97">27</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_100">PART&#160;II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_100">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_103">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_103">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_103">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_106">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_106">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_106">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_109">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_109">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_109">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_112">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_112">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_112">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_115">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_115">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_115">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_118">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_118">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_118">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_121">Item 6:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_121">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_121">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_124">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMy0xLTEtMS02NjU1_a684fb54-9925-4b08-8490-f04181c1e116">13,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMy0zLTEtMS02NjU1_20338b4c-7300-42a7-bb14-d9291a194c3e">130,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNC0xLTEtMS02NjU1_6229d7d0-e01c-4a8f-976e-8a8014c9e27e">120,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNC0zLTEtMS02NjU1_71dda192-1bef-4308-8a77-df8c31053f37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNS0xLTEtMS02NjU1_67f6c8b6-f3af-4b73-9912-13d95f1505d4">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNS0zLTEtMS02NjU1_fcccb547-9ac3-4d3d-993a-776912a8329c">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNi0xLTEtMS02NjU1_37780a46-8975-440a-adb8-e084dca5914b">3,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNi0zLTEtMS02NjU1_77ee5a26-5447-4a6d-b77a-8e9d6523220c">2,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNy0xLTEtMS02NjU1_abf69443-2975-479f-989f-d5519ef5c416">137,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNy0zLTEtMS02NjU1_3fb3f93b-68ab-49a0-9d54-78c42ee1f55e">133,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfOC0xLTEtMS02NjU1_4e6a7dfd-1ccc-4404-a03e-7bf9f27f06ae">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfOC0zLTEtMS02NjU1_f488436f-6f6b-4d58-999f-122e344d7031">624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTAtMS0xLTEtNjY1NQ_ffac4ffd-3cdb-4809-87fd-886fff0fa83d">3,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTAtMy0xLTEtNjY1NQ_41062b73-de7f-4333-bcc2-a25772852934">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTEtMS0xLTEtNjY1NQ_92de58a9-c217-415d-89bc-4498ad98e3e8">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTEtMy0xLTEtNjY1NQ_ebc5040a-b40a-413a-8ab6-97274191a50d">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTItMS0xLTEtNjY1NQ_85d93463-62d0-4a6f-9579-47202cc28fa9">141,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTItMy0xLTEtNjY1NQ_aa6ac707-cf2d-416c-b0ee-df8ae69dc441">134,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTYtMS0xLTEtNjY1NQ_df644028-4471-4fe6-b867-418086754d03">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTYtMy0xLTEtNjY1NQ_3001630d-9629-4f59-a66d-2146a45a134a">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTctMS0xLTEtNjY1NQ_cc821974-ac34-4cbe-b587-df3b3018a6d9">4,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTctMy0xLTEtNjY1NQ_ee1509ce-ab13-4dbd-8eaf-3384cc81b102">3,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTktMS0xLTEtNjY1NQ_deab76f8-97b4-415a-aa57-e3e302f0b0f9">594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTktMy0xLTEtNjY1NQ_67e1735b-3a4f-4909-8aaa-29bc428f32df">860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjAtMS0xLTEtNjY1NQ_51457a0d-e544-4d0e-897e-a525a3e28fba">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjAtMy0xLTEtNjY1NQ_584c5a4d-d4cd-48af-9e02-3ce5a7e81623">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjItMS0xLTEtNjY1NQ_873efcbb-149f-4e3c-bc12-85c3ea9f9e85">5,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjItMy0xLTEtNjY1NQ_b74ffb0b-5737-48d7-b887-23784f6d7b4a">6,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments&#8212;warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjMtMS0xLTEtNjY1NQ_39670048-cd44-4053-a759-327a8867ff66">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjMtMy0xLTEtNjY1NQ_79bcfc50-1d47-4436-a497-b8d7290af1ec">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjUtMS0xLTEtNjY1NQ_6bf30560-9bcd-4f54-9587-e401f6cae107">2,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjUtMy0xLTEtNjY1NQ_b8d849b9-3d35-4c89-8cab-3df32f563b20">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjctMS0xLTEtNjY1NQ_4f75aec2-110a-4856-aca2-f5d001be3564">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjctMy0xLTEtNjY1NQ_e0f20acb-bb54-4fc1-a683-07f9bcaeb8f7">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjgtMS0xLTEtNjY1NQ_dd0a1060-7d64-4b68-99aa-55242d3d5d23">7,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjgtMy0xLTEtNjY1NQ_355e687d-0ba8-42ce-bf37-c3d3c80ac477">6,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzAtMS0xLTEtNjY1NQ_7fe736fb-cb5b-47bb-937d-924f3504eef3"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzAtMy0xLTEtNjY1NQ_60b76554-a75d-40c4-b369-faf4ddb06265"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, <ix:nonFraction unitRef="shares" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzMtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjUxNTE3NDA0ZDZmMzQzMzY4M2RkZGI0MGYxOWZmZDk3XzIx_4faf658b-8474-4190-801c-228845eaba7b"><ix:nonFraction unitRef="shares" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzMtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjUxNTE3NDA0ZDZmMzQzMzY4M2RkZGI0MGYxOWZmZDk3XzIx_b9ef40a2-5f33-405f-8ea0-2a960275851e">20,000</ix:nonFraction></ix:nonFraction> shares authorized; (Note 7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzMtMS0xLTEtNjY1NQ_ce1ce1aa-cf9f-4389-b18b-f9e47cd83b03">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzMtMy0xLTEtNjY1NQ_fca953a9-3504-438c-b1aa-b609f7e53992">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzE5_4523fb31-5caf-46e9-bcd1-999ed942a423"><ix:nonFraction unitRef="usdPerShare" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzE5_da1bd84f-fe59-4a28-bc6f-8f260caf8268">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzMz_75584db5-1443-4d73-b78c-2a8c64e242d3"><ix:nonFraction unitRef="shares" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzMz_79c5240e-9ba0-4e57-a7fc-7c283e37723f">150,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzU1_19a144ec-3149-43f4-aec6-85f6c3d6e12f"><ix:nonFraction unitRef="shares" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzU1_7e2bc85f-7972-45bc-8073-ca5083e79978">39,552</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzYy_21ee8c9d-c29e-4f55-ae5b-01e8dcb0ce37"><ix:nonFraction unitRef="shares" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzYy_54e47fb5-dae7-442a-8b58-ed5ed9889165">36,781</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMS0xLTEtNjY1NQ_ee662fcc-a97c-4f50-a9fa-7eae43a50280">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMy0xLTEtNjY1NQ_771ebead-ae30-44e8-a187-b40142797767">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzUtMS0xLTEtNjY1NQ_c46ae29d-8022-4ae8-aac2-bdd34e20f847">384,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzUtMy0xLTEtNjY1NQ_55287873-a10f-4a48-ac4b-b39d92ef0c8b">361,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="crdf:ServiceReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzYtMS0xLTEtNjY1NQ_49b86e05-0a7a-4d0f-86d3-bc2137d82208">666</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="crdf:ServiceReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzYtMy0xLTEtNjY1NQ_91802da8-7b09-4354-b5d5-60cd78a3cbd0">2,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzctMS0xLTEtNjY1NQ_a8941083-ddbb-4d17-80c8-3e7f3cfc5c89">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzctMy0xLTEtNjY1NQ_063d8cc3-3d2b-4b9b-8e57-3654fd628f05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzgtMS0xLTEtNjY1NQ_56a251fe-6403-4060-955c-722a14830ddd">250,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzgtMy0xLTEtNjY1NQ_4b6398c8-7b38-44cd-9ac2-cc679fe85b14">231,495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzktMS0xLTEtNjY1NQ_fe812b09-9234-4bd3-a853-0ac92608628b">133,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzktMy0xLTEtNjY1NQ_8c428b12-ad39-49bf-951d-88788be3705e">128,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNDAtMS0xLTEtNjY1NQ_e123f17c-7689-4d81-b8aa-35890c9b43d5">141,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNDAtMy0xLTEtNjY1NQ_01131029-b438-4eb0-a8db-57d0d63104a7">134,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMy0xLTEtMS02NjU1_e24df43b-d7b6-4037-ae96-03727b903329">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMy0zLTEtMS02NjU1_601c97dd-7a46-4970-b50f-3fdd60cda5d6">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMy01LTEtMS02NjU1_9968d32e-b5c0-4c0b-b94e-2f8def4d7bb3">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMy03LTEtMS02NjU1_8e08f3bc-17cc-4574-a8f6-46d48246270f">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfNS0xLTEtMS02NjU1_59342ff5-d373-47c4-9c41-a9547d27ed39">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfNS0zLTEtMS02NjU1_2b6eb4ea-99bd-4de0-909f-d866c7b568d5">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfNS01LTEtMS02NjU1_a4d9b7b4-4f4f-4c35-a25f-d9306fb90b44">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfNS03LTEtMS02NjU1_118cfafc-859e-433e-8ca9-932d40b409d1">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOC0xLTEtMS02NjU1_4773837b-9aa3-4a56-b4e5-975ae8c4414a">4,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOC0zLTEtMS02NjU1_e0ce1241-4cbf-48db-a422-ca2a0f45852b">2,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOC01LTEtMS02NjU1_24011992-7716-45e2-8558-2060bd3202bd">11,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOC03LTEtMS02NjU1_69acf749-6fa3-4590-a68f-ee4fc407756e">8,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOS0xLTEtMS02NjU1_0807db0d-65d7-4272-ae47-18d8c3f1699a">2,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOS0zLTEtMS02NjU1_85477f69-63a5-4fdf-8177-433701ab7b14">1,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOS01LTEtMS02NjU1_4865d4bc-36d5-40e7-b2a6-3717c7578858">8,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOS03LTEtMS02NjU1_fbd907e0-a689-4472-8522-874b827bdbee">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTItMS0xLTEtNjY1NQ_5ce43461-32eb-46f0-a908-aff8732925c4">7,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTItMy0xLTEtNjY1NQ_e9bc0fca-36c2-49de-9841-1d31353364c7">4,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTItNS0xLTEtNjY1NQ_d5beec81-64ae-45c4-a6c9-716ea6eaa49f">19,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTItNy0xLTEtNjY1NQ_76220de6-df1b-4c2f-8cac-f9f5da05c5c4">12,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTQtMS0xLTEtNjY1NQ_d4637095-ebe0-4f79-b730-0bd82736dc02">6,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTQtMy0xLTEtNjY1NQ_ef47adc8-d94b-45f4-ae54-daf5a9309bda">4,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTQtNS0xLTEtNjY1NQ_d0825783-0db5-4930-b026-6223ae9d321b">19,329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTQtNy0xLTEtNjY1NQ_df3c3672-bd07-42d0-b2de-5fe87f136d2f">12,589</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTYtMS0xLTEtNjY1NQ_827b05de-5e68-43af-a045-6470b398a04b">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTYtMy0xLTEtNjY1NQ_380e2c32-f243-460c-9a2f-e1ff95cc3f44">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTYtNS0xLTEtNjY1NQ_ef24d32a-7e87-40f9-964e-fb8863621926">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTYtNy0xLTEtNjY1NQ_6eccb3df-b975-48ee-851b-3d085519af8b">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from change in fair value of derivative financial instruments&#8212;warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTgtMS0xLTEtNjY1NQ_055e140c-475b-4747-93e1-e251ec2dbe48">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTgtMy0xLTEtNjY1NQ_c3d56326-231c-4afb-8e7c-372989badff2">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTgtNS0xLTEtNjY1NQ_e389c28a-0717-419f-8480-997f51dfe2d7">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTgtNy0xLTEtNjY1NQ_1626f316-c469-4422-ac03-edaf5990ec5f">186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjAtMS0xLTEtNjY1NQ_25270158-95a8-4ab3-953a-27b371480573">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjAtMy0xLTEtNjY1NQ_2cb88ad9-454e-4396-8c2b-f14022c4dca4">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjAtNS0xLTEtNjY1NQ_9fe2100c-24db-4ff7-88d6-d7ec9cd3baea">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjAtNy0xLTEtNjY1NQ_7c135862-1bcb-456a-9ce4-76d5742cc293">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjEtMS0xLTEtNjY1NQ_32097d79-e395-43ce-80f0-c65f2cd9f6d8">6,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjEtMy0xLTEtNjY1NQ_7f30d0d2-8025-4614-8762-a96830c2793b">4,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjEtNS0xLTEtNjY1NQ_519a16a2-8123-4595-a637-117532f1b66e">18,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjEtNy0xLTEtNjY1NQ_b9a03efa-e6bb-4049-b376-1a134289aaeb">12,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjMtMS0xLTEtNjY1NQ_f564ab75-18db-461e-9d36-3fc4fbc5c1ba">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjMtMy0xLTEtNjY1NQ_bd2103fe-a69c-46d8-b6c8-c7f162b8c786">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjMtNS0xLTEtNjY1NQ_93e4ec2e-54e9-4f50-b516-96dcf9a2b1ef">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjMtNy0xLTEtNjY1NQ_a7690b39-19ed-46d7-9972-2ee83673f388">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series D Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d1b29ac93e4d80933267bf7ecf68b5_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjYtMS0xLTEtNjY1NQ_62e511e9-acc6-41dc-8652-233d39afaeaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5016562f414703bd929a2aa895f388_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjYtMy0xLTEtNjY1NQ_f80731e0-3825-4553-91fa-c83c881dbce6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19a2c1f7f0b479188b45d6f374dbc81_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjYtNS0xLTEtNjY1NQ_bb6cc246-0ff3-4785-9a2a-95edf74eccb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia35d15a9dfb646fcbffcffbb9d8262b1_D20200101-20200930" decimals="-3" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjYtNy0xLTEtNjY1NQ_c850b905-1db5-47da-87f5-83cb9bccc025">602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series E Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8da7726f257f43acb1bea9b40eef263e_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjctMS0xLTEtNjY1NQ_8430ab25-c263-4759-a69f-bab42db056dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cf61f0afd274f019119b3ea148e5dd3_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjctMy0xLTEtNjY1NQ_18f1e1bf-e92c-4a77-9376-2fe71828d473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcfb466ee9f44377b4e807b87d71fd6a_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjctNS0xLTEtNjY1NQ_52c9b1e9-c51d-46cf-84ee-bdeac7d6ed9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c1a472218714bdea2c26e2f2f2bc0a7_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjctNy0xLTEtNjY1NQ_d127be50-ad9b-4144-8b0e-71a2f1049ad6">2,665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjktMS0xLTEtNjY1NQ_1a8393df-6302-4ad3-9740-4f44175a33b9">6,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjktMy0xLTEtNjY1NQ_5ab607b5-2932-40bc-9001-96a23d9fb6f2">4,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjktNS0xLTEtNjY1NQ_da17d7fa-8fb1-4314-b782-8ff856bfea4c">18,867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjktNy0xLTEtNjY1NQ_c545c291-c20d-44e3-b9cd-39f38256c781">15,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtMS0xLTEtNjY1NQ_8dbfc723-92fe-40cf-b781-0bb078517360"><ix:nonFraction unitRef="usdPerShare" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtMS0xLTEtNjY1NQ_dbedc34d-3626-4b98-8646-c941baf3689e">0.17</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtMy0xLTEtNjY1NQ_7b57aa0d-93e1-4d45-8a77-c3d88ae93ffd"><ix:nonFraction unitRef="usdPerShare" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtMy0xLTEtNjY1NQ_fadfa83b-ceee-4fdb-93fa-1ccf23944b3b">0.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtNS0xLTEtNjY1NQ_0f95e248-c8e1-438e-af47-2504d0088930"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtNS0xLTEtNjY1NQ_bae2ffad-eaa2-445f-8c31-278560f58724">0.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtNy0xLTEtNjY1NQ_5c359fbb-9d96-4215-9186-dce7056bcc07"><ix:nonFraction unitRef="usdPerShare" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtNy0xLTEtNjY1NQ_9e3b6058-2fb0-4a0b-9c21-65d39f3b3d0f">1.00</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtMS0xLTEtNjY1NQ_59c677ab-eb95-4f79-b853-7c3484c69871"><ix:nonFraction unitRef="shares" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtMS0xLTEtNjY1NQ_b2e06aea-13f4-4fbe-8fa1-b72b7c09a7e5">39,552</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtMy0xLTEtNjY1NQ_2ddf5405-b9ae-4ee2-bc70-81581ec718b2"><ix:nonFraction unitRef="shares" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtMy0xLTEtNjY1NQ_f40635a3-4353-4152-8bd5-d00f36b4c64d">23,341</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtNS0xLTEtNjY1NQ_15f4919a-08ac-456e-9552-a086cc15541d"><ix:nonFraction unitRef="shares" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtNS0xLTEtNjY1NQ_da06ddf9-3020-49c0-9ec7-e31eb8e2b135">38,501</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtNy0xLTEtNjY1NQ_2f844085-0d46-4ff9-877f-0e5ca1b416e5"><ix:nonFraction unitRef="shares" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtNy0xLTEtNjY1NQ_dd31cd78-729d-4f70-bebd-0be52d578f0c">15,942</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMi0xLTEtMS02NjU1_5fbc5690-dbda-4b25-80c5-2aaedf1c45fb">6,913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMi0zLTEtMS02NjU1_3140e15b-673d-4f90-ac51-1f1a6614d87d">4,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMi01LTEtMS02NjU1_9eadf5ff-de9f-410d-a004-bd2bf7fbf028">18,849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMi03LTEtMS02NjU1_feb76fbd-44d0-43bc-9f8f-105effc0c8b5">12,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized gain on securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNC0xLTEtMS02NjU1_1cc1c504-7f92-43ba-af61-7ca29f50db97">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNC0zLTEtMS02NjU1_451bc017-23c1-42c7-93e0-274b8db917a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNC01LTEtMS02NjU1_79dc4341-ee87-4326-8273-b821884b3648">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNC03LTEtMS02NjU1_00baa0f8-075e-4538-bd4e-dc2f50244a52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNS0xLTEtMS02NjU1_83ddb908-4235-4a3b-b789-900452a7bc01">6,887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNS0zLTEtMS02NjU1_d5cc6125-0a91-471d-9c40-800f179c6b15">4,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNS01LTEtMS02NjU1_23e80159-a214-41cd-9838-435add03ef2c">18,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNS03LTEtMS02NjU1_42280265-7f9a-47b6-8027-db5119b19395">12,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNy0xLTEtMS02NjU1_425da13d-3f2e-471d-b1df-32291e52a197">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNy0zLTEtMS02NjU1_273964a1-3f19-4950-901f-3198fc2fadbb">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNy01LTEtMS02NjU1_c2d828c5-719c-4ce3-9219-a16e96247ee5">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNy03LTEtMS02NjU1_5b590859-50d5-4b85-8637-29d54c434559">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series D Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d1b29ac93e4d80933267bf7ecf68b5_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTAtMS0xLTEtNjY1NQ_64cf9397-692d-4758-a897-6c2b38f4e8d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5016562f414703bd929a2aa895f388_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTAtMy0xLTEtNjY1NQ_5a379a86-1d40-4b88-89a0-0dd894fd435b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19a2c1f7f0b479188b45d6f374dbc81_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTAtNS0xLTEtNjY1NQ_ab727028-4539-45fd-bf0a-fbfe82422f61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia35d15a9dfb646fcbffcffbb9d8262b1_D20200101-20200930" decimals="-3" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTAtNy0xLTEtNjY1NQ_0b874777-4abf-4b0a-97c8-cc6b47e32498">602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series E Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8da7726f257f43acb1bea9b40eef263e_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTEtMS0xLTEtNjY1NQ_f850c80f-7ce5-46d2-b40c-92d1583765e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cf61f0afd274f019119b3ea148e5dd3_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTEtMy0xLTEtNjY1NQ_67b37e40-26b3-4f0c-9892-e7a5c63ca8ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcfb466ee9f44377b4e807b87d71fd6a_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTEtNS0xLTEtNjY1NQ_bad34168-8533-44ad-b359-56add1d74ecf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c1a472218714bdea2c26e2f2f2bc0a7_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTEtNy0xLTEtNjY1NQ_8084bfcd-5a70-4b82-8b58-c6811fb43f46">2,665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to common stockholders</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTMtMS0xLTEtNjY1NQ_a1ad04e0-3994-4259-8236-51c4cf572ed3">6,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTMtMy0xLTEtNjY1NQ_3c4272c2-ac68-4e66-afe5-6fffd243be69">4,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTMtNS0xLTEtNjY1NQ_d3e54c83-d59b-4cd9-8b35-6974601449d3">18,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTMtNy0xLTEtNjY1NQ_d1e861ed-cfa5-4277-a418-a59c7b50fe40">15,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17d10d73626940a1bfac19a0e15cf9bf_I20201231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS0xLTEtMS02NjU1_bb2107fe-0221-4c88-ad73-5044de68fb53">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d10d73626940a1bfac19a0e15cf9bf_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS0zLTEtMS02NjU1_72b87635-4237-4eef-8132-8b13c205c5b9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6ed485db45c4a5f8022e1d59b12bf4d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS01LTEtMS02NjU1_c977f888-c44f-4e09-b8cb-e3c8efbb2c1b">36,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ed485db45c4a5f8022e1d59b12bf4d_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS03LTEtMS02NjU1_6184ca49-79af-4f7c-bc9d-0027241fc03e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice871a4562a84cd4b52a4356d2cb860e_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS05LTEtMS02NjU1_491afe7c-84ac-4fb5-bff1-94776447fdc3">361,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb627674086848deba17572418728d83_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS0xMS0xLTEtNjY1NQ_9c05e733-372e-4ff4-a859-97730fcd20a9">2,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d058c8bebe4a3a9d2336d08237e91c_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS0xMy0xLTEtNjY1NQ_a13278c1-17cc-4c4e-9a75-7113a748c2e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ca2109088ac4793a57a5fce35eb3903_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS0xNS0xLTEtNjY1NQ_398d9917-f6db-473a-a482-3db23278971a">231,495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS0xNy0xLTEtNjY1NQ_66a97bf0-39e8-44ae-9ca9-7dfc22f67632">128,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10e530a8190d4a178d02e013246439d8_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMi05LTEtMS02NjU1_0918c7bb-5f7f-4c3e-b068-74a6dcc95556">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c1a7cba4434a29a666db82f58a89f0_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMi0xNy0xLTEtNjY1NQ_807eb210-ec13-4db5-ac49-551ca8d49c4a">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7083bc457c04ea7b4169c892901eaf8_D20210101-20210331" decimals="-3" name="crdf:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfNC01LTEtMS02NjU1_ade5c510-bb39-4390-98c7-2ba18a61dd87">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10e530a8190d4a178d02e013246439d8_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfNC05LTEtMS02NjU1_5c7fd151-aea0-4ff5-9e01-0da4677189e2">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c1a7cba4434a29a666db82f58a89f0_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfNC0xNy0xLTEtNjY1NQ_bac5e5ec-c421-44c2-b530-8030520b8e14">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i205895823e59424a919b3d93617d9f2c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfNi0xMy0xLTEtNjY1NQ_5c9786c5-73e4-4881-af9e-f3cf2e613b1f">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5c1a7cba4434a29a666db82f58a89f0_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfNi0xNy0xLTEtNjY1NQ_32e6926e-6af8-4e8a-ba84-00f6e84ba5d7">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i482f9e2b8aa14c00bc8e55d73914ccd7_D20210101-20210331" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfNy0xNS0xLTEtNjY1NQ_58ca9d19-2936-4c59-9183-e295df65e721">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5c1a7cba4434a29a666db82f58a89f0_D20210101-20210331" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfNy0xNy0xLTEtNjY1NQ_9f29954b-af82-4581-bf35-4b744d7e3223">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7880684c50674dbb8cfd7f810fc1727a_D20210101-20210331" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfOC0xMS0xLTEtNjY1NQ_05d5a89f-bfd3-4c31-8d72-302bfe46134e">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c1a7cba4434a29a666db82f58a89f0_D20210101-20210331" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfOC0xNy0xLTEtNjY1NQ_9b9d3bba-8c0a-4e90-ba80-f5382e432879">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i482f9e2b8aa14c00bc8e55d73914ccd7_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfOS0xNS0xLTEtNjY1NQ_27c89d6d-1ab4-4956-ba23-9f1c519b3559">5,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5c1a7cba4434a29a666db82f58a89f0_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfOS0xNy0xLTEtNjY1NQ_4605c802-b6ba-4ca5-b793-f7c68c929712">5,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6eefd6a8f9ad4956b669740bb2b8c353_I20210331" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtMS0xLTEtNjY1NQ_5473b37a-5fa3-4d55-b861-06780b8db57c">716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eefd6a8f9ad4956b669740bb2b8c353_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtMy0xLTEtNjY1NQ_8592fce4-c585-44cb-9ae3-b90f2a084d83">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a0df33fbbec49a5a57d580b1dcf380b_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtNS0xLTEtNjY1NQ_8aca48bc-dc65-4b75-bddc-478fbb5bcbd1">37,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0df33fbbec49a5a57d580b1dcf380b_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtNy0xLTEtNjY1NQ_2a3ee6c6-e9f2-46e4-ba15-e9cfd8619371">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd12c54fcda54b7ebf4612de0f518a99_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtOS0xLTEtNjY1NQ_ff37cd90-f695-4b3e-aa64-7ffb2a8009f8">363,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71acb7a4b79649b297dc1e8c8c73d504_I20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtMTEtMS0xLTY2NTU_c7eb2d65-5e30-49a9-871a-b49c6a08840e">1,791</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e8063e7fb6749e0af8bd1ecebda0314_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtMTMtMS0xLTY2NTU_bef21507-99de-413d-aa8f-ce9f74dd6ef4">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib30b6ac5d0cd4c369a9097268eb12984_I20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtMTUtMS0xLTY2NTU_c38972c2-140b-4c26-bdd4-ef214e49077a">236,680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24420ff79ce74c9b9b895204b192740b_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtMTctMS0xLTY2NTU_75d45995-0301-4d84-a20b-5332de520d33">124,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3282128780c4055854a3cc8fbe4a2e0_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTEtOS0xLTEtNjY1NQ_b06f6500-8ba5-47fd-b57f-491bdb85dbec">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41602febb1074927adedec6da8eb37fe_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTEtMTctMS0xLTY2NTU_27a155bf-6b2d-4b69-8c90-85f029311ce8">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Sale of common stock, net of expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2465b36c344b4703902f0880f5e52116_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItNS0xLTEtNjY1NQ_7234ddc5-b679-4fc0-a393-e948e7d69e05">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3282128780c4055854a3cc8fbe4a2e0_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItOS0xLTEtNjY1NQ_1b881f8f-1dfb-4cc2-a134-d47449a4a1f3">19,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41602febb1074927adedec6da8eb37fe_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItMTctMS0xLTY2NTU_59530542-f04c-47ab-b223-2db7c69d1645">19,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other comprehensive gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b018ac82a04fb590b1485d91230d8d_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTMtMTMtMS0xLTY2NTU_5a4e688a-4ce5-4d56-933d-5d790c280bf3">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41602febb1074927adedec6da8eb37fe_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTMtMTctMS0xLTY2NTU_f7a7cf50-9773-4ea5-8f18-bff3721b756a">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ca563e0d06f4599a46a722d3581dd74_D20210401-20210630" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTQtMTUtMS0xLTY2NTU_ea5cb9ae-1beb-4a05-95e2-39ce4f40d37a">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41602febb1074927adedec6da8eb37fe_D20210401-20210630" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTQtMTctMS0xLTY2NTU_2aedb09a-5679-43b0-bf89-935ecd903bac">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15e882bdfea4fdf952e43b08bc2429b_D20210401-20210630" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTUtMTEtMS0xLTY2NTU_2aaa62dc-45d2-48bd-b180-3f5021f80cfa">546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41602febb1074927adedec6da8eb37fe_D20210401-20210630" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTUtMTctMS0xLTY2NTU_b8a8db7a-2e9f-422f-950a-902ed4127543">546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ca563e0d06f4599a46a722d3581dd74_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTYtMTUtMS0xLTY2NTU_920faad8-2a96-4d4a-b35b-d94c4acf93b9">6,757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41602febb1074927adedec6da8eb37fe_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTYtMTctMS0xLTY2NTU_44044422-2028-49a1-bb61-32ee46cceef7">6,757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i350d28ef78674e3eab8458411c7fcc81_I20210630" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctMS0xLTEtNjY1NQ_656085ce-6e5c-4321-a20d-047c5717786d">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350d28ef78674e3eab8458411c7fcc81_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctMy0xLTEtNjY1NQ_b6a0a902-6848-458c-bb76-9f4a01fb592f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf1c65b7a7224893adb36ad9e8cbe745_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctNS0xLTEtNjY1NQ_e58fc72b-8855-43fe-a8a3-9ceb8ab49284">39,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf1c65b7a7224893adb36ad9e8cbe745_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctNy0xLTEtNjY1NQ_f400d94d-9edf-478b-90d7-e9d647edc207">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5336d0a252e4aeb98ca683a43ba06b0_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctOS0xLTEtNjY1NQ_87da8aa9-4718-44a2-8f6c-4f28c6354fb1">383,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5824d16b9ba441788705b462bc177803_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctMTEtMS0xLTY2NTU_c6ce005a-b53b-408e-840c-d5d33f3bbfa9">1,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33e4526f7e164ab8b705c8f15dd1b690_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctMTMtMS0xLTY2NTU_4b00415d-069e-4f41-9be3-34e7f6091341">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia14d6cd1be5f488284a0548acc13b622_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctMTUtMS0xLTY2NTU_caa095ab-ab97-458a-9bac-2dbd8f1c3b60">243,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402f50ca14e9498daade666a2aba16c6_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctMTctMS0xLTY2NTU_17fdb243-578e-47f2-b9e2-7f98b0c57cb5">138,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic553804c0eaf41af8f0aea771674f3de_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTgtOS0xLTEtMjAyMjI_9102dd6c-f429-42c6-911e-cfdcc9539673">940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTgtMTctMS0xLTIwMjI5_4dd32a7a-f99a-459c-8cc0-40eeb5703ecf">940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other comprehensive gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56cfeedf0a7846a480b68514e6ec597c_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTktMTMtMS0xLTIwMjIy_3f60d6fd-8477-472d-a057-26e8c47e6117">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTktMTctMS0xLTIwMjI5_0339b283-c11c-4692-ad34-98eadd43cc5e">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i583e90cffdc74283ad12fcd0e679a613_D20210701-20210930" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjAtMTUtMS0xLTIwMjIy_c8180f4c-4cc1-4405-8b53-ad29550c0a63">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjAtMTctMS0xLTIwMjI5_e82814c9-52ef-4b37-8bc4-0431509a2552">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7fb9b1347f54faaa7e69ff2ccf6a961_D20210701-20210930" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjEtMTEtMS0xLTIwMjIy_f37a4b64-1399-40e8-9374-7bb9fc44df0d">579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjEtMTctMS0xLTIwMjI5_f12a90e1-4c52-40e7-b235-cb463ce53190">579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i583e90cffdc74283ad12fcd0e679a613_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjItMTUtMS0xLTIwMjIy_99610928-ebd5-4c45-a5d2-9f4f84faa84b">6,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjItMTctMS0xLTIwMjI5_4a6360e0-55fd-4579-8d24-4e8c69abacd5">6,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33912183705e412b83ed2cef39eddc1c_I20210930" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtMS0xLTEtMjEwMTE_e599ff38-c06a-4b00-8503-2561c6dbe950">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33912183705e412b83ed2cef39eddc1c_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtMy0xLTEtMjEwMTE_6b6de2cd-b380-4a07-9cf1-a1dcc9a9211a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic25a7e642c104708a790b647db5d1ded_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtNS0xLTEtMjEwMTE_227f0299-af93-4b0b-9b87-2da4b5dd6f51">39,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25a7e642c104708a790b647db5d1ded_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtNy0xLTEtMjEwMTE_2099683f-e01b-4733-801e-989f9b00b321">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7086816a72204fa58a1df8fa6c35a63a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtOS0xLTEtMjEwMTE_31fb1b5a-f953-41e2-ad2c-dac8491bd8c9">384,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied522f508b844f94be0b94767cf40167_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtMTEtMS0xLTIxMDEx_9447970c-db9c-460a-a275-f0c3069560bb">666</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4805fa04ec446eab0d6af2de913c7c_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtMTMtMS0xLTIxMDEx_7583f273-86ae-4563-9792-5d9de0e91feb">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45e23d0997d94ed9a6bbb2f8fc1ee85e_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtMTUtMS0xLTIxMDEx_31584136-3e98-4169-be1a-c656edcb6cdc">250,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtMTctMS0xLTIxMDEx_2bdccc67-73d5-4d56-9fe7-adce16d25194">133,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk4_21f0155c-d8e7-41c8-8d42-1264084126c7" footnoteRole="http://www.xbrl.org/2003/role/footnote">Net of expenses of $<ix:nonFraction unitRef="usd" contextRef="i41602febb1074927adedec6da8eb37fe_D20210401-20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMTIz_9ea76d1d-be5b-431b-89d4-9c4c6eb4edd6">0.8</ix:nonFraction>&#160;million.</ix:footnote></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.236%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib94e5739ad98459497e72c9a6bc0ad84_I20191231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS0xLTEtMS02NjU1_664f71bc-c61a-4cb6-97a2-ba760fb57fd4">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94e5739ad98459497e72c9a6bc0ad84_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS0zLTEtMS02NjU1_79d225fb-539f-477d-845c-6babd15ed16b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83bc7c42c1824b15a08376355aa11ba3_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS01LTEtMS02NjU1_c13a4ef2-dfcc-47c2-b081-563a3739d110">8,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83bc7c42c1824b15a08376355aa11ba3_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS03LTEtMS02NjU1_8a427627-41e3-4038-9ac0-a6f78aa391fd">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aa726d5321245c1a96ba3990871ca22_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS05LTEtMS02NjU1_e1a00579-5572-46d4-8665-81722876eeff">217,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf57c9859a8a4e38b67c19c2be236a90_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS0xMS0xLTEtNjY1NQ_9b1563d8-3d7a-470b-b578-510d7f67593f">972</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i631d652218464d15843c3a80ff37978c_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS0xMy0xLTEtNjY1NQ_aaaca603-196f-41d5-b7cd-f170e596fdc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i953e77c8d38e45e6974947b84da4f172_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS0xNS0xLTEtNjY1NQ_f2fccea7-ea56-4307-ad67-f75b53b90f7b">208,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0e2ceae22248b4a0ebd0aa20fa60c6_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS0xNy0xLTEtNjY1NQ_7673c9ca-f66a-494f-899e-8173956a4cbb">7,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff0a01a8a61a458184bb5efcbdd6cdae_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMi05LTEtMS02NjU1_5119c6a5-3412-41ae-a80c-c7ce406348c8">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMi0xNy0xLTEtNjY1NQ_fd7c2bde-dbea-4efa-b8f0-67278f9cc601">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Sale of common stock and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98824144f8e24c5cad08193a1247420c_D20200101-20200331" decimals="-3" sign="-" name="crdf:SaleOfStockCommonAndWarrantsNetShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMy01LTEtMS02NjU1_bb9be4fc-3762-46b7-a236-1a31d1a06d9c">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff0a01a8a61a458184bb5efcbdd6cdae_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="crdf:SaleOfStockValueCommonAndWarrantsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMy05LTEtMS02NjU1_8689fef9-a6dd-4dea-8ce1-5b621a48c4f1">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="crdf:SaleOfStockValueCommonAndWarrantsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMy0xNy0xLTEtNjY1NQ_a1ecbb7e-9b3b-48f4-9416-5835b07b2a5e">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98824144f8e24c5cad08193a1247420c_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="crdf:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNC01LTEtMS02NjU1_bb9acb11-89f6-4c7c-b616-ba1bd1176ba9">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff0a01a8a61a458184bb5efcbdd6cdae_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNC05LTEtMS02NjU1_d4d8cea1-2ea1-41a6-beee-c9331c5c3cd1">1,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNC0xNy0xLTEtNjY1NQ_92875080-b636-4c6e-804c-ec637318419a">1,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98824144f8e24c5cad08193a1247420c_D20200101-20200331" decimals="-3" name="crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNS01LTEtMS02NjU1_62716f65-e18b-49a6-88a5-ab2c0109d191">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd2c102f2b6845ce95560b93eba83063_D20200101-20200331" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNi0xNS0xLTEtNjY1NQ_5446dcb4-fee1-4c09-b62c-1c1628cd50f0">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNi0xNy0xLTEtNjY1NQ_5bbb0f23-e915-41a1-8a0d-1d7ecd5dcfeb">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i451d0811b3544bcc912debf2a8ede85a_D20200101-20200331" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNy0xMS0xLTEtNjY1NQ_874ffcc5-aca3-4f50-ab0c-25e519c056e7">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNy0xNy0xLTEtNjY1NQ_37a42f90-8c82-4420-9e40-a55443790ae9">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd2c102f2b6845ce95560b93eba83063_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOC0xNS0xLTEtNjY1NQ_abb505c5-381c-4667-8ab2-c66d66968c8a">4,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOC0xNy0xLTEtNjY1NQ_3b5e2674-60c0-43df-944e-539be20b1b4e">4,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2cd86fa1857349e7b73861b629a3a124_I20200331" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS0xLTEtMS02NjU1_b5637034-d920-4a2a-b6c4-cc2dfab62148">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cd86fa1857349e7b73861b629a3a124_I20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS0zLTEtMS02NjU1_da35b6a1-787c-407e-8f8d-6c6e3a2b3fe3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49c8e30388454e01b1713f33c031e81a_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS01LTEtMS02NjU1_fb42161b-dec8-48a7-b11a-6a1461b6a7f4">11,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c8e30388454e01b1713f33c031e81a_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS03LTEtMS02NjU1_3efdc5da-bf08-47c8-8ae9-64b786bdc62f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac2c0c6030c476080cddc898da2fdbe_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS05LTEtMS02NjU1_55cdcf81-c351-4522-a525-d9c7a94a751f">219,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icaebc49a046040e29e5e4565fd900bcb_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS0xMS0xLTEtNjY1NQ_85b12796-898f-4989-baf0-be118175a0e5">679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63aaf8a8792b4035ba42f8b374bd567e_I20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS0xMy0xLTEtNjY1NQ_2a94a42d-8bef-4ea7-b973-256b6b9fbaa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c0e65a2de674c8a814d4c385ed678a6_I20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS0xNS0xLTEtNjY1NQ_daa18449-a752-4a84-8438-2cc97587a957">212,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a2c6673bb34fcfaba41b7f80484177_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS0xNy0xLTEtNjY1NQ_afe0c5f4-4d21-423d-8a9f-500b75765777">6,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110b9bf586124339b177542a41284804_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTAtOS0xLTEtNjY1NQ_043a8246-1f43-4938-9b22-93e080742f9d">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTAtMTctMS0xLTY2NTU_a8a5e2af-8b1f-4ab5-a308-9bcb7f89714c">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18b0e382e0084fe29c322a52a6d9fb60_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTEtMS0xLTEtNjY1NQ_8bdcda0e-6034-4244-acaa-077a0e16b884">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28dd1563898f43d9b46b76dc77925f8e_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTEtNS0xLTEtNjY1NQ_19b13695-b291-49af-9409-d4bf84a62003">603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110b9bf586124339b177542a41284804_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTEtOS0xLTEtNjY1NQ_9a32f22b-3d70-48e3-a818-6f90b8378f2b">2,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i449d2f3eb8d0492f8052bba28b62b75d_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTEtMTEtMS0xLTY2NTU_845576a5-1809-472b-830e-b87802b97169">2,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTEtMTctMS0xLTY2NTU_f39bb0c8-7c68-436d-8aa5-5ad3d1c59fee">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series D Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic80c59f86e5f4a4186743622863a59c7_D20200401-20200630" decimals="-3" name="crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTItOS0xLTEtNjY1NQ_229be52d-ad9b-49ed-8b67-b9249f36f8d6">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2636d69182a44bceacd8ee49296aa242_D20200401-20200630" decimals="-3" sign="-" name="crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTItMTUtMS0xLTY2NTU_5ef97e18-046f-4b7f-bf43-ee770b2433aa">602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series E Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib95b420a99f04c7ea8d5bc830d3e1aba_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTMtOS0xLTEtNjY1NQ_53f9be33-8a59-4fb1-a09c-1d8f60058c84">2,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i205347e8f5484902aba963f9ad58ff6a_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTMtMTUtMS0xLTY2NTU_05110476-e646-4d08-a6ab-93f6fea8872b">2,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of common stock, preferred stock and warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18b0e382e0084fe29c322a52a6d9fb60_D20200401-20200630" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMS0xLTEtNjY1NQ_2cb15daf-5623-463f-b164-40c2c32e26af">866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b0e382e0084fe29c322a52a6d9fb60_D20200401-20200630" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMy0xLTEtNjY1NQ_0c21b0be-0a08-4608-bbad-fb219c020305">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28dd1563898f43d9b46b76dc77925f8e_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtNS0xLTEtNjY1NQ_c480c886-f66a-4315-9261-61b886b3ff94">4,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dd1563898f43d9b46b76dc77925f8e_D20200401-20200630" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtNy0xLTEtNjY1NQ_f2aa8f4b-04f8-4b63-911b-932ff2860817">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110b9bf586124339b177542a41284804_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtOS0xLTEtNjY1NQ_bce4f6d3-de3c-4401-99d8-dad63b036878">17,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMTctMS0xLTY2NTU_250d4afb-d517-49b4-ae52-055936d7d7c9">17,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28dd1563898f43d9b46b76dc77925f8e_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="crdf:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTUtNS0xLTEtNjY1NQ_5f93d3d2-1100-4060-bdef-868b8ff6aebc">3,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110b9bf586124339b177542a41284804_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTUtOS0xLTEtNjY1NQ_7b10faad-6e43-40ae-ac9a-85ace846f59e">4,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTUtMTctMS0xLTY2NTU_bb730793-e889-49cc-9f9f-6825ce3ce0f5">4,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28dd1563898f43d9b46b76dc77925f8e_D20200401-20200630" decimals="-3" name="crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTYtNS0xLTEtNjY1NQ_01188eea-d65c-48a6-9842-6fd7db1ded01">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon conversion of Series D Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2f820ff8f6c24d05b3ffd3339f0dcfc9_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTctMS0xLTEtNjY1NQ_30d1624f-c8ce-4123-8754-e1bd86915cfe">155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e7e9d9d6bd7457098d60b651db0d39f_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTctNS0xLTEtNjY1NQ_105b317a-1cbd-439f-98f2-6d6ddec12033">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb79d8dc23ad4047a11793096554a73c_D20200401-20200630" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTgtMTUtMS0xLTY2NTU_a66489fb-82c2-4ad7-bd78-0e78d304fcaf">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTgtMTctMS0xLTY2NTU_690c5cba-2fe9-427b-b5d5-3f61fcf55dd4">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449d2f3eb8d0492f8052bba28b62b75d_D20200401-20200630" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTktMTEtMS0xLTY2NTU_dc0064e8-8b7b-4ec5-9f15-e6b0f1f5cef0">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTktMTctMS0xLTY2NTU_7d7c3056-f61a-47e8-9fc6-b4fb4d475df0">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb79d8dc23ad4047a11793096554a73c_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjAtMTUtMS0xLTY2NTU_107adca0-8073-44b3-a8b9-b4988c1bd2e5">4,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjAtMTctMS0xLTY2NTU_af355baf-67d3-4f5f-b896-fe2939686f0b">4,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfabfd86abc84c9d8332a7d6522f0b05_I20200630" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtMS0xLTEtNjY1NQ_5da2babe-e3f9-4d87-b3c5-c92ee938d518">927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfabfd86abc84c9d8332a7d6522f0b05_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtMy0xLTEtNjY1NQ_6993acf2-eb3f-461e-9aed-769b172dda34">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d9ab8d6d1f3471aada01b6d9a78f35d_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtNS0xLTEtNjY1NQ_31de97ba-ab6f-421d-86ed-c668e44fbfee">21,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d9ab8d6d1f3471aada01b6d9a78f35d_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtNy0xLTEtNjY1NQ_dc81cd6c-76d0-454e-8231-02db961245e9">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd2c993874045f0903171fafd6a6737_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtOS0xLTEtNjY1NQ_c4653ef3-9772-4ed0-a233-1d92218f075d">247,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02b12865eb164c1b8daa72971befc365_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtMTEtMS0xLTY2NTU_36d2d961-e09b-49db-95f6-1fe942aa722a">2,766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7223f8f5e4b7451fac6e9a53f511b618_I20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtMTMtMS0xLTY2NTU_078ec2fd-030b-4a4b-9c92-59f93ce8974a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb8b40a3759d4dd8bdff04839d6af29e_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtMTUtMS0xLTY2NTU_aa64409e-8fc4-4e82-afc1-bdecdf1c6109">220,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b2d2a3f17d4b329211ee5e90f04d9c_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtMTctMS0xLTY2NTU_1ede8dc7-1826-4d18-af4a-192d2da648b9">24,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6b51a15c074437984b0293d4935aae9_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjItOS0xLTEtNjc2Mg_b93a2ca1-ab57-4a2d-b2c4-f3836f3b9c5f">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjItMTctMS0xLTY3NjI_fc6ae462-d52f-4ce2-9c3c-e9970dd8bc3a">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i793b333bdcf34df8a736118d629cb3b7_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="crdf:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjMtNS0xLTEtNjg2MQ_c925f0ad-29ae-4538-8a0e-cc25d210edf0">4,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i793b333bdcf34df8a736118d629cb3b7_D20200701-20200930" decimals="-3" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjMtNy0xLTEtNjg2MQ_592fbbcd-fed8-416c-849a-fa6b5914ca6d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6b51a15c074437984b0293d4935aae9_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjMtOS0xLTEtNjg2MQ_44b0f88b-b0c1-4e53-9dee-0d38300e8880">12,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjMtMTctMS0xLTY4NjE_ebaa412b-9512-49dc-8dd7-dce694897c69">12,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i793b333bdcf34df8a736118d629cb3b7_D20200701-20200930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjQtNS0xLTEtMjEwNjQ_6cecdc03-6619-486a-a211-6981e79b6e71">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6b51a15c074437984b0293d4935aae9_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjQtOS0xLTEtMjEwNjQ_f633d5f6-cc5f-4d2f-b25b-3d0774fe08c5">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjQtMTctMS0xLTIxMDY0_0ca6e876-7b10-4a49-9e31-ad6b4b8d9bdf">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i793b333bdcf34df8a736118d629cb3b7_D20200701-20200930" decimals="INF" name="crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjUtNS0xLTEtNjg3NQ_1ef20895-3749-4435-b3be-751b9002489c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8768b38297214afab61b468bbf429f52_D20200701-20200930" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjYtMTUtMS0xLTY4OTc_fe4d3395-6c5e-4c7c-a107-627f1f7c6d36">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjYtMTctMS0xLTY4OTc_a1307de2-9337-4ddf-bf3d-35ade8d34c3e">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.236%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a7ab6cbc6374029b4bffd3ec9b17e0c_D20200701-20200930" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjctMTEtMS0xLTY5MDk_69a08848-3aef-44c2-b8ac-36fd8383d64d">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjctMTctMS0xLTY5MDk_5b82c423-4e41-4e8b-8148-750146293c93">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8768b38297214afab61b468bbf429f52_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjgtMTUtMS0xLTY5MzM_7abd4561-23c7-4bcd-b74b-4dc353719f94">4,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjgtMTctMS0xLTY5MzM_753ade59-1578-430d-a3d1-ad54254ae288">4,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie26a981245d5493394cff84a3e0e6e70_I20200930" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktMS0xLTEtNjk0NQ_c9e851e3-d25b-4071-a698-16c5300935a8">927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie26a981245d5493394cff84a3e0e6e70_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktMy0xLTEtNjk0OA_5358590a-3820-4c47-bcc2-5fa0a441e806">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i775faff3942e4e5db3e5bd022093d60f_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktNS0xLTEtMjEwMDk_026db4f6-dafb-4f08-9ff2-d7edaef2af91">26,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775faff3942e4e5db3e5bd022093d60f_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktNy0xLTEtMjEwMDk_0ae79145-67bf-40c2-a80a-20cf8b88846a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e14a5109df413e81014c0b81871037_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktOS0xLTEtMjEwMDk_7c0c98e5-fb37-49fa-a691-7553615618d6">260,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51efe940143345028a304e5a815b9230_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktMTEtMS0xLTIxMDA5_dd1bf80f-7614-412a-bd75-eecb94e2fe4b">2,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if45c6805e8814c47933df9000082c117_I20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktMTMtMS0xLTIxMDA5_ed3219f3-0f1b-4f81-9594-90c3a5bd41b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i057b4c0f72d44fdb8719e1f993ada81b_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktMTUtMS0xLTIxMDA5_e765d1cf-77cc-4d9f-a3aa-366f862c13c9">224,893</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41cb574ec6224df9954670aecbbdd57c_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktMTctMS0xLTIxMDA5_0a017562-cb42-40bf-bf6a-d1b204c64b5b">33,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk3_c69ce9de-335f-478e-9ba5-d6131c0a2877" footnoteRole="http://www.xbrl.org/2003/role/footnote">Net of expenses of $<ix:nonFraction unitRef="usd" contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630" decimals="-5" format="ixt:num-dot-decimal" name="crdf:CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMjIz_925c7062-640d-4e89-a0ce-01899019ffc9">0.6</ix:nonFraction>&#160;million, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $<ix:nonFraction unitRef="usd" contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630" decimals="-5" format="ixt:num-dot-decimal" name="crdf:WarrantsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzIx_bf62510d-e195-48d4-aef2-348d18456f35">0.4</ix:nonFraction>&#160;million.</ix:footnote></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_31"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMy0xLTEtMS02NjU1_822454bb-7e24-46fe-b3f8-2f1eaa5bf277">18,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMy0zLTEtMS02NjU1_99da45c7-cfe8-4919-9200-fceac59e3fef">12,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNS0xLTEtMS02NjU1_5bd69d19-ec60-4615-9ba3-42fe4c5f51bc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNS0zLTEtMS02NjU1_14a88f5f-e8cb-4611-95af-d59561830117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OperatingLeaseImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNi0xLTEtMS02NjU1_3130df22-15ee-4ce2-8c67-a8a607d440ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNi0zLTEtMS02NjU1_49efd1d1-a743-43ab-ac10-b7c64abeca76">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNy0xLTEtMS02NjU1_1620803f-16b0-4db0-9d75-be70a49806fa">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNy0zLTEtMS02NjU1_5df42498-48f5-41c5-8242-295987c21675">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfOC0xLTEtMS02NjU1_46b8e457-195f-4a11-96a7-b76af7989110">2,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfOC0zLTEtMS02NjU1_7164c63c-468b-4081-b10b-bad2654a8e0d">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTMtMS0xLTEtNjY1NQ_e88285d2-d1e3-4abd-ba8a-f713cee534a2">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTMtMy0xLTEtNjY1NQ_753983fe-afb4-429f-8654-25c9093d8c93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments&#8212;warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTYtMS0xLTEtNjY1NQ_4fa2c931-7d50-4ec3-8847-a0ab9c3a999f">280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTYtMy0xLTEtNjY1NQ_7535a7a1-c20e-4b7a-8b36-c1b9f513e9be">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTctMS0xLTEtNjY1NQ_602a993f-1696-4e9f-b75e-227730e60eb9">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTctMy0xLTEtNjY1NQ_3a3fdd04-55d5-4030-826e-7272d6dbebd7">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTktMS0xLTEtNjY1NQ_0485aaf3-38ed-4110-b01c-611bad32c189">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTktMy0xLTEtNjY1NQ_57994ce0-3bc8-41ed-8ae2-317d399421c9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjAtMS0xLTEtNjY1NQ_723cf002-d5bf-4007-b8cf-97a15a16aa96">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjAtMy0xLTEtNjY1NQ_3c482417-f2b7-4260-97da-9a23f0e0c5d5">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjEtMS0xLTEtNjY1NQ_d6fb3119-5d5b-41da-b3e4-e6353bba896c">741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjEtMy0xLTEtNjY1NQ_3b96a056-7ffc-4410-9943-4e0b6d5c2047">624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" name="crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjItMS0xLTEtNjY1NQ_273ed4df-24ba-4121-8b40-d5bdd6072669">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" name="crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjItMy0xLTEtNjY1NQ_4858db91-d561-4a66-881f-707fd9d140d0">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjMtMS0xLTEtNjY1NQ_31fd8f22-0632-4eae-9b33-3b87f6ed7caa">830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjMtMy0xLTEtNjY1NQ_6c69434a-0ccc-44ad-bc99-29622f19e7e8">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" name="crdf:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjQtMS0xLTEtNjY1NQ_9ef196f7-0bc9-4b4f-a61d-5d8e2f0a15c1">645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" name="crdf:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjQtMy0xLTEtNjY1NQ_d34bba15-81a0-4cd9-aa3c-1c2a4f48c4a7">636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjUtMS0xLTEtNjY1NQ_219b036d-5a45-43f0-b9b1-ad232af414a8">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjUtMy0xLTEtNjY1NQ_9f228ca0-74bd-4693-b645-603285780742">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjYtMS0xLTEtNjY1NQ_ee520244-a23c-48d1-9781-9b6ecefd4ca9">15,650</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjYtMy0xLTEtNjY1NQ_8a8d15c9-3bf4-4507-b45b-fd5651ee52a1">11,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzAtMS0xLTEtNjY1NQ_07c83fda-41a7-4054-a5fe-dc6640b9e8a4">98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzAtMy0xLTEtNjY1NQ_594b4bc6-cf15-40c2-a405-0c90e1d9304d">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzEtMS0xLTEtNjY1NQ_082ec3ef-2c4e-4bc6-8b99-ef56610111e2">15,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzEtMy0xLTEtNjY1NQ_c5fc9f14-6f0e-4e45-bde8-6705876c925c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzItMS0xLTEtNjY1NQ_0639e6cb-a38b-4974-bdec-2a75be8ed34c">146,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzItMy0xLTEtNjY1NQ_17fd6a02-47fb-4900-897c-c60e76006cb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzMtMS0xLTEtNjY1NQ_06c8de99-0230-470d-9494-1e9388903d0b">8,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzMtMy0xLTEtNjY1NQ_bee10c07-4f8b-41a5-8c13-b34a4a0876ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzQtMS0xLTEtNjY1NQ_b4f8c18f-3418-423a-bc6a-0cdcbfa1058f">122,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzQtMy0xLTEtNjY1NQ_a5d872e3-85f4-4e8c-aabd-bc2f92697ec7">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of common stock, preferred stock and warrants, net of expenses of $<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzctMC0xLTEtNjY1NS90ZXh0cmVnaW9uOmZlZDY4ZDRkODczYzRiYjc4MDFjNDRjNDMzZGJmNzdmXzkw_5899e386-72fe-4304-8575-2260b3e31dc2">776</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzctMC0xLTEtNjY1NS90ZXh0cmVnaW9uOmZlZDY4ZDRkODczYzRiYjc4MDFjNDRjNDMzZGJmNzdmXzk3_6bd85a92-8b2a-43f8-80dc-b22bbc69fb56">634</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzctMS0xLTEtNjY1NQ_78edbe38-6f1e-4922-87c2-dea6ec714dec">19,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzctMy0xLTEtNjY1NQ_c7395a6f-be6e-434b-8667-2ee6915bac00">18,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs related to the clinical trial funding commitment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzktMS0xLTEtNjY1NQ_cf72558d-63cb-4a2b-b2b8-748d3875e7c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzktMy0xLTEtNjY1NQ_889bab33-9565-4e55-9cf0-152014b9cc85">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDAtMS0xLTEtNjY1NQ_f6087eae-77d9-438a-bb9f-dd53a8e10eea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDAtMy0xLTEtNjY1NQ_879d1c3f-6396-414d-a0f6-e15e166e48b7">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDEtMS0xLTEtNjY1NQ_7abe9451-5f92-4044-9550-d9a498049f1a">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDEtMy0xLTEtNjY1NQ_f249aff4-18f1-4e6e-938c-41978e70f83d">18,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings under note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDMtMS0xLTEtNjY1NQ_ff6707d9-0a06-4351-9180-b9b17776d3c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDMtMy0xLTEtNjY1NQ_3daa1abd-0f10-436b-b578-4f16e7b79a03">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDctMS0xLTEtNjY1NQ_db22e757-3422-483c-9ef4-09045da822a1">20,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDctMy0xLTEtNjY1NQ_50f8b2c9-1e56-4276-9009-0f3f63ffdceb">37,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDktMS0xLTEtNjY1NQ_959acc64-9bac-4fa3-9cb5-898bc91b2240">117,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDktMy0xLTEtNjY1NQ_da3c862f-5f68-4683-804f-134b6163cb44">26,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;Beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNTAtMS0xLTEtNjY1NQ_45ca21de-6e57-4017-a6bd-ac8bd693f1ef">130,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0e2ceae22248b4a0ebd0aa20fa60c6_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNTAtMy0xLTEtNjY1NQ_d1618dca-088c-4cf8-af7d-30e393161c23">10,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;End of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNTEtMS0xLTEtNjY1NQ_3d340e2b-31ac-4637-954d-9f89b8464248">13,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41cb574ec6224df9954670aecbbdd57c_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNTEtMy0xLTEtNjY1NQ_f015265d-48ae-497f-ab3c-6e17a8862729">36,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosure of cash flow activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNTQtMS0xLTEtNjY1NQ_c4c9a19c-62d8-42ce-bad9-855f432b4156">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNTQtMy0xLTEtNjY1NQ_f91ded16-74db-4363-af9d-2234f8d31135">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="crdf:PreferredStockDividendAccrued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjAtMS0xLTEtNjY1NQ_a7030e9e-7a16-40ae-b410-00a2a79ca2cd">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="crdf:PreferredStockDividendAccrued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjAtMy0xLTEtNjY1NQ_104084f2-84e1-4021-ac76-b9cb787363cf">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized for beneficial conversion features of Series D Convertible Preferred Stock issuance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19a2c1f7f0b479188b45d6f374dbc81_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjMtMS0xLTEtNjY1NQ_c017a6c6-bdbe-4419-a85c-2ad5ff03031b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia35d15a9dfb646fcbffcffbb9d8262b1_D20200101-20200930" decimals="-3" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjMtMy0xLTEtNjY1NQ_d1e583c4-88fc-4b83-b441-54606ee8fa41">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized for beneficial conversion features of Series E Convertible Preferred Stock issuance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcfb466ee9f44377b4e807b87d71fd6a_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjQtMS0xLTEtNjY1NQ_e7eb4503-943c-4ffb-a830-9bf395ad8d10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c1a472218714bdea2c26e2f2f2bc0a7_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjQtMy0xLTEtNjY1NQ_f6a4a943-fd09-4cf2-9ac1-dde715010ba8">2,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, Series D Convertible Preferred Stock and warrants issued in connection with clinical trial funding commitment, net of discount of $<ix:nonFraction unitRef="usd" contextRef="ie19a2c1f7f0b479188b45d6f374dbc81_D20210101-20210930" decimals="-3" name="crdf:DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjYtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjgyNmY3MDk5NDQxOTRjZTVhYTEwZTQ2MGI4YmE0NTVkXzEwOTk1MTE2Mjc5NDk_78c1de96-02bd-4f54-97d9-a6a2b9ffd8a9">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia35d15a9dfb646fcbffcffbb9d8262b1_D20200101-20200930" decimals="-3" name="crdf:DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjYtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjgyNmY3MDk5NDQxOTRjZTVhYTEwZTQ2MGI4YmE0NTVkXzE1NQ_efea714d-584d-426e-851e-9f77735c5192">488</ix:nonFraction>, respectively</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19a2c1f7f0b479188b45d6f374dbc81_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjYtMS0xLTEtNjY1NQ_98f90610-541e-4082-9d8d-f79747119247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia35d15a9dfb646fcbffcffbb9d8262b1_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjYtMy0xLTEtNjY1NQ_819c624d-ce54-46af-83c1-0984fb06442a">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:83.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80MC9mcmFnOjIzYTg5YWFlYWVkMzRiZGU4Y2I0M2MxZTI0ZTg3ODY4L3RleHRyZWdpb246MjNhODlhYWVhZWQzNGJkZThjYjQzYzFlMjRlODc4NjhfMzExNg_cf6b9af6-e9ee-4282-9a26-a27a12b8e47d" continuedAt="ib3960bf1cf384567a45607e2dbccbab0" escape="true">Organization and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="ib3960bf1cf384567a45607e2dbccbab0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Organization and Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology, Inc. (&#8220;Cardiff Oncology&#8221; or the &#8220;Company&#8221;) headquartered in San Diego, California, is a clinical-stage oncology company with the mission of developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need, including KRAS-mutated metastatic colorectal cancer, metastatic pancreatic cancer and metastatic castration-resistant prostate cancer. The Company's common stock is listed on the Nasdaq Capital Market under the ticker symbol "CRDF".</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form&#160;10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules&#160;and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company&#8217;s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December&#160;31, 2020 included in the Company&#8217;s annual report on Form&#160;10-K filed with the SEC on February&#160;25, 2021.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since its inception and has negative operating cash flows. As of September&#160;30, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80MC9mcmFnOjIzYTg5YWFlYWVkMzRiZGU4Y2I0M2MxZTI0ZTg3ODY4L3RleHRyZWdpb246MjNhODlhYWVhZWQzNGJkZThjYjQzYzFlMjRlODc4NjhfMjI1Nw_7908e06c-31c8-4fd8-af5c-bbcc281cc2c7">134.0</ix:nonFraction>&#160;million in cash, cash equivalents and short-term investments and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#8217;s stockholders may experience additional dilution. The economic effects of COVID-19 could also have an adverse effect on the Company's ability to raise additional capital. See Note 10 to the condensed financial statements for further information.</span></div></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RleHRyZWdpb246MGI3YjUyMGU3MTc0NGVjN2JlYTRkNTQxY2QzZjljMDRfNDQyMA_8c8c261d-08b7-44b0-89d5-8462dabd9f3b" continuedAt="i951a3eb45bc747ba986983f304649de6" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i951a3eb45bc747ba986983f304649de6" continuedAt="i228a8c39b399446fbfb100f5fe73988a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, there have been no changes to the Company&#8217;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, other than the addition of investment securities as described below.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RleHRyZWdpb246MGI3YjUyMGU3MTc0NGVjN2JlYTRkNTQxY2QzZjljMDRfNDQyMg_7a9f77c0-ef1f-4b04-b922-f5a624a63892" continuedAt="ib2178380d4a74839bafd5f84f6cbc745" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Securities</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#8217;s ability to liquidate the investment for use in operations within the next 12 months.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><ix:continuation id="i228a8c39b399446fbfb100f5fe73988a"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib2178380d4a74839bafd5f84f6cbc745">Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#8217;s investment holdings are in the form of debt securities or certificates of deposit, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.</ix:continuation></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RleHRyZWdpb246MGI3YjUyMGU3MTc0NGVjN2JlYTRkNTQxY2QzZjljMDRfNDQxOA_4c1cc438-382e-4a86-8246-31600e080aa1" continuedAt="i0c1f3dc83dfb4141a4df66cfabeda9f4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0c1f3dc83dfb4141a4df66cfabeda9f4">Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RleHRyZWdpb246MGI3YjUyMGU3MTc0NGVjN2JlYTRkNTQxY2QzZjljMDRfNDQxOQ_dbe423f4-54ec-46fa-a205-a4099de8e3e6" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17ac44632d4944509820a9395d78c529_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfMi0xLTEtMS02NjU1_7e524171-e783-443d-8b35-0d5f00b7b295">3,566,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55b121d890664785a96f2abd68d7743a_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfMi0zLTEtMS02NjU1_ee8420c8-799b-4284-bf5f-73a2b533b6d6">1,920,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4778f546e098429f8ad5e7ca4beac4b6_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfMy0xLTEtMS02NjU1_d7f586d5-5ecd-479d-ba91-a06c6a3a2d54">4,490,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7cd4aae3ff4246df84edcf2ab4da4c2b_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfMy0zLTEtMS02NjU1_b2736a70-b390-45ef-9b93-61753140cea3">7,373,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5afbd3931f114b889cf2b6d1fcba9d91_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfNC0xLTEtMS02NjU1_724e283a-0a71-4bdf-8629-8d76c37c9d2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i472a131094f2474fb3218a9b6bc0594c_D20200101-20200930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfNC0zLTEtMS02NjU1_06894c5c-1e30-4bf1-9d02-27b64590cdc7">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4544f5428574ef481cdcbd193499f68_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfNS0xLTEtMS02NjU1_a27fcb85-5376-41c1-83cf-d30264004260">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3bc75745225b41fda9b79e00c8ab8c58_D20200101-20200930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfNS0zLTEtMS02NjU1_de644100-8715-46b9-9460-2d68ef4c5b8c">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21f389c33c2b4cb0969bd99011bcb8db_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfNy0xLTEtMS02NjU1_34fa1911-81ee-4f30-a6f7-f7ff2b7815c8">2,684,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie73becd6b06646ffad08290d5060d468_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfNy0zLTEtMS02NjU1_1cbe8784-a24f-46c1-ae49-cbb2e189ec50">3,548,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfOC0xLTEtMS02NjU1_164c5196-1fd4-404e-86ee-c6bb86a9b401">10,742,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfOC0zLTEtMS02NjU1_e076682c-b433-49d1-b2f6-3e9b6e2118b6">12,844,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RleHRyZWdpb246MGI3YjUyMGU3MTc0NGVjN2JlYTRkNTQxY2QzZjljMDRfNDQxMQ_940c9aa1-6182-435b-b312-38249a270e95" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncement Not Yet Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04 ("ASU 2021-04), Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;<ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RleHRyZWdpb246MGE2OGE0MTI4NTllNDRkMjgxYzRkOGYzNmVjNTcxZWVfMTEwMw_8fd72eff-537f-4d59-87b2-4ce38b725ebc" continuedAt="i56e1090895ca4aa0a02cc8ba5b5d4a18" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i56e1090895ca4aa0a02cc8ba5b5d4a18" continuedAt="i752f7a585fd047a48cb118e63c78e382"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RleHRyZWdpb246MGE2OGE0MTI4NTllNDRkMjgxYzRkOGYzNmVjNTcxZWVfMTEwNA_2866c984-53b8-40f4-a7ba-ec4e7c7a4468" continuedAt="i3e8f13384ad34581bc63c8baaf106824" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September&#160;30, 2021 and December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c421333d9e842cd938364a79a347e01_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMy0xLTEtMS02NjU1_d2b498e2-b70b-4ad6-9a70-1d54bed315d2">12,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4871ed60f064988846d5339b4cefb37_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMy0zLTEtMS02NjU1_45d64a8a-591a-4ad5-89b4-2c6738bd83fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab1f91262aa4961bfa27744b525f31a_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMy01LTEtMS02NjU1_818308dd-1c06-45a1-b0e1-1a557ffc0a1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a924190f51c43a6b7d3270fde532fa2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMy03LTEtMS02NjU1_3190e82f-5074-4436-8f31-d8fbd42c5169">12,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f837af10c4e49b681e48bb6553d03bb_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfNS0xLTEtMS02NjU1_b7495227-4fb2-4c3e-b46a-91a51c7d1aa1">12,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc20b1e7fdcf4fb4b59ce226be19d676_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfNS0zLTEtMS02NjU1_0ac0ecdf-55e5-4e1c-a839-cfa521104111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cac633b9fd54f2a99fe41969f58f594_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfNS01LTEtMS02NjU1_fe78529b-c3d9-4df9-8611-c56902843a02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie508430c486f4b33b819c76634f5166c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfNS03LTEtMS02NjU1_1bc02c6f-21ce-4fa6-a27f-539c11d7a5c3">12,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2272875d1e6040bbbc4cb41775efc0c5_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOC0xLTEtMS02NjU1_6b9e29f3-29c1-49c4-814f-a94556572f93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcadbd307c7048f089ba63bc4e00d913_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOC0zLTEtMS02NjU1_c7bf91ff-69d1-4997-b99f-c26a617caa5b">2,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab14befe92264008986e1a141957af7d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOC01LTEtMS02NjU1_f93ceb16-6cb8-4c8c-b944-a79dc29cd0ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ffd53bdfd4d459c8b703013a42d0264_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOC03LTEtMS02NjU1_a1a2f926-e237-43af-ba19-d23bc51ae678">2,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92b222fd62f45f2b838481f5c639808_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOS0xLTEtMS02NjU1_a28df43a-eef8-40b5-82ef-a7d1e7199588">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41d19fc393f4c7c97eb7bcda789a9d9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOS0zLTEtMS02NjU1_b3bf8b6b-9e3e-4a93-b53d-26418812c755">77,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id79faeb4f57d4754840ae281b5c51f1c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOS01LTEtMS02NjU1_456a1cdb-60a0-4fb8-820b-ab504d9f3843">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec2c0b1298ef43bd8a6cf6425715b928_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOS03LTEtMS02NjU1_f2b27fa0-1ddd-4938-8706-b5638051b365">77,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic693b77303c24a2a99b2842d76d72241_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTAtMS0xLTEtNjY1NQ_07941594-7f2c-4703-bd26-5d257118bf07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b0c6cd52a849caa99be52f924b86e2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTAtMy0xLTEtNjY1NQ_b4bc98d3-1686-4c21-932c-ab10053ee145">12,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a9858e566ca4451af2bd491f1fdcdad_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTAtNS0xLTEtNjY1NQ_2d717ac6-a995-419d-b61b-4fe97be52d10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065815c78e2d4c5cb9a8ed1ec7b1f4db_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTAtNy0xLTEtNjY1NQ_ee39270e-bec6-439a-935f-12fbddf8770f">12,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf531bc123047f2adcdb4ad64487d5d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTEtMS0xLTEtNjY1NQ_5f5f26d9-ff59-4016-85aa-a915ebe1d92d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce0447ee3b24f7b8e5c636200fa056d_I20210930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTEtMy0xLTEtNjY1NQ_be44518c-09ed-47d1-8fe0-71fe2d963948">732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00578720dda04f5e803f8dd40e53c600_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTEtNS0xLTEtNjY1NQ_72d52678-42fb-4491-b700-f1556c478846">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c645e1dbc2452aa3d3d3e63a2097ab_I20210930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTEtNy0xLTEtNjY1NQ_967cc1a9-6d05-46e3-9bb7-b9ec1eea3ef6">732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90db4c568644361b2954142f5e9ef53_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTItMS0xLTEtNjY1NQ_493fc779-4cfb-4bea-8718-216cfcbfbabb">27,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f802e75c98e40ab9791dea64340ce78_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTItMy0xLTEtNjY1NQ_20c1482d-2697-45cd-a8ed-82362df20bf8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b041904ffe4c919883330668092c9b_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTItNS0xLTEtNjY1NQ_58326bfe-b0b8-4039-a05d-cde4e899c1c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica2abb6ba5634bf2bf4bf896d7c9258c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTItNy0xLTEtNjY1NQ_1ab8cd15-6012-4c95-9db9-f9ed5d57b36e">27,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f837af10c4e49b681e48bb6553d03bb_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTMtMS0xLTEtNjY1NQ_891e8196-36a9-497c-a530-fe23440e20ef">27,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc20b1e7fdcf4fb4b59ce226be19d676_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTMtMy0xLTEtNjY1NQ_ec1a9d6a-533b-4ac1-bde1-95e6c42ae2a3">93,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cac633b9fd54f2a99fe41969f58f594_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTMtNS0xLTEtNjY1NQ_ee613028-3fe2-44f6-a1b1-8840b6d9c1f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie508430c486f4b33b819c76634f5166c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTMtNy0xLTEtNjY1NQ_7d7e9cbb-2e5a-4a6e-868a-a3f86c13dae9">120,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f837af10c4e49b681e48bb6553d03bb_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTUtMS0xLTEtNjY1NQ_e7dbb24b-885a-4212-ae51-0c0a28937440">39,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc20b1e7fdcf4fb4b59ce226be19d676_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTUtMy0xLTEtNjY1NQ_3c407e54-ec7d-49f2-aa12-34f9a3551551">93,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cac633b9fd54f2a99fe41969f58f594_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTUtNS0xLTEtNjY1NQ_b1d95fc1-60e9-426f-baea-a08ecf732f4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie508430c486f4b33b819c76634f5166c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTUtNy0xLTEtNjY1NQ_cf1c6c2a-984d-482b-86b2-8472967f1b9d">133,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants (3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f837af10c4e49b681e48bb6553d03bb_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTctMS0xLTEtNjY1NQ_0504ec86-86c4-4b3f-8006-05ec85502785">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc20b1e7fdcf4fb4b59ce226be19d676_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTctMy0xLTEtNjY1NQ_ecb4c9f7-57a3-4ab9-9d74-87265a61789d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cac633b9fd54f2a99fe41969f58f594_I20210930" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTctNS0xLTEtNjY1NQ_400aef38-8e54-4790-ad48-e20c42acfac5">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie508430c486f4b33b819c76634f5166c_I20210930" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTctNy0xLTEtNjY1NQ_3350993b-8659-49fb-aaf2-aff8ec48d401">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f837af10c4e49b681e48bb6553d03bb_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTgtMS0xLTEtNjY1NQ_72141c62-7d85-45c2-a37c-d801bc445948">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc20b1e7fdcf4fb4b59ce226be19d676_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTgtMy0xLTEtNjY1NQ_63dddb58-358f-4066-99d2-cda549bcef3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cac633b9fd54f2a99fe41969f58f594_I20210930" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTgtNS0xLTEtNjY1NQ_1a4fd038-9845-4d96-b3a7-1176d58cf1b7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie508430c486f4b33b819c76634f5166c_I20210930" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTgtNy0xLTEtNjY1NQ_f3ea467e-791c-42ca-a0d0-5e95739cdfc7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund (1)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ffcbb6630ed443ea2e088b433bc9ce4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMy0xLTEtMS02NjU1_4db24a5e-62e1-4d81-bfab-23f6813dd81f">129,988</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bc267f79c2a489989a67cdc20d3a3c6_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMy0zLTEtMS02NjU1_f63acfb5-2806-4e40-b47d-e7e0bf3f587d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6e261cb9904caaadea9698ea51a5af_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMy01LTEtMS02NjU1_3fd574e6-02a2-453c-b271-5911bd7c98a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0222ae72231f44db9f7d8ea289ba7e70_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMy03LTEtMS02NjU1_cd85b4cb-2b08-4966-b586-903bfcbbd482">129,988</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d1e68d697c4ef0aff6b17bcd0598d3_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfNy0xLTEtMS02NjU1_3cc6b48c-c2ed-4a95-8a29-150537ea9811">129,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb4ce146f5434b44a3a5c1272c9610ba_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfNy0zLTEtMS02NjU1_2dad7502-fc48-4091-91af-31078e1df440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86124e9d3ce549fb84e7bdc9a8ebe5d8_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfNy01LTEtMS02NjU1_e691d063-8aa7-4c02-8310-d300c47b9c29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813279dffe5742cdb683aadf13c65b58_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfNy03LTEtMS02NjU1_afa742dc-01b1-422b-882b-a6cbb13ff496">129,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants (3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d1e68d697c4ef0aff6b17bcd0598d3_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfOS0xLTEtMS02NjU1_f3b3a08a-40c9-4ef8-b73c-0485a6da58d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb4ce146f5434b44a3a5c1272c9610ba_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfOS0zLTEtMS02NjU1_28d6230e-2b11-48da-a92c-c2fc80e1c06d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86124e9d3ce549fb84e7bdc9a8ebe5d8_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfOS01LTEtMS02NjU1_70695e50-bb5b-458d-902c-abee55536675">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813279dffe5742cdb683aadf13c65b58_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfOS03LTEtMS02NjU1_5e0bbacb-b3a8-4ebe-98e4-1f2150d2cefc">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value on a recurring basis</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d1e68d697c4ef0aff6b17bcd0598d3_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMTAtMS0xLTEtNjY1NQ_d24110b4-79c4-467e-84bf-6b0e7e3acf8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb4ce146f5434b44a3a5c1272c9610ba_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMTAtMy0xLTEtNjY1NQ_8837ac86-68df-4da5-930d-a1ea915d33fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86124e9d3ce549fb84e7bdc9a8ebe5d8_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMTAtNS0xLTEtNjY1NQ_ada60f11-96e0-4b28-9e8e-e6ee0778104d">285</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813279dffe5742cdb683aadf13c65b58_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMTAtNy0xLTEtNjY1NQ_0663367d-8aab-43fb-a3ae-653d74c8656b">285</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;Included as a component of cash and cash equivalents on the accompanying condensed balance sheets. Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Included in short-term investments in the accompanying condensed balance sheets. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, all assets and liabilities for which the fair value </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i752f7a585fd047a48cb118e63c78e382"><ix:continuation id="i3e8f13384ad34581bc63c8baaf106824">measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 6 to the condensed financial statements for further information.</ix:continuation></ix:continuation></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RleHRyZWdpb246MTczM2YxNjZiODQ3NDYzN2JmNmY5N2FiMGNlZTUxNjRfMTcx_032792c6-18c7-4845-a638-a029e3cee5ac" continuedAt="i008bc1be244d4c36b78bc1831859d2d0" escape="true">Supplementary Balance Sheet Information</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i008bc1be244d4c36b78bc1831859d2d0"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RleHRyZWdpb246MTczM2YxNjZiODQ3NDYzN2JmNmY5N2FiMGNlZTUxNjRfMTY2_864e4974-1cab-45e3-89ae-3bc6299a91bf" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available for sale consist of the following: </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a78ea25d06f4f24a1e99abe072332f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMi0xLTEtMS02NjU1_6b081169-ef1f-45ca-a4d1-4fa17cebd608">2,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a78ea25d06f4f24a1e99abe072332f0_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMi0zLTEtMS02NjU1_4d966a3a-a09e-44c3-8a48-84939b867d48">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a78ea25d06f4f24a1e99abe072332f0_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMi01LTEtMS02NjU1_acf5d47e-5e04-441e-8afe-15bedc40acda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a78ea25d06f4f24a1e99abe072332f0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMi03LTEtMS02NjU1_45aa9740-40c5-4383-9923-f5cb2769852f">2,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62c3a0c6662345618211a584192ca26a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMy0xLTEtMS02NjU1_0d60c855-6386-47d2-967d-f5e7fc097305">77,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62c3a0c6662345618211a584192ca26a_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMy0zLTEtMS02NjU1_77f71843-b534-4319-bed9-294569c2dafe">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62c3a0c6662345618211a584192ca26a_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMy01LTEtMS02NjU1_d28568dc-709f-4d44-92b2-a696b980359f">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62c3a0c6662345618211a584192ca26a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMy03LTEtMS02NjU1_0e655f9e-92bd-4367-b910-3d548bda8d5f">77,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib20f35230bce4c59b8a12b5a5680b915_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNC0xLTEtMS02NjU1_622c3b24-730b-4da9-82bc-08fc87a2f55b">12,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib20f35230bce4c59b8a12b5a5680b915_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNC0zLTEtMS02NjU1_c749b4df-aaf3-49f2-a615-67647e4136ce">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib20f35230bce4c59b8a12b5a5680b915_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNC01LTEtMS02NjU1_6641f44b-71f4-4332-9f1e-a20960c8d5c0">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib20f35230bce4c59b8a12b5a5680b915_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNC03LTEtMS02NjU1_73398c7a-f745-48d7-93c6-1fb780d44562">12,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31763bf591274c6bb305e9bff5fff3d0_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNS0xLTEtMS02NjU1_3d4447f7-ea33-4143-ba42-0c9873181a6e">732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31763bf591274c6bb305e9bff5fff3d0_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNS0zLTEtMS02NjU1_68f7c4cd-5932-41be-bd62-9b971c83d2dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31763bf591274c6bb305e9bff5fff3d0_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNS01LTEtMS02NjU1_90ec0ee1-1112-4193-8f2e-a406e48ba3f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31763bf591274c6bb305e9bff5fff3d0_I20210930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNS03LTEtMS02NjU1_c767e7be-afef-4688-bc1a-aa8ae6834438">732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bc90bddda41caa182ab326e680cfd_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNi0xLTEtMS02NjU1_421694aa-aaec-4c96-84c0-5b3a4c02a705">27,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bc90bddda41caa182ab326e680cfd_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNi0zLTEtMS02NjU1_5e6eef29-dd9f-4497-b484-e55993c99fad">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e4bc90bddda41caa182ab326e680cfd_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNi01LTEtMS02NjU1_a337b2e7-bf32-42a7-8b19-a79425ef12d5">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4bc90bddda41caa182ab326e680cfd_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNi03LTEtMS02NjU1_c1a75755-2d63-446c-8751-13c7fb8c55a1">27,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNy0xLTEtMS02NjU1_08010def-7944-41f5-9a71-0bdc1d3cb736">120,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNy0zLTEtMS02NjU1_3b99d2fe-263a-4661-9dbf-5601172a8eb7">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNy01LTEtMS02NjU1_9f56338d-af37-4bec-b4fd-88ea3c834a1d">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNy03LTEtMS02NjU1_814651b3-6a0b-4256-8417-e6638fd671ee">120,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RleHRyZWdpb246MTczM2YxNjZiODQ3NDYzN2JmNmY5N2FiMGNlZTUxNjRfMTY3_5936da55-1689-4d25-9c90-38f2e016b673" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96238e9478424ff983eea316b3b6d48c_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfMS0xLTEtMS02NjU1_42950f85-3912-4d04-ad31-4e6a48971d1d">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15293ce702ad4f1994f5e08e17c540fb_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfMS0zLTEtMS02NjU1_0ae7bfbb-29bc-44a0-84e3-c54d9e9916fe">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81df56d144dd4aef8aa1484cbced739d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfMi0xLTEtMS02NjU1_526715a6-7df2-4613-a467-05f8bc749cf8">1,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267b2ad37e64532bdf3ce1ab2728c95_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfMi0zLTEtMS02NjU1_1e15d8cb-9b78-4ccc-b9bd-15d0b72a1081">1,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e08014d936d49259c36229cca64a87f_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfMy0xLTEtMS02NjU1_304d057b-29f1-432f-bfaf-1c80b31452aa">884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c2c267750ac4a1f8c2d127cc7cb6594_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfMy0zLTEtMS02NjU1_d3189924-3520-4edb-8325-2c291df6d514">868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfNC0xLTEtMS02NjU1_1666dc3e-813b-447f-aaa0-4491904dfa9d">3,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfNC0zLTEtMS02NjU1_023cb2a7-67b6-4e05-b572-d4bf09fbfe07">3,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfNS0xLTEtMS02NjU1_5e97384f-5c7c-4e62-a691-b47f8c5cf3ba">3,329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfNS0zLTEtMS02NjU1_2f6ba3ed-dff4-4549-817b-db1bb54ded98">3,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfNi0xLTEtMS02NjU1_44e949c4-eb47-4a51-95e3-1e0839e90758">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfNi0zLTEtMS02NjU1_6c770cd9-8008-423a-a6d7-83a48a82386e">624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTUxMg_09147319-238f-4a96-96a4-6bafd5163a42" continuedAt="if393637924f04356b40846a40d324396" escape="true"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTUzMQ_33fc412f-a567-4dbf-8fd2-c1245aeeebc8" continuedAt="i9d19ccfb182441f18feef742cb25c62d" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:continuation id="if393637924f04356b40846a40d324396" continuedAt="idd29f5e5272d4e1ebae526d9b9b1bbd7"><ix:continuation id="i9d19ccfb182441f18feef742cb25c62d" continuedAt="i2edeb43de674489f9f6c14193c0dae32"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company (as a sublessor) also subleases portions of its facility to third parties under <ix:nonFraction unitRef="lease" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="crdf:LessorNumberOfSubleases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMjY2_453b22e8-26ab-4c1b-aab8-5b72d820f241">three</ix:nonFraction> separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently occupies <ix:nonFraction unitRef="sqft" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="crdf:LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTA5OTUxMTYzNzM1Mw_e8f50e3f-c7d4-4116-a98a-0e8d4f391f91">9,500</ix:nonFraction> square feet of office and lab space in San Diego. During July 2021, the Company entered into an amended lease agreement to increase its occupied space to <ix:nonFraction unitRef="sqft" contextRef="ieb7822e6be894e0796c8f0e8eac7e29a_D20220101-20270228" decimals="0" format="ixt:num-dot-decimal" name="crdf:LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTA5OTUxMTYzNzM2MQ_f8da2b7e-2201-4c9c-94d9-7b88c82c1114">12,300</ix:nonFraction> square feet which commences on January 1, 2022 and expires on February 28, 2027. Under the current master facility lease, which expires on December 31, 2021, the Company leases <ix:nonFraction unitRef="sqft" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="crdf:LesseeOperatingLeaseAreaOfLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTA5OTUxMTYzNzM2NQ_9cb73d2c-0364-4001-944a-e64d226bf81e">26,100</ix:nonFraction> square feet of office and lab space. This includes <ix:nonFraction unitRef="sqft" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="crdf:LessorAreaOfSublease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTA5OTUxMTYzNzM2OA_5e9a72ca-fe1f-4032-8225-12832fcae247">16,600</ix:nonFraction> square feet of space that is subleased to third parties, all of which expires on December 31, 2021. The minimum monthly rent under the amended lease is $<ix:nonFraction unitRef="usd" contextRef="ide4c82a6d8fc4a50b3c355ad46b5663c_D20220101-20221231" decimals="-3" format="ixt:num-dot-decimal" name="crdf:LesseeOperatingLeaseMonthlyRentPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTY0OTI2NzQ0NTE4OA_e4f06b3c-9037-4474-af78-4d00d7968238">55,000</ix:nonFraction> with an annual rent escalation of <ix:nonFraction unitRef="number" contextRef="ieb7822e6be894e0796c8f0e8eac7e29a_D20220101-20270228" decimals="INF" name="crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTY0OTI2NzQ0NTIyNg_7398aec1-58ad-4694-b943-b975f5ec5ef5">3</ix:nonFraction>% per year beginning on January 1, 2022. Through December 31, 2021 rent payments are approximately $<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="crdf:LesseeOperatingLeaseMonthlyRentPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfNjEz_e38e3818-2e7d-419a-84f2-dbf7911f7c3c">80,000</ix:nonFraction> per month. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under <ix:nonFraction unitRef="lease" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="crdf:LessorNumberOfSubleases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTEwMg_91558be5-1fd0-44ff-8221-3cfef04391ff">three</ix:nonFraction> separate sublease agreements, which all expire on December 31, 2021. The Company as a sublessor is leasing approximately <ix:nonFraction unitRef="sqft" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="crdf:LessorAreaOfSublease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTY0OTI2NzQ0ODIzMg_be9e037e-52f4-46b9-8f35-34e9787876fa">16,600</ix:nonFraction> square feet of space to third parties as of September 30, 2021.  </span></div></ix:continuation></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><ix:continuation id="idd29f5e5272d4e1ebae526d9b9b1bbd7"><ix:continuation id="i2edeb43de674489f9f6c14193c0dae32"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTUyMA_dc9966ad-0e95-4b92-bea1-ae747d105057" continuedAt="iee79d398cc294be18278cae62da2160e" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMi0xLTEtMS02NjU1_67507869-862b-4d8e-a8cc-26f8ede2dc29">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMi0zLTEtMS02NjU1_62ab36bf-689b-4ae8-8642-075878387a0e">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMi01LTEtMS02NjU1_8dc28686-0e46-4960-9de8-5f60814b3936">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMi03LTEtMS02NjU1_f1a9d078-8c3e-4f26-b7ee-0b5be3fe92e5">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMy0xLTEtMS02NjU1_ce9f503b-3ec0-4603-a3b2-4e4ba3dac477">101</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMy0zLTEtMS02NjU1_6026ea41-e9f4-4132-9c3a-30bfa8ffbce4">73</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMy01LTEtMS02NjU1_a1fc4b2b-8b8f-4a38-b500-970cbf93e59c">303</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMy03LTEtMS02NjU1_0e26e9d1-f761-4d9c-bfd8-3a6e9d9c0bd2">218</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfNC0xLTEtMS02NjU1_e9ad3643-50fc-4025-9d0d-b790cf5f8e1e">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfNC0zLTEtMS02NjU1_7d094e8e-759a-4e0c-b845-4e656f041c47">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfNC01LTEtMS02NjU1_5c6a1149-3c6a-4807-b741-b873c75f4797">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfNC03LTEtMS02NjU1_cf100626-202f-42b9-b073-b1f48e50300e">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="crdf:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTUyMw_abe19a9a-15a3-4195-99eb-a3ba9a014f3f" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfMS0xLTEtMS02NjU1_19089f5b-5105-424b-867a-44573081e0ff">3,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfMS0zLTEtMS02NjU1_4d23dc60-1e7b-42e7-916f-4bbf01ee14b3">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfMy0xLTEtMS02NjU1_d347074f-dc93-4d14-8c3f-adfcc5d2c21e">594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfMy0zLTEtMS02NjU1_e83f0902-882c-4ccd-a556-37f34460d726">860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfNC0xLTEtMS02NjU1_c2056591-37ff-406b-87a7-d2731d2137ea">2,691</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfNC0zLTEtMS02NjU1_a1f42100-edac-4068-936e-28fa69b9796e">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfNS0xLTEtMS02NjU1_23fd69f9-2a65-47ce-9c7c-65369fd192ea">3,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfNS0zLTEtMS02NjU1_8589a702-dabb-4ab1-87ff-be45ed0fa1d3">869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfNy0xLTEtMS02NjU1_09eb92cd-cde3-463e-b6cd-b64dc5492458">5.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfNy0zLTEtMS02NjU1_43d44844-ecf2-4b4f-8306-84ce01cb1adf">1.0</ix:nonNumeric> year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfOC0xLTEtMS02NjU1_89e44826-04c5-412a-91cd-75a43e586309">7.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfOC0zLTEtMS02NjU1_6e5096c3-e2e6-4657-9666-3f0d4b4bdbc8">6.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:continuation id="iee79d398cc294be18278cae62da2160e"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfMy0xLTEtMS02NjU1_417d1888-14fb-4976-aa6c-ef53d4bd67e5">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfMy0zLTEtMS02NjU1_63557e59-1421-407d-a611-088a0ce08b97">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfMy01LTEtMS02NjU1_8ae4006d-93a3-4e6e-a2f4-a05d5713083b">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfMy03LTEtMS02NjU1_645117d2-c193-4920-87d3-2788e7d18aaa">706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfNS0xLTEtMS0xOTc5MA_778a72d6-a7c3-4f24-a506-a458de5e597d">3,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfNS0zLTEtMS0xOTc5MA_1edf2a94-7fb7-45c0-86e6-95f9fb90c53a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfNS01LTEtMS0xOTc5MA_165a57c8-87ba-4efa-b729-dd8ab971e91f">3,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfNS03LTEtMS0xOTc5MA_75b9e242-59da-45f5-aa9f-12199d5d2350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTUxNQ_e0a7bd5c-ba7f-4bfa-b8d0-dd75ad6e426b" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div style="text-align:center;text-indent:33.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Sublease Income </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Operating Leases </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September 31, 2021)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfMy0xLTEtMS02NjU1_bfc8fb3e-120e-43e8-81d2-71c9790a6b6b">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfMy0zLTEtMS02NjU1_04410116-d643-4ba0-b07e-cb252fac1ab1">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfMy01LTEtMS02NjU1_53c75410-e1e1-4752-9db5-98cd053408e8">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNC0xLTEtMS02NjU1_4f5b8181-7219-4f3a-9199-05b0829ba190">610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNC0zLTEtMS02NjU1_e66c12b3-9c3c-4fcf-85fd-5a38b6c42653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNC01LTEtMS02NjU1_86afae18-ff6a-4c63-91c5-06a99d46b48e">610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNS0xLTEtMS02NjU1_093b2d27-4793-4d89-8b1d-c9a80d468203">737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNS0zLTEtMS02NjU1_762d5900-8615-4dd1-85d6-fca2ca9f583c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNS01LTEtMS02NjU1_c880adf5-6702-448a-a3ab-5dd7ace03599">737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNi0xLTEtMS02NjU1_0c5412de-c2af-4284-91c8-6922de33eb1d">754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNi0zLTEtMS02NjU1_856f9c68-f076-4c4a-b978-1a0775ee5304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNi01LTEtMS02NjU1_2d275ce6-1a34-454b-9239-96c0ec11121c">754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNy0xLTEtMS0xOTg1MQ_9d72b117-4e90-4351-8726-ae0a6652a3db">775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNy0zLTEtMS0xOTg1MQ_45af9466-651b-48a8-be66-ece00b7fbf8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNy01LTEtMS0xOTg1MQ_18dfdd9f-2ed5-49c3-8407-980ace3b399f">775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="crdf:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfOS0xLTEtMS0xOTg1OQ_5d78f21c-ec76-41ed-9e6e-02227f065aa2">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:fixed-zero" name="crdf:LessorOperatingLeasePaymentToBeReceivedAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfOS0zLTEtMS0xOTg1OQ_d03fd012-1062-4e73-9e70-a93002ae0bd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfOS01LTEtMS0xOTg1OQ_17bc428c-2d07-4046-8b16-e967bab212c7">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNy0xLTEtMS02NjU1_62d5c064-8fef-4ce9-be58-16f0582ab718">3,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNy0zLTEtMS02NjU1_3bace139-11c4-44e7-8fb0-6555cf36dbc5">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNy01LTEtMS02NjU1_43af959b-2a4b-42ca-b4cc-ebf2370d5b83">3,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfOC0xLTEtMS02NjU1_a11830e0-62b5-4775-bf61-4ba84561f644">687</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfOS0xLTEtMS02NjU1_a982f2be-deeb-41cc-ad9f-83b0813ff17e">3,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;<ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RleHRyZWdpb246YzYwNjYxOTIwYWU1NDQ1NWIzNWJkZDkyNTc2Yzc3ZGNfMTUyNg_727d8fcb-2dc4-45d6-9e02-38be84265467" continuedAt="i42431d3bb8e048c8a45d1252ce2e01bc" escape="true">Derivative Financial Instruments &#8212; Warrants</ix:nonNumeric></span></div><ix:continuation id="i42431d3bb8e048c8a45d1252ce2e01bc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the Company&#8217;s analysis of the criteria contained in ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 815-40&#8221;) or ASC Topic 480-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 480-10&#8221;), Cardiff Oncology determined that certain warrants issued in connection with the execution of certain equity financings must be recorded as derivative liabilities.&#160;In accordance with ASC 815-40 and ASC 480-10, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company&#8217;s condensed statements of operations.&#160;The Company estimates the fair value of these warrants using the Black-Scholes option pricing model.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i2c7f42dfef2c4958ba29b2e28bb9b35d_D20210101-20210930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RleHRyZWdpb246YzYwNjYxOTIwYWU1NDQ1NWIzNWJkZDkyNTc2Yzc3ZGNfMTUyNw_94c786c0-387b-4244-8e83-05a307328f8b" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to determine the fair value of the warrants using the Black-Scholes option pricing model were:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i27c1821fc9ab463284b24faa6a39aeca_I20210930" decimals="2" name="crdf:EstimatedFairValueOfWarrant" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfMS0xLTEtMS02NjU1_9ca91e54-2de9-448f-be51-027097b81f3a">6.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i81c4317e30404c12b737872399063ecb_I20201231" decimals="2" name="crdf:EstimatedFairValueOfWarrant" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfMS0zLTEtMS02NjU1_9c98cd67-23e3-4216-ac1e-f968fb1e4b0b">17.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id32688583be64531a4c3b6f8dda463e1_I20210930" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfMi0xLTEtMS02NjU1_83738741-9812-4b07-be6d-0521a0463174">1.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i870cb7768ebe4cd9a47cae43d43fa560_I20201231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfMi0zLTEtMS02NjU1_4543b61b-2e59-4d20-a707-25f8bff60695">2.1</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i22ae9743fe9e485bb2f97b84bd14ef48_I20210930" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfMy0xLTEtMS02NjU1_6314e2e7-5b61-467a-ba8f-bd6a284d1088">0.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93a076cf959748b68d0895f7a702037c_I20201231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfMy0zLTEtMS02NjU1_315a5ade-423f-4e7f-958d-8d5cb3be4967">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i577dc0d878144b149b1dd7752563c6fe_I20210930" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfNC0xLTEtMS02NjU1_863d60d2-3975-438b-9e17-d0313920fda2">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1e8bf7f73344b78ab04d1ba7ddea8a2_I20201231" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfNC0zLTEtMS02NjU1_b5616d7b-7b89-427a-b990-1627d5095a45">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2f22ed10e3b4e019378ae1db12695ed_I20210930" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfNS0xLTEtMS02NjU1_b55aa903-39bd-48cf-a28e-59c3b30946be">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebfd4c8685c349cca9ac74c079a51df8_I20201231" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfNS0zLTEtMS02NjU1_71e13688-2a89-42a0-9bb6-c220d66e6cc5">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility is based on historical volatility of Cardiff Oncology&#8217;s common stock.&#160;The warrants have a transferability provision, accordingly, Cardiff Oncology used the remaining contractual term as the expected term of the warrants.&#160;The risk-free rate is based on the U.S.&#160;Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i2c7f42dfef2c4958ba29b2e28bb9b35d_D20210101-20210930" name="crdf:ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RleHRyZWdpb246YzYwNjYxOTIwYWU1NDQ1NWIzNWJkZDkyNTc2Yzc3ZGNfMTUxNw_f48739c5-a458-4b04-9b81-efe151dd17c6" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of changes in the Company&#8217;s derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for number of warrants)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>Instrument<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a2fc422184c4397bfd8fde6fbfdd4f8_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjAxZGE0Yjg2MTA1NTRiZDk5YTE0MDc5YTg5NzBjMDllL3RhYmxlcmFuZ2U6MDFkYTRiODYxMDU1NGJkOTlhMTQwNzlhODk3MGMwOWVfMi00LTEtMS02NjU1_1485aa52-6e1b-4c33-aad5-33b593f4530e">64,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a2fc422184c4397bfd8fde6fbfdd4f8_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjAxZGE0Yjg2MTA1NTRiZDk5YTE0MDc5YTg5NzBjMDllL3RhYmxlcmFuZ2U6MDFkYTRiODYxMDU1NGJkOTlhMTQwNzlhODk3MGMwOWVfMi02LTEtMS02NjU1_d239881f-64ff-41b4-8565-7d069b265e26">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants during the period recognized as a gain in the condensed statements of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb2a438ab8374c9284bc780389cd9e66_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjAxZGE0Yjg2MTA1NTRiZDk5YTE0MDc5YTg5NzBjMDllL3RhYmxlcmFuZ2U6MDFkYTRiODYxMDU1NGJkOTlhMTQwNzlhODk3MGMwOWVfNC02LTEtMS02NjU1_ea957dca-47c0-42a7-94fb-f3c128fbe232">280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b6a8197ab2846cf8242cf259266a02c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjAxZGE0Yjg2MTA1NTRiZDk5YTE0MDc5YTg5NzBjMDllL3RhYmxlcmFuZ2U6MDFkYTRiODYxMDU1NGJkOTlhMTQwNzlhODk3MGMwOWVfNS00LTEtMS02NjU1_ba5e220b-715e-4462-bba2-37887ae2f6b2">64,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b6a8197ab2846cf8242cf259266a02c_I20210930" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjAxZGE0Yjg2MTA1NTRiZDk5YTE0MDc5YTg5NzBjMDllL3RhYmxlcmFuZ2U6MDFkYTRiODYxMDU1NGJkOTlhMTQwNzlhODk3MGMwOWVfNS02LTEtMS02NjU1_777330a5-55b4-43e3-97bb-0d2ce454388d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;<ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjU5Ng_61404128-5ddb-4c86-bec2-32776629cede" continuedAt="i24e343b693f94d8e8f9d2c32d813090b" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i24e343b693f94d8e8f9d2c32d813090b" continuedAt="i1a57b210abc94de298cfbf829bcf3867"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjYwNg_4cd3c2f3-051b-41c8-86d3-9d9606918fcc" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e92eec12814d63b23dec15ee3a82e2_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfMy0xLTEtMS02NjU1_e3c1fd61-a8f7-4d36-be8e-b2f861a04da9">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951a79658a174acdabb183cc6c576e38_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfMy0zLTEtMS02NjU1_2ded9470-3e4b-4795-97f1-49fb664550ee">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44d179594bba4e1dad1a989df3916c06_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfMy01LTEtMS02NjU1_9c78f8fc-32b2-4942-bc76-4f01105eeb79">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c42cef5a93d477d8d01cdeb0d9a6497_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfMy03LTEtMS02NjU1_12aa7d5b-7f94-4686-af93-22af47ef594b">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f4bdbe2cd9a4216b241d6c0f58f92af_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNC0xLTEtMS02NjU1_22ad757b-3bad-4347-a1be-d208c0e085b8">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd0cbb07f2c48e9809d2340ba480ed4_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNC0zLTEtMS02NjU1_c95f7e0f-7fff-4ef7-b334-c8a7b842b91d">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec5f94b33da24052af9749b10b28f208_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNC01LTEtMS02NjU1_5bab89b4-10db-4a50-bc07-edd37fecd355">1,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i429dafc4192b4a51aac45b680a2ebe82_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNC03LTEtMS02NjU1_c3829237-9650-4070-9b42-6e044a34394f">570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNy0xLTEtMS02NjU1_1d99e203-68db-45ae-b348-3e02359eab80">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNy0zLTEtMS02NjU1_2a9057cb-01ab-4510-b494-958d48a62646">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNy01LTEtMS02NjU1_ff78ba44-997b-4522-9361-af0633db6541">2,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNy03LTEtMS02NjU1_287c9bef-329a-42ef-bb8a-5da615fce7ed">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized compensation cost related to non-vested stock options outstanding at September&#160;30, 2021, net of estimated forfeitures, was $<ix:nonFraction unitRef="usd" contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMzA2_fe1a0405-793a-4d4c-9b52-f1fbf1110865">10.1</ix:nonFraction> million, which is expected to be recognized over a weighted-average remaining vesting period of <ix:nonNumeric contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMzk3_cedeb5cd-9c7e-484e-91cf-074438ed04ec">3.3</ix:nonNumeric> years.&#160;The weighted-average remaining contractual term of outstanding options as of September&#160;30, 2021 was </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><ix:continuation id="i1a57b210abc94de298cfbf829bcf3867" continuedAt="i50002ee7e49d49f6b00e756834a03473"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately <ix:nonNumeric contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfNDk5_4ccc26b7-16af-4824-9092-45696544c7ca">8.9</ix:nonNumeric> years. The total fair value of stock options vested during the nine months ended September 30, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfNTc0_d28be51e-9eba-4bf8-b0ab-6330de33f9f9">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfNTgx_e9c8f1e3-a334-4440-ab73-ff880199d06e">0.8</ix:nonFraction> million, respectively.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjYwMQ_6a2906b5-1e9f-4a77-86ad-2a2f56ee015b" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfMi0xLTEtMS02NjU1_b0293d5c-f545-4cf9-8456-07ecffd7de0a">0.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i918a2f804e04472a831f145c622bff4c_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfMi0zLTEtMS02NjU1_a82c4ca7-9aca-4f45-9d91-a18bb097c85c">0.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfMy0xLTEtMS02NjU1_2049c640-4ce8-4bbb-8f94-f8eff09fed27">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i918a2f804e04472a831f145c622bff4c_D20200101-20200930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfMy0zLTEtMS02NjU1_024df8fc-a98d-468b-9822-a7f53b998570">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfNC0xLTEtMS02NjU1_2018cc4a-71c5-4da6-9c06-16583eb32b27">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i918a2f804e04472a831f145c622bff4c_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfNC0zLTEtMS02NjU1_5d76c905-9a53-432f-acef-06fca11a1e5e">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfNS0xLTEtMS02NjU1_2ea64ac4-3edb-4cbb-aa86-addbbbdf6bbe">6.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i918a2f804e04472a831f145c622bff4c_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfNS0zLTEtMS02NjU1_4992c90f-a42a-4e88-86d3-e6dc361259ac">5.9</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjYyMw_aa5ef558-a536-4b03-94d5-c68b0a6d2b5c" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and changes in stock options outstanding is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ec0a3e52eaa44bfbbe255b9105dd595_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfMS0xLTEtMS02NjU1_9932440b-de91-4bd1-89c3-adbd1d2575ca">1,860,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ec0a3e52eaa44bfbbe255b9105dd595_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfMS0zLTEtMS02NjU1_396ab57a-638c-4346-b72a-d560bde64ea1">7.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ec0a3e52eaa44bfbbe255b9105dd595_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfMS01LTEtMS02NjU1_58e6a0f1-91df-43b0-a3d3-ab837204a234">27,963,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfMi0xLTEtMS02NjU1_1f6ed4db-c6d6-4b42-b281-8f010df8f355">1,721,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfMi0zLTEtMS02NjU1_27cf51d6-bc19-4a38-8b4b-a2e71c85474c">7.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled / Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNC0xLTEtMS02NjU1_320030d2-b2f5-4957-b763-967b9c3836fc">10,770</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNC0zLTEtMS02NjU1_17301ae9-3bbd-4a57-9395-bc15686374b7">2.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNS0xLTEtMS02NjU1_4327f100-865a-4d78-a365-cc0d9d923906">4,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930" decimals="2" name="crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNS0zLTEtMS02NjU1_0d73c83e-5684-454a-a360-8b9d52d63197">216.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNi0xLTEtMS02NjU1_5fa80b68-203d-4e4c-85da-ea9623e51512">3,566,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNi0zLTEtMS02NjU1_92a41d39-3e16-465b-b326-b67a0c8f0f75">7.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNi01LTEtMS02NjU1_8d58a5c5-f95f-493f-913c-a47342592060">7,522,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNy0xLTEtMS02NjU1_ad3e411b-5b45-4d11-945c-d9c2938f166d">1,281,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNy0zLTEtMS02NjU1_286ed7f5-f211-4a5c-a814-6636a0a23563">8.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNy01LTEtMS02NjU1_42fce5f4-006a-4a1c-8e18-25fc9d2de7ac">5,103,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfOC0xLTEtMS02NjU1_792e5ad6-0f41-44a0-9a8b-7d85c7024dab">3,466,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfOC0zLTEtMS02NjU1_e758b079-9120-446d-9f5d-1ea2ba012a1b">7.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfOC01LTEtMS02NjU1_4fd5a3ed-4b16-4735-b395-c8a65504412b">7,344,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Equity Incentive Plan</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the Company's stockholders approved the 2021 Omnibus Equity Incentive Plan ("2021 Plan"). The number of authorized shares in the 2021 plan is equal to the sum of (i) <ix:nonFraction unitRef="shares" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMTEzMw_701b8214-d174-459c-a61b-5939753a108e">3,150,000</ix:nonFraction> shares, plus (ii) the number of shares of Common Stock reserved, but unissued under the 2014 Plan; and (iii) the number of shares of Common Stock underlying forfeited awards under the 2014 Plan. As of September&#160;30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="ia67d1806a46a419689781a32baf40aff_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMTM1Mg_4e9b1b8d-6720-4442-9e9f-08aa1f14b444">2,289,902</ix:nonFraction> shares available for issuance under the 2021 Plan. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2014 Equity Incentive Plan</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the adoption of the 2021 Plan, no additional equity awards can be made under the terms of the 2014 Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inducement Grants</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company began issuing equity awards to certain new employees as inducement grants outside of its 2021 Plan. As of September&#160;30, 2021, an aggregate of <ix:nonFraction unitRef="shares" contextRef="idd65b030d4494709b2f9be0748ec2b5f_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMTY0OTI2NzQ0NTE3Mg_42222c72-4d62-4515-b353-d409efd29453">590,000</ix:nonFraction> shares were issuable upon the exercise of inducement grant stock options approved by the Company.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Modification of Stock Options</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 two of the Company's directors' terms ended. At the conclusion of their term, the Compensation Committee passed a resolution to extend the expiration date of the departing directors vested stock options, and to immediately accelerate the vesting of one of the directors unvested options. The Company recorded incremental stock compensation expenses of$<ix:nonFraction unitRef="usd" contextRef="i3e1d4f2076ee4dce9307fbd38c110992_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMTk2OA_9490b704-550e-401f-b482-46a734713de9">0.6</ix:nonFraction>&#160;million during the nine months ended September 30, 2021, related to the modifications. </span></div></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><ix:continuation id="i50002ee7e49d49f6b00e756834a03473"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjYwNw_36475e94-2855-466a-8c3c-abdced58082c" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity is presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair Value<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cf797ce4852460992cc81f91f71ee21_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfMS0xLTEtMS02NjU1_09166e5c-4a01-4e35-a5e4-cf9f7c768712">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cf797ce4852460992cc81f91f71ee21_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfMS0zLTEtMS02NjU1_2fbb437c-475d-4e60-9724-cb97d23f77a7">147.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf797ce4852460992cc81f91f71ee21_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfMS01LTEtMS02NjU1_e690e53e-f6a7-44d0-b11f-75c673e3de19">8,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i419dd88bc1ef4b699ca582afa2243156_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfMy0xLTEtMS02NjU1_7c40c8b4-9010-43df-99a8-43d111810d52">491</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i419dd88bc1ef4b699ca582afa2243156_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfMy0zLTEtMS02NjU1_8845bf11-dd04-41e9-b396-48d29cf96038">147.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i967f68e7c70142858d962d262e96d5a5_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfNS0xLTEtMS02NjU1_42be364f-919c-42ff-8728-86e7dc2e727c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i967f68e7c70142858d962d262e96d5a5_I20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfNS0zLTEtMS02NjU1_a9ca079f-1342-483a-b890-4c75eb1651b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i967f68e7c70142858d962d262e96d5a5_I20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfNS01LTEtMS02NjU1_53e57d01-ebc6-47dc-ae62-2904f3d261f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of vested RSUs during the nine months ended September 30, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="i419dd88bc1ef4b699ca582afa2243156_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjE4Ng_6eb1dbf1-b536-4f1c-bba2-15460fcb7fd1">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i53d86dcdd30e4e97a88db626c3ce171f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjE5Mw_c299618f-239f-428b-b124-23508fa62384">0.1</ix:nonFraction> million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjYxNA_090baf66-53e8-4c2e-9f1f-83bded68a19b" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining&#160;Contractual<br/>Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfMS0xLTEtMS02NjU1_551f813b-9454-4f61-a550-afb91f36831d">5,260,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8176bd16da194dae836e30659930f9a9_I20201231" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfMS0zLTEtMS02NjU1_8e4b3fb3-2722-4062-8035-6e3b4720d2df">5.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9e7dd4c9b04a4f348fa618cc15a91b23_D20210101-20210630" format="ixt-sec:duryear" name="crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfMS01LTEtMS02NjU1_97186668-1239-4336-901c-cbba1048e4b0">4.1</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="crdf:ClassOfWarrantOrRightNumberExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfMy0xLTEtMS02NjU1_0ed50ccb-5858-4ef2-b9cf-ce4252403ce5">770,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfMy0zLTEtMS02NjU1_f9b9fce3-79dd-43f4-ba8a-eb0783f14a18">1.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfNS0xLTEtMS02NjU1_4061a1f5-09a9-46aa-9cf2-d6a867437551">4,490,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfNS0zLTEtMS02NjU1_c5c8e9ab-cb2a-4927-9ab3-f0b88e9c1baa">5.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" format="ixt-sec:duryear" name="crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfNS01LTEtMS02NjU1_26bbacb0-f621-46b7-a847-8709a3f64b3a">3.2</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjYwOQ_9a0a5c64-dbfb-4a8d-ab39-d11d2074b8dd" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation preference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7086b0baa05e4031aa8f4f411b551b42_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMi0yLTEtMS02NjU1_0a7a64df-59b1-4922-9c8e-044e89ed4712">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7086b0baa05e4031aa8f4f411b551b42_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMi00LTEtMS02NjU1_563b4e8e-3599-4b84-9839-88f0db64e3ed">277,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7086b0baa05e4031aa8f4f411b551b42_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMi02LTEtMS02NjU1_b06714e9-daa5-4141-8de9-2b29857a13fa">606,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7086b0baa05e4031aa8f4f411b551b42_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMi04LTEtMS02NjU1_1b550391-d44d-4009-a8cf-19610c06366f">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id64a71bd7b9f42509949a24fc02bdde8_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMi0xMC0xLTEtNjY1NQ_060fee95-da05-461f-9f9f-9bbc39011291">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id69610f358d94455a4cc69212cec3ba1_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMy0yLTEtMS02NjU1_9f2ef9df-c264-48fe-abe4-c0736ade02de">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id69610f358d94455a4cc69212cec3ba1_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMy00LTEtMS02NjU1_e707cf15-5462-48f4-bbca-326acaf0e73e">8,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id69610f358d94455a4cc69212cec3ba1_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMy04LTEtMS02NjU1_2b6591bc-9f4d-4f06-b98d-d6e2ea0deb16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8110c72e246c4d70b73aed2bc0bde2d2_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMy0xMC0xLTEtNjY1NQ_7c94dba8-48fb-4862-b7dc-7adedaab5491">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7451a3efe7274af285d44ebc3dd77d40_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNC0yLTEtMS02NjU1_993a26c0-17a9-4225-92e0-6c906c94a946">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7451a3efe7274af285d44ebc3dd77d40_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNC00LTEtMS02NjU1_8f325748-95be-487c-bdeb-919324249e53">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7451a3efe7274af285d44ebc3dd77d40_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNC04LTEtMS02NjU1_8d6daaa2-c9d7-4413-9d4a-d0f99454e9d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9eff0db6959b461584bc397787961a0d_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNC0xMC0xLTEtNjY1NQ_81cce1be-b840-446a-b140-5e266bc730a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e88f2da585d4200bcee660bbd23922a_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNS0yLTEtMS02NjU1_492eaa64-6f44-4c3b-a2c6-3d8a46b72118">0.0001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e88f2da585d4200bcee660bbd23922a_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNS00LTEtMS02NjU1_796e7488-45fc-4926-8337-63e19f15ea00">154,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e88f2da585d4200bcee660bbd23922a_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNS04LTEtMS02NjU1_ff8c1ad8-88ee-4aa2-89db-11edd91ec478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38a9fc7a1cf3406fa656608bfd2022aa_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNS0xMC0xLTEtNjY1NQ_96badb5f-2c0d-462c-83fb-f1a1674413d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i90efb04788c94a62b210da8a40d1537a_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNi0yLTEtMS02NjU1_c945c500-fe34-4cc1-ab53-2d98deb11c86">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90efb04788c94a62b210da8a40d1537a_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNi00LTEtMS02NjU1_bb2b501c-96ea-4ad7-9983-62ae53b9efc2">865,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90efb04788c94a62b210da8a40d1537a_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNi04LTEtMS02NjU1_8100e4d8-1ba6-4ccc-862a-2adb6f9699e4">655,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9421b674007949588bce3135aff1f1ee_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNi0xMC0xLTEtNjY1NQ_841c7fd5-21e4-4513-89da-5cf87a72ef62">655,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82MS9mcmFnOjg3NjA4NzhiYjQ5ODRhMDNhZGFmZmM4MjUyZGY5MDNiL3RleHRyZWdpb246ODc2MDg3OGJiNDk4NGEwM2FkYWZmYzgyNTJkZjkwM2JfMjE3Mw_f0092232-1933-4c05-8924-2e9ff22e0892" continuedAt="i1f9ba0849b614fc7864bdb35e13929a8" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i1f9ba0849b614fc7864bdb35e13929a8" continuedAt="ie8aa897e8f9e4fc2b7904280a9be875b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><ix:continuation id="ie8aa897e8f9e4fc2b7904280a9be875b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development and Clinical Trial Agreements</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib. Onvansertib, an investigational drug, is an oral, and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK1. The Company is developing onvansertib in cancer indications with the greatest medical need for new treatment options. The Company was committed to order $<ix:nonFraction unitRef="usd" contextRef="i6585aa9e614148a98914993084f4d834_I20170331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82MS9mcmFnOjg3NjA4NzhiYjQ5ODRhMDNhZGFmZmM4MjUyZGY5MDNiL3RleHRyZWdpb246ODc2MDg3OGJiNDk4NGEwM2FkYWZmYzgyNTJkZjkwM2JfNzY5_6f249ae2-85b9-49a3-9699-4ac8d70ab6f8">1.0</ix:nonFraction> million of future services provided by Nerviano, such as the cost to manufacture drug product, no later than June 30, 2019, and these services have been purchased. Terms of the agreement also provide for the Company to pay development milestones and royalties based on sales volume.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is a party of various agreements under which it licenses technology on an exclusive basis in the field of oncology therapeutics. These agreements include License fees, Royalties and Milestone payments. The company also has a legacy license agreement in the field of oncology diagnostics under which royalty payments are due. These royalty payments are calculated as a percent of revenue. For the three and nine months ended September&#160;30, 2021 and 2020, payments have not been material.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company&#8217;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#8217;s business or financial condition.</span></div></ix:continuation><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMTM1OQ_eb627edf-5b3c-4aa8-8c0c-583f92f4262c" continuedAt="ib814ea7b144447f69f4b991e92552cad" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib814ea7b144447f69f4b991e92552cad" continuedAt="i969dcee6b2064d96afce082a1ae3f2d6"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gary Pace Securities Purchase Agreement</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company entered into a Securities Purchase Agreement with Gary W. Pace, one of the Company's directors. Dr. Pace purchased <ix:nonFraction unitRef="shares" contextRef="ide58ed83af2b4d2ebaccb755576f716c_D20200501-20200531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMjE3_8f83b1ed-9818-4745-8380-a0cab34c3836">447,761</ix:nonFraction> shares of the Company's common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="i18a95e66b28b495995cc5b43de061428_I20200531" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMjYw_69b7baa1-4063-4413-a95e-9b1843446fdd">1.34</ix:nonFraction> per share for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ide58ed83af2b4d2ebaccb755576f716c_D20200501-20200531" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMzA4_11bfc7e1-8440-4661-82ad-6bac11403f8c">600,000</ix:nonFraction>.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leucadia Life Sciences</span></div></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i969dcee6b2064d96afce082a1ae3f2d6">In November 2018, the Company entered into a Material Transfer Agreement (&#8220;MTA&#8221;) with Leucadia Life Sciences (&#8220;Leucadia&#8221;) pursuant to which Leucadia developed a PCR-based assay for onvansertib for Acute Myeloid Leukemia (&#8220;AML&#8221;). This assay was completed in December 2020. During the duration of the agreement, one of the Company's directors Dr. Thomas Adams (who is no longer a director as of June 2021), was a principal stockholder of Leucadia. In connection with the MTA, the Company entered into a consulting agreement with Tommy Adams, Co-Founder &amp; Chief Operating Officer of Leucadia, who is the son of Dr. Adams. During the three months ended September&#160;30, 2021 and 2020 the Company incurred and recorded research and development expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i23b7b762231f4268ada27fef1b3fbde1_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMTA4MQ_a33cb0e7-2f94-4457-b11e-3b96855707c4">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8d5c6bcbeb3143e6819f6adceffa7b49_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMTA4OA_b50734de-846c-4b6f-b2ca-73a09baeeeb2">0.3</ix:nonFraction> million, respectively, for services performed by Leucadia and Tommy Adams. During the nine months ended September&#160;30, 2021 and 2020 the Company incurred and recorded research and development expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i7613ce60f5ae411799a4b34ca529c402_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMTI4MQ_7e30684d-ee2b-4220-9b30-bd44e5201a2e">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i16cbd98a78db40d8a92555d8d4608ec6_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMTI4OA_d506c801-e9c4-4f4a-9ea3-1bc3b3dc893e">0.8</ix:nonFraction>&#160;million, respectively, for services performed by Leucadia and Tommy Adams.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930" name="us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82Ny9mcmFnOjY1YThiNDA0YmZiNzRhOTI5MGZjM2M5MjVjNWZlOTJiL3RleHRyZWdpb246NjVhOGI0MDRiZmI3NGE5MjkwZmMzYzkyNWM1ZmU5MmJfMTc1Mg_0372f6b5-9422-4f6a-9804-86ade9a27073" continuedAt="i3d472168470c4395ba80831eeba543df" escape="true">COVID-19</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3d472168470c4395ba80831eeba543df"> The COVID-19 outbreak in the United States has caused significant business disruption. Thus far COVID-19 has not caused material disruptions to the Company's operational and financial performance. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance the development of its drugs and raise additional capital.</ix:continuation></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form&#160;10-Q includes forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).&#160;All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.&#160;These forward-looking statements are subject to a number of risks, uncertainties and assumptions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business and financial performance may be affected by the factors that are discussed under &#8220;Risk Factors&#8221; in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020, filed on February&#160;25, 2021.&#160;Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events.&#160;We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur.&#160;Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis is qualified in its entirety by, and should be read in conjunction with, the more detailed information set forth in the financial statements and the notes thereto appearing elsewhere in this Quarterly Report on Form&#160;10-Q. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future.&#160;Such discussion represents only the best present assessment of our management.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations that overcome disease resistance and improve disease response to standard treatment regimens and to increase overall survival. We are developing onvansertib, an oral highly-selective Polo-like Kinase 1 ("PLK1") inhibitor, in combination with standard-of-care anti-cancer therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to refine assessment of patient response to treatment.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We licensed onvansertib from Nerviano Medical Sciences ("NMS") pursuant to a license agreement with NMS dated March 13, 2017. This exclusive, world-wide license agreement includes 3 issued patents for onvansertib which cover composition of matter, salt forms of onvansertib and combination of onvansertib with other drugs. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Onvansertib is a novel PLK1 selective adenosine triphosphate ("ATP") competitive inhibitor with oral bioavailability, and a relatively short drug half-life of 24 hours. Onvansertib is highly potent against the PLK1 enzyme (concentration for 50% inhibition [IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">]=5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#177;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3 nM), whereas low or no activity was observed on a panel of 63 kinases (IC50&gt;500 nM), including the PLK members PLK2 and PLK3 (IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&gt;10 &#956;M). </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PLK1, a serine/threonine kinase, is a master regulator of mitotic progression with various roles and localizations during the different mitotic phases. Upon PLK1 depletion in cancer cells by RNA interference ("RNAi"), inhibition of proliferation, and decreased viability, resulting from cell cycle arrest with 4N DNA content followed by apoptosis, are observed. PLK1 depletion also results in an increase in the number of cells containing abnormal spindle formation and misaligned chromosomes. Expression of PLK1 is seen in all proliferating normal tissues, and PLK1 is overexpressed in a number of tumors (including colorectal, pancreatic, prostate, ovary, breast and lung cancer), as well as in hematologic cancers.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although 5 different PLK family members are described in humans, the inhibition of the enzymatic activity or the depletion of PLK1 is sufficient to induce a G2/M cell cycle block and apoptosis in tumor cell lines and tumor regression in xenograft models. In addition, a tumor suppressor function has been described for PLK2 and PLK3 (but not PLK1), and they are reported to be expressed in non-proliferating, differentiated postmitotic cells, such as neurons, indicating a potentially better safety profile for a PLK1-selective compound. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onvansertib is a highly selective inhibitor of PLK1. The fumarate salt of the compound was formulated for oral administration and is in clinical development for the treatment of a wide range of tumor types. There are 3 ongoing clinical studies of onvansertib in combination treatment: second line treatment in patients with KRAS-mutated metastatic colorectal cancer ("mCRC"), second line treatment in patients with metastatic pancreatic ductal adenocarcinoma ("mPDAC"), and in patients with metastatic castration-resistant prostate cancer ("mCRPC") showing resistance to abiraterone.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In vitro studies have shown synergistic effects when onvansertib was administered in combination with different cytotoxic agents including antimicrotubule agents, topoisomerase 1 inhibitors, antimetabolites, alkylating agents, proteasome inhibitors, kinase inhibitors, BCL-2 inhibitors, and androgen biosynthesis inhibitors.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in vivo combination studies have confirmed the positive results obtained in vitro and synergistic effects have been observed in xenograft models of onvansertib in combination with abiraterone, 5-fluorouracil (5 FU), irinotecan (including NKTR-102), quizartinib, venetoclax, and paclitaxel, while additive effects in combination with cytarabine or bevacizumab have been demonstrated.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the high-selectivity of onvansertib to PLK1, its 24-hour half-life, oral bioavailability, and flexible dosing schedule, as well as evidence of favorable safety and clinical benefit, with expected on-target, easy to manage and reversible side effects, may prove beneficial in addressing clinical therapeutic needs across a variety of cancers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Ongoing Clinical Programs Update:</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TROV-054 is a Phase 1b/2 open-label multi- center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab ("Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the second line treatment of patients with KRAS-mutated mCRC, which is being conducted at 7 clinical trial sites across the U.S. - USC Norris Comprehensive Cancer Center, The Mayo Clinic Cancer Centers (Arizona, Minnesota and Florida), Kansas University Medical Center, Inova Schar Cancer Institute and CARTI Cancer Center; </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CRDF-001 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan (&#8220;Onivyde</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), leucovorin, and fluorouracil for second line treatment of patients with mPDAC, which is being conducted at 6 clinical trial sites across the U.S. &#8211; The Mayo Clinic Cancer Centers (Arizona, Minnesota and Florida), Kansas University Medical Center, University of Nebraska Medical Center and Inova Schar Cancer Institute;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TROV-053 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with abiraterone acetate (Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and prednisone in patients with mCRPC, which is being conducted at 3 clinical trial sites - Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">KRAS-mutated mCRC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-054 is a Phase 1b/2 clinical trial of onvansertib for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer ("mCRC") in combination with standard-of-care FOLFIRI and bevacizumab (Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of this trial is to evaluate the dose-limiting toxicities ("DLTs") and maximum tolerated dose ("MTD") or recommended Phase 2 dose ("RP2D") of onvansertib in combination with FOLFIRI and bevacizumab (Phase 1b) and to continue to assess the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab (Phase 2).</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rationale for this clinical trial is based on three key principles including synthetic lethality, synergy and proof-of-concept clinical benefit. Synthetic lethality arises when a combination of deficiencies in the expression of two genes leads to cell death, whereas a deficiency in only one of these genes does not. The deficiencies can arise through mutations, epigenetic alterations or inhibitors of the protein encoded by one of the genes. In reference to onvansertib, CRC tumor cells harboring KRAS mutations are more vulnerable to cell death with PLK1 inhibition versus KRAS wild-type isogenic cells. Synergy occurs when the combination of two drugs results in an unexpected greater activity than an expected additive effect of the two drugs. Onvansertib in combination with irinotecan and in combination with 5-FU (components of FOLFIRI) demonstrate synergy in colorectal cancer cell lines and both combinations have demonstrated significantly greater tumor growth inhibition than either </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug alone.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proof-of-concept clinical response has been demonstrated in a previously completed Phase 1 trial in solid tumors in which 3 of 5 patients showing stable disease had tumors with a KRAS mutation; 2 in colorectal cancer and 1 in pancreatic cancer.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data presented on September 8, 2021, at a key opinion leader webinar, provided an update of the ongoing phase 1b/2 clinical trial in KRAS-mutated metastatic colorectal cancer. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">8 of 19 (42%) patients treated per protocol at the recommended Phase 2 dose ("RP2D") of onvansertib 15 mg/m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> who were evaluable for disease response as of the data cut-off achieved a partial response ("PR"). Historically, objective response rates ("ORR") of 5-13% have been reported in a similar patient population treated with standard of care chemotherapy;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">12 of 32 (38%) patients evaluable for response as of data cutoff date across all dose levels achieved a PR;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Median progression-free survival ("mPFS") across all response-evaluable patients is 9.4 months and has not yet been reached in those treated per protocol at the RP2D. Historically, mPFS of ~4.5-5.7 months has been reported in a similar patient population treated with standard of care chemotherapy;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The combination regimen of onvansertib plus FOLFIRI/bevacizumab is well tolerated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">mPDAC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRDF-001 is a Phase 2 clinical trial of onvansertib in combination with nanoliposomal irinotecan and 5-FU for the second line treatment of patients with metastatic pancreatic ductal adenocarcinoma ("mPDAC").  The first patient was dosed in June 2021. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of this trial is to assess the safety and preliminary efficacy of onvansertib in combination with nanoliposomal irinotecan (Onyvide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), 5-FU and leucovorin as a second-line treatment in patients with mPDAC who have failed first-line gemcitabine-based therapy. The trial is expected to enroll approximately 45 patients across six sites in the U.S. including the three Mayo Clinic Cancer Centers (Arizona, Minnesota and Florida), Kansas University Medical Center, University of Nebraska Medical Center and Inova Schar Cancer Institute.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">mCRPC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-053 is a Phase 2 clinical trial of onvansertib in combination with Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (abiraterone) and prednisone for the treatment of patients with metastatic castration resistant prostate cancer ("mCRPC").</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of this trial is to observe the effects of onvansertib in combination with abiraterone and prednisone on disease control as assessed by prostate specific antigen ("PSA") decline or stabilization after 12 weeks of treatment in patients with mCRPC showing early signs of resistance to abiraterone.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rationale for this trial is based on the mechanism of action ("MOA") of onvansertib and Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the synergy of these two drugs when used in combination in pre-clinical experiments. Onvansertib inhibits tumor cell division (mitosis) by inducing G2/M arrest of tumor cells and the combination of onvansertib and Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> significantly increases mitotic arrest and is synergistic when used in combination.  Additionally, PLK1 inhibition appears to enhance the efficacy of androgen signaling blockade in castration-resistant prostate cancer.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data as of July 2, 2021, as follow-up to the data presented on February 11, 2021, at the American Society of Clinical Oncology Genitourinary Cancers Symposium (&#8220;ASCO-GU&#8221;) provided evidence of the safety and efficacy of onvansertib in combination with abiraterone. Arms A (n=17) and B (n=20) and C (13) showed 29%, 40% and 54% of patients, respectively, achieving the primary endpoint of disease control at 12 weeks. The more continuous dosing schedule of Arm C has shown an increase in the rate of patients achieving disease stabilization, to-date. Evidence of efficacy was observed in patients harboring AR alterations across all 3 arms. ctDNA analysis revealed differences in baseline genomic profiles of patients achieving SD at 12 weeks vs. patients progressing before or at 12 weeks. Mutations exclusively present in patients with SD were associated with cell cycle and DNA repair pathways that may result in increased sensitivity to onvansertib and efficacy of the combination. Onvansertib plus abiraterone has demonstrated safety across all 3 dosing schedules.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Company Updates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Company</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 12, 2021, we announced the appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer. We entered into an employment agreement with Mr. Levine on July 12, 2021 and with Dr. Ruffner on August 4, 2021. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accumulated deficit through September&#160;30, 2021 is $250.4 million.&#160;To date, we have generated minimal revenues and expect to incur additional losses to perform further research and development activities.&#160;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug development efforts are in their early stages, and we cannot make estimates of the costs or the time that our development efforts will take to complete, or the timing and amount of revenues related to the sale of our drugs.&#160;The risk of completion of any program is high because of the many uncertainties involved in developing new drug candidates to market, including the long duration of clinical testing, the specific performance of proposed products under stringent clinical trial protocols, extended regulatory approval and review cycles, our ability to raise additional capital, the nature and timing of research and development expenses, and competing technologies being developed by organizations with significantly greater resources.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no off-balance sheet arrangements as of September&#160;30, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting policies are described in ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS of our Annual Report on Form&#160;10-K as of and for the year ended December&#160;31, 2020, filed with the SEC on February&#160;25, 2021.&#160;There have been no changes to our critical accounting policies since December&#160;31, 2020.</span></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2021 and 2020 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues were $86,000 for the three months ended September 30, 2021 as compared to $136,000 for the prior period. Revenues are from our sales-based or usage-based royalties on other intellectual property licenses, unrelated to onvansertib. Revenue recognition of the royalty depends on the timing and overall sales activities of the licensees. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials, outside services, and lab supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,855&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $1.3 million for the three months ended September 30, 2021 compared to the same period in 2020.&#160;The overall increase in research and development expenses was primarily due to costs associated with clinical programs and outside service costs for three ongoing clinical trials related to the development of our lead drug candidate, onvansertib. Facilities costs increased due to amending our operating lease. Salaries and staff costs increased primarily due to increased headcount in the current period. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside services and professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $1.3 million for the three months ended September 30, 2021 compared to the same period in 2020.&#160;The significant components of the increase were outside services and stock-based compensation. The increase in stock-based compensation is primarily due to new stock option grants issued to employees and directors. The increase in outside services and professional fees is primarily due to increased investor relations fees, recruiting fees, and legal fees related to the expansion of our patent portfolio.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Derivative Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued warrants that are accounted for as derivative liabilities.&#160;As of September&#160;30, 2021, the derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liabilities were revalued to $5,000, resulting in an increase in value of $12,000 from June&#160;30, 2021, based primarily upon the fluctuation in our stock price as well as the decrease in the remaining life of the warrants.&#160;The decrease in value upon remeasurement at September&#160;30, 2021 was recorded as a gain from the change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants in the condensed statement of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss and per share amounts were as follows:</span></div><div style="text-indent:33.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,913)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,497)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common&#160;shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,919)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,503)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increase in net loss attributable to common shareholders was primarily the result of an increase of operating expenses for the three months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> September&#160;30, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to the same period in the prior year. The $0.02 decrease in net loss per share was impacted by the increase in basic weighted average shares outstanding resulting primarily from the issuance of approximately 13.3 million shares of common stock and common stock equivalents from October 1, 2020 through September&#160;30, 2021. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2021 and 2020 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues were $226,000 for the nine months ended September 30, 2021 as compared to $247,000 for the prior period. Revenues are from our sales-based or usage-based royalties on other intellectual property licenses, unrelated to onvansertib. Revenue recognition of the royalty depends on the timing and overall sales activities of the licensees. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials, outside services, and lab supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $3.5 million for the nine months ended September 30, 2021 compared to the same period in 2020.&#160;The overall increase in research and development expenses was primarily due to costs associated with clinical programs and outside service costs for three ongoing clinical trials related to the development of our lead drug candidate, onvansertib. Salaries and staff costs decreased primarily due to departmental changes of certain executives in the current period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside services and professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,203&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $3.2 million for the nine months ended September 30, 2021 compared to the same period in 2020.&#160;The significant components of the increase were outside services and stock-based compensation. The increase in stock-based compensation is primarily due to additional stock option grants to employees and directors during the period and the modification of stock option grants for departing directors in June 2021. The increase in outside services and professional fees is primarily due to increased legal fees related to the expansion of our patent portfolio. Outside services also increased from recruiting fees and board of directors fees. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Derivative Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued warrants that are accounted for as derivative liabilities.&#160;As of September&#160;30, 2021, the derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liabilities were revalued to $5,000, resulting in a decrease in value of $280,000 from December&#160;31, 2020, based primarily upon the fluctuation in our stock price, as well as the decrease in the remaining life of the warrants.&#160;The change in value upon remeasurement at September&#160;30, 2021 was recorded as a gain from the change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants in the condensed statement of operations.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss and per share amounts were as follows:</span></div><div style="text-indent:33.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,849)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,710)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common&#160;shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,867)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,995)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.00)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $2.9 million increase</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in net loss attributable to common shareholders was primarily the result of an increase in operating expenses, offset by a decrease in preferred stock dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the nine months ended September 30, 2021 compared to the same period in the prior year. The $0.51 decrease in basic net loss per share was impacted by the increase in weighted average shares outstanding resulting primarily from the issuance of approximately 13.3 million shares of common stock from October 1, 2020 through September&#160;30, 2021. </span></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak in the United States has caused business disruptions. Thus far COVID-19 has not caused material disruptions to our operational and financial performance. The extent of the impact of COVID-19 on our future operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, and impact on our clinical trials, employees and vendors, all of which are uncertain and cannot be predicted. The economic effects of the outbreak could also have an adverse effect on our ability to raise additional capital. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the nine months ended September 30, 2021 was $15.7 million, compared to $11.2 million for the nine months ended September&#160;30, 2020.&#160;Our use of cash was primarily a result of the net loss of $18.8 million for the nine months ended September 30, 2021, adjusted for non-cash items related to stock-based compensation of $2.2 million, release of clinical trial funding commitment of $1.5 million, amortization of premiums on short-term investments $1.2 million, and depreciation of $0.3 million.&#160;The net change in our operating assets and liabilities was $1.8 million increasing cash used in operations.&#160;At our current and anticipated level of operating loss, we expect to continue to incur an operating cash outflow for the next several years.</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $122.7 million primarily related to net purchases of marketable securities during the nine months ended September 30, 2021, compared to $0.2 million investing activities for the same period in 2020. </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided in financing activities was $20.5 million during the nine months ended September 30, 2021, compared to $37.6 million for the same period in 2020. Net cash provided in financing activities during the nine months ended September 30, 2021&#160;was $19.2 million from the sale of common stock  and $1.3 million proceeds from the exercise of warrants. Net cash provided in financing activities during the nine months ended September 30, 2020 was from $19.0 million of proceeds from the exercise of warrants and $18.3 million from the sale of common stock, preferred stock and warrants.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, and December&#160;31, 2020, we had working capital of $132.7 million and $127.2 million, respectively.&#160;</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception and have negative operating cash flows. As of September&#160;30, 2021, we had $134.0 million in cash, cash equivalents and short-term investments and we believe we have sufficient cash to meet our funding requirements for at least the next 12 months following the issuance date of this Quarterly Report on Form 10-Q. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, we expect to continue to incur losses and require additional capital to further advance our clinical trial programs and support our other operations. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we can raise additional funds by issuing equity securities, our stockholders may experience additional dilution. The economic effects of COVID-19 could also have an adverse effect on our ability to raise additional capital. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have performed an evaluation under the supervision and with the participation of our management, including our principal executive officer (CEO) and principal financial officer (CFO), of the effectiveness of our disclosure controls and procedures, as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).&#160;Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of September&#160;30, 2021 to provide reasonable assurance that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures will prevent or detect all errors and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company have been detected.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control&#160;over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting during the three months ended September&#160;30, 2021 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II.&#160; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes from the risk factors disclosed in our Form&#160;10-K for the year ended December&#160;31, 2020.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_121"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description&#160;of&#160;Exhibit</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-093021exhibit311.htm">Certification of Principal Executive Officer required by Rule&#160;13a-14(a)/15d-14(a)&#160;under the Exchange Act.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-093021exhibit312.htm">Certification of Principal Financial Officer required by Rule&#160;13a-14(a)/15d-14(a)&#160;under the Exchange Act.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-093021exhibit321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-093021exhibit322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - the cover page from the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 is formatted in Inline XBRL</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i3eee0da1123f4c6a852a858aeb9c6ca6_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i3eee0da1123f4c6a852a858aeb9c6ca6_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Levine</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>crdf-093021exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i786a0810efd44eec890dfc34887b13ac_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark Erlander, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form&#160;10-Q of Cardiff Oncology,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>crdf-093021exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if7ea9c0a72ea408f98c7a5578d2685a5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Levine, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form&#160;10-Q of Cardiff Oncology,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>crdf-093021exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iedeacd4657c94d70a377ccad789a5ca3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Cardiff Oncology,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the three months ended September&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, Mark Erlander, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>crdf-093021exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5b3b35834b4f4faca01fd1645d7f1b27_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Cardiff Oncology,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the three months ended September&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, James Levine, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>crdf-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9c181793-10cf-46b3-9b0e-d8b69a1f5f61,g:a6a36519-15ad-476d-ae18-99a2aa63eb87-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:crdf="http://www.cardiffoncology.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardiffoncology.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cardiffoncology.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETSParenthetical" roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1004005 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1006007 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1007008 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical">
        <link:definition>1008009 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurements">
        <link:definition>2107103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsTables">
        <link:definition>2308302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails">
        <link:definition>2409403 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformation" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation">
        <link:definition>2110104 - Disclosure - Supplementary Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationTables" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables">
        <link:definition>2311303 - Disclosure - Supplementary Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails">
        <link:definition>2412404 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails">
        <link:definition>2413405 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cardiffoncology.com/role/Leases">
        <link:definition>2114105 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cardiffoncology.com/role/LeasesTables">
        <link:definition>2315304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cardiffoncology.com/role/LeasesNarrativeDetails">
        <link:definition>2416406 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2417407 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>2418408 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>2419409 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>2420410 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2420410 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsWarrants" roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants">
        <link:definition>2121106 - Disclosure - Derivative Financial Instruments - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsWarrantsTables" roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables">
        <link:definition>2322305 - Disclosure - Derivative Financial Instruments - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsWarrantsDetails" roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails">
        <link:definition>2423411 - Disclosure - Derivative Financial Instruments - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.cardiffoncology.com/role/StockholdersEquity">
        <link:definition>2124107 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityTables">
        <link:definition>2325306 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockbasedCompensationExpenseDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails">
        <link:definition>2426412 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionActivityDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails">
        <link:definition>2427413 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockUnitsDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails">
        <link:definition>2428414 - Disclosure - Stockholders' Equity - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityWarrantsDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails">
        <link:definition>2429415 - Disclosure - Stockholders' Equity - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityPreferredStockDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails">
        <link:definition>2430416 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingencies">
        <link:definition>2131108 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2432417 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.cardiffoncology.com/role/RelatedPartyTransactions">
        <link:definition>2133109 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2434418 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COVID19" roleURI="http://www.cardiffoncology.com/role/COVID19">
        <link:definition>2135110 - Disclosure - COVID-19</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="crdf_PreferredStockDividendAccrued" abstract="false" name="PreferredStockDividendAccrued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ServiceReceivableMember" abstract="true" name="ServiceReceivableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_InducementGrantStockOptionsMember" abstract="true" name="InducementGrantStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_BlackScholesOptionPricingMethodMember" abstract="true" name="BlackScholesOptionPricingMethodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_SeriesDConvertiblePreferredStockMember" abstract="true" name="SeriesDConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_SaleOfStockValueCommonAndWarrantsNet" abstract="false" name="SaleOfStockValueCommonAndWarrantsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" abstract="false" name="LessorOperatingLeasePaymentToBeReceivedAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ReleaseOfClinicalTrialFundingCommitment" abstract="false" name="ReleaseOfClinicalTrialFundingCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" abstract="false" name="ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_EquityIncentivePlan2021Member" abstract="true" name="EquityIncentivePlan2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_WarrantsAndRightsRollForward" abstract="true" name="WarrantsAndRightsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_NorvianoMember" abstract="true" name="NorvianoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_SaleOfStockCommonAndWarrantsNetShares" abstract="false" name="SaleOfStockCommonAndWarrantsNetShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_FurnitureAndOfficeEquipmentMember" abstract="true" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseMonthlyRentPayment" abstract="false" name="LesseeOperatingLeaseMonthlyRentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_DerivativeFinancialInstrumentsLiabilityRollForward" abstract="true" name="DerivativeFinancialInstrumentsLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_LessorNumberOfSubleases" abstract="false" name="LessorNumberOfSubleases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" abstract="false" name="LesseeOperatingLeaseAnnualRentIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="crdf_SeriesCConvertiblePreferredStockMember" abstract="true" name="SeriesCConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" abstract="false" name="ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany" abstract="false" name="LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="crdf_ServiceReceivable" abstract="false" name="ServiceReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" abstract="false" name="BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseAreaOfLease" abstract="false" name="LesseeOperatingLeaseAreaOfLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" abstract="false" name="Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SeriesBConvertiblePreferredStockMember" abstract="true" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" abstract="false" name="ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" abstract="false" name="CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_EstimatedFairValueOfWarrant" abstract="false" name="EstimatedFairValueOfWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="crdf_WarrantsFairValue" abstract="false" name="WarrantsFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" abstract="true" name="LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" abstract="false" name="DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="crdf_LessorAreaOfSublease" abstract="false" name="LessorAreaOfSublease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased" abstract="false" name="StockIssuedDuringPeriodRestrictedStockUnitsReleased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="crdf_SeriesAConvertiblePreferredStockMember" abstract="true" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightNumberExercised" abstract="false" name="ClassOfWarrantOrRightNumberExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" abstract="false" name="DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="crdf_SeriesEConvertiblePreferredStockMember" abstract="true" name="SeriesEConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_IncreaseDecreaseInOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>crdf-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9c181793-10cf-46b3-9b0e-d8b69a1f5f61,g:a6a36519-15ad-476d-ae18-99a2aa63eb87-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a67f2c52-7483-4eb7-a624-cf4e7c70a288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3a4e93ab-5564-41d2-8dc3-3b986a3fd245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a67f2c52-7483-4eb7-a624-cf4e7c70a288" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3a4e93ab-5564-41d2-8dc3-3b986a3fd245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_98c1b860-fbf2-43ce-aa6e-d25be792a49b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a67f2c52-7483-4eb7-a624-cf4e7c70a288" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_98c1b860-fbf2-43ce-aa6e-d25be792a49b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_71ff8ff9-7cee-4350-a12d-d6f7cc73a8f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a67f2c52-7483-4eb7-a624-cf4e7c70a288" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_71ff8ff9-7cee-4350-a12d-d6f7cc73a8f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f29a7488-0c48-45fd-a8b6-7e27228c1767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a67f2c52-7483-4eb7-a624-cf4e7c70a288" xlink:to="loc_us-gaap_ShortTermInvestments_f29a7488-0c48-45fd-a8b6-7e27228c1767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9cb260d-2b79-4141-8b88-20132449c14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e13fc663-7e67-4fae-b85f-3d11612a137d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9cb260d-2b79-4141-8b88-20132449c14f" xlink:to="loc_us-gaap_Liabilities_e13fc663-7e67-4fae-b85f-3d11612a137d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_67303a6e-4a7d-4449-a17f-1879f3c00d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9cb260d-2b79-4141-8b88-20132449c14f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_67303a6e-4a7d-4449-a17f-1879f3c00d66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fe24f909-6dca-4feb-8284-58c6208a2fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9cb260d-2b79-4141-8b88-20132449c14f" xlink:to="loc_us-gaap_StockholdersEquity_fe24f909-6dca-4feb-8284-58c6208a2fd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8034e723-8a2c-4027-b4ae-b2df31b4f1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6bb0b632-73c2-47e1-85bd-57fd03661bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8034e723-8a2c-4027-b4ae-b2df31b4f1c3" xlink:to="loc_us-gaap_PreferredStockValue_6bb0b632-73c2-47e1-85bd-57fd03661bd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_13898022-b992-4721-8a42-f761f029c9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8034e723-8a2c-4027-b4ae-b2df31b4f1c3" xlink:to="loc_us-gaap_CommonStockValue_13898022-b992-4721-8a42-f761f029c9ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6b264de9-2645-4ed2-ba3e-69faeff39350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8034e723-8a2c-4027-b4ae-b2df31b4f1c3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6b264de9-2645-4ed2-ba3e-69faeff39350" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivable_91cec450-b71b-403c-bb43-575d7c202d47" xlink:href="crdf-20210930.xsd#crdf_ServiceReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8034e723-8a2c-4027-b4ae-b2df31b4f1c3" xlink:to="loc_crdf_ServiceReceivable_91cec450-b71b-403c-bb43-575d7c202d47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8bb107de-9d9a-4471-9797-0e85a665b1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8034e723-8a2c-4027-b4ae-b2df31b4f1c3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8bb107de-9d9a-4471-9797-0e85a665b1cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5e91718b-f3f7-4fbf-a86e-28bea88b1da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8034e723-8a2c-4027-b4ae-b2df31b4f1c3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5e91718b-f3f7-4fbf-a86e-28bea88b1da8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_091ea98e-36e6-4b53-9715-d3e5dbb7c45d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d3d011ba-52ae-4458-a310-d39fba1b2fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_091ea98e-36e6-4b53-9715-d3e5dbb7c45d" xlink:to="loc_us-gaap_AccountsPayableCurrent_d3d011ba-52ae-4458-a310-d39fba1b2fd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b96a7408-2358-4547-8d17-c6a2c89f8c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_091ea98e-36e6-4b53-9715-d3e5dbb7c45d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b96a7408-2358-4547-8d17-c6a2c89f8c5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6569cf90-42a1-4825-8239-e83cc9ff872d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_091ea98e-36e6-4b53-9715-d3e5dbb7c45d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6569cf90-42a1-4825-8239-e83cc9ff872d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ec36f61a-66c6-4417-90fa-9425562730ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_091ea98e-36e6-4b53-9715-d3e5dbb7c45d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ec36f61a-66c6-4417-90fa-9425562730ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7a4e137a-d3cd-47b5-a5f9-fb4f657cf196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_23d09c2c-60a9-4446-9af6-feb89a627900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7a4e137a-d3cd-47b5-a5f9-fb4f657cf196" xlink:to="loc_us-gaap_AssetsCurrent_23d09c2c-60a9-4446-9af6-feb89a627900" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_816c8b8a-37c2-46b0-bd84-d9adb82d935c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7a4e137a-d3cd-47b5-a5f9-fb4f657cf196" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_816c8b8a-37c2-46b0-bd84-d9adb82d935c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d2b24878-bf44-4d7b-8b11-516b0ff40d61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7a4e137a-d3cd-47b5-a5f9-fb4f657cf196" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d2b24878-bf44-4d7b-8b11-516b0ff40d61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_874dec64-d7a0-4425-8149-f7f0a940a70e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7a4e137a-d3cd-47b5-a5f9-fb4f657cf196" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_874dec64-d7a0-4425-8149-f7f0a940a70e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_70380321-fed8-4971-aa7a-772cd42f1789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2d31d5dd-1be0-4685-86ea-1d97b564cb7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_70380321-fed8-4971-aa7a-772cd42f1789" xlink:to="loc_us-gaap_LiabilitiesCurrent_2d31d5dd-1be0-4685-86ea-1d97b564cb7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_f9923026-15f5-4734-b90a-7bd7405c134d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_70380321-fed8-4971-aa7a-772cd42f1789" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_f9923026-15f5-4734-b90a-7bd7405c134d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_45c8bafc-0fd8-42ac-8e42-4168ef53075c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_70380321-fed8-4971-aa7a-772cd42f1789" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_45c8bafc-0fd8-42ac-8e42-4168ef53075c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c90562e8-dee1-4057-b26c-7d0fa4e88175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_70380321-fed8-4971-aa7a-772cd42f1789" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c90562e8-dee1-4057-b26c-7d0fa4e88175" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a82ff825-d016-491f-8664-4301b022f54d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_f24a582c-464c-4ca3-bf2c-db9a9be25d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a82ff825-d016-491f-8664-4301b022f54d" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_f24a582c-464c-4ca3-bf2c-db9a9be25d6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_8d242f36-d8a7-45e3-a8e7-4b61ef583b2d" xlink:href="crdf-20210930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a82ff825-d016-491f-8664-4301b022f54d" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_8d242f36-d8a7-45e3-a8e7-4b61ef583b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1ba0a7f8-798f-4945-94db-5f9296765c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a82ff825-d016-491f-8664-4301b022f54d" xlink:to="loc_us-gaap_NetIncomeLoss_1ba0a7f8-798f-4945-94db-5f9296765c5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f6bc7af3-e94e-4348-be39-24dd84ac5b72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_673e9e05-354f-4b82-b764-22e5a66d9169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f6bc7af3-e94e-4348-be39-24dd84ac5b72" xlink:to="loc_us-gaap_OperatingIncomeLoss_673e9e05-354f-4b82-b764-22e5a66d9169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_ce2af222-4742-42e7-b909-4bd42d3d5200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f6bc7af3-e94e-4348-be39-24dd84ac5b72" xlink:to="loc_us-gaap_InterestIncomeOperating_ce2af222-4742-42e7-b909-4bd42d3d5200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_e7dd6f7a-1381-4429-8a88-6f6ec5bcd55f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f6bc7af3-e94e-4348-be39-24dd84ac5b72" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_e7dd6f7a-1381-4429-8a88-6f6ec5bcd55f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6073726f-8c49-4134-85b3-a6d4d15642c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f6bc7af3-e94e-4348-be39-24dd84ac5b72" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6073726f-8c49-4134-85b3-a6d4d15642c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fb98da89-81ab-4ace-a927-7aceb09b4637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1bbe047b-d640-471b-ac7b-a8551d947c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_fb98da89-81ab-4ace-a927-7aceb09b4637" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1bbe047b-d640-471b-ac7b-a8551d947c47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6d6b5148-b8ec-49d9-ab88-4e055f5c526a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_14588c73-41ba-469d-b2df-24cd76b9b5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6d6b5148-b8ec-49d9-ab88-4e055f5c526a" xlink:to="loc_us-gaap_Revenues_14588c73-41ba-469d-b2df-24cd76b9b5b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5dd516d3-3264-4e3c-b086-5bfcf971be1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6d6b5148-b8ec-49d9-ab88-4e055f5c526a" xlink:to="loc_us-gaap_OperatingExpenses_5dd516d3-3264-4e3c-b086-5bfcf971be1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c577e214-a0ee-45f2-b589-99e2e3c89c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_a4cab5dc-b8e3-4ff7-8189-bc235c79711a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c577e214-a0ee-45f2-b589-99e2e3c89c3b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_a4cab5dc-b8e3-4ff7-8189-bc235c79711a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_23a68f92-253f-4c22-97aa-2fbbda555ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c577e214-a0ee-45f2-b589-99e2e3c89c3b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_23a68f92-253f-4c22-97aa-2fbbda555ed0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_36987fec-bdc0-4170-9da8-7adeb54b12a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ace754b2-309f-4f1f-b92c-28b9ce182356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_36987fec-bdc0-4170-9da8-7adeb54b12a3" xlink:to="loc_us-gaap_NetIncomeLoss_ace754b2-309f-4f1f-b92c-28b9ce182356" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9b5d4e7e-a301-4695-bcb5-8d1d89fdd750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_36987fec-bdc0-4170-9da8-7adeb54b12a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9b5d4e7e-a301-4695-bcb5-8d1d89fdd750" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_87d0fbb4-c927-41a4-ac03-dcb95c8d6d83" xlink:href="crdf-20210930.xsd#crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6fd0568e-aeff-4b91-a9ec-47336fab9575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_87d0fbb4-c927-41a4-ac03-dcb95c8d6d83" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6fd0568e-aeff-4b91-a9ec-47336fab9575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_f45b04b5-0512-4069-9c53-ff6b784e9db3" xlink:href="crdf-20210930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_87d0fbb4-c927-41a4-ac03-dcb95c8d6d83" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_f45b04b5-0512-4069-9c53-ff6b784e9db3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_4338eb57-41e2-4717-8d73-8ea96160a111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_87d0fbb4-c927-41a4-ac03-dcb95c8d6d83" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_4338eb57-41e2-4717-8d73-8ea96160a111" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_314ca7b3-aefe-4c55-8b88-444bf1599e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_us-gaap_NetIncomeLoss_314ca7b3-aefe-4c55-8b88-444bf1599e6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a6bd7b6c-73b4-4600-8d2c-b7c23f8abee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a6bd7b6c-73b4-4600-8d2c-b7c23f8abee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_21332051-4dcd-42fb-a8ad-a827a6291c70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_us-gaap_ShareBasedCompensation_21332051-4dcd-42fb-a8ad-a827a6291c70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_24ee942c-9fcc-47c0-b4f6-36130451459b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_24ee942c-9fcc-47c0-b4f6-36130451459b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_22f9bd3a-4868-4079-a417-41bce1938a4a" xlink:href="crdf-20210930.xsd#crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_22f9bd3a-4868-4079-a417-41bce1938a4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ab3855a7-468b-49a4-a273-e1c48e029477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ab3855a7-468b-49a4-a273-e1c48e029477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a5b8a4b0-3ae6-4f62-9163-c0871f3f25fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a5b8a4b0-3ae6-4f62-9163-c0871f3f25fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_6ec175a2-a8a4-45eb-aea3-9fb76fb5fc06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_6ec175a2-a8a4-45eb-aea3-9fb76fb5fc06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3d2ec321-5027-4519-b2fb-87304310bd26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3d2ec321-5027-4519-b2fb-87304310bd26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_9d961262-15ca-4409-8112-24f55cbe0358" xlink:href="crdf-20210930.xsd#crdf_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_9d961262-15ca-4409-8112-24f55cbe0358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_ac64e921-5983-44f4-b696-367ca1f33c40" xlink:href="crdf-20210930.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_ac64e921-5983-44f4-b696-367ca1f33c40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_59cc2d2a-3613-4626-8afd-24c05eb34ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_59cc2d2a-3613-4626-8afd-24c05eb34ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_85160765-409d-4732-bd52-3ca47dd0b16a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_85160765-409d-4732-bd52-3ca47dd0b16a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_02e777ae-2ae5-4890-b554-e0ccb1354c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_02e777ae-2ae5-4890-b554-e0ccb1354c2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_a38bfd6b-e430-4da0-acc7-6d76141ac748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36a3c86c-f44e-4414-9095-15559eb54263" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_a38bfd6b-e430-4da0-acc7-6d76141ac748" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ded953a1-0983-4068-8751-2725903bcd5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc47552d-98d6-42d6-877a-776604c456da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ded953a1-0983-4068-8751-2725903bcd5f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc47552d-98d6-42d6-877a-776604c456da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8d4497c6-f4e2-4fb5-9fc4-afde563ca060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ded953a1-0983-4068-8751-2725903bcd5f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8d4497c6-f4e2-4fb5-9fc4-afde563ca060" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_060e263f-ee56-41e2-8d9c-fae77a5f4f3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ded953a1-0983-4068-8751-2725903bcd5f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_060e263f-ee56-41e2-8d9c-fae77a5f4f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5713ff4-a7ad-4957-8ce7-5b0941cc3004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_4dddddfd-5be0-46cd-a122-695fb10f6b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5713ff4-a7ad-4957-8ce7-5b0941cc3004" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_4dddddfd-5be0-46cd-a122-695fb10f6b4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_cbddaed0-a2bc-4bde-b1de-32a00cfcf64a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5713ff4-a7ad-4957-8ce7-5b0941cc3004" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_cbddaed0-a2bc-4bde-b1de-32a00cfcf64a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ee0b3d31-4f57-4e4f-a208-9a9d00f2b440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5713ff4-a7ad-4957-8ce7-5b0941cc3004" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ee0b3d31-4f57-4e4f-a208-9a9d00f2b440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_00532504-2926-4801-9bbb-42b05294f922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5713ff4-a7ad-4957-8ce7-5b0941cc3004" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_00532504-2926-4801-9bbb-42b05294f922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5b2597cf-c68b-4145-a228-df1b06ba1462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5713ff4-a7ad-4957-8ce7-5b0941cc3004" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5b2597cf-c68b-4145-a228-df1b06ba1462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_96f92249-7e4e-4509-aa22-602e735ea22b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4e8ac8c1-c7f3-4e0d-87fa-4810495285fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_96f92249-7e4e-4509-aa22-602e735ea22b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4e8ac8c1-c7f3-4e0d-87fa-4810495285fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d3b4413d-ae21-4cf4-9155-a3c0d0e7f0a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_96f92249-7e4e-4509-aa22-602e735ea22b" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d3b4413d-ae21-4cf4-9155-a3c0d0e7f0a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0c41bb41-39f9-4a6f-a93e-992247b1aebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_96f92249-7e4e-4509-aa22-602e735ea22b" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0c41bb41-39f9-4a6f-a93e-992247b1aebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cfb245e2-09eb-4477-8bf2-1cbb5e2da056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_96f92249-7e4e-4509-aa22-602e735ea22b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cfb245e2-09eb-4477-8bf2-1cbb5e2da056" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_a51c963c-9b28-43c8-9fbf-009959177837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_081408a6-71b9-41fb-ad5a-c41d60be3b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_a51c963c-9b28-43c8-9fbf-009959177837" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_081408a6-71b9-41fb-ad5a-c41d60be3b67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b87b57ac-6fc8-4196-8405-882b8eb0d14b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8a13166c-85e0-4e56-9d7c-9b1b5d4d9a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b87b57ac-6fc8-4196-8405-882b8eb0d14b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8a13166c-85e0-4e56-9d7c-9b1b5d4d9a0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_42ba4856-4811-4d27-88ff-4260f548c872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b87b57ac-6fc8-4196-8405-882b8eb0d14b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_42ba4856-4811-4d27-88ff-4260f548c872" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9d669ef6-ef39-4521-b528-7cc5b1f7b77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f8cf5db0-f0f6-43e1-b63e-bec2ddcec502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9d669ef6-ef39-4521-b528-7cc5b1f7b77b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f8cf5db0-f0f6-43e1-b63e-bec2ddcec502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c603706e-10a2-4421-8dd8-b8e95ab4ce88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9d669ef6-ef39-4521-b528-7cc5b1f7b77b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c603706e-10a2-4421-8dd8-b8e95ab4ce88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9567d0a0-17e1-4532-965d-826784468bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9d669ef6-ef39-4521-b528-7cc5b1f7b77b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9567d0a0-17e1-4532-965d-826784468bb3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c012bb43-bec4-4343-9194-0a7589b23b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d8f679df-1321-413c-87e6-9c806a26bb72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c012bb43-bec4-4343-9194-0a7589b23b2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d8f679df-1321-413c-87e6-9c806a26bb72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a777847b-fba0-4ff5-b7f9-9f14dea33a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c012bb43-bec4-4343-9194-0a7589b23b2f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a777847b-fba0-4ff5-b7f9-9f14dea33a50" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_7615277b-357e-4d7e-8349-b9bca354864c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ce7a9585-c4cb-44b3-a583-77dd93abbd20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7615277b-357e-4d7e-8349-b9bca354864c" xlink:to="loc_us-gaap_OperatingLeaseCost_ce7a9585-c4cb-44b3-a583-77dd93abbd20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_926c00a0-b9d0-429f-8323-12ad554777f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7615277b-357e-4d7e-8349-b9bca354864c" xlink:to="loc_us-gaap_SubleaseIncome_926c00a0-b9d0-429f-8323-12ad554777f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_26f4ea92-772d-476a-9e1c-a9f9f119378e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_afde8683-d942-4ffa-919f-31229d4cdd45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_26f4ea92-772d-476a-9e1c-a9f9f119378e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_afde8683-d942-4ffa-919f-31229d4cdd45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35dffb4e-452a-434a-8a8c-8a00edd08b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_26f4ea92-772d-476a-9e1c-a9f9f119378e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35dffb4e-452a-434a-8a8c-8a00edd08b43" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_9bf74b08-5a67-4320-b99d-03a0750bc106" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3aea720f-72b0-41b4-886c-48d5418acc5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_9bf74b08-5a67-4320-b99d-03a0750bc106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3aea720f-72b0-41b4-886c-48d5418acc5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c9c282c9-0c4d-484f-b095-4380042f8ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_9bf74b08-5a67-4320-b99d-03a0750bc106" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c9c282c9-0c4d-484f-b095-4380042f8ca8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_07aab733-c41f-46f1-96b9-245bb4eee4cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_0125393c-c9a7-44d6-9985-b74aec9051e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_07aab733-c41f-46f1-96b9-245bb4eee4cc" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_0125393c-c9a7-44d6-9985-b74aec9051e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_3e5d3397-3474-45ab-b45b-a30e8bde8915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_07aab733-c41f-46f1-96b9-245bb4eee4cc" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_3e5d3397-3474-45ab-b45b-a30e8bde8915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_749dc3b7-5e2e-4398-a7a3-86843ead33f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_07aab733-c41f-46f1-96b9-245bb4eee4cc" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_749dc3b7-5e2e-4398-a7a3-86843ead33f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_96883e1b-1443-486a-8579-947976250fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_07aab733-c41f-46f1-96b9-245bb4eee4cc" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_96883e1b-1443-486a-8579-947976250fed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_f96270d4-3ee6-4d25-bdb0-79834bd685a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_07aab733-c41f-46f1-96b9-245bb4eee4cc" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_f96270d4-3ee6-4d25-bdb0-79834bd685a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_55b2990f-3891-411d-aab2-83136eb7cff7" xlink:href="crdf-20210930.xsd#crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_07aab733-c41f-46f1-96b9-245bb4eee4cc" xlink:to="loc_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_55b2990f-3891-411d-aab2-83136eb7cff7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_54272323-24b4-4b40-b083-c2effde65c98" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e030e7f2-f788-4a7e-8bbd-b39e66515ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_54272323-24b4-4b40-b083-c2effde65c98" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e030e7f2-f788-4a7e-8bbd-b39e66515ccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_3318a182-ce9f-465b-9103-d4a77c8e5aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_54272323-24b4-4b40-b083-c2effde65c98" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_3318a182-ce9f-465b-9103-d4a77c8e5aaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_ff13e33b-1236-43fb-8dbe-5bf92353ebaa" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_41118511-1bf3-4eed-8da3-8d0a69d2e8a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_ff13e33b-1236-43fb-8dbe-5bf92353ebaa" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_41118511-1bf3-4eed-8da3-8d0a69d2e8a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_852e529c-5c60-4613-9937-77eade6ad1f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_ff13e33b-1236-43fb-8dbe-5bf92353ebaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_852e529c-5c60-4613-9937-77eade6ad1f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour_b6cacc1d-a28c-4f65-83bc-137cdc525362" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_f3673a6b-f14a-4c35-9527-36fc668fb428" xlink:href="crdf-20210930.xsd#crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour_b6cacc1d-a28c-4f65-83bc-137cdc525362" xlink:to="loc_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_f3673a6b-f14a-4c35-9527-36fc668fb428" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_99c5cdad-fc9b-4a8f-af19-3c88b5fdfc6d" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour_b6cacc1d-a28c-4f65-83bc-137cdc525362" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_99c5cdad-fc9b-4a8f-af19-3c88b5fdfc6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_fca66d71-9690-4ae1-99b6-65d046af9847" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_784a47bb-7cca-4706-bbc8-06209eb94225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_fca66d71-9690-4ae1-99b6-65d046af9847" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_784a47bb-7cca-4706-bbc8-06209eb94225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_1ac3b76f-4842-4d94-913b-1890e6eb1456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_fca66d71-9690-4ae1-99b6-65d046af9847" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_1ac3b76f-4842-4d94-913b-1890e6eb1456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_d286fe6e-8124-47bc-88a2-f9ce5b64697d" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_803ba830-8956-4c2b-ae39-72b5ada4bbfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_d286fe6e-8124-47bc-88a2-f9ce5b64697d" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_803ba830-8956-4c2b-ae39-72b5ada4bbfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_eeacb0a8-d2ce-451a-ba97-550d01ae7aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_d286fe6e-8124-47bc-88a2-f9ce5b64697d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_eeacb0a8-d2ce-451a-ba97-550d01ae7aa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d8e7dffd-deed-4950-9908-65dccef2132d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_814bd11b-c62d-49ff-a8e9-966293588da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d8e7dffd-deed-4950-9908-65dccef2132d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_814bd11b-c62d-49ff-a8e9-966293588da7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6e35f60c-3573-452f-9bdf-153f1fd65faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d8e7dffd-deed-4950-9908-65dccef2132d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6e35f60c-3573-452f-9bdf-153f1fd65faa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d63ad52f-ed6a-46b3-815e-f0deb829fff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d8e7dffd-deed-4950-9908-65dccef2132d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d63ad52f-ed6a-46b3-815e-f0deb829fff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e51ff137-92b9-4ff9-9f74-e425a87ccc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d8e7dffd-deed-4950-9908-65dccef2132d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e51ff137-92b9-4ff9-9f74-e425a87ccc1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_33174f5a-cf9b-4c0f-b966-d9b5c4d0e5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d8e7dffd-deed-4950-9908-65dccef2132d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_33174f5a-cf9b-4c0f-b966-d9b5c4d0e5ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_2ee32a04-28f0-401c-9da9-d842af289520" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d8e7dffd-deed-4950-9908-65dccef2132d" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_2ee32a04-28f0-401c-9da9-d842af289520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour_9ff9bc1e-a6f1-4aa5-aa15-c4721a88a472" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d7900cdd-5e32-4874-a4b7-d091cd8bceb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour_9ff9bc1e-a6f1-4aa5-aa15-c4721a88a472" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d7900cdd-5e32-4874-a4b7-d091cd8bceb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_ed68d79d-4143-4ca9-9d6b-a37d45ea6ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour_9ff9bc1e-a6f1-4aa5-aa15-c4721a88a472" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_ed68d79d-4143-4ca9-9d6b-a37d45ea6ec1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="crdf-20210930.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4eb9952-c470-4197-a8da-1b41a2779af8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37d5d43b-35b8-42d3-8291-3470649c6d76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4eb9952-c470-4197-a8da-1b41a2779af8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37d5d43b-35b8-42d3-8291-3470649c6d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e41119be-c260-410c-8d8c-42ee0ba4b59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4eb9952-c470-4197-a8da-1b41a2779af8" xlink:to="loc_us-gaap_OperatingLeaseLiability_e41119be-c260-410c-8d8c-42ee0ba4b59d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_0afddeef-e92c-443f-91dc-a5be44705b89" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_7db005cb-7a57-432b-9044-c5256615517a" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_0afddeef-e92c-443f-91dc-a5be44705b89" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_7db005cb-7a57-432b-9044-c5256615517a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_229ef046-6622-4283-9d5a-9ba8c26ca4c4" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_0afddeef-e92c-443f-91dc-a5be44705b89" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_229ef046-6622-4283-9d5a-9ba8c26ca4c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_46f97ddc-f639-4069-a8ee-b2b1b79c840e" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_0afddeef-e92c-443f-91dc-a5be44705b89" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_46f97ddc-f639-4069-a8ee-b2b1b79c840e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_25954e55-3d9f-483f-a6a8-83e0f143ac44" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_0afddeef-e92c-443f-91dc-a5be44705b89" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_25954e55-3d9f-483f-a6a8-83e0f143ac44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour_a25765c6-0d3b-4b0c-8003-ab62a0ed84b1" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_0afddeef-e92c-443f-91dc-a5be44705b89" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour_a25765c6-0d3b-4b0c-8003-ab62a0ed84b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour_433426f3-927c-4620-b8a7-862f3a461329" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_0afddeef-e92c-443f-91dc-a5be44705b89" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour_433426f3-927c-4620-b8a7-862f3a461329" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>crdf-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9c181793-10cf-46b3-9b0e-d8b69a1f5f61,g:a6a36519-15ad-476d-ae18-99a2aa63eb87-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="idb53ea07f82944adba048a5ecbe3a1e8_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d7d68abd-05fe-4e5d-af5c-41741cdc6fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_RevenuesAbstract_d7d68abd-05fe-4e5d-af5c-41741cdc6fd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5849713-7ebb-4908-8d1f-744dd4c05937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_d7d68abd-05fe-4e5d-af5c-41741cdc6fd9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5849713-7ebb-4908-8d1f-744dd4c05937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f0ebe0aa-6d01-43ff-9c84-0b488b37b169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_d7d68abd-05fe-4e5d-af5c-41741cdc6fd9" xlink:to="loc_us-gaap_Revenues_f0ebe0aa-6d01-43ff-9c84-0b488b37b169" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c1c97e53-9224-4b04-8773-e58613db7f78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c1c97e53-9224-4b04-8773-e58613db7f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bf734c8f-5783-4adc-bf22-72cf582124b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c1c97e53-9224-4b04-8773-e58613db7f78" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bf734c8f-5783-4adc-bf22-72cf582124b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_062c57fb-f0c5-4a74-bd5b-1c54036a9672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c1c97e53-9224-4b04-8773-e58613db7f78" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_062c57fb-f0c5-4a74-bd5b-1c54036a9672" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b8cff493-525c-479a-9f5e-953904700141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c1c97e53-9224-4b04-8773-e58613db7f78" xlink:to="loc_us-gaap_OperatingExpenses_b8cff493-525c-479a-9f5e-953904700141" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b893454f-1eab-440b-aad1-0583fc4b211e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_OperatingIncomeLoss_b893454f-1eab-440b-aad1-0583fc4b211e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_d9b221cf-7b21-47de-9ee1-acbfc68e5592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_InterestIncomeOperating_d9b221cf-7b21-47de-9ee1-acbfc68e5592" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_3387dc1c-d49e-408a-8bc1-7845b61bafc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_3387dc1c-d49e-408a-8bc1-7845b61bafc2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2c654578-887f-48c7-9240-7ea50ea47f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2c654578-887f-48c7-9240-7ea50ea47f66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d94245fb-c5d3-49a4-8fb3-a084bc6e4f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_NetIncomeLoss_d94245fb-c5d3-49a4-8fb3-a084bc6e4f86" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_8c430395-606f-4252-8c0f-4bfb0f458fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_8c430395-606f-4252-8c0f-4bfb0f458fca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_0cae6232-e110-433e-9442-1ab558b9fa58" xlink:href="crdf-20210930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_0cae6232-e110-433e-9442-1ab558b9fa58" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f083e2b6-a017-4d38-bd9a-7836dadbc351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f083e2b6-a017-4d38-bd9a-7836dadbc351" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8fc9d2c3-59b3-41b5-b617-34e43182a21d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_EarningsPerShareBasic_8fc9d2c3-59b3-41b5-b617-34e43182a21d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3d6cb868-afe2-43a7-8e31-83d60c3b0185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3d6cb868-afe2-43a7-8e31-83d60c3b0185" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f173a8d-9765-47ad-a781-06e93f0a1b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f173a8d-9765-47ad-a781-06e93f0a1b46" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd9d367f-a563-4ff7-af9f-b881b1158edd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd9d367f-a563-4ff7-af9f-b881b1158edd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3082a786-76c4-49b4-b4a2-9dcece933db1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_StatementTable_3082a786-76c4-49b4-b4a2-9dcece933db1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cf6daa62-5498-4c68-a4f3-15097a38967f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3082a786-76c4-49b4-b4a2-9dcece933db1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cf6daa62-5498-4c68-a4f3-15097a38967f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cf6daa62-5498-4c68-a4f3-15097a38967f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cf6daa62-5498-4c68-a4f3-15097a38967f" xlink:to="loc_us-gaap_ClassOfStockDomain_cf6daa62-5498-4c68-a4f3-15097a38967f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b4611c80-c807-443a-b1b4-61ef54012a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cf6daa62-5498-4c68-a4f3-15097a38967f" xlink:to="loc_us-gaap_ClassOfStockDomain_b4611c80-c807-443a-b1b4-61ef54012a8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_abbd4f06-3331-4ac4-a062-0fbcf3e91a83" xlink:href="crdf-20210930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b4611c80-c807-443a-b1b4-61ef54012a8d" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_abbd4f06-3331-4ac4-a062-0fbcf3e91a83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_f818145e-646a-4ca0-afd3-98763d310ef6" xlink:href="crdf-20210930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b4611c80-c807-443a-b1b4-61ef54012a8d" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_f818145e-646a-4ca0-afd3-98763d310ef6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended" id="i39a4e0bd968145eebe05a458572ee32b_CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_18e911ae-624c-4ab8-bcef-9ff2a4d22961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:to="loc_us-gaap_NetIncomeLoss_18e911ae-624c-4ab8-bcef-9ff2a4d22961" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8013516f-7274-4869-89a4-5437c16dfc37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8013516f-7274-4869-89a4-5437c16dfc37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1d9fcc7f-f058-40ca-84d5-c6c5eff2cbac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8013516f-7274-4869-89a4-5437c16dfc37" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1d9fcc7f-f058-40ca-84d5-c6c5eff2cbac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b774e4de-f728-4702-a437-eb1dba0aadca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b774e4de-f728-4702-a437-eb1dba0aadca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_138ced82-8ae2-4911-bd95-d2d8e1e7028f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_138ced82-8ae2-4911-bd95-d2d8e1e7028f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_a906e65d-53f4-4b7b-93af-4847ddcae695" xlink:href="crdf-20210930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_a906e65d-53f4-4b7b-93af-4847ddcae695" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_dc126206-662e-4069-92f9-c78b4f01ec63" xlink:href="crdf-20210930.xsd#crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:to="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_dc126206-662e-4069-92f9-c78b4f01ec63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1e5e2e81-087b-4b72-b0af-c9c6a0a8686c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:to="loc_us-gaap_StatementTable_1e5e2e81-087b-4b72-b0af-c9c6a0a8686c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_469d8632-ba7c-468b-b100-978c09a78238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1e5e2e81-087b-4b72-b0af-c9c6a0a8686c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_469d8632-ba7c-468b-b100-978c09a78238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_469d8632-ba7c-468b-b100-978c09a78238_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_469d8632-ba7c-468b-b100-978c09a78238" xlink:to="loc_us-gaap_ClassOfStockDomain_469d8632-ba7c-468b-b100-978c09a78238_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7061e610-cdc3-48db-affc-84dde34dbfc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_469d8632-ba7c-468b-b100-978c09a78238" xlink:to="loc_us-gaap_ClassOfStockDomain_7061e610-cdc3-48db-affc-84dde34dbfc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_33623fbd-fa2c-4d23-b3f9-314df2f19108" xlink:href="crdf-20210930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7061e610-cdc3-48db-affc-84dde34dbfc8" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_33623fbd-fa2c-4d23-b3f9-314df2f19108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_0ffed6d6-fdd2-4f1d-affb-34d7fecc5c01" xlink:href="crdf-20210930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7061e610-cdc3-48db-affc-84dde34dbfc8" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_0ffed6d6-fdd2-4f1d-affb-34d7fecc5c01" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i21b10b4d3d194a28a8f90dde5b37e6fb_CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4325a44f-199a-4380-9f96-718cbfb76da9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4325a44f-199a-4380-9f96-718cbfb76da9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_dc3926f8-5e07-4a97-a68b-d5452c999ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_SharesIssued_dc3926f8-5e07-4a97-a68b-d5452c999ef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9dc1f497-794a-4755-8ee5-5e8ac3676335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockholdersEquity_9dc1f497-794a-4755-8ee5-5e8ac3676335" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_14a910c6-56c0-46e9-a31b-a09b8373dbd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_14a910c6-56c0-46e9-a31b-a09b8373dbd7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_aed76e8d-5bdf-47c7-8e7b-91f8cc96fd82" xlink:href="crdf-20210930.xsd#crdf_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_aed76e8d-5bdf-47c7-8e7b-91f8cc96fd82" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_4be5b247-8e27-46a3-99e3-b9041ef6b6a4" xlink:href="crdf-20210930.xsd#crdf_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_4be5b247-8e27-46a3-99e3-b9041ef6b6a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d47df68b-3f1f-4e4f-8fd6-f47f6e7724a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d47df68b-3f1f-4e4f-8fd6-f47f6e7724a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_651ac6d1-2c15-4625-90da-3bf290a382a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_DividendsPreferredStock_651ac6d1-2c15-4625-90da-3bf290a382a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_fab2910d-1208-4dfd-b158-6515050f5565" xlink:href="crdf-20210930.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_fab2910d-1208-4dfd-b158-6515050f5565" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5ebb832e-dba1-4780-811c-98cf1044a640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_NetIncomeLoss_5ebb832e-dba1-4780-811c-98cf1044a640" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5a1c381e-20eb-44fb-bbc7-135b956af3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5a1c381e-20eb-44fb-bbc7-135b956af3b7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_29d841dc-b8f9-4feb-8212-d9089f0a0183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_29d841dc-b8f9-4feb-8212-d9089f0a0183" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockCommonAndWarrantsNetShares_56298817-14f6-4d39-a41b-e05234b12c4b" xlink:href="crdf-20210930.xsd#crdf_SaleOfStockCommonAndWarrantsNetShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_crdf_SaleOfStockCommonAndWarrantsNetShares_56298817-14f6-4d39-a41b-e05234b12c4b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockValueCommonAndWarrantsNet_0da1b91e-97ec-464a-bb17-5f1442bf20fd" xlink:href="crdf-20210930.xsd#crdf_SaleOfStockValueCommonAndWarrantsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_crdf_SaleOfStockValueCommonAndWarrantsNet_0da1b91e-97ec-464a-bb17-5f1442bf20fd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased_a4c36d62-9dc1-4a7e-8760-138dd4d88f92" xlink:href="crdf-20210930.xsd#crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased_a4c36d62-9dc1-4a7e-8760-138dd4d88f92" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_b1ecd47d-fa1d-45a0-bcbb-48c95eebfb05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_b1ecd47d-fa1d-45a0-bcbb-48c95eebfb05" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_b90b082c-ecf8-4169-be2c-8375d0f7436b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_b90b082c-ecf8-4169-be2c-8375d0f7436b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_7c7f1169-525d-4253-b94b-dcbd89c2036a" xlink:href="crdf-20210930.xsd#crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_7c7f1169-525d-4253-b94b-dcbd89c2036a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1493410a-f856-4237-bf87-e8a1d024ce2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1493410a-f856-4237-bf87-e8a1d024ce2b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bd88d6e7-47eb-4e2f-b525-b972fb502159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bd88d6e7-47eb-4e2f-b525-b972fb502159" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fa470c69-327b-40af-94b0-17dfa6d29fcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fa470c69-327b-40af-94b0-17dfa6d29fcf" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b0fe9b3b-f0b6-4f4e-b325-f6dbb4b6a5a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b0fe9b3b-f0b6-4f4e-b325-f6dbb4b6a5a5" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9d0ce68b-bb12-4dde-86e6-81117fe986ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9d0ce68b-bb12-4dde-86e6-81117fe986ca" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_7875a081-0a9d-4080-9ffb-8088c4f622be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f5b17036-1790-478c-a23d-6693bed9dcb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c7a0feb1-728a-4c7d-8637-623735cc9d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4325a44f-199a-4380-9f96-718cbfb76da9" xlink:to="loc_us-gaap_StatementTable_c7a0feb1-728a-4c7d-8637-623735cc9d06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_377c8a6f-4c8a-4edc-9c37-a3f5609f810f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c7a0feb1-728a-4c7d-8637-623735cc9d06" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_377c8a6f-4c8a-4edc-9c37-a3f5609f810f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_377c8a6f-4c8a-4edc-9c37-a3f5609f810f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_377c8a6f-4c8a-4edc-9c37-a3f5609f810f" xlink:to="loc_us-gaap_EquityComponentDomain_377c8a6f-4c8a-4edc-9c37-a3f5609f810f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_377c8a6f-4c8a-4edc-9c37-a3f5609f810f" xlink:to="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_048b0bdf-522f-4710-8b74-cfdfae7bf5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:to="loc_us-gaap_PreferredStockMember_048b0bdf-522f-4710-8b74-cfdfae7bf5e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_144140e9-113f-43ac-8b88-c34b77bac8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:to="loc_us-gaap_CommonStockMember_144140e9-113f-43ac-8b88-c34b77bac8ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2b94d189-e03f-4d36-b907-4fe3cae2a8b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2b94d189-e03f-4d36-b907-4fe3cae2a8b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember_5065bece-ba90-49b0-9dc4-416537b985ab" xlink:href="crdf-20210930.xsd#crdf_ServiceReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:to="loc_crdf_ServiceReceivableMember_5065bece-ba90-49b0-9dc4-416537b985ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_93a29b72-5e42-4f6f-a6e7-76230e5d6d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_93a29b72-5e42-4f6f-a6e7-76230e5d6d79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cad5dca2-d565-443a-9518-c815b2035c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:to="loc_us-gaap_RetainedEarningsMember_cad5dca2-d565-443a-9518-c815b2035c74" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_863a5177-ee4b-44e5-bde1-5cef1296400b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c7a0feb1-728a-4c7d-8637-623735cc9d06" xlink:to="loc_us-gaap_StatementClassOfStockAxis_863a5177-ee4b-44e5-bde1-5cef1296400b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_863a5177-ee4b-44e5-bde1-5cef1296400b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_863a5177-ee4b-44e5-bde1-5cef1296400b" xlink:to="loc_us-gaap_ClassOfStockDomain_863a5177-ee4b-44e5-bde1-5cef1296400b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_da40e8f2-b65d-4246-9bcb-0548f2410d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_863a5177-ee4b-44e5-bde1-5cef1296400b" xlink:to="loc_us-gaap_ClassOfStockDomain_da40e8f2-b65d-4246-9bcb-0548f2410d24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_b03d59b1-c45c-46c6-ad83-7cdaf9ea5190" xlink:href="crdf-20210930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_da40e8f2-b65d-4246-9bcb-0548f2410d24" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_b03d59b1-c45c-46c6-ad83-7cdaf9ea5190" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_08164e66-e66f-4495-872a-b12c2dde4b9d" xlink:href="crdf-20210930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_da40e8f2-b65d-4246-9bcb-0548f2410d24" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_08164e66-e66f-4495-872a-b12c2dde4b9d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="iba1160ecf74943c588d0bcd9116bb13a_CONDENSEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_891b5b24-85ed-43a8-aba9-2733a53271a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_891b5b24-85ed-43a8-aba9-2733a53271a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ae3bc316-f462-41e9-b088-d18de58e830b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_891b5b24-85ed-43a8-aba9-2733a53271a2" xlink:to="loc_us-gaap_NetIncomeLoss_ae3bc316-f462-41e9-b088-d18de58e830b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_891b5b24-85ed-43a8-aba9-2733a53271a2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_d10f5dbb-7ee8-46a0-b0df-fd91865147f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_d10f5dbb-7ee8-46a0-b0df-fd91865147f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_c2842032-21dc-4fe9-938d-07b93a3c88cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_c2842032-21dc-4fe9-938d-07b93a3c88cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_72d6c74f-c239-4d62-aba7-e21d89de8ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_72d6c74f-c239-4d62-aba7-e21d89de8ebd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a0e3f1e0-cad8-4dd3-9d7d-537886252731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_us-gaap_ShareBasedCompensation_a0e3f1e0-cad8-4dd3-9d7d-537886252731" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b58886b7-776f-4573-989f-519c81521f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b58886b7-776f-4573-989f-519c81521f94" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_f941fbc9-a607-43f3-9915-55338a783797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_f941fbc9-a607-43f3-9915-55338a783797" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_33b5daf5-f7b3-428f-9be4-5dfcdcfe1817" xlink:href="crdf-20210930.xsd#crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_33b5daf5-f7b3-428f-9be4-5dfcdcfe1817" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2b8e0e66-9453-4ac3-b741-c0d82088c7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2b8e0e66-9453-4ac3-b741-c0d82088c7e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dc5af865-f37f-493f-8940-1dc869abbfd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dc5af865-f37f-493f-8940-1dc869abbfd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_86b68273-74b8-4ab6-b43c-df2eb8054a97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_86b68273-74b8-4ab6-b43c-df2eb8054a97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_25ca8536-e9e7-47b2-9900-67afe5184a31" xlink:href="crdf-20210930.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_25ca8536-e9e7-47b2-9900-67afe5184a31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ab57fc3d-2bb1-4a0d-960b-1933f3b7fbed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ab57fc3d-2bb1-4a0d-960b-1933f3b7fbed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_ee0e638f-908c-41af-b59d-bfe8f3be6a54" xlink:href="crdf-20210930.xsd#crdf_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_ee0e638f-908c-41af-b59d-bfe8f3be6a54" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_733ae1b2-bd8d-47c9-b060-a6122bc9d3a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_733ae1b2-bd8d-47c9-b060-a6122bc9d3a9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dfcc0722-7966-4f00-b985-ac7a96332572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_891b5b24-85ed-43a8-aba9-2733a53271a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dfcc0722-7966-4f00-b985-ac7a96332572" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd12d7b0-d954-4214-b870-7c1635bfea28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd12d7b0-d954-4214-b870-7c1635bfea28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b1a23290-812e-4fd7-a704-c1504fcd850b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd12d7b0-d954-4214-b870-7c1635bfea28" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b1a23290-812e-4fd7-a704-c1504fcd850b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9669b01e-4000-4560-be67-10bcd33f64fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd12d7b0-d954-4214-b870-7c1635bfea28" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9669b01e-4000-4560-be67-10bcd33f64fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1972fdfc-3af4-4a6d-84cb-a9f8aec0ade4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd12d7b0-d954-4214-b870-7c1635bfea28" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1972fdfc-3af4-4a6d-84cb-a9f8aec0ade4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ba65efd7-f7a8-4a87-8206-e0a339de2cac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd12d7b0-d954-4214-b870-7c1635bfea28" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ba65efd7-f7a8-4a87-8206-e0a339de2cac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0c4ee3b-1c38-453e-b044-89d581d7e82d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd12d7b0-d954-4214-b870-7c1635bfea28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0c4ee3b-1c38-453e-b044-89d581d7e82d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_61db33d2-3490-49d2-8615-edb60098e5c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_61db33d2-3490-49d2-8615-edb60098e5c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_760ad873-d207-4fc5-9c2b-bc48d0ed2846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_760ad873-d207-4fc5-9c2b-bc48d0ed2846" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4a9ea00d-9dba-4a07-8e07-25e516750a95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4a9ea00d-9dba-4a07-8e07-25e516750a95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_4d72f6cc-f3b7-4049-90be-8eee0abb9252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_4d72f6cc-f3b7-4049-90be-8eee0abb9252" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ad976e61-be77-46cf-a2aa-13450116bfe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ad976e61-be77-46cf-a2aa-13450116bfe8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc69154c-a664-4f35-90cd-2b7985f0a2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc69154c-a664-4f35-90cd-2b7985f0a2ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f35f0012-933a-451d-8ead-56af2049dc1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f35f0012-933a-451d-8ead-56af2049dc1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c81dfe76-9779-43be-a96a-3462673c3ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c81dfe76-9779-43be-a96a-3462673c3ab6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7b0066f0-af56-48d1-9618-588e2cb02a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_ca59cd8e-f484-4ec4-984d-217fc8652e22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_ca59cd8e-f484-4ec4-984d-217fc8652e22" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_6eb7c8fa-17bb-4929-af98-560de1ee51c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ca59cd8e-f484-4ec4-984d-217fc8652e22" xlink:to="loc_us-gaap_IncomeTaxesPaid_6eb7c8fa-17bb-4929-af98-560de1ee51c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b118ba9-1c45-4dfd-af91-84c5968f42be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b118ba9-1c45-4dfd-af91-84c5968f42be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockDividendAccrued_e429d2ae-30b8-465a-8a0d-60d0aee176aa" xlink:href="crdf-20210930.xsd#crdf_PreferredStockDividendAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b118ba9-1c45-4dfd-af91-84c5968f42be" xlink:to="loc_crdf_PreferredStockDividendAccrued_e429d2ae-30b8-465a-8a0d-60d0aee176aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_445fe606-417a-4b8f-9f55-9fa2e328a7a8" xlink:href="crdf-20210930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b118ba9-1c45-4dfd-af91-84c5968f42be" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_445fe606-417a-4b8f-9f55-9fa2e328a7a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_d823ee4f-8260-40fe-83a9-564467a36340" xlink:href="crdf-20210930.xsd#crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b118ba9-1c45-4dfd-af91-84c5968f42be" xlink:to="loc_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_d823ee4f-8260-40fe-83a9-564467a36340" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_48499dbb-2c2f-4ace-b5b0-168d7783477c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_StatementTable_48499dbb-2c2f-4ace-b5b0-168d7783477c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d95fe390-316b-470a-8b78-938fd37044a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_48499dbb-2c2f-4ace-b5b0-168d7783477c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d95fe390-316b-470a-8b78-938fd37044a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d95fe390-316b-470a-8b78-938fd37044a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d95fe390-316b-470a-8b78-938fd37044a6" xlink:to="loc_us-gaap_ClassOfStockDomain_d95fe390-316b-470a-8b78-938fd37044a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2a6032b6-3070-4a42-9b5c-729d3585b87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d95fe390-316b-470a-8b78-938fd37044a6" xlink:to="loc_us-gaap_ClassOfStockDomain_2a6032b6-3070-4a42-9b5c-729d3585b87c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_a5b1d621-39df-401e-ae1f-0b4d83e08857" xlink:href="crdf-20210930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2a6032b6-3070-4a42-9b5c-729d3585b87c" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_a5b1d621-39df-401e-ae1f-0b4d83e08857" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_cfcf85fe-1982-4b68-97cd-0d01e71f3426" xlink:href="crdf-20210930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2a6032b6-3070-4a42-9b5c-729d3585b87c" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_cfcf85fe-1982-4b68-97cd-0d01e71f3426" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="extended" id="i34e4820345d249ac98d2158aff323d9a_CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_be3431e6-d88d-472a-9fe3-f15fe1dfac50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_06b26d02-eb90-4397-9690-23ab12fee0a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_be3431e6-d88d-472a-9fe3-f15fe1dfac50" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_06b26d02-eb90-4397-9690-23ab12fee0a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment_35aab7ea-0d84-4cdd-ae55-79c3edfb47de" xlink:href="crdf-20210930.xsd#crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_be3431e6-d88d-472a-9fe3-f15fe1dfac50" xlink:to="loc_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment_35aab7ea-0d84-4cdd-ae55-79c3edfb47de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b016e8d5-a2d5-4d27-9543-4fee07cb9d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_be3431e6-d88d-472a-9fe3-f15fe1dfac50" xlink:to="loc_us-gaap_StatementTable_b016e8d5-a2d5-4d27-9543-4fee07cb9d6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_50e9f99e-0a98-46eb-824e-866f74f5807e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b016e8d5-a2d5-4d27-9543-4fee07cb9d6d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_50e9f99e-0a98-46eb-824e-866f74f5807e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_50e9f99e-0a98-46eb-824e-866f74f5807e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50e9f99e-0a98-46eb-824e-866f74f5807e" xlink:to="loc_us-gaap_ClassOfStockDomain_50e9f99e-0a98-46eb-824e-866f74f5807e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8eb71426-1b37-46db-854a-97c871023617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50e9f99e-0a98-46eb-824e-866f74f5807e" xlink:to="loc_us-gaap_ClassOfStockDomain_8eb71426-1b37-46db-854a-97c871023617" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_626cd332-c036-4e21-8a6e-5aa5abcda89c" xlink:href="crdf-20210930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8eb71426-1b37-46db-854a-97c871023617" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_626cd332-c036-4e21-8a6e-5aa5abcda89c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended" id="if302175a987c4c43b9b611978715fdad_SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_076f94e6-e6b3-43a9-8f7f-c9f423d37df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aeaab252-3256-426e-9a8b-1df0470dae6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_076f94e6-e6b3-43a9-8f7f-c9f423d37df3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aeaab252-3256-426e-9a8b-1df0470dae6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23a1a6e3-0cf1-4aae-8a82-28332179c3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_076f94e6-e6b3-43a9-8f7f-c9f423d37df3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23a1a6e3-0cf1-4aae-8a82-28332179c3ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_48458cff-3a46-47b1-91bc-33009fe0d69c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23a1a6e3-0cf1-4aae-8a82-28332179c3ae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_48458cff-3a46-47b1-91bc-33009fe0d69c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_48458cff-3a46-47b1-91bc-33009fe0d69c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_48458cff-3a46-47b1-91bc-33009fe0d69c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_48458cff-3a46-47b1-91bc-33009fe0d69c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_748b8cd4-6ff6-4643-8e6a-408e6151b086" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_48458cff-3a46-47b1-91bc-33009fe0d69c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_748b8cd4-6ff6-4643-8e6a-408e6151b086" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c9dd36d6-c325-462b-bf7a-ce26c5e5dc34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_748b8cd4-6ff6-4643-8e6a-408e6151b086" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c9dd36d6-c325-462b-bf7a-ce26c5e5dc34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_24948ab4-b484-4a9b-91a8-f1e357caba35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_748b8cd4-6ff6-4643-8e6a-408e6151b086" xlink:to="loc_us-gaap_WarrantMember_24948ab4-b484-4a9b-91a8-f1e357caba35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4902c0ce-5158-4b6a-b047-46cefd3710c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_748b8cd4-6ff6-4643-8e6a-408e6151b086" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4902c0ce-5158-4b6a-b047-46cefd3710c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5d329895-a434-4a73-8b82-74d25814ce5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_748b8cd4-6ff6-4643-8e6a-408e6151b086" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5d329895-a434-4a73-8b82-74d25814ce5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_121ee473-9348-44f1-9630-6b3bd585857e" xlink:href="crdf-20210930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_748b8cd4-6ff6-4643-8e6a-408e6151b086" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_121ee473-9348-44f1-9630-6b3bd585857e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended" id="iee8a9aff6f8b4086aca50adc87830882_FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0dad4467-2004-458d-9656-2c8f05c16019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_9937d382-d869-49a3-b2d0-f67fadd1448e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0dad4467-2004-458d-9656-2c8f05c16019" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_9937d382-d869-49a3-b2d0-f67fadd1448e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3bb53f02-553e-4b97-8e39-c9d0f73be096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9937d382-d869-49a3-b2d0-f67fadd1448e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3bb53f02-553e-4b97-8e39-c9d0f73be096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc6bce46-1df4-46be-a47e-120dcc86331b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9937d382-d869-49a3-b2d0-f67fadd1448e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc6bce46-1df4-46be-a47e-120dcc86331b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9d772f98-cbb5-4992-acf3-c7a58de66980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9937d382-d869-49a3-b2d0-f67fadd1448e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9d772f98-cbb5-4992-acf3-c7a58de66980" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_40533604-7ebc-4861-b067-24a35b091724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0dad4467-2004-458d-9656-2c8f05c16019" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_40533604-7ebc-4861-b067-24a35b091724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_0483aa65-b4e7-46d6-a27b-89054c770cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_40533604-7ebc-4861-b067-24a35b091724" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_0483aa65-b4e7-46d6-a27b-89054c770cbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_fe33db45-165c-44cb-a38a-3f39621f1743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_40533604-7ebc-4861-b067-24a35b091724" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_fe33db45-165c-44cb-a38a-3f39621f1743" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5014418f-f28a-4bb7-9a51-8811381f1c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0dad4467-2004-458d-9656-2c8f05c16019" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5014418f-f28a-4bb7-9a51-8811381f1c15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_797b7909-9424-42d6-bdb9-6554b8c8ec81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5014418f-f28a-4bb7-9a51-8811381f1c15" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_797b7909-9424-42d6-bdb9-6554b8c8ec81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_797b7909-9424-42d6-bdb9-6554b8c8ec81_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_797b7909-9424-42d6-bdb9-6554b8c8ec81" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_797b7909-9424-42d6-bdb9-6554b8c8ec81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_646d8f95-84b8-4a64-98f1-3146020964a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_797b7909-9424-42d6-bdb9-6554b8c8ec81" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_646d8f95-84b8-4a64-98f1-3146020964a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6d31a30b-bc5f-414d-9b31-6f0051c673c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_646d8f95-84b8-4a64-98f1-3146020964a0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6d31a30b-bc5f-414d-9b31-6f0051c673c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_20d807c9-167a-4929-b438-acfc5caa5b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5014418f-f28a-4bb7-9a51-8811381f1c15" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_20d807c9-167a-4929-b438-acfc5caa5b2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_20d807c9-167a-4929-b438-acfc5caa5b2d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_20d807c9-167a-4929-b438-acfc5caa5b2d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_20d807c9-167a-4929-b438-acfc5caa5b2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c964db6-b218-4ccf-9504-e2fb8312b16e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_20d807c9-167a-4929-b438-acfc5caa5b2d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c964db6-b218-4ccf-9504-e2fb8312b16e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_17a06a0f-fd9a-4c84-ae03-a7ee56acb687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c964db6-b218-4ccf-9504-e2fb8312b16e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_17a06a0f-fd9a-4c84-ae03-a7ee56acb687" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_923c355c-e0b0-4783-841c-1440b07c36df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c964db6-b218-4ccf-9504-e2fb8312b16e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_923c355c-e0b0-4783-841c-1440b07c36df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5b19771a-4f3a-4e64-a1ed-b127054bbbd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c964db6-b218-4ccf-9504-e2fb8312b16e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5b19771a-4f3a-4e64-a1ed-b127054bbbd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_e2010eb7-8712-4664-907c-86b82ffbe147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5014418f-f28a-4bb7-9a51-8811381f1c15" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_e2010eb7-8712-4664-907c-86b82ffbe147" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e2010eb7-8712-4664-907c-86b82ffbe147_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e2010eb7-8712-4664-907c-86b82ffbe147" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e2010eb7-8712-4664-907c-86b82ffbe147_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4b020f32-83bb-4eb9-8220-f2021f404216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e2010eb7-8712-4664-907c-86b82ffbe147" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4b020f32-83bb-4eb9-8220-f2021f404216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_19cb41be-07f7-44da-b4da-98a50b832e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4b020f32-83bb-4eb9-8220-f2021f404216" xlink:to="loc_us-gaap_MoneyMarketFundsMember_19cb41be-07f7-44da-b4da-98a50b832e76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fbe3a5bb-d48d-4378-9783-edd58c96a213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5014418f-f28a-4bb7-9a51-8811381f1c15" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fbe3a5bb-d48d-4378-9783-edd58c96a213" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fbe3a5bb-d48d-4378-9783-edd58c96a213_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fbe3a5bb-d48d-4378-9783-edd58c96a213" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fbe3a5bb-d48d-4378-9783-edd58c96a213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b11d64a5-5125-4b02-9c8a-ae2e21ac07f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fbe3a5bb-d48d-4378-9783-edd58c96a213" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b11d64a5-5125-4b02-9c8a-ae2e21ac07f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_92930599-e99c-46b7-b16d-09e8eba21816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b11d64a5-5125-4b02-9c8a-ae2e21ac07f0" xlink:to="loc_us-gaap_CertificatesOfDepositMember_92930599-e99c-46b7-b16d-09e8eba21816" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b0d67c34-001b-4b73-ba56-36d6eb51f7c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b11d64a5-5125-4b02-9c8a-ae2e21ac07f0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b0d67c34-001b-4b73-ba56-36d6eb51f7c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d3338cd0-44c7-4816-b814-54b7b7ed5a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b11d64a5-5125-4b02-9c8a-ae2e21ac07f0" xlink:to="loc_us-gaap_CommercialPaperMember_d3338cd0-44c7-4816-b814-54b7b7ed5a1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_49505039-faf9-4576-9685-38982aa0467d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b11d64a5-5125-4b02-9c8a-ae2e21ac07f0" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_49505039-faf9-4576-9685-38982aa0467d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5048c001-5c95-4d5a-8451-576cbaf5305f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b11d64a5-5125-4b02-9c8a-ae2e21ac07f0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5048c001-5c95-4d5a-8451-576cbaf5305f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="extended" id="i60c1fa3ff3414a31b18ceeebed224454_SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cefcf350-7e5f-4dff-8cef-bea7a49e0ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_af7a9ffa-d435-4ca1-9d8f-0ad7b49b5d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cefcf350-7e5f-4dff-8cef-bea7a49e0ce1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_af7a9ffa-d435-4ca1-9d8f-0ad7b49b5d99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c6fb7f05-e1ae-48da-832a-4dc1387ffeb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cefcf350-7e5f-4dff-8cef-bea7a49e0ce1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c6fb7f05-e1ae-48da-832a-4dc1387ffeb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ca3c9e57-4415-490d-b262-c9feb97e7374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cefcf350-7e5f-4dff-8cef-bea7a49e0ce1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ca3c9e57-4415-490d-b262-c9feb97e7374" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dd352b34-3205-433e-a41f-b0bef0f2d8fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cefcf350-7e5f-4dff-8cef-bea7a49e0ce1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dd352b34-3205-433e-a41f-b0bef0f2d8fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c67ef28-5bcf-4bc6-8273-48a950ca9200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cefcf350-7e5f-4dff-8cef-bea7a49e0ce1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c67ef28-5bcf-4bc6-8273-48a950ca9200" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5d735d44-893f-4990-9e50-470396a80a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c67ef28-5bcf-4bc6-8273-48a950ca9200" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5d735d44-893f-4990-9e50-470396a80a1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d735d44-893f-4990-9e50-470396a80a1f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5d735d44-893f-4990-9e50-470396a80a1f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d735d44-893f-4990-9e50-470396a80a1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e121cd-27b2-476d-82b9-5a46ff056ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5d735d44-893f-4990-9e50-470396a80a1f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e121cd-27b2-476d-82b9-5a46ff056ddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f6c1ca27-a622-4c9e-9fd8-5467b20a293f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e121cd-27b2-476d-82b9-5a46ff056ddc" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f6c1ca27-a622-4c9e-9fd8-5467b20a293f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_192f61ea-117b-48ea-8dbf-8b8b94c30e94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e121cd-27b2-476d-82b9-5a46ff056ddc" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_192f61ea-117b-48ea-8dbf-8b8b94c30e94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4de149ef-b330-44fc-af4b-7fce1dfda0a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e121cd-27b2-476d-82b9-5a46ff056ddc" xlink:to="loc_us-gaap_CommercialPaperMember_4de149ef-b330-44fc-af4b-7fce1dfda0a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_5857e58e-25cd-42bd-8f7e-ac518c119e41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e121cd-27b2-476d-82b9-5a46ff056ddc" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_5857e58e-25cd-42bd-8f7e-ac518c119e41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_47860530-be4a-4a2d-a727-2c8f92ae3751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e121cd-27b2-476d-82b9-5a46ff056ddc" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_47860530-be4a-4a2d-a727-2c8f92ae3751" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended" id="ide344d16cb4c4ce7b5d94128ff383004_SupplementaryBalanceSheetInformationPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c3a9dfb-af17-48cc-bbc5-4fb7980fc90b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_40732f46-92bc-4e9c-9557-2c03ff4e256e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c3a9dfb-af17-48cc-bbc5-4fb7980fc90b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_40732f46-92bc-4e9c-9557-2c03ff4e256e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f41b048-e2dc-4617-8e7b-2a9c8b80b7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c3a9dfb-af17-48cc-bbc5-4fb7980fc90b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f41b048-e2dc-4617-8e7b-2a9c8b80b7ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a9d85f92-ca66-4186-aa03-a15657eabafc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c3a9dfb-af17-48cc-bbc5-4fb7980fc90b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a9d85f92-ca66-4186-aa03-a15657eabafc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74afa3a7-a2f2-4134-8d1f-c6dfedb707d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c3a9dfb-af17-48cc-bbc5-4fb7980fc90b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74afa3a7-a2f2-4134-8d1f-c6dfedb707d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2595f3d-7876-49f6-88af-f29ad5639a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74afa3a7-a2f2-4134-8d1f-c6dfedb707d9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2595f3d-7876-49f6-88af-f29ad5639a27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c2595f3d-7876-49f6-88af-f29ad5639a27_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2595f3d-7876-49f6-88af-f29ad5639a27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c2595f3d-7876-49f6-88af-f29ad5639a27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_969852c3-6808-4c0a-84b4-bf4a07f7142e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2595f3d-7876-49f6-88af-f29ad5639a27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_969852c3-6808-4c0a-84b4-bf4a07f7142e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember_bc9f74af-9110-43f5-9c23-f443225649b8" xlink:href="crdf-20210930.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_969852c3-6808-4c0a-84b4-bf4a07f7142e" xlink:to="loc_crdf_FurnitureAndOfficeEquipmentMember_bc9f74af-9110-43f5-9c23-f443225649b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0f396c74-0688-404a-88dd-aa995f9525ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_969852c3-6808-4c0a-84b4-bf4a07f7142e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0f396c74-0688-404a-88dd-aa995f9525ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c9f074ba-a3ca-485c-8100-7a94e9fe8091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_969852c3-6808-4c0a-84b4-bf4a07f7142e" xlink:to="loc_us-gaap_EquipmentMember_c9f074ba-a3ca-485c-8100-7a94e9fe8091" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i2b7f49b5e0cc40049b6b7b5f9c7ad8f4_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorNumberOfSubleases_4f2ae0b7-22d4-4d63-8c2c-1ddbba727754" xlink:href="crdf-20210930.xsd#crdf_LessorNumberOfSubleases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_crdf_LessorNumberOfSubleases_4f2ae0b7-22d4-4d63-8c2c-1ddbba727754" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany_f2bb4342-5b38-447d-ae9e-0c0080566746" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany_f2bb4342-5b38-447d-ae9e-0c0080566746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease_eb505a40-f994-479c-8ef4-0562c685afc7" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease_eb505a40-f994-479c-8ef4-0562c685afc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAreaOfLease_b11fbe25-7982-496b-9ba1-7abbe9de876a" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseAreaOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_crdf_LesseeOperatingLeaseAreaOfLease_b11fbe25-7982-496b-9ba1-7abbe9de876a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorAreaOfSublease_9652a06e-24b8-40e4-be08-7b996137f451" xlink:href="crdf-20210930.xsd#crdf_LessorAreaOfSublease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_crdf_LessorAreaOfSublease_9652a06e-24b8-40e4-be08-7b996137f451" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_f841f6a8-10c7-432a-adf5-2471846128f0" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_f841f6a8-10c7-432a-adf5-2471846128f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_8b79c9bd-e6e3-40dc-87bf-33446a771635" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_8b79c9bd-e6e3-40dc-87bf-33446a771635" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_888e204d-066d-4801-a081-92f652d2ebf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_888e204d-066d-4801-a081-92f652d2ebf6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3a014bc7-1850-4c8d-98f1-83c5819571c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_888e204d-066d-4801-a081-92f652d2ebf6" xlink:to="loc_srt_StatementScenarioAxis_3a014bc7-1850-4c8d-98f1-83c5819571c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3a014bc7-1850-4c8d-98f1-83c5819571c4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_3a014bc7-1850-4c8d-98f1-83c5819571c4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3a014bc7-1850-4c8d-98f1-83c5819571c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_62b8fc5f-6554-4ab2-b360-9ce63300d371" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_3a014bc7-1850-4c8d-98f1-83c5819571c4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_62b8fc5f-6554-4ab2-b360-9ce63300d371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_1ab81ab7-911d-4398-894a-cd7bce52c621" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_62b8fc5f-6554-4ab2-b360-9ce63300d371" xlink:to="loc_srt_ScenarioForecastMember_1ab81ab7-911d-4398-894a-cd7bce52c621" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="simple" xlink:href="crdf-20210930.xsd#DerivativeFinancialInstrumentsWarrantsTables"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="extended" id="iea3eb5aeb2714c409787f92f2cc54b9f_DerivativeFinancialInstrumentsWarrantsTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_696cca43-9f8c-483f-a906-986393790d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7bfe934b-5688-4d95-8dc5-c310934aeaa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_696cca43-9f8c-483f-a906-986393790d34" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7bfe934b-5688-4d95-8dc5-c310934aeaa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_82f7099d-3165-4122-9fd3-a486f84f37f5" xlink:href="crdf-20210930.xsd#crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_696cca43-9f8c-483f-a906-986393790d34" xlink:to="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_82f7099d-3165-4122-9fd3-a486f84f37f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e6d0b972-3c66-492e-9b1e-71f1bdd75f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_696cca43-9f8c-483f-a906-986393790d34" xlink:to="loc_us-gaap_DerivativeTable_e6d0b972-3c66-492e-9b1e-71f1bdd75f84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_d33cc67d-85ca-479e-b607-9c9d0f8ff5a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e6d0b972-3c66-492e-9b1e-71f1bdd75f84" xlink:to="loc_us-gaap_ValuationTechniqueAxis_d33cc67d-85ca-479e-b607-9c9d0f8ff5a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_d33cc67d-85ca-479e-b607-9c9d0f8ff5a8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_d33cc67d-85ca-479e-b607-9c9d0f8ff5a8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_d33cc67d-85ca-479e-b607-9c9d0f8ff5a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_e5dfb0f7-a1bb-41ed-8c93-464095fe6069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_d33cc67d-85ca-479e-b607-9c9d0f8ff5a8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_e5dfb0f7-a1bb-41ed-8c93-464095fe6069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember_1d6fcada-1cd1-45b3-9ab2-1b7ee22f420d" xlink:href="crdf-20210930.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_e5dfb0f7-a1bb-41ed-8c93-464095fe6069" xlink:to="loc_crdf_BlackScholesOptionPricingMethodMember_1d6fcada-1cd1-45b3-9ab2-1b7ee22f420d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#DerivativeFinancialInstrumentsWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="extended" id="i07b93d3ccf874a3699e9173cc092412b_DerivativeFinancialInstrumentsWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_edd59a85-9da8-4544-95dd-e0574daa2cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_97b51f8c-ca09-4548-9537-486307b20812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_edd59a85-9da8-4544-95dd-e0574daa2cf5" xlink:to="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_97b51f8c-ca09-4548-9537-486307b20812" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EstimatedFairValueOfWarrant_e91f86e3-3f55-4748-ace8-28c157401523" xlink:href="crdf-20210930.xsd#crdf_EstimatedFairValueOfWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_97b51f8c-ca09-4548-9537-486307b20812" xlink:to="loc_crdf_EstimatedFairValueOfWarrant_e91f86e3-3f55-4748-ace8-28c157401523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4f85fa51-2d33-4823-8ba2-b2db69dec54a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_97b51f8c-ca09-4548-9537-486307b20812" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4f85fa51-2d33-4823-8ba2-b2db69dec54a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_723fed94-5d5d-44d0-a414-3a3a97dcacf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_97b51f8c-ca09-4548-9537-486307b20812" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_723fed94-5d5d-44d0-a414-3a3a97dcacf2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_4941f84b-7776-487a-a312-8dad803c2b84" xlink:href="crdf-20210930.xsd#crdf_DerivativeFinancialInstrumentsLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_edd59a85-9da8-4544-95dd-e0574daa2cf5" xlink:to="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_4941f84b-7776-487a-a312-8dad803c2b84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_23bcfb32-9024-429f-9b7e-16594ceee2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_4941f84b-7776-487a-a312-8dad803c2b84" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_23bcfb32-9024-429f-9b7e-16594ceee2c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_55920375-3ff4-405c-99ad-ae34da5efc07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_533629ad-e5c7-4037-b09e-6c3f7d875780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_4941f84b-7776-487a-a312-8dad803c2b84" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_533629ad-e5c7-4037-b09e-6c3f7d875780" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_4b0d464a-bef9-41ba-81f8-e1366faa7b0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_4941f84b-7776-487a-a312-8dad803c2b84" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_4b0d464a-bef9-41ba-81f8-e1366faa7b0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_743c95a6-6ed3-454d-9af8-f91b06df295e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_a691153d-1917-451c-8d7c-9f582ad0a12c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_edd59a85-9da8-4544-95dd-e0574daa2cf5" xlink:to="loc_us-gaap_DerivativeTable_a691153d-1917-451c-8d7c-9f582ad0a12c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1f3c1885-3e0b-4486-901c-23fefc257871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a691153d-1917-451c-8d7c-9f582ad0a12c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1f3c1885-3e0b-4486-901c-23fefc257871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1f3c1885-3e0b-4486-901c-23fefc257871_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1f3c1885-3e0b-4486-901c-23fefc257871" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1f3c1885-3e0b-4486-901c-23fefc257871_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1b5d0d16-6bae-43f1-8e88-72e1cf2b6307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1f3c1885-3e0b-4486-901c-23fefc257871" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1b5d0d16-6bae-43f1-8e88-72e1cf2b6307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_80b7e371-8fed-43c5-b21d-553914dfde4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1b5d0d16-6bae-43f1-8e88-72e1cf2b6307" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_80b7e371-8fed-43c5-b21d-553914dfde4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8aa42be1-66b7-4655-989a-fdb0f858b17b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1b5d0d16-6bae-43f1-8e88-72e1cf2b6307" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8aa42be1-66b7-4655-989a-fdb0f858b17b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_b7c66a8d-d94b-47a1-bbbf-6e824fda598a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1b5d0d16-6bae-43f1-8e88-72e1cf2b6307" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_b7c66a8d-d94b-47a1-bbbf-6e824fda598a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_87177ba6-5d90-4952-a809-582f02a63eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1b5d0d16-6bae-43f1-8e88-72e1cf2b6307" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_87177ba6-5d90-4952-a809-582f02a63eca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_14db4c4d-a2c4-426e-8cc5-22b1197141ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a691153d-1917-451c-8d7c-9f582ad0a12c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_14db4c4d-a2c4-426e-8cc5-22b1197141ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_14db4c4d-a2c4-426e-8cc5-22b1197141ad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_14db4c4d-a2c4-426e-8cc5-22b1197141ad" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_14db4c4d-a2c4-426e-8cc5-22b1197141ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_341d1582-ee41-42cc-91f1-5e8a685db943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_14db4c4d-a2c4-426e-8cc5-22b1197141ad" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_341d1582-ee41-42cc-91f1-5e8a685db943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_51b0cc44-357e-4fe5-a608-ce84a8578f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_341d1582-ee41-42cc-91f1-5e8a685db943" xlink:to="loc_us-gaap_WarrantMember_51b0cc44-357e-4fe5-a608-ce84a8578f0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_3914306e-31da-45eb-8881-1b2d9dfa6c33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a691153d-1917-451c-8d7c-9f582ad0a12c" xlink:to="loc_us-gaap_ValuationTechniqueAxis_3914306e-31da-45eb-8881-1b2d9dfa6c33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_3914306e-31da-45eb-8881-1b2d9dfa6c33_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_3914306e-31da-45eb-8881-1b2d9dfa6c33" xlink:to="loc_us-gaap_ValuationTechniqueDomain_3914306e-31da-45eb-8881-1b2d9dfa6c33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_89b47d2e-ef41-44c5-abad-fe5d21d63ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_3914306e-31da-45eb-8881-1b2d9dfa6c33" xlink:to="loc_us-gaap_ValuationTechniqueDomain_89b47d2e-ef41-44c5-abad-fe5d21d63ae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember_5337efc8-c502-4964-8b94-cffb194fa094" xlink:href="crdf-20210930.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_89b47d2e-ef41-44c5-abad-fe5d21d63ae6" xlink:to="loc_crdf_BlackScholesOptionPricingMethodMember_5337efc8-c502-4964-8b94-cffb194fa094" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#StockholdersEquityStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="extended" id="i8c02591af7434648bf7cdf2d8b79c356_StockholdersEquityStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15c9a475-d119-4686-862c-9e075ba7fe67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6838c07d-a526-43b7-861e-c99415a48a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15c9a475-d119-4686-862c-9e075ba7fe67" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6838c07d-a526-43b7-861e-c99415a48a30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_343b9c27-dd1f-4df7-89c3-bd1be2e02f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15c9a475-d119-4686-862c-9e075ba7fe67" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_343b9c27-dd1f-4df7-89c3-bd1be2e02f4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_53e7cdfd-caf9-4e83-8d77-1506f4a834ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15c9a475-d119-4686-862c-9e075ba7fe67" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_53e7cdfd-caf9-4e83-8d77-1506f4a834ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8bfd6294-6f8f-4552-a0b9-b3e00788867f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15c9a475-d119-4686-862c-9e075ba7fe67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8bfd6294-6f8f-4552-a0b9-b3e00788867f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7792726a-5a07-4900-a671-61e24d514f74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15c9a475-d119-4686-862c-9e075ba7fe67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7792726a-5a07-4900-a671-61e24d514f74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_95763f0d-6665-41a1-bae2-2eafe7352309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15c9a475-d119-4686-862c-9e075ba7fe67" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_95763f0d-6665-41a1-bae2-2eafe7352309" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_42aa37b1-e4d4-4d82-a7bb-af0c1939877f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_95763f0d-6665-41a1-bae2-2eafe7352309" xlink:to="loc_us-gaap_AwardTypeAxis_42aa37b1-e4d4-4d82-a7bb-af0c1939877f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42aa37b1-e4d4-4d82-a7bb-af0c1939877f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_42aa37b1-e4d4-4d82-a7bb-af0c1939877f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42aa37b1-e4d4-4d82-a7bb-af0c1939877f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f907d249-c2f6-4a1a-be10-86c2b6f38297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_42aa37b1-e4d4-4d82-a7bb-af0c1939877f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f907d249-c2f6-4a1a-be10-86c2b6f38297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f19ad6a5-72b4-410f-86e7-a4781f009dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f907d249-c2f6-4a1a-be10-86c2b6f38297" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f19ad6a5-72b4-410f-86e7-a4781f009dc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5e20b4d8-d77d-4831-ad59-1ee08403b9e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_95763f0d-6665-41a1-bae2-2eafe7352309" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5e20b4d8-d77d-4831-ad59-1ee08403b9e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5e20b4d8-d77d-4831-ad59-1ee08403b9e0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5e20b4d8-d77d-4831-ad59-1ee08403b9e0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5e20b4d8-d77d-4831-ad59-1ee08403b9e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5634452d-9dee-40a9-bf36-07d7ca6a5457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5e20b4d8-d77d-4831-ad59-1ee08403b9e0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5634452d-9dee-40a9-bf36-07d7ca6a5457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7a815354-9679-456c-ae0d-d6af5837b60a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5634452d-9dee-40a9-bf36-07d7ca6a5457" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7a815354-9679-456c-ae0d-d6af5837b60a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_62b2e109-d488-4b89-8a86-9b89f970d0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5634452d-9dee-40a9-bf36-07d7ca6a5457" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_62b2e109-d488-4b89-8a86-9b89f970d0f9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#StockholdersEquityStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="extended" id="iff6a708ae7174966b2d5d77943f1ceb8_StockholdersEquityStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9b9abe0a-647d-4338-92c8-4b9767fd3281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9b9abe0a-647d-4338-92c8-4b9767fd3281" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e6f906fe-a211-4829-9e12-a7db42086daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9b9abe0a-647d-4338-92c8-4b9767fd3281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e6f906fe-a211-4829-9e12-a7db42086daa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6b7b4bf2-6e18-4522-8760-4826874bea6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9b9abe0a-647d-4338-92c8-4b9767fd3281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6b7b4bf2-6e18-4522-8760-4826874bea6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66a0cb8d-7539-4da0-8d49-a12e3502beb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9b9abe0a-647d-4338-92c8-4b9767fd3281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66a0cb8d-7539-4da0-8d49-a12e3502beb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2d7b5612-a050-4b24-abd2-abe93135af6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9b9abe0a-647d-4338-92c8-4b9767fd3281" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2d7b5612-a050-4b24-abd2-abe93135af6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6b635b6b-6c62-44a4-b9ca-039eabf188fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6b635b6b-6c62-44a4-b9ca-039eabf188fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59b7fb9b-43cf-42f1-bd83-a3ee48fe5d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6b635b6b-6c62-44a4-b9ca-039eabf188fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59b7fb9b-43cf-42f1-bd83-a3ee48fe5d6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75547163-524e-411b-9339-16941770d1ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6b635b6b-6c62-44a4-b9ca-039eabf188fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75547163-524e-411b-9339-16941770d1ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_54095d5b-779e-4ec1-9719-8ce84c679827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6b635b6b-6c62-44a4-b9ca-039eabf188fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_54095d5b-779e-4ec1-9719-8ce84c679827" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_e486dda0-3d67-4f9f-b264-bee1233979ce" xlink:href="crdf-20210930.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6b635b6b-6c62-44a4-b9ca-039eabf188fb" xlink:to="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_e486dda0-3d67-4f9f-b264-bee1233979ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ffd25437-7bbc-45a6-b9e4-5edf47069c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e72f8f1e-2c68-4184-8018-571548f32371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e72f8f1e-2c68-4184-8018-571548f32371" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_081ab2ee-42fa-417f-a276-f059a9298dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_081ab2ee-42fa-417f-a276-f059a9298dd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_994697f8-cf1d-4189-abc4-2048a708a960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_994697f8-cf1d-4189-abc4-2048a708a960" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5479c13-5a3f-47bc-9ad5-9e6f3b722af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_994697f8-cf1d-4189-abc4-2048a708a960" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5479c13-5a3f-47bc-9ad5-9e6f3b722af7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_595fa5c5-b150-4cbd-b8bd-502c2c1c2baf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_994697f8-cf1d-4189-abc4-2048a708a960" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_595fa5c5-b150-4cbd-b8bd-502c2c1c2baf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ace62d3-bc75-421d-bb57-fdce8b53bd1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_994697f8-cf1d-4189-abc4-2048a708a960" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ace62d3-bc75-421d-bb57-fdce8b53bd1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_adfea892-ac0d-4b3d-84a1-8817935e4123" xlink:href="crdf-20210930.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_994697f8-cf1d-4189-abc4-2048a708a960" xlink:to="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_adfea892-ac0d-4b3d-84a1-8817935e4123" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1906e382-5dbb-4151-8cf0-c1d79b59e213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6a4d1f14-40d0-4b5a-b24c-6539f894cb90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6a4d1f14-40d0-4b5a-b24c-6539f894cb90" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9fd47669-095c-44ca-8e1e-67dbdd05cb8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9fd47669-095c-44ca-8e1e-67dbdd05cb8f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_28f3ac9b-0895-4815-91bf-7c4612483ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_28f3ac9b-0895-4815-91bf-7c4612483ff3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4ccf8c60-c746-420b-a517-19a6745d6a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_28f3ac9b-0895-4815-91bf-7c4612483ff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4ccf8c60-c746-420b-a517-19a6745d6a30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5c0ccfda-bb55-4b37-bcc8-adc6361e5a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_28f3ac9b-0895-4815-91bf-7c4612483ff3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5c0ccfda-bb55-4b37-bcc8-adc6361e5a39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2acaee1d-4b53-437e-a880-f2b2f93a8a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_28f3ac9b-0895-4815-91bf-7c4612483ff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2acaee1d-4b53-437e-a880-f2b2f93a8a32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f1ba1b0f-6915-4dc3-a0d9-e21aad7203a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f1ba1b0f-6915-4dc3-a0d9-e21aad7203a8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7cd18053-bd8b-4821-9702-a6081ae4416f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7cd18053-bd8b-4821-9702-a6081ae4416f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_93474808-463c-45d1-84db-7e50516b55b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_93474808-463c-45d1-84db-7e50516b55b5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c1ec5c-65c9-4395-af13-1e7552d9d81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c1ec5c-65c9-4395-af13-1e7552d9d81d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d66e832a-8f0e-4c76-b41e-88555c055262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c1ec5c-65c9-4395-af13-1e7552d9d81d" xlink:to="loc_us-gaap_PlanNameAxis_d66e832a-8f0e-4c76-b41e-88555c055262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d66e832a-8f0e-4c76-b41e-88555c055262_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d66e832a-8f0e-4c76-b41e-88555c055262" xlink:to="loc_us-gaap_PlanNameDomain_d66e832a-8f0e-4c76-b41e-88555c055262_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_771251d2-98e7-4dad-84bf-4a6dd66033f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d66e832a-8f0e-4c76-b41e-88555c055262" xlink:to="loc_us-gaap_PlanNameDomain_771251d2-98e7-4dad-84bf-4a6dd66033f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2021Member_fd2c70d3-7177-45ae-82bb-6bc2936131f8" xlink:href="crdf-20210930.xsd#crdf_EquityIncentivePlan2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_771251d2-98e7-4dad-84bf-4a6dd66033f3" xlink:to="loc_crdf_EquityIncentivePlan2021Member_fd2c70d3-7177-45ae-82bb-6bc2936131f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3df8a092-b6ca-4905-9530-d18a8bec942f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c1ec5c-65c9-4395-af13-1e7552d9d81d" xlink:to="loc_us-gaap_AwardTypeAxis_3df8a092-b6ca-4905-9530-d18a8bec942f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3df8a092-b6ca-4905-9530-d18a8bec942f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3df8a092-b6ca-4905-9530-d18a8bec942f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3df8a092-b6ca-4905-9530-d18a8bec942f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7bde6f-4fc9-4995-8d6a-fcd54854a3d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3df8a092-b6ca-4905-9530-d18a8bec942f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7bde6f-4fc9-4995-8d6a-fcd54854a3d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_23e432e3-86ac-4d15-a3fa-07c8d38786bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7bde6f-4fc9-4995-8d6a-fcd54854a3d9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_23e432e3-86ac-4d15-a3fa-07c8d38786bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_InducementGrantStockOptionsMember_4ea319b5-1358-47c7-a07b-45c5c4331da0" xlink:href="crdf-20210930.xsd#crdf_InducementGrantStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7bde6f-4fc9-4995-8d6a-fcd54854a3d9" xlink:to="loc_crdf_InducementGrantStockOptionsMember_4ea319b5-1358-47c7-a07b-45c5c4331da0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#StockholdersEquityRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails" xlink:type="extended" id="i10572ad3f5ba4566a4d8076686d4a71c_StockholdersEquityRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6826854e-1a49-4644-8a4a-6ab422bf4f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86da1e92-808a-4f14-b2d9-4c47db56b948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6826854e-1a49-4644-8a4a-6ab422bf4f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86da1e92-808a-4f14-b2d9-4c47db56b948" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e7e6c145-f048-4ea1-a78e-c7a30ae8400b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86da1e92-808a-4f14-b2d9-4c47db56b948" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e7e6c145-f048-4ea1-a78e-c7a30ae8400b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_78397d21-1866-44f8-9d99-9fb94d46371c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86da1e92-808a-4f14-b2d9-4c47db56b948" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_78397d21-1866-44f8-9d99-9fb94d46371c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40fff31e-e38d-4ff4-972d-1f6670a223ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a191db9-ac6d-41e1-a3f0-31fb5935b8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6826854e-1a49-4644-8a4a-6ab422bf4f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a191db9-ac6d-41e1-a3f0-31fb5935b8ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0aa26ff1-baeb-4a21-93f1-62420d9392ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a191db9-ac6d-41e1-a3f0-31fb5935b8ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0aa26ff1-baeb-4a21-93f1-62420d9392ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7edeb28f-0862-444c-b5f0-d3b01c6ca236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a191db9-ac6d-41e1-a3f0-31fb5935b8ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7edeb28f-0862-444c-b5f0-d3b01c6ca236" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a0985cce-077d-4ddd-bb46-1a3c147ed754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_f03ad61c-350f-49c4-8d1b-d76ba7088b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6826854e-1a49-4644-8a4a-6ab422bf4f1e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_f03ad61c-350f-49c4-8d1b-d76ba7088b59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b28203ea-b617-49e4-96aa-479030706b55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6826854e-1a49-4644-8a4a-6ab422bf4f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b28203ea-b617-49e4-96aa-479030706b55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f03dd704-c48c-4f9f-850f-1c6b64cfb6b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6826854e-1a49-4644-8a4a-6ab422bf4f1e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f03dd704-c48c-4f9f-850f-1c6b64cfb6b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7931be6e-b66c-46dd-80f8-e682a6917c62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f03dd704-c48c-4f9f-850f-1c6b64cfb6b2" xlink:to="loc_us-gaap_AwardTypeAxis_7931be6e-b66c-46dd-80f8-e682a6917c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7931be6e-b66c-46dd-80f8-e682a6917c62_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7931be6e-b66c-46dd-80f8-e682a6917c62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7931be6e-b66c-46dd-80f8-e682a6917c62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57ed280a-792a-4062-9c81-9d8bb5f8f706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7931be6e-b66c-46dd-80f8-e682a6917c62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57ed280a-792a-4062-9c81-9d8bb5f8f706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a9c53003-afe8-495a-a9c3-767313a3daa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57ed280a-792a-4062-9c81-9d8bb5f8f706" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a9c53003-afe8-495a-a9c3-767313a3daa5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended" id="i1d3a6d51b1cd415fadc168299d16036c_StockholdersEquityPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_269f8c85-5099-47c7-92b5-b73e343b0388" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_03cda905-719a-4785-ab2d-28264bbd45b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_269f8c85-5099-47c7-92b5-b73e343b0388" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_03cda905-719a-4785-ab2d-28264bbd45b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ccdc128c-a968-4780-a593-bd39f5027959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_269f8c85-5099-47c7-92b5-b73e343b0388" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ccdc128c-a968-4780-a593-bd39f5027959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_3e4502cb-ab77-43ad-b9de-3254e3def20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_269f8c85-5099-47c7-92b5-b73e343b0388" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_3e4502cb-ab77-43ad-b9de-3254e3def20d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2f82219e-7512-4ab1-ad3b-7ccfd0d159a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_269f8c85-5099-47c7-92b5-b73e343b0388" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2f82219e-7512-4ab1-ad3b-7ccfd0d159a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5b7e9f69-2a61-407f-86be-5eb6381feab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_269f8c85-5099-47c7-92b5-b73e343b0388" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5b7e9f69-2a61-407f-86be-5eb6381feab9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bad6c08f-fed1-44d0-9fc9-841fa8f81f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5b7e9f69-2a61-407f-86be-5eb6381feab9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bad6c08f-fed1-44d0-9fc9-841fa8f81f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bad6c08f-fed1-44d0-9fc9-841fa8f81f40_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bad6c08f-fed1-44d0-9fc9-841fa8f81f40" xlink:to="loc_us-gaap_ClassOfStockDomain_bad6c08f-fed1-44d0-9fc9-841fa8f81f40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6d14cd60-c824-48d4-b0f8-a89f435fde05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bad6c08f-fed1-44d0-9fc9-841fa8f81f40" xlink:to="loc_us-gaap_ClassOfStockDomain_6d14cd60-c824-48d4-b0f8-a89f435fde05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember_59cd4b56-1fdc-419f-9935-4ebc03c06e4f" xlink:href="crdf-20210930.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6d14cd60-c824-48d4-b0f8-a89f435fde05" xlink:to="loc_crdf_SeriesAConvertiblePreferredStockMember_59cd4b56-1fdc-419f-9935-4ebc03c06e4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember_89a9b14e-9e1d-403a-a4af-54e2a9f403d0" xlink:href="crdf-20210930.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6d14cd60-c824-48d4-b0f8-a89f435fde05" xlink:to="loc_crdf_SeriesBConvertiblePreferredStockMember_89a9b14e-9e1d-403a-a4af-54e2a9f403d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_5cf321ca-ccb0-44b1-8e21-9488d53053e0" xlink:href="crdf-20210930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6d14cd60-c824-48d4-b0f8-a89f435fde05" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_5cf321ca-ccb0-44b1-8e21-9488d53053e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_c7fc43d7-ae47-4547-8f3c-bf986ee5e58f" xlink:href="crdf-20210930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6d14cd60-c824-48d4-b0f8-a89f435fde05" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_c7fc43d7-ae47-4547-8f3c-bf986ee5e58f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_39f73c90-f37c-4c4c-875a-9f80f44186f3" xlink:href="crdf-20210930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6d14cd60-c824-48d4-b0f8-a89f435fde05" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_39f73c90-f37c-4c4c-875a-9f80f44186f3" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="id24b88686b4946b99a14fde5beef9df2_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_ae4c0ac9-b9a0-4eb5-8199-17b31197a0cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_6965b963-e8d5-4ad4-a4f4-31948e6c47f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ae4c0ac9-b9a0-4eb5-8199-17b31197a0cb" xlink:to="loc_us-gaap_PurchaseObligation_6965b963-e8d5-4ad4-a4f4-31948e6c47f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_8c51a0ab-8c22-4cdf-a6a3-58725b4c47bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ae4c0ac9-b9a0-4eb5-8199-17b31197a0cb" xlink:to="loc_us-gaap_OtherCommitmentsTable_8c51a0ab-8c22-4cdf-a6a3-58725b4c47bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1c06a68e-2881-46a0-b7e9-32e9863d9d59" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_8c51a0ab-8c22-4cdf-a6a3-58725b4c47bc" xlink:to="loc_srt_CounterpartyNameAxis_1c06a68e-2881-46a0-b7e9-32e9863d9d59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c06a68e-2881-46a0-b7e9-32e9863d9d59_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1c06a68e-2881-46a0-b7e9-32e9863d9d59" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c06a68e-2881-46a0-b7e9-32e9863d9d59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4e3bf3a-bef1-4ae0-8740-d489ca850e06" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1c06a68e-2881-46a0-b7e9-32e9863d9d59" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4e3bf3a-bef1-4ae0-8740-d489ca850e06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_NorvianoMember_5c859eeb-a57a-4289-8017-9edb182981ef" xlink:href="crdf-20210930.xsd#crdf_NorvianoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4e3bf3a-bef1-4ae0-8740-d489ca850e06" xlink:to="loc_crdf_NorvianoMember_5c859eeb-a57a-4289-8017-9edb182981ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="ia8e175d0ca4047f08d4ba4ec26231900_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_bded4fa8-196a-4b15-a672-90edb9762d78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_96ac9a3c-6b5d-4e7d-99be-3bbbf157eaa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bded4fa8-196a-4b15-a672-90edb9762d78" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_96ac9a3c-6b5d-4e7d-99be-3bbbf157eaa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7cdfea1c-589d-4b30-8300-03667c1bf3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bded4fa8-196a-4b15-a672-90edb9762d78" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7cdfea1c-589d-4b30-8300-03667c1bf3f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2d9c4726-ce5a-467a-bfb1-553f07e9e72f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bded4fa8-196a-4b15-a672-90edb9762d78" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2d9c4726-ce5a-467a-bfb1-553f07e9e72f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_339d299c-3ee3-4d20-af15-c0c5c19601d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bded4fa8-196a-4b15-a672-90edb9762d78" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_339d299c-3ee3-4d20-af15-c0c5c19601d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_583aa8fd-3583-4d80-b717-17e1539dda2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bded4fa8-196a-4b15-a672-90edb9762d78" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_583aa8fd-3583-4d80-b717-17e1539dda2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19f7382f-95fe-485b-88a1-677dc3ce91d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_583aa8fd-3583-4d80-b717-17e1539dda2d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19f7382f-95fe-485b-88a1-677dc3ce91d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_19f7382f-95fe-485b-88a1-677dc3ce91d3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19f7382f-95fe-485b-88a1-677dc3ce91d3" xlink:to="loc_us-gaap_RelatedPartyDomain_19f7382f-95fe-485b-88a1-677dc3ce91d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_642245c9-4a13-4e08-bfef-9476dd59839b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19f7382f-95fe-485b-88a1-677dc3ce91d3" xlink:to="loc_us-gaap_RelatedPartyDomain_642245c9-4a13-4e08-bfef-9476dd59839b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_f4f0aef1-c5b3-491e-8b35-0ef6baac2c6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_642245c9-4a13-4e08-bfef-9476dd59839b" xlink:to="loc_srt_DirectorMember_f4f0aef1-c5b3-491e-8b35-0ef6baac2c6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAffiliatesMember_f74a725e-e6b3-44d9-a56b-36fc105200a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAffiliatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_642245c9-4a13-4e08-bfef-9476dd59839b" xlink:to="loc_us-gaap_OtherAffiliatesMember_f74a725e-e6b3-44d9-a56b-36fc105200a7" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>crdf-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9c181793-10cf-46b3-9b0e-d8b69a1f5f61,g:a6a36519-15ad-476d-ae18-99a2aa63eb87-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_966d25e5-e2b6-4e24-84a8-29d909443b2e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b50ff576-dce2-43e7-a032-ef0a6ceecf5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_32e88482-eef7-4d35-bce2-cce1e8c71b2a_negatedTerseLabel_en-US" xlink:label="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</link:label>
    <link:label id="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_f72902e3-8eac-412c-a7d0-75e2d4f6db38_terseLabel_en-US" xlink:label="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</link:label>
    <link:label id="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_label_en-US" xlink:label="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock</link:label>
    <link:label id="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_documentation_en-US" xlink:label="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:href="crdf-20210930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:to="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_cb2861d3-9182-446e-99cf-b741eee74554_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_94f8c2cc-fb68-47b3-9c58-30fe1217a82d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b6a29f7c-06f4-459a-9a12-6eddfb6300ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_923fb8ec-328c-4f53-b776-63f3f9baab97_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_6020d22c-5d9a-4904-842f-9a8c687f0173_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series&#160;A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_194db43d-1250-4cd2-a32c-31ef4af3d4e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ServiceReceivable_1225ebbf-1d32-4ddb-91bb-d1ebac07f3d7_negatedTerseLabel_en-US" xlink:label="lab_crdf_ServiceReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service receivables</link:label>
    <link:label id="lab_crdf_ServiceReceivable_label_en-US" xlink:label="lab_crdf_ServiceReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable</link:label>
    <link:label id="lab_crdf_ServiceReceivable_documentation_en-US" xlink:label="lab_crdf_ServiceReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivable" xlink:href="crdf-20210930.xsd#crdf_ServiceReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ServiceReceivable" xlink:to="lab_crdf_ServiceReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_261a7ecf-681b-4d15-91a5-aefdfe978ff0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested, weighted average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_08ef0121-3d98-4520-b646-9113783b6a5e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised_e064ba24-76ad-419f-b0e3-23f2706d4ed2_terseLabel_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The equity impact during the period due to the cash exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="crdf-20210930.xsd#crdf_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_54f7f8cc-4d32-498b-9e49-7d0da0ded632_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Warrant Activity and Changes in Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany_03426a2b-3f21-44d6-9936-028680ef64e8_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of lease occupied by company</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Lease Occupied By Company</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Lease Occupied By Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany" xlink:to="lab_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_5eabe74b-a7fe-47c4-9c5c-37383249e164_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_46ba8e49-8a0f-40a5-bdbf-a88ae90424b9_terseLabel_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_label_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment For Services Received</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_documentation_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment For Services Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:href="crdf-20210930.xsd#crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:to="lab_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_343f7274-6f5f-4b9b-803e-0633c5884afc_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ced31e9f-c915-4520-9af9-014cb6a41e7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability_12e95a9e-4f42-4790-822e-56733c2e3ded_terseLabel_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Liability</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="crdf-20210930.xsd#crdf_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5ec857aa-7a8f-4471-ae1a-226d08bd09ff_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments - Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_5dd6a7a1-9230-4206-91ea-c6aab777d78d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_706fc777-f98a-410c-bc1c-927adb7484b7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings under note payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8fa8f5a9-3be4-4479-8b86-c722f174eee9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ac357a2a-d55b-4e35-8746-d4c1f941e86d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8128b8de-eb8d-406b-b4ba-609235c5bc8b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, weighted average grant date fair value at end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6d3a03a8-e620-4ea5-9d4a-7bdeb60aff5b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, weighted average grant date fair value at end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b74c367d-86ea-426b-9ac4-623b3108c917_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1f6a805f-6327-435b-852d-40ad41849154_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_358010e8-78fe-4584-ae12-1447a82dc1d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_08338e89-5a47-41e4-a466-17b39123ab56_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f81b0dbf-fa4c-4594-9ebd-41b9f54a223f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_bb2ac552-ade5-47b7-8f1d-ded22c8393de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_a1ca3e19-d35d-4d91-8945-9619058c8522_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1846075f-6abb-4852-a126-5a8d95435a77_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_a198064b-c59d-4ad7-9a7d-10c57f08068f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_b8f95c16-dca6-429e-8463-aa2c34896fb0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4ce460b7-5b28-42b3-8d18-3fdd625b6880_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_cdc870d4-a714-4f2c-8947-29ac06a5684c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (excluding the nine months ended September 31, 2021)</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_09322a05-a0df-4c30-80ec-b22f694d4d8b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_ccdf355d-36b0-4225-a4dd-03d336c0a0a8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_115c578e-3057-4075-912d-7ea28c4efb6b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_fce9c3c0-9df4-4963-85d7-e0d7350d4986_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8a3590d-b82f-472e-8a1e-df258039e5d5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_580bc276-2256-435f-8fe7-064b73704f94_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a8ae852d-e0c0-46f3-a00a-4fdf19d82981_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_065b1785-a7d3-4c75-b223-88c58daf7af7_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, 20,000 shares authorized; (Note 7)</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_2433f992-5d6e-45e4-ba91-a44241612aa3_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_9eaff3d3-f5b1-4691-a8e8-d91f5c6c87cf_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0762ecac-80eb-464c-94b3-260ad66bd78f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2a3cd723-4a58-444a-a3f9-ec217b4c9db1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_cbcccfdb-e409-4dab-939a-349a7f3f9de3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_03ac5c77-1442-4cf9-ab6f-39e5db77e74c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9ce5ce7c-83cd-4dc6-a536-3502ed48560d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EquityIncentivePlan2021Member_42a50628-5e66-4c61-b493-429200cceabc_terseLabel_en-US" xlink:label="lab_crdf_EquityIncentivePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2021</link:label>
    <link:label id="lab_crdf_EquityIncentivePlan2021Member_label_en-US" xlink:label="lab_crdf_EquityIncentivePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2021 [Member]</link:label>
    <link:label id="lab_crdf_EquityIncentivePlan2021Member_documentation_en-US" xlink:label="lab_crdf_EquityIncentivePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2021Member" xlink:href="crdf-20210930.xsd#crdf_EquityIncentivePlan2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EquityIncentivePlan2021Member" xlink:to="lab_crdf_EquityIncentivePlan2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6b42a1c3-a71e-4fd1-badc-3f3ae758c7b5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested, fair value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_db690a2f-0cd2-49f0-8fde-045fa748d2a7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_198a472d-787e-4105-bac1-39c58a195b3e_terseLabel_en-US" xlink:label="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in the Company's derivative financial instruments liability balance</link:label>
    <link:label id="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_label_en-US" xlink:label="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:href="crdf-20210930.xsd#crdf_DerivativeFinancialInstrumentsLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:to="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7021494a-9dbc-4369-8804-6276229bfe9c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_ec3f3649-29f5-4f48-b19c-c9058bffd97a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_f7db7c81-afd4-4141-ad4b-1c8e48a1f683_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7ecd8bd2-fe99-4956-94ee-e164fe7a5747_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_WarrantsAndRightsRollForward_6c4e903f-89fb-4b19-afd8-56d718ffc54d_terseLabel_en-US" xlink:label="lab_crdf_WarrantsAndRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Warrants</link:label>
    <link:label id="lab_crdf_WarrantsAndRightsRollForward_label_en-US" xlink:label="lab_crdf_WarrantsAndRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsAndRightsRollForward" xlink:href="crdf-20210930.xsd#crdf_WarrantsAndRightsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_WarrantsAndRightsRollForward" xlink:to="lab_crdf_WarrantsAndRightsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_077a8527-15b6-4152-954b-f37aa439fa31_terseLabel_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_label_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_documentation_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:href="crdf-20210930.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:to="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3dece8ff-3e3d-4666-8060-23c62b9af1fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_85caed2b-f9b1-40b4-a234-0e6cbf858bb8_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_cf162def-50d8-4d3d-9adb-325e3e1ea7ec_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_483d2c6c-9aa7-43fb-bb6f-7e0c36aef599_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_140e80b5-8bc6-490b-91e3-3a0ea2f784d1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_512ba081-edfe-403d-b6be-ff1a23fc60d2_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_cfd6a476-f8fc-4696-9d21-1c6d32cc7e50_terseLabel_en-US" xlink:label="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both [Abstract]</link:label>
    <link:label id="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_label_en-US" xlink:label="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:to="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_fa3b0d73-2064-494a-a121-335bd516e3c4_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rent increase, percentage</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Increase, Percentage</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:to="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_b5236701-faf4-47ce-95ea-46993cc2a55b_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_8312aae9-70b4-40ee-b55f-3e3c868feef0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments - warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_8168d6c8-e5e8-4249-a3d7-323b3c210347_periodStartLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of derivative financial instruments liability at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_4fd2c40d-2be2-4766-912b-ba996adecb25_periodEndLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of derivative financial instruments liability at the end of the period</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_314acd2a-3226-4a4d-bbcc-35502d016af8_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_5997e9f4-8433-48e8-9e53-cda521d4cedf_periodStartLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of warrants at the beginning of the period (in USD per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_e9407878-b773-455e-b28b-6d269e688faf_periodEndLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of warrants at the end of the period (in USD per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the weighted average exercise price of each class of warrants or rights outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:href="crdf-20210930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberExercised_e0f91731-8dd1-485a-87a4-5ba447094a4a_negatedTerseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberExercised_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Number Exercised</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberExercised_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberExercised" xlink:href="crdf-20210930.xsd#crdf_ClassOfWarrantOrRightNumberExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightNumberExercised" xlink:to="lab_crdf_ClassOfWarrantOrRightNumberExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_a116e7bc-21a2-478b-bb42-5e90353d7640_terseLabel_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of shares issued during the period upon cash exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="crdf-20210930.xsd#crdf_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0284f15f-0cb3-4cc0-880d-668022dd894d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment_6145446a-13c1-412d-af8c-e43744c4aa30_terseLabel_en-US" xlink:label="lab_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment_label_en-US" xlink:label="lab_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Of Issuance Of Common Stock, Preferred Stock And Warrants For Clinical Trial Funding Commitment</link:label>
    <link:label id="lab_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment_documentation_en-US" xlink:label="lab_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Of Issuance Of Common Stock, Preferred Stock And Warrants For Clinical Trial Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" xlink:href="crdf-20210930.xsd#crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" xlink:to="lab_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9d54cc4f-b192-4e76-98a1-ad7ab024f24c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_745564d0-721b-4e83-be5d-95d0a015cc11_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4979d1e9-1c9e-4de4-8b0e-1d7b1ed887d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_d14f4c23-07c7-4bba-a918-b21665673ee1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_19522af2-ca92-4455-8b18-38f608b31212_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of common stock, preferred stock and warrants, net of expenses of $776 and $634, respectively</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_87167c5d-a13a-437d-a657-df2ce2c39d2c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f7f0a9cd-e03b-484f-b42d-34598bc7d86a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_355b5dce-e551-4a2d-a0b9-bac673422341_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease_3c4d592a-b9d0-4b51-bd98-4be4e4e256d0_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease not yet commenced, area</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Area Of Lease</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Area Of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease" xlink:to="lab_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f1880d26-d4dc-4bee-aa72-3cd893a3622b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized shares under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_WarrantsFairValue_42d756b2-c06d-4316-aa8a-6421a08e12b7_terseLabel_en-US" xlink:label="lab_crdf_WarrantsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, fair value</link:label>
    <link:label id="lab_crdf_WarrantsFairValue_label_en-US" xlink:label="lab_crdf_WarrantsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Fair Value</link:label>
    <link:label id="lab_crdf_WarrantsFairValue_documentation_en-US" xlink:label="lab_crdf_WarrantsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsFairValue" xlink:href="crdf-20210930.xsd#crdf_WarrantsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_WarrantsFairValue" xlink:to="lab_crdf_WarrantsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3eb74897-cca9-4468-9f54-d4626e71a6e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of remaining shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2b17d3c-ac1c-47b0-8350-3c465adc5449_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bc6da4d4-7b9c-426d-bea1-7826cfcc9661_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_ebb1cabf-4520-4da8-8a65-62eb5cdd9e92_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_69073403-e674-4f4e-9196-ea1f5f85cd56_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_bf874b05-8588-4279-a785-8d1b53f42e5d_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly rent payments</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Payment</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:to="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_588f9e21-8b25-4d1c-8492-d4ad36e8756a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_0e89c595-2ccc-4678-856b-664626892136_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_567d3ac4-fb2e-42c3-af25-e65a6d885b92_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b55fb559-f3e3-4bc9-9301-923d0575c57f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_86ade7ab-cc47-41d8-93e7-439cd1317537_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_6ca7567d-db7d-4c9a-8976-3e1a535a166e_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining&#160;Contractual Term</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Term of Outstanding Warrants or Rights</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period over which each class of warrants or rights outstanding may be exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:href="crdf-20210930.xsd#crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:to="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6726f1ac-6353-4d1e-a37b-c8baa96b5e6d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_38050907-a216-45a6-b1aa-73a3701a5eb3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_b4741c49-e35e-453b-9cd7-9e1381a95ca3_negatedTerseLabel_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="crdf-20210930.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0f02ff04-01ed-43b7-bbbf-481a814b3fbb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_48a857eb-c65d-45a3-be43-356e35a21622_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_d5d13803-d3b3-412b-931f-6619277d55ea_totalLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_0cd8d8ca-fe5a-4952-aa2f-f497f301860c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_2c4072bc-9dee-446a-b837-eda979a98b8e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d8bb5936-e0ff-4073-af81-690833e914c7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_52c0b919-995d-4035-8aca-d7ae4eb7055f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dd327c23-5aab-4a43-9623-9d59b05a77e5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_554dcfd3-9b12-46f5-bad9-21923d5f9b0b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_7b51a02c-8106-41b3-a333-9ba0d14cd193_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_d146247c-9896-4084-9d8f-b5beb9c90168_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_d2585a13-459d-46b0-bf2f-b59746bfb34a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Expense and Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e7fb59f4-b28b-409b-9738-507064ed5ffe_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_048dba2e-49a9-4dda-9780-e1680bba1342_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_001e7cdf-3b48-47cd-a344-5d60cde1ef56_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_124c23eb-aa75-4990-8c10-e15545d9f5d1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock, net of expenses</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c1499ea3-ad90-444f-816c-ae5732bbfe8d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_603ec324-25e7-4edc-9b14-495c803888dd_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2da95859-1677-4ac3-b989-c93386d67820_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_dc3b72ac-00b7-40c6-8c40-6493f50924d3_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased_bbc195db-25a0-412b-8313-0d0c2dddbd5d_terseLabel_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased_label_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Restricted Stock Units Released</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased_documentation_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Restricted Stock Units Released</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased" xlink:href="crdf-20210930.xsd#crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased" xlink:to="lab_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_b370a3ce-c503-4507-a72e-bedf4324e92b_terseLabel_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in USD per share)</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expired in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:href="crdf-20210930.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_6b0ecab6-d743-4023-816f-fc591419a542_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non U.S. government</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f0c7a776-db21-4fd8-9883-36459745a47c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_69d83c8b-e6fd-421c-8501-c733fa00e54e_negatedTerseLabel_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_label_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired in Period</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_documentation_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:href="crdf-20210930.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:to="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f0875d52-1335-40d3-8d38-3ff6b0f6b3bb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SaleOfStockCommonAndWarrantsNetShares_a3f0942e-1e84-40f5-b890-9126680f79f3_negatedLabel_en-US" xlink:label="lab_crdf_SaleOfStockCommonAndWarrantsNetShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock and warrants (in shares)</link:label>
    <link:label id="lab_crdf_SaleOfStockCommonAndWarrantsNetShares_label_en-US" xlink:label="lab_crdf_SaleOfStockCommonAndWarrantsNetShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Common And Warrants, Net, Shares</link:label>
    <link:label id="lab_crdf_SaleOfStockCommonAndWarrantsNetShares_documentation_en-US" xlink:label="lab_crdf_SaleOfStockCommonAndWarrantsNetShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Common And Warrants, Net, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockCommonAndWarrantsNetShares" xlink:href="crdf-20210930.xsd#crdf_SaleOfStockCommonAndWarrantsNetShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SaleOfStockCommonAndWarrantsNetShares" xlink:to="lab_crdf_SaleOfStockCommonAndWarrantsNetShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_49e5592e-b554-43f3-8521-e579906c4e4c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_576ff18a-8240-429d-b1b1-85e7a081a5f4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_e7de2b1e-206d-4bef-bc9c-08a293f89442_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5456f1a0-63a5-4a93-b639-1f885693b37b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a3057ce1-aa97-4dad-a522-9a15db3b7a2a_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LessorNumberOfSubleases_a910ba50-7eba-403d-beed-a38fd1906a86_terseLabel_en-US" xlink:label="lab_crdf_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subleases</link:label>
    <link:label id="lab_crdf_LessorNumberOfSubleases_label_en-US" xlink:label="lab_crdf_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Number Of Subleases</link:label>
    <link:label id="lab_crdf_LessorNumberOfSubleases_documentation_en-US" xlink:label="lab_crdf_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Number Of Subleases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorNumberOfSubleases" xlink:href="crdf-20210930.xsd#crdf_LessorNumberOfSubleases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LessorNumberOfSubleases" xlink:to="lab_crdf_LessorNumberOfSubleases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2cae8464-b55a-409b-8466-4269ed183e23_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_12cbdf16-2681-4757-8546-c877be8fb30b_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Leases</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019b41b7-ea83-4d41-b7a9-90a26e215ec5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining vesting period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9bd369a6-d3a3-4fe6-a44e-d1878cc23115_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_8518965b-5299-44c6-8d19-2e6ee4274da8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b309cbad-c45b-4ec2-add6-41b81117db60_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ed886492-c843-40bf-acc8-f50a4273b35f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_36894324-95a1-4b7c-a947-22215b59b242_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_256507f0-bf6e-4af1-8aa1-7e316c2a28b1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9ec14558-3a5b-4b84-b84a-414b5c3896bb_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c5863c30-1f4e-46e4-acdd-1ddbad0cf3e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_456113e4-b692-459f-9772-3a1f0f05a521_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5bfc00e3-f7c5-49ef-8de3-d139efb0866e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_bda77e9f-b675-474b-8940-e06ba9ce383f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from change in fair value of derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_9b25c193-8df1-44ad-bf32-1f24b7d61b74_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_a1099ae6-ed67-4cce-b8bc-0b5c98810159_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative financial instruments&#8212;warrants during the period recognized as a gain in the condensed statements of operations</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_a2b8b09d-0ff6-449e-937d-75c036324178_totalLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year One</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4de29b7d-5a12-4207-8bb1-70d6bd21220a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_6b7d3659-8dc4-4648-a2b4-311a94dd73a9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected warrant term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_849480ad-21a4-40b9-b788-6892312ef512_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_f02252ee-80ad-421d-9673-2c0c5d720d63_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_adec90fa-705b-4d2c-bed7-0b6400ead6f9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_689fe198-aa51-48bf-9275-e6bde0d2d024_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_0de2e496-2205-4891-b550-d77f6471e9c7_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b4c278d2-dc80-49e4-bac0-c99e419246d4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f0a1165d-bc27-43fe-9722-e5e0e2fd12d6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_eca3419c-a088-4ef9-bac9-84cf13abd9ad_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c350bbe3-b348-451e-a666-1401b7eb2879_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the beginning of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_09e16683-3046-4062-83f4-a15c0de1a619_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the end of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7118011d-ab18-4ec6-90f1-ba147f6fd279_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_164b28b4-e205-4407-812f-24812ee15be8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d04a41e5-0a83-435e-a62f-87e724cd84b4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_b23d2c24-512a-4564-a12b-84e866221a95_totalLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (excluding the nine months ended September 31, 2021)</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Remainder Of Fiscal Year</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Remainder Of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_4c6c27b0-e0c5-43cb-aa21-39302d5e2833_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_fb09f61a-56f3-411a-a436-2bfedd7477fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1f2e8d38-e4ab-494d-ab2b-b564e0418f06_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_ea1abc91-0e3b-4987-b050-4d3ef145e923_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_268d8d43-e6de-4efc-ae29-1534b7487f87_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_869e5333-87d5-4cac-bdbb-27025adf3e3a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_58c84b2a-aea0-4ca7-89ab-fb623c80aceb_terseLabel_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_label_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to furniture and office equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember" xlink:href="crdf-20210930.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_FurnitureAndOfficeEquipmentMember" xlink:to="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_edfbc38f-73dd-450b-83c6-5656e0cf9afe_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4cf5a7ce-a532-4576-96b7-f878820624e8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_6ed556b3-52ea-44af-b5c8-901b30c3819c_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights [Abstract]</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:href="crdf-20210930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_ee1efd40-649b-4f6b-8e6d-efc7b8c84913_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_75f005c3-8d42-4c59-80d2-316be86fe104_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_62bf98ae-6141-4f93-a9ce-1da78a8eaa5e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_7665c61e-51a3-45a7-b055-1296ab888f87_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment_61edadf8-6ac7-4013-bca5-30a55d7ad771_terseLabel_en-US" xlink:label="lab_crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of issuance of common stock, preferred stock and warrants</link:label>
    <link:label id="lab_crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment_label_en-US" xlink:label="lab_crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Issuance Of Common Stock, Preferred Stock And Warrants For Clinical Trial Funding Commitment</link:label>
    <link:label id="lab_crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment_documentation_en-US" xlink:label="lab_crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Issuance Of Common Stock, Preferred Stock And Warrants For Clinical Trial Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" xlink:href="crdf-20210930.xsd#crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" xlink:to="lab_crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_897483a1-2c8d-4342-b486-21a4472797d4_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8365599f-9561-49dd-bd65-9cf85441e26b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4c2a877d-8ebd-4731-a5d2-e7ba5507d58e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour_4adee3f1-6d11-4a6f-8976-e9e53dae82f4_totalLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Four</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LessorAreaOfSublease_ef4f8290-32da-4911-88b5-9768acafbc85_terseLabel_en-US" xlink:label="lab_crdf_LessorAreaOfSublease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of sublease</link:label>
    <link:label id="lab_crdf_LessorAreaOfSublease_label_en-US" xlink:label="lab_crdf_LessorAreaOfSublease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Area Of Sublease</link:label>
    <link:label id="lab_crdf_LessorAreaOfSublease_documentation_en-US" xlink:label="lab_crdf_LessorAreaOfSublease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Area Of Sublease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorAreaOfSublease" xlink:href="crdf-20210930.xsd#crdf_LessorAreaOfSublease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LessorAreaOfSublease" xlink:to="lab_crdf_LessorAreaOfSublease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2484d71e-cda6-4b4f-a6e4-f83d02170399_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_4206714a-33d1-4e7f-9cd9-f1f3ae1bf94e_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_7930d74e-fdf9-44ab-ac4a-b1f896019fa8_totalLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_ca1daa91-d1ca-4cb1-bfe2-9415e0fe40cb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_35cc0347-e3c1-44d1-a9ca-db1c01502c58_totalLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_7ac4f633-5b0a-4dd2-8d55-3da8a33fd820_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f1d312b2-1fc2-4cea-93f0-6f94581ea14a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8f4260b6-f14c-4fe4-9ede-95600179b867_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs related to the clinical trial funding commitment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_906bef94-914c-4eb6-b573-71d7a6510a8b_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Term of Warrants or Rights [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:href="crdf-20210930.xsd#crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:to="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_d3949b19-a285-496d-8d21-4c5f58fba0fc_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_cf03ffa8-da20-4d3b-af5a-700bcc9ab1f5_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_57cbc307-3c1e-4650-b1bc-9c7a54c76848_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5938e807-4a62-4908-aba1-b526be0d56e2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_8d7761fa-17b3-44b4-ba3d-82a96c67b6e4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_f259a9cd-7501-49ca-ac96-bdb8c290a84e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SaleOfStockValueCommonAndWarrantsNet_c7e34b80-5361-4456-818f-93cd97a93b3c_negatedLabel_en-US" xlink:label="lab_crdf_SaleOfStockValueCommonAndWarrantsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock and warrants</link:label>
    <link:label id="lab_crdf_SaleOfStockValueCommonAndWarrantsNet_label_en-US" xlink:label="lab_crdf_SaleOfStockValueCommonAndWarrantsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Value, Common And Warrants, Net</link:label>
    <link:label id="lab_crdf_SaleOfStockValueCommonAndWarrantsNet_documentation_en-US" xlink:label="lab_crdf_SaleOfStockValueCommonAndWarrantsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Value, Common And Warrants, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockValueCommonAndWarrantsNet" xlink:href="crdf-20210930.xsd#crdf_SaleOfStockValueCommonAndWarrantsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SaleOfStockValueCommonAndWarrantsNet" xlink:to="lab_crdf_SaleOfStockValueCommonAndWarrantsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_f5514d24-d67e-4c45-a618-dab4c19c92de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3cf1c875-9b31-4b0d-a61e-e2e8827ad990_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums on short-term investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_6dec113f-8795-4b20-9184-0dcf1a536937_negatedTerseLabel_en-US" xlink:label="lab_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_label_en-US" xlink:label="lab_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment To Be Received, After Year Four</link:label>
    <link:label id="lab_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_documentation_en-US" xlink:label="lab_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment To Be Received, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:href="crdf-20210930.xsd#crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:to="lab_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6e521a4a-605f-4351-9de9-8cebaec7c616_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_39dd811e-318e-4d1f-9f09-fe6fa6a8228e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total available for sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6836cdce-7fb4-4400-a288-4e1ff2faef53_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b4445223-7926-4f70-91eb-bf0526dce351_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_ac9dd232-8e46-4fba-a41f-82350c922409_totalLabel_en-US" xlink:label="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to common stockholders</link:label>
    <link:label id="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Available To Common Stockholders, Basic</link:label>
    <link:label id="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_documentation_en-US" xlink:label="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Available To Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:href="crdf-20210930.xsd#crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_063f212b-2a29-4ccb-a319-abbd0ed56852_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_06f2da36-27f3-49ce-b8af-08e7c5a648f4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9f47f108-7d7a-4bfb-bfb9-fc10c4d4bd6c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_21eb11b8-cb7b-40dc-8976-d32ba453087c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_fd87e5b4-8b8a-4b6d-978c-3b36e654f6af_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_88b122de-45ee-4354-b066-ad972e35ca5a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Company&#8217;s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_79225abf-a071-4b8f-8e5d-250c7886f71c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions to Estimate Fair Value of Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9a87afa2-bfc2-4c09-9fab-633d84e8801e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_6d7f2c59-912e-426d-b45c-a96e908f458d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8876d2b2-64da-4fb8-ac90-d0b2c7aad80e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ed45be3d-9b2e-4819-ac07-dae3b4c7841f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_f95d2f27-adb8-4ae3-b069-1b5aa46170b0_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitment</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_add862b0-739d-44c8-9031-cf8aea22fe32_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity and of Changes in Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_bb45307e-fe98-44f5-a0f2-efd33dd03bb0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_046f0cf3-f937-4155-ad3c-3689f86088de_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation preference</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_26aa1de8-3233-41e5-815f-a7fb76756e65_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_62943a53-dd08-44db-98bc-0882a32fd29e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_8cd7eeb9-fad5-4f9d-aaa8-d7e5501e79f7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7fde067a-f8ee-407e-8d28-9a8377c028c2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate&#8211;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_df299d86-2e85-455b-b175-31c05ffca793_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_6ec19853-e239-450f-950e-aa8df2425b0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e84bfa35-bccc-48cd-8fc1-5845c607e610_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3fa76dfe-324b-44f6-8bcb-78728a079c98_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ea4f093a-3569-4547-aa4d-ab3d539fce73_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_fd498990-6a5b-4ecb-91c5-17b0b9bd6a2d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and unbilled receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37aea551-28cd-4d97-8d37-4067dede9382_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_4f3487c6-dde8-4e0c-b992-b1b1397d9c71_negatedLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_be5b85e1-c187-432b-8ca3-c49cf665587a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7520b01d-28b9-48c6-9e77-9c5adafd09c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8f19721b-c3cc-4029-827d-62ca58eb4888_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7e408ce4-2b2a-4607-b1c7-cd7aaf3ecebd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_29a405ca-6fb9-4fcd-9322-9d5f828ee43d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used to Determine the Fair Value of the Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_03250cca-7bd1-46b5-b47e-ebcbb555a796_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_87e473d4-1f61-4c8f-973c-156224396c46_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_4ae5750b-5e8d-45a8-ba24-1951f1b28d04_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of warrants outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_92fc3784-3b79-4766-872e-b6d5fa29e01e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of warrants outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_64e118e9-43c7-4206-9ae8-40f5b5053673_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PreferredStockDividendAccrued_77525fc2-d1ff-4c38-91f9-d00095f064b4_terseLabel_en-US" xlink:label="lab_crdf_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_PreferredStockDividendAccrued_label_en-US" xlink:label="lab_crdf_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividend Accrued</link:label>
    <link:label id="lab_crdf_PreferredStockDividendAccrued_documentation_en-US" xlink:label="lab_crdf_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the value of preferred stock dividend accrued during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockDividendAccrued" xlink:href="crdf-20210930.xsd#crdf_PreferredStockDividendAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PreferredStockDividendAccrued" xlink:to="lab_crdf_PreferredStockDividendAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_af7e2d51-7e86-484c-a577-0394c2e3a611_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2d81f4c3-284a-497e-a688-86b4de7a5f73_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_8a8df764-c1fb-4ede-a94b-1f0a5d6e348c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f5a01dd6-6a2d-45fe-87c0-37c69b14de1d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled / Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_adc89095-0daa-4b3c-8a54-1f6e63ad4300_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a2fe6550-7435-45ef-9c30-ce5a32bf5f86_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dedc92f9-a17c-4121-8e65-3d5c8c0897da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_575cf7e3-7540-4233-88c0-8c57b1182c29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at June 30, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_37b5b200-9f8c-40b2-9d4c-5b3048147877_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e870c73-525e-4054-8eb5-87dd303f0cca_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_35bac334-c6a1-41bb-af77-2bde18363d88_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0a3369a3-b95b-4406-a439-47e28918c1b8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_633465b2-a988-43d8-a864-d4dc43f49730_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b0c47e50-2942-4a2f-a0f1-5e7cf975f545_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term&#8211;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_43dd3cd3-bdd4-490c-9756-498608f82276_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_8508aade-1627-4b31-ac9a-f3d3b97c30c3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8742c4b4-f3c2-4cfb-bac8-9ca53c86a9c3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_250596cc-1969-4010-83ee-700bf7d24ef5_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_6f415227-16c6-4a64-be62-b996c5b51bc3_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a925be6a-57c4-4286-8eff-a9048b764d37_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value, 150,000 shares authorized; 39,552 and 36,781 shares issued and outstanding at September 30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_38d836ab-0ae2-44c1-a37b-4b9f26805952_terseLabel_en-US" xlink:label="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Changes in the Company&#8217;s Derivative Financial Instruments Liability Balance</link:label>
    <link:label id="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_label_en-US" xlink:label="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Changes in Derivative Financial Liability [Table Text Block]</link:label>
    <link:label id="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the reconciliation of a concept from the beginning of a period to the end of the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:href="crdf-20210930.xsd#crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:to="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_07063d9e-2cab-4f77-ae5b-bdbf5d9a528b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_2e645f6a-bada-427e-ac07-216661fb08c0_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6b8354b0-b25c-4042-bfa1-8fe4bfc48cbc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_78bb1fa9-b3e4-43cc-9571-3c7197d11e50_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f6bfd0c0-9783-48b1-b8bd-5698b9d661c2_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_b53ef6c4-53e2-4779-affc-5e42481fbda7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_ba545fe9-2e67-4ec8-ab57-e7cf773b56a6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility of Cardiff Oncology common stock</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9ea86dae-49c2-4199-b925-ca38b5783cff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2fcc76ab-59fc-45c9-ace0-be464172bc20_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_d60ec195-184f-4b32-93f6-291d92092adf_terseLabel_en-US" xlink:label="lab_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_label_en-US" xlink:label="lab_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_documentation_en-US" xlink:label="lab_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:href="crdf-20210930.xsd#crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:to="lab_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ServiceReceivableMember_43848061-3d6c-4cd3-8ba0-c477b41421ee_terseLabel_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable</link:label>
    <link:label id="lab_crdf_ServiceReceivableMember_label_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable [Member]</link:label>
    <link:label id="lab_crdf_ServiceReceivableMember_documentation_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember" xlink:href="crdf-20210930.xsd#crdf_ServiceReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ServiceReceivableMember" xlink:to="lab_crdf_ServiceReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8404ad7f-5b3f-409d-ad99-a77bf112e988_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e971cbd5-e68e-4e77-aa77-f8a8ceb3365e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_fb29b87e-78d3-4ed8-ba0e-0f436d0eda55_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8605c96b-c822-4055-9153-a8f8263c5a85_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0935ade4-5470-4f53-b731-b9ca91c4e29e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9fb041f9-ddb8-49c0-8d8b-5d5440a36b77_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and unbilled receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_598abc48-dec3-4e84-a357-07634c7bad9c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a404c34f-178f-4828-a1a6-dc75da2079dd_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_697d5bbe-81e0-4321-84b1-181cb7954ec8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2aaa7ae5-9934-49a9-a469-6378e3fec0e8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_195ec5e6-c690-4c22-8e3f-411bec3fd2b8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_f4917cca-513e-40fb-9e9b-c1b0791b97f8_terseLabel_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="crdf-20210930.xsd#crdf_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_06803667-f652-4a7d-beee-4f6c4e1c38aa_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4674319a-ea2f-4e7c-b919-440b7e631e0c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_272d6476-18f8-4384-95be-7b290e428d57_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b337044-f199-4abc-92c6-17e457354f23_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3f3f2ece-79a9-4797-9d22-7c3dfaea18d0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_b3caaa0b-8215-469c-8eec-a69a9841d2d7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EstimatedFairValueOfWarrant_dc7fc02d-6db5-4ffc-bf4b-1089c0960303_terseLabel_en-US" xlink:label="lab_crdf_EstimatedFairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of Cardiff Oncology common stock (in dollars per share)</link:label>
    <link:label id="lab_crdf_EstimatedFairValueOfWarrant_label_en-US" xlink:label="lab_crdf_EstimatedFairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value of Warrant</link:label>
    <link:label id="lab_crdf_EstimatedFairValueOfWarrant_documentation_en-US" xlink:label="lab_crdf_EstimatedFairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the estimated fair value of warrant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EstimatedFairValueOfWarrant" xlink:href="crdf-20210930.xsd#crdf_EstimatedFairValueOfWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EstimatedFairValueOfWarrant" xlink:to="lab_crdf_EstimatedFairValueOfWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_da354923-faec-4f47-967d-7c58285946dc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b9cbd28c-4106-4d16-bfb5-02f7d29628ff_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_518e65d7-b7c5-475e-b316-7cfa6255d0eb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_0c80fdf6-2579-41d9-9969-496cd8b8834d_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b70d9f12-0895-4915-be26-fabcea60f784_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d89a2fb0-02b1-44ee-9ed4-dd1bd07d1f9c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8ef14040-6668-4b8d-a00e-e2bb70cb536c_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_03b39707-9748-44d9-bfe0-c537c314c8b8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_eeaa42d2-1c36-4229-9b5e-040bb50a4055_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected warrant term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_708d2252-5ed4-4832-9021-1e5e8f46e21a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_28d3c9e7-b4cb-464f-92af-e8fbb011cad6_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0717bb05-2b87-4de7-80a7-10743cba8a2c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e50a5e9-6c48-4a36-a2e3-3b052820fe43_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_1c8701c5-e93f-4181-9323-ec68c03d5366_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_63334c78-bd3c-4db6-9a8d-b494eb009b6d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (excluding the nine months ended September 31, 2021)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d0be6171-7a84-43f6-8d52-d3dae8cb9f6e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_90eaeabf-bd16-48e6-88a7-1b966a97b9ba_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5caa344e-c93d-49bc-bcc3-e966ad7f4631_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e6e198e0-b890-4462-81d6-60581172d3e8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_c1f8ae2a-367a-439c-8a67-0e08b07a7f01_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_4b6194d7-2ffd-4798-a16c-881599427d31_terseLabel_en-US" xlink:label="lab_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend</link:label>
    <link:label id="lab_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_documentation_en-US" xlink:label="lab_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:href="crdf-20210930.xsd#crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:to="lab_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_37efdc8e-25ad-4605-977f-daa4f79aed54_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_d9a178db-b66a-4fdd-8b34-9e2d3c638fe5_terseLabel_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock that may be exchanged into common shares at the owner's option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember" xlink:href="crdf-20210930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesCConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_InducementGrantStockOptionsMember_099a4ebe-b7af-43a9-bb4f-f5600c7c6c5b_terseLabel_en-US" xlink:label="lab_crdf_InducementGrantStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grant Stock Options</link:label>
    <link:label id="lab_crdf_InducementGrantStockOptionsMember_label_en-US" xlink:label="lab_crdf_InducementGrantStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grant Stock Options [Member]</link:label>
    <link:label id="lab_crdf_InducementGrantStockOptionsMember_documentation_en-US" xlink:label="lab_crdf_InducementGrantStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grant Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_InducementGrantStockOptionsMember" xlink:href="crdf-20210930.xsd#crdf_InducementGrantStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_InducementGrantStockOptionsMember" xlink:to="lab_crdf_InducementGrantStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0b5d4e86-1964-4323-96ee-4fae87c99997_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5a75426f-e624-46ec-9529-30da2fdf3851_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5313131d-22a9-4d10-86d4-243666967569_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_ff4b3e3a-9059-46d1-981e-c718a71becc9_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_9b000c95-8d89-4419-aa6b-362f181e806f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of cash flow activity:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_1c9e81ab-f037-4115-9d07-a41551e2dacf_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5cafb96f-c2bc-461e-9130-affdf379b337_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_974af141-696f-4630-bc3d-d6621952edbe_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ef31bdf9-4f20-48c1-aa7b-56727d00a068_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_8c213109-5f9c-42a5-996d-653346cd6ea8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_112e4dbd-ead9-4063-8281-e46b3398e7cb_terseLabel_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember" xlink:href="crdf-20210930.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesBConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_6c9ae7ec-d141-46ce-8b20-155fea892247_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Exercised</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the weighted average exercise price of each class of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:href="crdf-20210930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a6b3b3d9-7a1f-4184-9b91-54a9f0a7ab52_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_cf8a9768-0aeb-4740-8423-3bdf81575e93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_015b6ddc-cbc2-4a24-9a75-da42e25a27a8_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a65498ee-a26c-4851-b964-8bbd9e9162a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock, net of expenses (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_bae259eb-c58a-40ff-acbb-614426de4e71_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_205d21e0-d76c-42a9-85d7-34cfe0691162_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_f308ae96-78fd-4b77-98e1-cb3159f62825_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_66873081-b628-491f-b163-f606046b9bfd_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less&#8212;accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2e6b6aa7-ac27-47dc-88fb-afc859552e8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at March 31, 2021, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_667a8a40-5da0-4462-91a7-d97904cbff02_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9aec7be4-e080-48e8-9bc7-d29f58f9d262_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_4f259785-0b3e-4938-bfda-d5c71e4abdbf_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1ce6bdb-1eeb-4f57-aff8-5f3af1bb82f2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9db50ffd-b29e-459a-86c6-4d8432f1deaa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStock_99e86928-5c7f-4742-8819-70c9d5b3ee78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStock_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStock" xlink:to="lab_us-gaap_DividendsPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_b7df6582-d497-40de-bb9b-ae4c4be635a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of assumptions used to determine the fair value of warrants</link:label>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_056020bb-30df-41ef-8c1f-af25cca44bb0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_831aacaa-5c80-4ec8-ae50-b0a3f8058bc1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ebfb236a-670a-4805-b540-d483a3c83d35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_510540a9-e091-42c5-ac76-7956f2272ac4_terseLabel_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember" xlink:href="crdf-20210930.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesAConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f7687655-2029-4727-99c9-962cec12696e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled / Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_4017af5a-9c6f-4ae2-8a24-acdc158ce5db_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour_fbe6351e-37b4-42fe-8fa5-25ad50a3743b_totalLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due After Year Four</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_ed35dd4e-1752-41e6-88cb-91e1fecd495e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dff16915-ad5e-4bb1-8f4e-7450bbca536a_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets obtained in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d1ce7a71-bb68-479c-8881-a6d523a64834_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAffiliatesMember_7644bbef-c334-4843-91ae-429a4ee06018_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_us-gaap_OtherAffiliatesMember_label_en-US" xlink:label="lab_us-gaap_OtherAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Affiliates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAffiliatesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAffiliatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAffiliatesMember" xlink:to="lab_us-gaap_OtherAffiliatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_4b07d116-61a3-44a1-a94f-79c71aa1a54d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_f1030318-ca70-48c9-8550-5ac684d4e43c_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_45834c28-2917-47fe-8669-eed432cc05d9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b50aa6a-cf92-472d-bf6c-dab3341d69f1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b61c4730-5dbe-46ef-9bda-19609b52e90b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_26852573-84bf-457d-a3e6-edcf0d445ed3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_dff8efdb-f340-4218-8909-da5cf7994949_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c9cfe0da-d723-4bea-9bc9-ca3008ac151f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a4efc68b-8232-43e3-9dec-789b053167bf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3f041d0d-9167-4597-82e7-112c7b417951_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0fe2ac4a-94fa-4423-a439-a48f585ecf8b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d51b11be-9cba-4390-91fc-a413f99a6bbc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_2bbd7224-5194-47fe-a4c7-d39994ace16a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_1e9e6c8f-000e-4ff5-8aa1-83f0848c832e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Accelerated Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_15c8af1f-ac11-4932-a0fd-71a744eb9d1f_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_37752035-679d-4c2e-8f06-137e9d0aa061_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_BlackScholesOptionPricingMethodMember_257189d6-1d71-4a30-bb7e-16cedbc08763_terseLabel_en-US" xlink:label="lab_crdf_BlackScholesOptionPricingMethodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black Scholes Option Pricing Method</link:label>
    <link:label id="lab_crdf_BlackScholesOptionPricingMethodMember_label_en-US" xlink:label="lab_crdf_BlackScholesOptionPricingMethodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black Scholes Option Pricing Method [Member]</link:label>
    <link:label id="lab_crdf_BlackScholesOptionPricingMethodMember_documentation_en-US" xlink:label="lab_crdf_BlackScholesOptionPricingMethodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the Black-Scholes option pricing method which is used for valuation of derivative instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember" xlink:href="crdf-20210930.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_BlackScholesOptionPricingMethodMember" xlink:to="lab_crdf_BlackScholesOptionPricingMethodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e3c60b66-d878-40bb-b3a5-a05d518c3685_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5fc040dc-90fc-42d9-80e9-32be027d3926_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_221018a4-3b30-4372-8ce4-150abf94bd62_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_efaa34cd-3db0-4606-a7fa-c2f53fbc4028_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_686846ad-7b40-4780-9236-b87ec3d88859_terseLabel_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember" xlink:href="crdf-20210930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesDConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_cec0890c-8d8a-46a9-bc8d-b95215ec27b1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_08955a2c-b2a4-4d37-8dd9-2ba304a7d1c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value Per&#160;Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_55b92445-4b69-4529-80bf-845a162915da_terseLabel_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series&#160;E Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember" xlink:href="crdf-20210930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesEConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_dfe1dbe4-56bf-4a5e-82ba-cb49f7e2773e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity instruments other than options, vested in period, fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2082f357-fee6-451a-bd2b-ca5047a26c26_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_91bb4bf2-922a-4757-9ed6-a3a5aed27544_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares designated (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_98fec08d-48bc-41f0-ad1e-e63ebfe6785c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity instruments other than options, aggregate intrinsic value, nonvested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_2cc036a3-064a-4011-88a9-e82abbba4856_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:to="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_330da32a-91a9-4379-a55a-3eda471b486a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_377cbd53-d38f-4351-b19e-202140bcb202_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d2be0b4-53e9-4ad7-8860-d86f9c235a65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_67afbe8f-a271-418d-b259-6333b83fcba6_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5c75aae6-5785-494d-894d-34af563f30b5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4af9718d-25e7-4cdb-87be-bb684a249c0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8573c3e-d38d-4d4f-ab40-d1be14065128_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7232ba61-f687-4401-82f8-6896218eeff4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, weighted average contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_167e68c2-0575-4548-8700-1278b6955865_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ecc68975-bee6-433e-8200-2fc9343e865f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseAreaOfLease_b1761e64-6dd6-43c4-ac48-8257cc8459ed_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAreaOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of lease</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAreaOfLease_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAreaOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Lease</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAreaOfLease_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAreaOfLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAreaOfLease" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseAreaOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseAreaOfLease" xlink:to="lab_crdf_LesseeOperatingLeaseAreaOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_212b84b5-fc39-400e-8615-27524d4dd021_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9843aa7a-57c6-4d01-83a3-77b12170c5ff_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_79cd4548-1222-472c-bb8f-bcc89ea0a93d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_08ff1a04-de1b-4f43-96db-eeaa910d28c1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary Balance Sheet Information</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_NorvianoMember_d600324e-10ff-41d1-a0bc-84c7e3e0a9b3_terseLabel_en-US" xlink:label="lab_crdf_NorvianoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nerviano</link:label>
    <link:label id="lab_crdf_NorvianoMember_label_en-US" xlink:label="lab_crdf_NorvianoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norviano [Member]</link:label>
    <link:label id="lab_crdf_NorvianoMember_documentation_en-US" xlink:label="lab_crdf_NorvianoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nerviano [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_NorvianoMember" xlink:href="crdf-20210930.xsd#crdf_NorvianoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_NorvianoMember" xlink:to="lab_crdf_NorvianoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7868064a-6f62-4f77-b7df-fa24aa938a0d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_ad56dce1-e23a-4e97-93e6-383a003febd4_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3b72f243-9934-4238-9553-d91cdaedc753_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_839018aa-f39a-4547-91fd-ccb2e81cbaa8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_db5f5289-beb0-4d9a-9894-0b0a8581218e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_302f72b6-cff1-4555-8e7b-4a59a2c7e8b9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_754cebf8-177c-483c-80fb-7701d4c4bcc1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7eab2993-487d-43cd-9478-6b785606b8a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at June 30, 2021 (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_a2c48a6e-a201-49cf-9a9c-574fab7bd11a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38aa5588-1be4-4ef7-884f-0d384653560a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e39538d4-2039-4940-97dc-2e00294c79b1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_48bfbb6c-1574-411c-b44b-bf65ed30bbb6_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>crdf-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9c181793-10cf-46b3-9b0e-d8b69a1f5f61,g:a6a36519-15ad-476d-ae18-99a2aa63eb87-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CoverPage" xlink:type="simple" xlink:href="crdf-20210930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d28a9174-5f33-4e97-9cb9-2988bfb94727" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_DocumentType_d28a9174-5f33-4e97-9cb9-2988bfb94727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_9c003869-35f3-4933-8e3c-8bf53ca178c7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_DocumentQuarterlyReport_9c003869-35f3-4933-8e3c-8bf53ca178c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1cdec521-fb96-48ab-b50a-ceeca774a215" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_DocumentTransitionReport_1cdec521-fb96-48ab-b50a-ceeca774a215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_042279e4-bcef-4c3a-ab8d-fdbf86bd2e0d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_DocumentPeriodEndDate_042279e4-bcef-4c3a-ab8d-fdbf86bd2e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5474f697-d8e9-4267-85ef-1fc145d0b5db" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityFileNumber_5474f697-d8e9-4267-85ef-1fc145d0b5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f968d781-64bd-4cd2-a429-1b31dfbd8d70" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityRegistrantName_f968d781-64bd-4cd2-a429-1b31dfbd8d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d977f254-8e0f-4024-9798-dc0e2bd3cd78" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d977f254-8e0f-4024-9798-dc0e2bd3cd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fbf8ef26-10f3-4552-ade7-8d75d45fc6ca" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityTaxIdentificationNumber_fbf8ef26-10f3-4552-ade7-8d75d45fc6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_08f8085f-5989-4843-9538-1a0c74f0522b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityAddressAddressLine1_08f8085f-5989-4843-9538-1a0c74f0522b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ef4e0ad2-ba9b-4ce9-9835-1f126aeff973" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityAddressCityOrTown_ef4e0ad2-ba9b-4ce9-9835-1f126aeff973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_32806673-e619-4917-a85a-a1d4d2d01825" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityAddressStateOrProvince_32806673-e619-4917-a85a-a1d4d2d01825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_85edac72-c08c-4a99-954a-c94836f60290" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityAddressPostalZipCode_85edac72-c08c-4a99-954a-c94836f60290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8d972ee6-42a8-4893-a0df-77fe14a8aa9c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_CityAreaCode_8d972ee6-42a8-4893-a0df-77fe14a8aa9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_dd68c5bd-0fc2-4f89-9d33-a29a1f94c5b5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_LocalPhoneNumber_dd68c5bd-0fc2-4f89-9d33-a29a1f94c5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_00781013-182d-4293-a59f-f147d743798a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_Security12bTitle_00781013-182d-4293-a59f-f147d743798a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_04cdc993-2312-4bd7-ac3f-54569645afe0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_TradingSymbol_04cdc993-2312-4bd7-ac3f-54569645afe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_360d4d78-b36b-4e4c-ad22-a0d992cfd2b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityCurrentReportingStatus_360d4d78-b36b-4e4c-ad22-a0d992cfd2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_323682b8-1eac-473b-bf54-8b1b7c507294" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityInteractiveDataCurrent_323682b8-1eac-473b-bf54-8b1b7c507294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_30c20ee2-b84c-47a9-aba7-421d92dbe380" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityFilerCategory_30c20ee2-b84c-47a9-aba7-421d92dbe380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2e97f7bc-c8b1-4f5b-b15e-1a2ae7ae51fc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntitySmallBusiness_2e97f7bc-c8b1-4f5b-b15e-1a2ae7ae51fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c743b4bc-f50f-4b9f-a69c-cd251d4face1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityEmergingGrowthCompany_c743b4bc-f50f-4b9f-a69c-cd251d4face1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_188f0d3a-10ec-4620-919a-ec4812bd4543" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityShellCompany_188f0d3a-10ec-4620-919a-ec4812bd4543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ab03cc19-a8ec-4f06-a1fb-ae7b680fd0d6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ab03cc19-a8ec-4f06-a1fb-ae7b680fd0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5716d9a5-aa04-4f31-b68f-34edd972f630" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_EntityCentralIndexKey_5716d9a5-aa04-4f31-b68f-34edd972f630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ae249166-29a1-4262-81ae-ed60e1d2fbdf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_AmendmentFlag_ae249166-29a1-4262-81ae-ed60e1d2fbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e9f4f45c-d83e-49d3-9d00-b8230f662178" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_CurrentFiscalYearEndDate_e9f4f45c-d83e-49d3-9d00-b8230f662178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4dc175d1-c07f-4b62-90e4-37967179e235" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_DocumentFiscalYearFocus_4dc175d1-c07f-4b62-90e4-37967179e235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a7d640bc-3ca9-4ae6-a05a-e5e420e1e0cc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_352fe1ee-687f-4a29-bd77-13976b6a8cd3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a7d640bc-3ca9-4ae6-a05a-e5e420e1e0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_861baafb-7e15-4cac-938d-b5deef7adbda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9da4d851-3a83-42c2-b7c0-f50d5d6e6105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_861baafb-7e15-4cac-938d-b5deef7adbda" xlink:to="loc_us-gaap_AssetsAbstract_9da4d851-3a83-42c2-b7c0-f50d5d6e6105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4acfb13c-58a2-4ddd-8c5a-968ccbfedde1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9da4d851-3a83-42c2-b7c0-f50d5d6e6105" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4acfb13c-58a2-4ddd-8c5a-968ccbfedde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a287f40f-f70b-45bb-80a5-24b6fd7dac82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4acfb13c-58a2-4ddd-8c5a-968ccbfedde1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a287f40f-f70b-45bb-80a5-24b6fd7dac82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_a22d6d74-3154-4e74-a000-9747bd7a7dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4acfb13c-58a2-4ddd-8c5a-968ccbfedde1" xlink:to="loc_us-gaap_ShortTermInvestments_a22d6d74-3154-4e74-a000-9747bd7a7dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_52e2eaf1-c478-47a4-97b7-14650125dd54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4acfb13c-58a2-4ddd-8c5a-968ccbfedde1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_52e2eaf1-c478-47a4-97b7-14650125dd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_ea29d209-5e17-42e6-ae43-2daecb9a43ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4acfb13c-58a2-4ddd-8c5a-968ccbfedde1" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_ea29d209-5e17-42e6-ae43-2daecb9a43ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_afe5db32-dfb6-4284-8436-a5c44e5edd5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4acfb13c-58a2-4ddd-8c5a-968ccbfedde1" xlink:to="loc_us-gaap_AssetsCurrent_afe5db32-dfb6-4284-8436-a5c44e5edd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8e3da878-6d37-4ed2-8ab7-ee54d3e1937c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9da4d851-3a83-42c2-b7c0-f50d5d6e6105" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8e3da878-6d37-4ed2-8ab7-ee54d3e1937c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_59d1f568-8e92-4900-861d-b78abadd3770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9da4d851-3a83-42c2-b7c0-f50d5d6e6105" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_59d1f568-8e92-4900-861d-b78abadd3770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2bc97646-cd7c-434b-b544-b32f151ca87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9da4d851-3a83-42c2-b7c0-f50d5d6e6105" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2bc97646-cd7c-434b-b544-b32f151ca87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1c462a1e-0534-4376-abef-f6b8bfcee302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9da4d851-3a83-42c2-b7c0-f50d5d6e6105" xlink:to="loc_us-gaap_Assets_1c462a1e-0534-4376-abef-f6b8bfcee302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91b8d636-a2cf-4c63-aaf1-8f51946654e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_861baafb-7e15-4cac-938d-b5deef7adbda" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91b8d636-a2cf-4c63-aaf1-8f51946654e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_80a028e0-2aea-4852-9577-f0cc271ac91f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91b8d636-a2cf-4c63-aaf1-8f51946654e8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_80a028e0-2aea-4852-9577-f0cc271ac91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a294eb03-0447-4b82-8c60-050fcadc989f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80a028e0-2aea-4852-9577-f0cc271ac91f" xlink:to="loc_us-gaap_AccountsPayableCurrent_a294eb03-0447-4b82-8c60-050fcadc989f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b31b40c7-d536-4bb8-80cb-fce2e7b2dbc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80a028e0-2aea-4852-9577-f0cc271ac91f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b31b40c7-d536-4bb8-80cb-fce2e7b2dbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_809013e4-8834-4123-9446-fcc843901ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80a028e0-2aea-4852-9577-f0cc271ac91f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_809013e4-8834-4123-9446-fcc843901ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f6605a47-c941-48a1-9d79-099677d3d71e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80a028e0-2aea-4852-9577-f0cc271ac91f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f6605a47-c941-48a1-9d79-099677d3d71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_75779a3f-c24e-43e9-b265-8c6735246357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80a028e0-2aea-4852-9577-f0cc271ac91f" xlink:to="loc_us-gaap_LiabilitiesCurrent_75779a3f-c24e-43e9-b265-8c6735246357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_f2abcd7b-1971-43ac-b423-0aa390ad8dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91b8d636-a2cf-4c63-aaf1-8f51946654e8" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_f2abcd7b-1971-43ac-b423-0aa390ad8dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0fa70137-6621-4c03-beb0-13afe52a09f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91b8d636-a2cf-4c63-aaf1-8f51946654e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0fa70137-6621-4c03-beb0-13afe52a09f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_95ddd106-4235-457c-9b17-a547dcf4a6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91b8d636-a2cf-4c63-aaf1-8f51946654e8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_95ddd106-4235-457c-9b17-a547dcf4a6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2a4017cb-79f4-4489-b92a-7fe153b7a15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91b8d636-a2cf-4c63-aaf1-8f51946654e8" xlink:to="loc_us-gaap_Liabilities_2a4017cb-79f4-4489-b92a-7fe153b7a15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7df565c9-8f04-4ba7-8587-d23b7d1d4d15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91b8d636-a2cf-4c63-aaf1-8f51946654e8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7df565c9-8f04-4ba7-8587-d23b7d1d4d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_aba7e6ff-3164-4c78-99ce-a92882a171b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91b8d636-a2cf-4c63-aaf1-8f51946654e8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_aba7e6ff-3164-4c78-99ce-a92882a171b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5a675411-7c08-4638-8dec-eb9f7a7f2423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aba7e6ff-3164-4c78-99ce-a92882a171b3" xlink:to="loc_us-gaap_PreferredStockValue_5a675411-7c08-4638-8dec-eb9f7a7f2423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dbc6ec2e-eb86-4ee3-b656-405ec109c125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aba7e6ff-3164-4c78-99ce-a92882a171b3" xlink:to="loc_us-gaap_CommonStockValue_dbc6ec2e-eb86-4ee3-b656-405ec109c125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b3d49a96-be0f-46e0-a622-2766cdcba537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aba7e6ff-3164-4c78-99ce-a92882a171b3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b3d49a96-be0f-46e0-a622-2766cdcba537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivable_dfb3b859-3f29-40ce-9127-4528842db110" xlink:href="crdf-20210930.xsd#crdf_ServiceReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aba7e6ff-3164-4c78-99ce-a92882a171b3" xlink:to="loc_crdf_ServiceReceivable_dfb3b859-3f29-40ce-9127-4528842db110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62830b51-4ed4-4a36-a5a8-e4099f1f2f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aba7e6ff-3164-4c78-99ce-a92882a171b3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62830b51-4ed4-4a36-a5a8-e4099f1f2f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab277c81-4173-4ccd-bfce-c5e46af2a39c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aba7e6ff-3164-4c78-99ce-a92882a171b3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab277c81-4173-4ccd-bfce-c5e46af2a39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_84f84de6-8381-4d02-83d5-bd4ca905a9b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aba7e6ff-3164-4c78-99ce-a92882a171b3" xlink:to="loc_us-gaap_StockholdersEquity_84f84de6-8381-4d02-83d5-bd4ca905a9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dfdc6f94-a24c-4fe2-ae7f-d5f887efec5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91b8d636-a2cf-4c63-aaf1-8f51946654e8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_dfdc6f94-a24c-4fe2-ae7f-d5f887efec5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_38a42335-87e3-4066-9b6d-b28534567c02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_efe155d7-32fe-428b-a872-3dd7002201d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_38a42335-87e3-4066-9b6d-b28534567c02" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_efe155d7-32fe-428b-a872-3dd7002201d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_73df772c-21d8-42a7-8a90-73abdc9d294e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_38a42335-87e3-4066-9b6d-b28534567c02" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_73df772c-21d8-42a7-8a90-73abdc9d294e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8e751ff6-7b4d-4210-ab93-8e2939fa6c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_38a42335-87e3-4066-9b6d-b28534567c02" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8e751ff6-7b4d-4210-ab93-8e2939fa6c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4957552e-4824-4572-b664-b017e770fe5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_38a42335-87e3-4066-9b6d-b28534567c02" xlink:to="loc_us-gaap_CommonStockSharesIssued_4957552e-4824-4572-b664-b017e770fe5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_16f333d9-cbae-4327-8fc9-4ed287127e5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_38a42335-87e3-4066-9b6d-b28534567c02" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_16f333d9-cbae-4327-8fc9-4ed287127e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c6bc59ca-ede0-40de-bff8-7e84ae1544cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3082a786-76c4-49b4-b4a2-9dcece933db1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c6bc59ca-ede0-40de-bff8-7e84ae1544cc" xlink:to="loc_us-gaap_StatementTable_3082a786-76c4-49b4-b4a2-9dcece933db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cf6daa62-5498-4c68-a4f3-15097a38967f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3082a786-76c4-49b4-b4a2-9dcece933db1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cf6daa62-5498-4c68-a4f3-15097a38967f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b4611c80-c807-443a-b1b4-61ef54012a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cf6daa62-5498-4c68-a4f3-15097a38967f" xlink:to="loc_us-gaap_ClassOfStockDomain_b4611c80-c807-443a-b1b4-61ef54012a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_abbd4f06-3331-4ac4-a062-0fbcf3e91a83" xlink:href="crdf-20210930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b4611c80-c807-443a-b1b4-61ef54012a8d" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_abbd4f06-3331-4ac4-a062-0fbcf3e91a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_f818145e-646a-4ca0-afd3-98763d310ef6" xlink:href="crdf-20210930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b4611c80-c807-443a-b1b4-61ef54012a8d" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_f818145e-646a-4ca0-afd3-98763d310ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3082a786-76c4-49b4-b4a2-9dcece933db1" xlink:to="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d7d68abd-05fe-4e5d-af5c-41741cdc6fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_RevenuesAbstract_d7d68abd-05fe-4e5d-af5c-41741cdc6fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5849713-7ebb-4908-8d1f-744dd4c05937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d7d68abd-05fe-4e5d-af5c-41741cdc6fd9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5849713-7ebb-4908-8d1f-744dd4c05937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f0ebe0aa-6d01-43ff-9c84-0b488b37b169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d7d68abd-05fe-4e5d-af5c-41741cdc6fd9" xlink:to="loc_us-gaap_Revenues_f0ebe0aa-6d01-43ff-9c84-0b488b37b169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c1c97e53-9224-4b04-8773-e58613db7f78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c1c97e53-9224-4b04-8773-e58613db7f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bf734c8f-5783-4adc-bf22-72cf582124b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c1c97e53-9224-4b04-8773-e58613db7f78" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bf734c8f-5783-4adc-bf22-72cf582124b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_062c57fb-f0c5-4a74-bd5b-1c54036a9672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c1c97e53-9224-4b04-8773-e58613db7f78" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_062c57fb-f0c5-4a74-bd5b-1c54036a9672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b8cff493-525c-479a-9f5e-953904700141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c1c97e53-9224-4b04-8773-e58613db7f78" xlink:to="loc_us-gaap_OperatingExpenses_b8cff493-525c-479a-9f5e-953904700141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b893454f-1eab-440b-aad1-0583fc4b211e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_OperatingIncomeLoss_b893454f-1eab-440b-aad1-0583fc4b211e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_d9b221cf-7b21-47de-9ee1-acbfc68e5592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_InterestIncomeOperating_d9b221cf-7b21-47de-9ee1-acbfc68e5592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_3387dc1c-d49e-408a-8bc1-7845b61bafc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_3387dc1c-d49e-408a-8bc1-7845b61bafc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2c654578-887f-48c7-9240-7ea50ea47f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2c654578-887f-48c7-9240-7ea50ea47f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d94245fb-c5d3-49a4-8fb3-a084bc6e4f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_NetIncomeLoss_d94245fb-c5d3-49a4-8fb3-a084bc6e4f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_8c430395-606f-4252-8c0f-4bfb0f458fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_8c430395-606f-4252-8c0f-4bfb0f458fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_0cae6232-e110-433e-9442-1ab558b9fa58" xlink:href="crdf-20210930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_0cae6232-e110-433e-9442-1ab558b9fa58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f083e2b6-a017-4d38-bd9a-7836dadbc351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f083e2b6-a017-4d38-bd9a-7836dadbc351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8fc9d2c3-59b3-41b5-b617-34e43182a21d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_EarningsPerShareBasic_8fc9d2c3-59b3-41b5-b617-34e43182a21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3d6cb868-afe2-43a7-8e31-83d60c3b0185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3d6cb868-afe2-43a7-8e31-83d60c3b0185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f173a8d-9765-47ad-a781-06e93f0a1b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f173a8d-9765-47ad-a781-06e93f0a1b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd9d367f-a563-4ff7-af9f-b881b1158edd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4c0cd2-b373-4abd-ac57-9d73a8cf501e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd9d367f-a563-4ff7-af9f-b881b1158edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_53acded0-625f-44d5-9c7d-d9cd27002d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1e5e2e81-087b-4b72-b0af-c9c6a0a8686c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_53acded0-625f-44d5-9c7d-d9cd27002d8e" xlink:to="loc_us-gaap_StatementTable_1e5e2e81-087b-4b72-b0af-c9c6a0a8686c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_469d8632-ba7c-468b-b100-978c09a78238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1e5e2e81-087b-4b72-b0af-c9c6a0a8686c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_469d8632-ba7c-468b-b100-978c09a78238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7061e610-cdc3-48db-affc-84dde34dbfc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_469d8632-ba7c-468b-b100-978c09a78238" xlink:to="loc_us-gaap_ClassOfStockDomain_7061e610-cdc3-48db-affc-84dde34dbfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_33623fbd-fa2c-4d23-b3f9-314df2f19108" xlink:href="crdf-20210930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7061e610-cdc3-48db-affc-84dde34dbfc8" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_33623fbd-fa2c-4d23-b3f9-314df2f19108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_0ffed6d6-fdd2-4f1d-affb-34d7fecc5c01" xlink:href="crdf-20210930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7061e610-cdc3-48db-affc-84dde34dbfc8" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_0ffed6d6-fdd2-4f1d-affb-34d7fecc5c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1e5e2e81-087b-4b72-b0af-c9c6a0a8686c" xlink:to="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_18e911ae-624c-4ab8-bcef-9ff2a4d22961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:to="loc_us-gaap_NetIncomeLoss_18e911ae-624c-4ab8-bcef-9ff2a4d22961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8013516f-7274-4869-89a4-5437c16dfc37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8013516f-7274-4869-89a4-5437c16dfc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1d9fcc7f-f058-40ca-84d5-c6c5eff2cbac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8013516f-7274-4869-89a4-5437c16dfc37" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1d9fcc7f-f058-40ca-84d5-c6c5eff2cbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b774e4de-f728-4702-a437-eb1dba0aadca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b774e4de-f728-4702-a437-eb1dba0aadca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_138ced82-8ae2-4911-bd95-d2d8e1e7028f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_138ced82-8ae2-4911-bd95-d2d8e1e7028f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_a906e65d-53f4-4b7b-93af-4847ddcae695" xlink:href="crdf-20210930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_a906e65d-53f4-4b7b-93af-4847ddcae695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_dc126206-662e-4069-92f9-c78b4f01ec63" xlink:href="crdf-20210930.xsd#crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e168ff96-5ce4-4594-a6af-74c535460389" xlink:to="loc_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic_dc126206-662e-4069-92f9-c78b4f01ec63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7d750f14-e065-4ca8-b1a4-3aacaf76f342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c7a0feb1-728a-4c7d-8637-623735cc9d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7d750f14-e065-4ca8-b1a4-3aacaf76f342" xlink:to="loc_us-gaap_StatementTable_c7a0feb1-728a-4c7d-8637-623735cc9d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_377c8a6f-4c8a-4edc-9c37-a3f5609f810f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c7a0feb1-728a-4c7d-8637-623735cc9d06" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_377c8a6f-4c8a-4edc-9c37-a3f5609f810f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_377c8a6f-4c8a-4edc-9c37-a3f5609f810f" xlink:to="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_048b0bdf-522f-4710-8b74-cfdfae7bf5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:to="loc_us-gaap_PreferredStockMember_048b0bdf-522f-4710-8b74-cfdfae7bf5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_144140e9-113f-43ac-8b88-c34b77bac8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:to="loc_us-gaap_CommonStockMember_144140e9-113f-43ac-8b88-c34b77bac8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2b94d189-e03f-4d36-b907-4fe3cae2a8b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2b94d189-e03f-4d36-b907-4fe3cae2a8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember_5065bece-ba90-49b0-9dc4-416537b985ab" xlink:href="crdf-20210930.xsd#crdf_ServiceReceivableMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:to="loc_crdf_ServiceReceivableMember_5065bece-ba90-49b0-9dc4-416537b985ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_93a29b72-5e42-4f6f-a6e7-76230e5d6d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_93a29b72-5e42-4f6f-a6e7-76230e5d6d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cad5dca2-d565-443a-9518-c815b2035c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8c67229-7734-43cf-81e8-393786045e83" xlink:to="loc_us-gaap_RetainedEarningsMember_cad5dca2-d565-443a-9518-c815b2035c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_863a5177-ee4b-44e5-bde1-5cef1296400b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c7a0feb1-728a-4c7d-8637-623735cc9d06" xlink:to="loc_us-gaap_StatementClassOfStockAxis_863a5177-ee4b-44e5-bde1-5cef1296400b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_da40e8f2-b65d-4246-9bcb-0548f2410d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_863a5177-ee4b-44e5-bde1-5cef1296400b" xlink:to="loc_us-gaap_ClassOfStockDomain_da40e8f2-b65d-4246-9bcb-0548f2410d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_b03d59b1-c45c-46c6-ad83-7cdaf9ea5190" xlink:href="crdf-20210930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_da40e8f2-b65d-4246-9bcb-0548f2410d24" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_b03d59b1-c45c-46c6-ad83-7cdaf9ea5190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_08164e66-e66f-4495-872a-b12c2dde4b9d" xlink:href="crdf-20210930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_da40e8f2-b65d-4246-9bcb-0548f2410d24" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_08164e66-e66f-4495-872a-b12c2dde4b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4325a44f-199a-4380-9f96-718cbfb76da9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c7a0feb1-728a-4c7d-8637-623735cc9d06" xlink:to="loc_us-gaap_StatementLineItems_4325a44f-199a-4380-9f96-718cbfb76da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4325a44f-199a-4380-9f96-718cbfb76da9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_dc3926f8-5e07-4a97-a68b-d5452c999ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_SharesIssued_dc3926f8-5e07-4a97-a68b-d5452c999ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9dc1f497-794a-4755-8ee5-5e8ac3676335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockholdersEquity_9dc1f497-794a-4755-8ee5-5e8ac3676335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_14a910c6-56c0-46e9-a31b-a09b8373dbd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_14a910c6-56c0-46e9-a31b-a09b8373dbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_aed76e8d-5bdf-47c7-8e7b-91f8cc96fd82" xlink:href="crdf-20210930.xsd#crdf_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_aed76e8d-5bdf-47c7-8e7b-91f8cc96fd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_4be5b247-8e27-46a3-99e3-b9041ef6b6a4" xlink:href="crdf-20210930.xsd#crdf_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_4be5b247-8e27-46a3-99e3-b9041ef6b6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d47df68b-3f1f-4e4f-8fd6-f47f6e7724a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d47df68b-3f1f-4e4f-8fd6-f47f6e7724a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_651ac6d1-2c15-4625-90da-3bf290a382a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_DividendsPreferredStock_651ac6d1-2c15-4625-90da-3bf290a382a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_fab2910d-1208-4dfd-b158-6515050f5565" xlink:href="crdf-20210930.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_fab2910d-1208-4dfd-b158-6515050f5565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5ebb832e-dba1-4780-811c-98cf1044a640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_NetIncomeLoss_5ebb832e-dba1-4780-811c-98cf1044a640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5a1c381e-20eb-44fb-bbc7-135b956af3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5a1c381e-20eb-44fb-bbc7-135b956af3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_29d841dc-b8f9-4feb-8212-d9089f0a0183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_29d841dc-b8f9-4feb-8212-d9089f0a0183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockCommonAndWarrantsNetShares_56298817-14f6-4d39-a41b-e05234b12c4b" xlink:href="crdf-20210930.xsd#crdf_SaleOfStockCommonAndWarrantsNetShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_crdf_SaleOfStockCommonAndWarrantsNetShares_56298817-14f6-4d39-a41b-e05234b12c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockValueCommonAndWarrantsNet_0da1b91e-97ec-464a-bb17-5f1442bf20fd" xlink:href="crdf-20210930.xsd#crdf_SaleOfStockValueCommonAndWarrantsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_crdf_SaleOfStockValueCommonAndWarrantsNet_0da1b91e-97ec-464a-bb17-5f1442bf20fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased_a4c36d62-9dc1-4a7e-8760-138dd4d88f92" xlink:href="crdf-20210930.xsd#crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased_a4c36d62-9dc1-4a7e-8760-138dd4d88f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_b1ecd47d-fa1d-45a0-bcbb-48c95eebfb05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_b1ecd47d-fa1d-45a0-bcbb-48c95eebfb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_b90b082c-ecf8-4169-be2c-8375d0f7436b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_b90b082c-ecf8-4169-be2c-8375d0f7436b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_7c7f1169-525d-4253-b94b-dcbd89c2036a" xlink:href="crdf-20210930.xsd#crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_7c7f1169-525d-4253-b94b-dcbd89c2036a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1493410a-f856-4237-bf87-e8a1d024ce2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1493410a-f856-4237-bf87-e8a1d024ce2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bd88d6e7-47eb-4e2f-b525-b972fb502159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bd88d6e7-47eb-4e2f-b525-b972fb502159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fa470c69-327b-40af-94b0-17dfa6d29fcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fa470c69-327b-40af-94b0-17dfa6d29fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b0fe9b3b-f0b6-4f4e-b325-f6dbb4b6a5a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b0fe9b3b-f0b6-4f4e-b325-f6dbb4b6a5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9d0ce68b-bb12-4dde-86e6-81117fe986ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9d0ce68b-bb12-4dde-86e6-81117fe986ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_7875a081-0a9d-4080-9ffb-8088c4f622be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_SharesIssued_7875a081-0a9d-4080-9ffb-8088c4f622be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f5b17036-1790-478c-a23d-6693bed9dcb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fe7972b0-0bf3-44aa-b2cf-6e5efddf59bf" xlink:to="loc_us-gaap_StockholdersEquity_f5b17036-1790-478c-a23d-6693bed9dcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d591abc2-86a3-4376-973d-2a4ecfc612c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c118760a-d85d-4810-8739-a58a006e78a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d591abc2-86a3-4376-973d-2a4ecfc612c0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c118760a-d85d-4810-8739-a58a006e78a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment_92070636-276e-407a-91bf-c412f988130a" xlink:href="crdf-20210930.xsd#crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d591abc2-86a3-4376-973d-2a4ecfc612c0" xlink:to="loc_crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment_92070636-276e-407a-91bf-c412f988130a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsFairValue_b046e957-6ee5-4232-a2ac-bc52983164e1" xlink:href="crdf-20210930.xsd#crdf_WarrantsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d591abc2-86a3-4376-973d-2a4ecfc612c0" xlink:to="loc_crdf_WarrantsFairValue_b046e957-6ee5-4232-a2ac-bc52983164e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_abdfc7b5-8e5f-44f6-be80-4e1cbcefcf09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_48499dbb-2c2f-4ace-b5b0-168d7783477c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_abdfc7b5-8e5f-44f6-be80-4e1cbcefcf09" xlink:to="loc_us-gaap_StatementTable_48499dbb-2c2f-4ace-b5b0-168d7783477c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d95fe390-316b-470a-8b78-938fd37044a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_48499dbb-2c2f-4ace-b5b0-168d7783477c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d95fe390-316b-470a-8b78-938fd37044a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2a6032b6-3070-4a42-9b5c-729d3585b87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d95fe390-316b-470a-8b78-938fd37044a6" xlink:to="loc_us-gaap_ClassOfStockDomain_2a6032b6-3070-4a42-9b5c-729d3585b87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_a5b1d621-39df-401e-ae1f-0b4d83e08857" xlink:href="crdf-20210930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2a6032b6-3070-4a42-9b5c-729d3585b87c" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_a5b1d621-39df-401e-ae1f-0b4d83e08857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_cfcf85fe-1982-4b68-97cd-0d01e71f3426" xlink:href="crdf-20210930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2a6032b6-3070-4a42-9b5c-729d3585b87c" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_cfcf85fe-1982-4b68-97cd-0d01e71f3426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_48499dbb-2c2f-4ace-b5b0-168d7783477c" xlink:to="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_891b5b24-85ed-43a8-aba9-2733a53271a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_891b5b24-85ed-43a8-aba9-2733a53271a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ae3bc316-f462-41e9-b088-d18de58e830b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_891b5b24-85ed-43a8-aba9-2733a53271a2" xlink:to="loc_us-gaap_NetIncomeLoss_ae3bc316-f462-41e9-b088-d18de58e830b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_891b5b24-85ed-43a8-aba9-2733a53271a2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_d10f5dbb-7ee8-46a0-b0df-fd91865147f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_d10f5dbb-7ee8-46a0-b0df-fd91865147f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_c2842032-21dc-4fe9-938d-07b93a3c88cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_c2842032-21dc-4fe9-938d-07b93a3c88cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_72d6c74f-c239-4d62-aba7-e21d89de8ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_72d6c74f-c239-4d62-aba7-e21d89de8ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a0e3f1e0-cad8-4dd3-9d7d-537886252731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_us-gaap_ShareBasedCompensation_a0e3f1e0-cad8-4dd3-9d7d-537886252731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b58886b7-776f-4573-989f-519c81521f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b58886b7-776f-4573-989f-519c81521f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_f941fbc9-a607-43f3-9915-55338a783797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_f941fbc9-a607-43f3-9915-55338a783797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_33b5daf5-f7b3-428f-9be4-5dfcdcfe1817" xlink:href="crdf-20210930.xsd#crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived_33b5daf5-f7b3-428f-9be4-5dfcdcfe1817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5974c167-6299-47c7-bbb4-63d706cb066f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2b8e0e66-9453-4ac3-b741-c0d82088c7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2b8e0e66-9453-4ac3-b741-c0d82088c7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dc5af865-f37f-493f-8940-1dc869abbfd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dc5af865-f37f-493f-8940-1dc869abbfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_86b68273-74b8-4ab6-b43c-df2eb8054a97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_86b68273-74b8-4ab6-b43c-df2eb8054a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_25ca8536-e9e7-47b2-9900-67afe5184a31" xlink:href="crdf-20210930.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_25ca8536-e9e7-47b2-9900-67afe5184a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ab57fc3d-2bb1-4a0d-960b-1933f3b7fbed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ab57fc3d-2bb1-4a0d-960b-1933f3b7fbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_ee0e638f-908c-41af-b59d-bfe8f3be6a54" xlink:href="crdf-20210930.xsd#crdf_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_ee0e638f-908c-41af-b59d-bfe8f3be6a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_733ae1b2-bd8d-47c9-b060-a6122bc9d3a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5c7a74f-8089-433f-959f-0757f41f0e96" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_733ae1b2-bd8d-47c9-b060-a6122bc9d3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dfcc0722-7966-4f00-b985-ac7a96332572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_891b5b24-85ed-43a8-aba9-2733a53271a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dfcc0722-7966-4f00-b985-ac7a96332572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd12d7b0-d954-4214-b870-7c1635bfea28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd12d7b0-d954-4214-b870-7c1635bfea28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b1a23290-812e-4fd7-a704-c1504fcd850b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd12d7b0-d954-4214-b870-7c1635bfea28" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b1a23290-812e-4fd7-a704-c1504fcd850b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9669b01e-4000-4560-be67-10bcd33f64fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd12d7b0-d954-4214-b870-7c1635bfea28" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9669b01e-4000-4560-be67-10bcd33f64fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1972fdfc-3af4-4a6d-84cb-a9f8aec0ade4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd12d7b0-d954-4214-b870-7c1635bfea28" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1972fdfc-3af4-4a6d-84cb-a9f8aec0ade4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ba65efd7-f7a8-4a87-8206-e0a339de2cac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd12d7b0-d954-4214-b870-7c1635bfea28" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ba65efd7-f7a8-4a87-8206-e0a339de2cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0c4ee3b-1c38-453e-b044-89d581d7e82d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd12d7b0-d954-4214-b870-7c1635bfea28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0c4ee3b-1c38-453e-b044-89d581d7e82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_61db33d2-3490-49d2-8615-edb60098e5c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_61db33d2-3490-49d2-8615-edb60098e5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_760ad873-d207-4fc5-9c2b-bc48d0ed2846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_760ad873-d207-4fc5-9c2b-bc48d0ed2846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4a9ea00d-9dba-4a07-8e07-25e516750a95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4a9ea00d-9dba-4a07-8e07-25e516750a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_4d72f6cc-f3b7-4049-90be-8eee0abb9252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_4d72f6cc-f3b7-4049-90be-8eee0abb9252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ad976e61-be77-46cf-a2aa-13450116bfe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ad976e61-be77-46cf-a2aa-13450116bfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc69154c-a664-4f35-90cd-2b7985f0a2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9df1bf4-a43e-43c3-9565-1391d22e5394" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc69154c-a664-4f35-90cd-2b7985f0a2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f35f0012-933a-451d-8ead-56af2049dc1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f35f0012-933a-451d-8ead-56af2049dc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c81dfe76-9779-43be-a96a-3462673c3ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c81dfe76-9779-43be-a96a-3462673c3ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7b0066f0-af56-48d1-9618-588e2cb02a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7b0066f0-af56-48d1-9618-588e2cb02a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_ca59cd8e-f484-4ec4-984d-217fc8652e22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_ca59cd8e-f484-4ec4-984d-217fc8652e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_6eb7c8fa-17bb-4929-af98-560de1ee51c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ca59cd8e-f484-4ec4-984d-217fc8652e22" xlink:to="loc_us-gaap_IncomeTaxesPaid_6eb7c8fa-17bb-4929-af98-560de1ee51c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b118ba9-1c45-4dfd-af91-84c5968f42be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cac6c07a-d61c-4bd2-abbd-0ec869e188b8" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b118ba9-1c45-4dfd-af91-84c5968f42be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockDividendAccrued_e429d2ae-30b8-465a-8a0d-60d0aee176aa" xlink:href="crdf-20210930.xsd#crdf_PreferredStockDividendAccrued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b118ba9-1c45-4dfd-af91-84c5968f42be" xlink:to="loc_crdf_PreferredStockDividendAccrued_e429d2ae-30b8-465a-8a0d-60d0aee176aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_445fe606-417a-4b8f-9f55-9fa2e328a7a8" xlink:href="crdf-20210930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b118ba9-1c45-4dfd-af91-84c5968f42be" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_445fe606-417a-4b8f-9f55-9fa2e328a7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_d823ee4f-8260-40fe-83a9-564467a36340" xlink:href="crdf-20210930.xsd#crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b118ba9-1c45-4dfd-af91-84c5968f42be" xlink:to="loc_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_d823ee4f-8260-40fe-83a9-564467a36340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="crdf-20210930.xsd#CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9d22f4b4-003a-4f75-b4a6-82248bd21316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b016e8d5-a2d5-4d27-9543-4fee07cb9d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d22f4b4-003a-4f75-b4a6-82248bd21316" xlink:to="loc_us-gaap_StatementTable_b016e8d5-a2d5-4d27-9543-4fee07cb9d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_50e9f99e-0a98-46eb-824e-866f74f5807e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b016e8d5-a2d5-4d27-9543-4fee07cb9d6d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_50e9f99e-0a98-46eb-824e-866f74f5807e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8eb71426-1b37-46db-854a-97c871023617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50e9f99e-0a98-46eb-824e-866f74f5807e" xlink:to="loc_us-gaap_ClassOfStockDomain_8eb71426-1b37-46db-854a-97c871023617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_626cd332-c036-4e21-8a6e-5aa5abcda89c" xlink:href="crdf-20210930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8eb71426-1b37-46db-854a-97c871023617" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_626cd332-c036-4e21-8a6e-5aa5abcda89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_be3431e6-d88d-472a-9fe3-f15fe1dfac50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b016e8d5-a2d5-4d27-9543-4fee07cb9d6d" xlink:to="loc_us-gaap_StatementLineItems_be3431e6-d88d-472a-9fe3-f15fe1dfac50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_06b26d02-eb90-4397-9690-23ab12fee0a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_be3431e6-d88d-472a-9fe3-f15fe1dfac50" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_06b26d02-eb90-4397-9690-23ab12fee0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment_35aab7ea-0d84-4cdd-ae55-79c3edfb47de" xlink:href="crdf-20210930.xsd#crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_be3431e6-d88d-472a-9fe3-f15fe1dfac50" xlink:to="loc_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment_35aab7ea-0d84-4cdd-ae55-79c3edfb47de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="crdf-20210930.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0669d438-5aa9-4e42-8491-69abb0b1f52f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d624a214-446c-496e-8577-ba755bbfe7ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0669d438-5aa9-4e42-8491-69abb0b1f52f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d624a214-446c-496e-8577-ba755bbfe7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f1836116-e173-4c45-9637-caa79dcc60ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_2a4b6490-e41a-45be-8fe1-35dd05348642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f1836116-e173-4c45-9637-caa79dcc60ee" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_2a4b6490-e41a-45be-8fe1-35dd05348642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="crdf-20210930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c6792b01-4b39-47d8-b85a-25c028303727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7ceaa781-262a-49fc-a7ff-99f1f9448538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c6792b01-4b39-47d8-b85a-25c028303727" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7ceaa781-262a-49fc-a7ff-99f1f9448538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="crdf-20210930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7bc0badb-4cf7-4a58-a43e-cf5d1d38c0ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_9764cec9-9b1b-4243-b6b6-04510eea617e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7bc0badb-4cf7-4a58-a43e-cf5d1d38c0ed" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_9764cec9-9b1b-4243-b6b6-04510eea617e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_426900c0-3b18-499a-a175-85a9ff50a686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7bc0badb-4cf7-4a58-a43e-cf5d1d38c0ed" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_426900c0-3b18-499a-a175-85a9ff50a686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1c5a5204-a5d0-4703-9a34-0670353fb136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7bc0badb-4cf7-4a58-a43e-cf5d1d38c0ed" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1c5a5204-a5d0-4703-9a34-0670353fb136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="crdf-20210930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4f15359b-576c-47a9-b6fd-a2e455119203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_19c3e8a2-ee7e-493a-b13d-62bef8e4e5a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f15359b-576c-47a9-b6fd-a2e455119203" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_19c3e8a2-ee7e-493a-b13d-62bef8e4e5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_82b8f341-70d6-4d24-b9d2-a9e5dc93c319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23a1a6e3-0cf1-4aae-8a82-28332179c3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82b8f341-70d6-4d24-b9d2-a9e5dc93c319" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23a1a6e3-0cf1-4aae-8a82-28332179c3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_48458cff-3a46-47b1-91bc-33009fe0d69c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23a1a6e3-0cf1-4aae-8a82-28332179c3ae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_48458cff-3a46-47b1-91bc-33009fe0d69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_748b8cd4-6ff6-4643-8e6a-408e6151b086" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_48458cff-3a46-47b1-91bc-33009fe0d69c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_748b8cd4-6ff6-4643-8e6a-408e6151b086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c9dd36d6-c325-462b-bf7a-ce26c5e5dc34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_748b8cd4-6ff6-4643-8e6a-408e6151b086" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c9dd36d6-c325-462b-bf7a-ce26c5e5dc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_24948ab4-b484-4a9b-91a8-f1e357caba35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_748b8cd4-6ff6-4643-8e6a-408e6151b086" xlink:to="loc_us-gaap_WarrantMember_24948ab4-b484-4a9b-91a8-f1e357caba35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4902c0ce-5158-4b6a-b047-46cefd3710c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_748b8cd4-6ff6-4643-8e6a-408e6151b086" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4902c0ce-5158-4b6a-b047-46cefd3710c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5d329895-a434-4a73-8b82-74d25814ce5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_748b8cd4-6ff6-4643-8e6a-408e6151b086" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5d329895-a434-4a73-8b82-74d25814ce5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_121ee473-9348-44f1-9630-6b3bd585857e" xlink:href="crdf-20210930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_748b8cd4-6ff6-4643-8e6a-408e6151b086" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_121ee473-9348-44f1-9630-6b3bd585857e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_076f94e6-e6b3-43a9-8f7f-c9f423d37df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23a1a6e3-0cf1-4aae-8a82-28332179c3ae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_076f94e6-e6b3-43a9-8f7f-c9f423d37df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aeaab252-3256-426e-9a8b-1df0470dae6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_076f94e6-e6b3-43a9-8f7f-c9f423d37df3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aeaab252-3256-426e-9a8b-1df0470dae6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="crdf-20210930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_485fb303-2d8e-4c7c-99c4-a117161a18ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b5b5cd38-640d-4500-be66-6f4dba17f521" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_485fb303-2d8e-4c7c-99c4-a117161a18ec" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b5b5cd38-640d-4500-be66-6f4dba17f521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="crdf-20210930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_aba3428a-1acc-4381-8800-9290e6168204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_31efbbf6-1824-4ecc-a120-5a1d7b800c56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_aba3428a-1acc-4381-8800-9290e6168204" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_31efbbf6-1824-4ecc-a120-5a1d7b800c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6b02ba39-fe2c-4e5f-93ba-77e843e72e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5014418f-f28a-4bb7-9a51-8811381f1c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6b02ba39-fe2c-4e5f-93ba-77e843e72e72" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5014418f-f28a-4bb7-9a51-8811381f1c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_797b7909-9424-42d6-bdb9-6554b8c8ec81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5014418f-f28a-4bb7-9a51-8811381f1c15" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_797b7909-9424-42d6-bdb9-6554b8c8ec81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_646d8f95-84b8-4a64-98f1-3146020964a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_797b7909-9424-42d6-bdb9-6554b8c8ec81" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_646d8f95-84b8-4a64-98f1-3146020964a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6d31a30b-bc5f-414d-9b31-6f0051c673c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_646d8f95-84b8-4a64-98f1-3146020964a0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6d31a30b-bc5f-414d-9b31-6f0051c673c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_20d807c9-167a-4929-b438-acfc5caa5b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5014418f-f28a-4bb7-9a51-8811381f1c15" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_20d807c9-167a-4929-b438-acfc5caa5b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c964db6-b218-4ccf-9504-e2fb8312b16e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_20d807c9-167a-4929-b438-acfc5caa5b2d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c964db6-b218-4ccf-9504-e2fb8312b16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_17a06a0f-fd9a-4c84-ae03-a7ee56acb687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c964db6-b218-4ccf-9504-e2fb8312b16e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_17a06a0f-fd9a-4c84-ae03-a7ee56acb687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_923c355c-e0b0-4783-841c-1440b07c36df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c964db6-b218-4ccf-9504-e2fb8312b16e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_923c355c-e0b0-4783-841c-1440b07c36df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5b19771a-4f3a-4e64-a1ed-b127054bbbd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7c964db6-b218-4ccf-9504-e2fb8312b16e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5b19771a-4f3a-4e64-a1ed-b127054bbbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_e2010eb7-8712-4664-907c-86b82ffbe147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5014418f-f28a-4bb7-9a51-8811381f1c15" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_e2010eb7-8712-4664-907c-86b82ffbe147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4b020f32-83bb-4eb9-8220-f2021f404216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e2010eb7-8712-4664-907c-86b82ffbe147" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4b020f32-83bb-4eb9-8220-f2021f404216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_19cb41be-07f7-44da-b4da-98a50b832e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4b020f32-83bb-4eb9-8220-f2021f404216" xlink:to="loc_us-gaap_MoneyMarketFundsMember_19cb41be-07f7-44da-b4da-98a50b832e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fbe3a5bb-d48d-4378-9783-edd58c96a213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5014418f-f28a-4bb7-9a51-8811381f1c15" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fbe3a5bb-d48d-4378-9783-edd58c96a213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b11d64a5-5125-4b02-9c8a-ae2e21ac07f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fbe3a5bb-d48d-4378-9783-edd58c96a213" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b11d64a5-5125-4b02-9c8a-ae2e21ac07f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_92930599-e99c-46b7-b16d-09e8eba21816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b11d64a5-5125-4b02-9c8a-ae2e21ac07f0" xlink:to="loc_us-gaap_CertificatesOfDepositMember_92930599-e99c-46b7-b16d-09e8eba21816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b0d67c34-001b-4b73-ba56-36d6eb51f7c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b11d64a5-5125-4b02-9c8a-ae2e21ac07f0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b0d67c34-001b-4b73-ba56-36d6eb51f7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d3338cd0-44c7-4816-b814-54b7b7ed5a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b11d64a5-5125-4b02-9c8a-ae2e21ac07f0" xlink:to="loc_us-gaap_CommercialPaperMember_d3338cd0-44c7-4816-b814-54b7b7ed5a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_49505039-faf9-4576-9685-38982aa0467d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b11d64a5-5125-4b02-9c8a-ae2e21ac07f0" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_49505039-faf9-4576-9685-38982aa0467d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5048c001-5c95-4d5a-8451-576cbaf5305f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b11d64a5-5125-4b02-9c8a-ae2e21ac07f0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5048c001-5c95-4d5a-8451-576cbaf5305f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0dad4467-2004-458d-9656-2c8f05c16019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5014418f-f28a-4bb7-9a51-8811381f1c15" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0dad4467-2004-458d-9656-2c8f05c16019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_9937d382-d869-49a3-b2d0-f67fadd1448e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0dad4467-2004-458d-9656-2c8f05c16019" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_9937d382-d869-49a3-b2d0-f67fadd1448e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3bb53f02-553e-4b97-8e39-c9d0f73be096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9937d382-d869-49a3-b2d0-f67fadd1448e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3bb53f02-553e-4b97-8e39-c9d0f73be096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc6bce46-1df4-46be-a47e-120dcc86331b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9937d382-d869-49a3-b2d0-f67fadd1448e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc6bce46-1df4-46be-a47e-120dcc86331b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9d772f98-cbb5-4992-acf3-c7a58de66980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9937d382-d869-49a3-b2d0-f67fadd1448e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9d772f98-cbb5-4992-acf3-c7a58de66980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_40533604-7ebc-4861-b067-24a35b091724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0dad4467-2004-458d-9656-2c8f05c16019" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_40533604-7ebc-4861-b067-24a35b091724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_0483aa65-b4e7-46d6-a27b-89054c770cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_40533604-7ebc-4861-b067-24a35b091724" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_0483aa65-b4e7-46d6-a27b-89054c770cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_fe33db45-165c-44cb-a38a-3f39621f1743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_40533604-7ebc-4861-b067-24a35b091724" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_fe33db45-165c-44cb-a38a-3f39621f1743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation" xlink:type="simple" xlink:href="crdf-20210930.xsd#SupplementaryBalanceSheetInformation"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb5edd60-5de8-4356-b7c5-4f824d4a0182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8e87fe73-8032-4d3b-83d6-2860f4950f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb5edd60-5de8-4356-b7c5-4f824d4a0182" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8e87fe73-8032-4d3b-83d6-2860f4950f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables" xlink:type="simple" xlink:href="crdf-20210930.xsd#SupplementaryBalanceSheetInformationTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ad92308-9d1e-4d17-b6d9-31c55a905779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d40e1dbf-37f2-4622-9a1e-2060ead4a07a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ad92308-9d1e-4d17-b6d9-31c55a905779" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d40e1dbf-37f2-4622-9a1e-2060ead4a07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_37ec6e03-7fc1-4072-a0f4-f0b08f5b87dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ad92308-9d1e-4d17-b6d9-31c55a905779" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_37ec6e03-7fc1-4072-a0f4-f0b08f5b87dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_012f9d51-a819-48f1-a062-30d25ebf0faf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c67ef28-5bcf-4bc6-8273-48a950ca9200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_012f9d51-a819-48f1-a062-30d25ebf0faf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c67ef28-5bcf-4bc6-8273-48a950ca9200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5d735d44-893f-4990-9e50-470396a80a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c67ef28-5bcf-4bc6-8273-48a950ca9200" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5d735d44-893f-4990-9e50-470396a80a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e121cd-27b2-476d-82b9-5a46ff056ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5d735d44-893f-4990-9e50-470396a80a1f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e121cd-27b2-476d-82b9-5a46ff056ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f6c1ca27-a622-4c9e-9fd8-5467b20a293f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e121cd-27b2-476d-82b9-5a46ff056ddc" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f6c1ca27-a622-4c9e-9fd8-5467b20a293f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_192f61ea-117b-48ea-8dbf-8b8b94c30e94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e121cd-27b2-476d-82b9-5a46ff056ddc" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_192f61ea-117b-48ea-8dbf-8b8b94c30e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4de149ef-b330-44fc-af4b-7fce1dfda0a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e121cd-27b2-476d-82b9-5a46ff056ddc" xlink:to="loc_us-gaap_CommercialPaperMember_4de149ef-b330-44fc-af4b-7fce1dfda0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_5857e58e-25cd-42bd-8f7e-ac518c119e41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e121cd-27b2-476d-82b9-5a46ff056ddc" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_5857e58e-25cd-42bd-8f7e-ac518c119e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_47860530-be4a-4a2d-a727-2c8f92ae3751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e121cd-27b2-476d-82b9-5a46ff056ddc" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_47860530-be4a-4a2d-a727-2c8f92ae3751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cefcf350-7e5f-4dff-8cef-bea7a49e0ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c67ef28-5bcf-4bc6-8273-48a950ca9200" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cefcf350-7e5f-4dff-8cef-bea7a49e0ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_af7a9ffa-d435-4ca1-9d8f-0ad7b49b5d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cefcf350-7e5f-4dff-8cef-bea7a49e0ce1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_af7a9ffa-d435-4ca1-9d8f-0ad7b49b5d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c6fb7f05-e1ae-48da-832a-4dc1387ffeb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cefcf350-7e5f-4dff-8cef-bea7a49e0ce1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c6fb7f05-e1ae-48da-832a-4dc1387ffeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ca3c9e57-4415-490d-b262-c9feb97e7374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cefcf350-7e5f-4dff-8cef-bea7a49e0ce1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ca3c9e57-4415-490d-b262-c9feb97e7374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dd352b34-3205-433e-a41f-b0bef0f2d8fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cefcf350-7e5f-4dff-8cef-bea7a49e0ce1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dd352b34-3205-433e-a41f-b0bef0f2d8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e621e96-c015-4634-9825-2f04e099a875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74afa3a7-a2f2-4134-8d1f-c6dfedb707d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e621e96-c015-4634-9825-2f04e099a875" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74afa3a7-a2f2-4134-8d1f-c6dfedb707d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2595f3d-7876-49f6-88af-f29ad5639a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74afa3a7-a2f2-4134-8d1f-c6dfedb707d9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2595f3d-7876-49f6-88af-f29ad5639a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_969852c3-6808-4c0a-84b4-bf4a07f7142e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2595f3d-7876-49f6-88af-f29ad5639a27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_969852c3-6808-4c0a-84b4-bf4a07f7142e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember_bc9f74af-9110-43f5-9c23-f443225649b8" xlink:href="crdf-20210930.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_969852c3-6808-4c0a-84b4-bf4a07f7142e" xlink:to="loc_crdf_FurnitureAndOfficeEquipmentMember_bc9f74af-9110-43f5-9c23-f443225649b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0f396c74-0688-404a-88dd-aa995f9525ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_969852c3-6808-4c0a-84b4-bf4a07f7142e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0f396c74-0688-404a-88dd-aa995f9525ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c9f074ba-a3ca-485c-8100-7a94e9fe8091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_969852c3-6808-4c0a-84b4-bf4a07f7142e" xlink:to="loc_us-gaap_EquipmentMember_c9f074ba-a3ca-485c-8100-7a94e9fe8091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c3a9dfb-af17-48cc-bbc5-4fb7980fc90b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_74afa3a7-a2f2-4134-8d1f-c6dfedb707d9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c3a9dfb-af17-48cc-bbc5-4fb7980fc90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_40732f46-92bc-4e9c-9557-2c03ff4e256e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c3a9dfb-af17-48cc-bbc5-4fb7980fc90b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_40732f46-92bc-4e9c-9557-2c03ff4e256e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f41b048-e2dc-4617-8e7b-2a9c8b80b7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c3a9dfb-af17-48cc-bbc5-4fb7980fc90b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1f41b048-e2dc-4617-8e7b-2a9c8b80b7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a9d85f92-ca66-4186-aa03-a15657eabafc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c3a9dfb-af17-48cc-bbc5-4fb7980fc90b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a9d85f92-ca66-4186-aa03-a15657eabafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/Leases" xlink:type="simple" xlink:href="crdf-20210930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6685079d-518f-44db-937d-7c9435a1b97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_64824da8-6c2f-4357-b2ac-6e05454b3a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6685079d-518f-44db-937d-7c9435a1b97c" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_64824da8-6c2f-4357-b2ac-6e05454b3a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_6b1ac1c3-646b-449a-a284-9075537f408f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6685079d-518f-44db-937d-7c9435a1b97c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_6b1ac1c3-646b-449a-a284-9075537f408f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesTables" xlink:type="simple" xlink:href="crdf-20210930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_359bdc87-c255-4c90-a434-fb46dc5417a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_28dc1888-3705-49a6-9600-5a18df118d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_359bdc87-c255-4c90-a434-fb46dc5417a0" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_28dc1888-3705-49a6-9600-5a18df118d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_ccaf4dce-1ade-4057-af46-b6a607016cab" xlink:href="crdf-20210930.xsd#crdf_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_359bdc87-c255-4c90-a434-fb46dc5417a0" xlink:to="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_ccaf4dce-1ade-4057-af46-b6a607016cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a26d637e-4977-4609-bfb4-60eb47e0aa64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_359bdc87-c255-4c90-a434-fb46dc5417a0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a26d637e-4977-4609-bfb4-60eb47e0aa64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8c90295f-6bf0-4422-8082-178707eda94b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_888e204d-066d-4801-a081-92f652d2ebf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8c90295f-6bf0-4422-8082-178707eda94b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_888e204d-066d-4801-a081-92f652d2ebf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3a014bc7-1850-4c8d-98f1-83c5819571c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_888e204d-066d-4801-a081-92f652d2ebf6" xlink:to="loc_srt_StatementScenarioAxis_3a014bc7-1850-4c8d-98f1-83c5819571c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_62b8fc5f-6554-4ab2-b360-9ce63300d371" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_3a014bc7-1850-4c8d-98f1-83c5819571c4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_62b8fc5f-6554-4ab2-b360-9ce63300d371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_1ab81ab7-911d-4398-894a-cd7bce52c621" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_62b8fc5f-6554-4ab2-b360-9ce63300d371" xlink:to="loc_srt_ScenarioForecastMember_1ab81ab7-911d-4398-894a-cd7bce52c621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_888e204d-066d-4801-a081-92f652d2ebf6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorNumberOfSubleases_4f2ae0b7-22d4-4d63-8c2c-1ddbba727754" xlink:href="crdf-20210930.xsd#crdf_LessorNumberOfSubleases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_crdf_LessorNumberOfSubleases_4f2ae0b7-22d4-4d63-8c2c-1ddbba727754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany_f2bb4342-5b38-447d-ae9e-0c0080566746" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany_f2bb4342-5b38-447d-ae9e-0c0080566746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease_eb505a40-f994-479c-8ef4-0562c685afc7" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease_eb505a40-f994-479c-8ef4-0562c685afc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAreaOfLease_b11fbe25-7982-496b-9ba1-7abbe9de876a" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseAreaOfLease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_crdf_LesseeOperatingLeaseAreaOfLease_b11fbe25-7982-496b-9ba1-7abbe9de876a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorAreaOfSublease_9652a06e-24b8-40e4-be08-7b996137f451" xlink:href="crdf-20210930.xsd#crdf_LessorAreaOfSublease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_crdf_LessorAreaOfSublease_9652a06e-24b8-40e4-be08-7b996137f451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_f841f6a8-10c7-432a-adf5-2471846128f0" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_f841f6a8-10c7-432a-adf5-2471846128f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_8b79c9bd-e6e3-40dc-87bf-33446a771635" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_aba3c575-f831-4a61-86ad-e399fed0ca71" xlink:to="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_8b79c9bd-e6e3-40dc-87bf-33446a771635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bca7a5b2-940d-4b1f-825b-2b674dd0533c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_e5d65c9c-93a7-43ba-b6f6-c9e7751e6dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bca7a5b2-940d-4b1f-825b-2b674dd0533c" xlink:to="loc_us-gaap_OperatingLeaseCost_e5d65c9c-93a7-43ba-b6f6-c9e7751e6dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_796d22ac-ce2c-4baa-93f3-3f8aaa2bb5eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bca7a5b2-940d-4b1f-825b-2b674dd0533c" xlink:to="loc_us-gaap_SubleaseIncome_796d22ac-ce2c-4baa-93f3-3f8aaa2bb5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_44e1bb76-e6c8-4ff3-bbef-ae833ec4cbd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bca7a5b2-940d-4b1f-825b-2b674dd0533c" xlink:to="loc_us-gaap_LeaseCost_44e1bb76-e6c8-4ff3-bbef-ae833ec4cbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_221eb19c-5d82-4ef0-a862-66dbc54723b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5fe3b1fe-3f95-4866-a92f-44e0d5b71781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_221eb19c-5d82-4ef0-a862-66dbc54723b2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5fe3b1fe-3f95-4866-a92f-44e0d5b71781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b4000b78-4443-4584-8070-fcea882d44f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_221eb19c-5d82-4ef0-a862-66dbc54723b2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b4000b78-4443-4584-8070-fcea882d44f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f2ac9ba7-29e1-428b-929c-4b652a339d27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_221eb19c-5d82-4ef0-a862-66dbc54723b2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f2ac9ba7-29e1-428b-929c-4b652a339d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bc716c31-6e4d-4e9f-b078-e60ccd53ea6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_221eb19c-5d82-4ef0-a862-66dbc54723b2" xlink:to="loc_us-gaap_OperatingLeaseLiability_bc716c31-6e4d-4e9f-b078-e60ccd53ea6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c25bcf71-ca8a-437c-9c9d-7d4e7a904758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_221eb19c-5d82-4ef0-a862-66dbc54723b2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c25bcf71-ca8a-437c-9c9d-7d4e7a904758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_aaa57048-556e-4411-ad42-557419a44b72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_221eb19c-5d82-4ef0-a862-66dbc54723b2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_aaa57048-556e-4411-ad42-557419a44b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8689ce0f-7f67-4c9c-9bd3-0038116c2e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_1d43427f-8349-47b5-95ab-d8bb841d4f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8689ce0f-7f67-4c9c-9bd3-0038116c2e37" xlink:to="loc_us-gaap_OperatingLeasePayments_1d43427f-8349-47b5-95ab-d8bb841d4f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_209647c2-e85c-4e53-b568-eaea8920d03d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8689ce0f-7f67-4c9c-9bd3-0038116c2e37" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_209647c2-e85c-4e53-b568-eaea8920d03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b8d62be2-8fe4-4235-a58f-28ae338c2948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c7d2861f-8fd3-47c7-a3ea-60076721cadc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b8d62be2-8fe4-4235-a58f-28ae338c2948" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c7d2861f-8fd3-47c7-a3ea-60076721cadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_209c8fe0-7971-4bcb-8a0b-a7779f0d0f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c7d2861f-8fd3-47c7-a3ea-60076721cadc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_209c8fe0-7971-4bcb-8a0b-a7779f0d0f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c6157d9a-52c1-4cfa-af8a-f46b4f7fc444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c7d2861f-8fd3-47c7-a3ea-60076721cadc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c6157d9a-52c1-4cfa-af8a-f46b4f7fc444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b7267b59-c8c5-46f5-af7a-14d8c7e05a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c7d2861f-8fd3-47c7-a3ea-60076721cadc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b7267b59-c8c5-46f5-af7a-14d8c7e05a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_32fbc630-7eef-4927-83ff-e5d1420dff7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c7d2861f-8fd3-47c7-a3ea-60076721cadc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_32fbc630-7eef-4927-83ff-e5d1420dff7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c75c90ec-8ef0-4664-a69a-5c498b90c226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c7d2861f-8fd3-47c7-a3ea-60076721cadc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c75c90ec-8ef0-4664-a69a-5c498b90c226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_ff9d05f7-3651-455f-93e1-1bb7b1a1b13a" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c7d2861f-8fd3-47c7-a3ea-60076721cadc" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_ff9d05f7-3651-455f-93e1-1bb7b1a1b13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_be3d540c-d178-4f83-b6df-35febeaf5f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c7d2861f-8fd3-47c7-a3ea-60076721cadc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_be3d540c-d178-4f83-b6df-35febeaf5f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_46085d2f-7e32-44ce-825c-4a80d9ad9117" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c7d2861f-8fd3-47c7-a3ea-60076721cadc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_46085d2f-7e32-44ce-825c-4a80d9ad9117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b50f8238-fe3b-48f2-bb23-73b02280ad57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c7d2861f-8fd3-47c7-a3ea-60076721cadc" xlink:to="loc_us-gaap_OperatingLeaseLiability_b50f8238-fe3b-48f2-bb23-73b02280ad57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_21dc6124-1863-4f34-ad50-d69137285084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b8d62be2-8fe4-4235-a58f-28ae338c2948" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_21dc6124-1863-4f34-ad50-d69137285084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_936e2cc8-135c-4695-b142-5117a5a3c095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_21dc6124-1863-4f34-ad50-d69137285084" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_936e2cc8-135c-4695-b142-5117a5a3c095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_28ba228d-f1cc-4346-a290-3e30c05a994f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_21dc6124-1863-4f34-ad50-d69137285084" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_28ba228d-f1cc-4346-a290-3e30c05a994f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_24629280-cfd2-4668-be85-3b82b4c2a7be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_21dc6124-1863-4f34-ad50-d69137285084" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_24629280-cfd2-4668-be85-3b82b4c2a7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_b5a7b51b-e6c9-4946-a3ed-b93e813d5883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_21dc6124-1863-4f34-ad50-d69137285084" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_b5a7b51b-e6c9-4946-a3ed-b93e813d5883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_2b05f95e-725c-4c06-b76e-ec7b16027b83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_21dc6124-1863-4f34-ad50-d69137285084" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_2b05f95e-725c-4c06-b76e-ec7b16027b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_7c6e7d6c-ef01-41c1-a4d3-1d19b38fccd3" xlink:href="crdf-20210930.xsd#crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_21dc6124-1863-4f34-ad50-d69137285084" xlink:to="loc_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_7c6e7d6c-ef01-41c1-a4d3-1d19b38fccd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e468bb8e-3fa8-43bb-916f-bd8d5e9d8f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_21dc6124-1863-4f34-ad50-d69137285084" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e468bb8e-3fa8-43bb-916f-bd8d5e9d8f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_773a8d99-f03a-441d-9cb8-22c16c29d58c" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b8d62be2-8fe4-4235-a58f-28ae338c2948" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_773a8d99-f03a-441d-9cb8-22c16c29d58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_435d4353-e6bb-4ac5-9574-44cc34fc72cd" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_773a8d99-f03a-441d-9cb8-22c16c29d58c" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_435d4353-e6bb-4ac5-9574-44cc34fc72cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_d868eaba-dc79-4294-92ad-08f6f521cbad" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_773a8d99-f03a-441d-9cb8-22c16c29d58c" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_d868eaba-dc79-4294-92ad-08f6f521cbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_278baef3-6954-46d0-b6b5-0b7189389cf7" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_773a8d99-f03a-441d-9cb8-22c16c29d58c" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_278baef3-6954-46d0-b6b5-0b7189389cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_7b8083ff-5bee-44c8-9428-1547d48ea8a0" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_773a8d99-f03a-441d-9cb8-22c16c29d58c" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_7b8083ff-5bee-44c8-9428-1547d48ea8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour_db6318da-a467-439d-acba-273822a714f8" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_773a8d99-f03a-441d-9cb8-22c16c29d58c" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour_db6318da-a467-439d-acba-273822a714f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour_f55b27bd-50df-4785-b3d9-5c2c91a48615" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_773a8d99-f03a-441d-9cb8-22c16c29d58c" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour_f55b27bd-50df-4785-b3d9-5c2c91a48615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_8e754c5d-4c10-4e39-8bf2-ce137b30e204" xlink:href="crdf-20210930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_773a8d99-f03a-441d-9cb8-22c16c29d58c" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_8e754c5d-4c10-4e39-8bf2-ce137b30e204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="crdf-20210930.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="simple" xlink:href="crdf-20210930.xsd#DerivativeFinancialInstrumentsWarrants"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3b43fe14-cb0e-4e09-a0c8-e3d4756ae087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_7896a120-a1ea-4bc9-a815-d5a88ac4abdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3b43fe14-cb0e-4e09-a0c8-e3d4756ae087" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_7896a120-a1ea-4bc9-a815-d5a88ac4abdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="simple" xlink:href="crdf-20210930.xsd#DerivativeFinancialInstrumentsWarrantsTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0826cda9-8da8-41bf-aff3-4d4bba78aaf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e6d0b972-3c66-492e-9b1e-71f1bdd75f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0826cda9-8da8-41bf-aff3-4d4bba78aaf1" xlink:to="loc_us-gaap_DerivativeTable_e6d0b972-3c66-492e-9b1e-71f1bdd75f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_d33cc67d-85ca-479e-b607-9c9d0f8ff5a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e6d0b972-3c66-492e-9b1e-71f1bdd75f84" xlink:to="loc_us-gaap_ValuationTechniqueAxis_d33cc67d-85ca-479e-b607-9c9d0f8ff5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_e5dfb0f7-a1bb-41ed-8c93-464095fe6069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_d33cc67d-85ca-479e-b607-9c9d0f8ff5a8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_e5dfb0f7-a1bb-41ed-8c93-464095fe6069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember_1d6fcada-1cd1-45b3-9ab2-1b7ee22f420d" xlink:href="crdf-20210930.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_e5dfb0f7-a1bb-41ed-8c93-464095fe6069" xlink:to="loc_crdf_BlackScholesOptionPricingMethodMember_1d6fcada-1cd1-45b3-9ab2-1b7ee22f420d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_696cca43-9f8c-483f-a906-986393790d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e6d0b972-3c66-492e-9b1e-71f1bdd75f84" xlink:to="loc_us-gaap_DerivativeLineItems_696cca43-9f8c-483f-a906-986393790d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7bfe934b-5688-4d95-8dc5-c310934aeaa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_696cca43-9f8c-483f-a906-986393790d34" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7bfe934b-5688-4d95-8dc5-c310934aeaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_82f7099d-3165-4122-9fd3-a486f84f37f5" xlink:href="crdf-20210930.xsd#crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_696cca43-9f8c-483f-a906-986393790d34" xlink:to="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_82f7099d-3165-4122-9fd3-a486f84f37f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#DerivativeFinancialInstrumentsWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f747d852-df18-4348-8e7c-ced9d82d0adc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_a691153d-1917-451c-8d7c-9f582ad0a12c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f747d852-df18-4348-8e7c-ced9d82d0adc" xlink:to="loc_us-gaap_DerivativeTable_a691153d-1917-451c-8d7c-9f582ad0a12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1f3c1885-3e0b-4486-901c-23fefc257871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a691153d-1917-451c-8d7c-9f582ad0a12c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1f3c1885-3e0b-4486-901c-23fefc257871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1b5d0d16-6bae-43f1-8e88-72e1cf2b6307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1f3c1885-3e0b-4486-901c-23fefc257871" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1b5d0d16-6bae-43f1-8e88-72e1cf2b6307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_80b7e371-8fed-43c5-b21d-553914dfde4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1b5d0d16-6bae-43f1-8e88-72e1cf2b6307" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_80b7e371-8fed-43c5-b21d-553914dfde4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8aa42be1-66b7-4655-989a-fdb0f858b17b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1b5d0d16-6bae-43f1-8e88-72e1cf2b6307" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8aa42be1-66b7-4655-989a-fdb0f858b17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_b7c66a8d-d94b-47a1-bbbf-6e824fda598a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1b5d0d16-6bae-43f1-8e88-72e1cf2b6307" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_b7c66a8d-d94b-47a1-bbbf-6e824fda598a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_87177ba6-5d90-4952-a809-582f02a63eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1b5d0d16-6bae-43f1-8e88-72e1cf2b6307" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_87177ba6-5d90-4952-a809-582f02a63eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_14db4c4d-a2c4-426e-8cc5-22b1197141ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a691153d-1917-451c-8d7c-9f582ad0a12c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_14db4c4d-a2c4-426e-8cc5-22b1197141ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_341d1582-ee41-42cc-91f1-5e8a685db943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_14db4c4d-a2c4-426e-8cc5-22b1197141ad" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_341d1582-ee41-42cc-91f1-5e8a685db943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_51b0cc44-357e-4fe5-a608-ce84a8578f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_341d1582-ee41-42cc-91f1-5e8a685db943" xlink:to="loc_us-gaap_WarrantMember_51b0cc44-357e-4fe5-a608-ce84a8578f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_3914306e-31da-45eb-8881-1b2d9dfa6c33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a691153d-1917-451c-8d7c-9f582ad0a12c" xlink:to="loc_us-gaap_ValuationTechniqueAxis_3914306e-31da-45eb-8881-1b2d9dfa6c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_89b47d2e-ef41-44c5-abad-fe5d21d63ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_3914306e-31da-45eb-8881-1b2d9dfa6c33" xlink:to="loc_us-gaap_ValuationTechniqueDomain_89b47d2e-ef41-44c5-abad-fe5d21d63ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember_5337efc8-c502-4964-8b94-cffb194fa094" xlink:href="crdf-20210930.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_89b47d2e-ef41-44c5-abad-fe5d21d63ae6" xlink:to="loc_crdf_BlackScholesOptionPricingMethodMember_5337efc8-c502-4964-8b94-cffb194fa094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_edd59a85-9da8-4544-95dd-e0574daa2cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a691153d-1917-451c-8d7c-9f582ad0a12c" xlink:to="loc_us-gaap_DerivativeLineItems_edd59a85-9da8-4544-95dd-e0574daa2cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_97b51f8c-ca09-4548-9537-486307b20812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_edd59a85-9da8-4544-95dd-e0574daa2cf5" xlink:to="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_97b51f8c-ca09-4548-9537-486307b20812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EstimatedFairValueOfWarrant_e91f86e3-3f55-4748-ace8-28c157401523" xlink:href="crdf-20210930.xsd#crdf_EstimatedFairValueOfWarrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_97b51f8c-ca09-4548-9537-486307b20812" xlink:to="loc_crdf_EstimatedFairValueOfWarrant_e91f86e3-3f55-4748-ace8-28c157401523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4f85fa51-2d33-4823-8ba2-b2db69dec54a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_97b51f8c-ca09-4548-9537-486307b20812" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4f85fa51-2d33-4823-8ba2-b2db69dec54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_723fed94-5d5d-44d0-a414-3a3a97dcacf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_97b51f8c-ca09-4548-9537-486307b20812" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_723fed94-5d5d-44d0-a414-3a3a97dcacf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_4941f84b-7776-487a-a312-8dad803c2b84" xlink:href="crdf-20210930.xsd#crdf_DerivativeFinancialInstrumentsLiabilityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_edd59a85-9da8-4544-95dd-e0574daa2cf5" xlink:to="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_4941f84b-7776-487a-a312-8dad803c2b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_23bcfb32-9024-429f-9b7e-16594ceee2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_4941f84b-7776-487a-a312-8dad803c2b84" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_23bcfb32-9024-429f-9b7e-16594ceee2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_55920375-3ff4-405c-99ad-ae34da5efc07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_4941f84b-7776-487a-a312-8dad803c2b84" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_55920375-3ff4-405c-99ad-ae34da5efc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_533629ad-e5c7-4037-b09e-6c3f7d875780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_4941f84b-7776-487a-a312-8dad803c2b84" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_533629ad-e5c7-4037-b09e-6c3f7d875780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_4b0d464a-bef9-41ba-81f8-e1366faa7b0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_4941f84b-7776-487a-a312-8dad803c2b84" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_4b0d464a-bef9-41ba-81f8-e1366faa7b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_743c95a6-6ed3-454d-9af8-f91b06df295e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_4941f84b-7776-487a-a312-8dad803c2b84" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_743c95a6-6ed3-454d-9af8-f91b06df295e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquity" xlink:type="simple" xlink:href="crdf-20210930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_328adb8c-8441-43a0-b923-f259eff2c05e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_61db9cc7-c4e2-4dea-a56f-13a9b23c920d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_328adb8c-8441-43a0-b923-f259eff2c05e" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_61db9cc7-c4e2-4dea-a56f-13a9b23c920d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="crdf-20210930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a9177d6f-ff66-4874-b7f4-82d92ded1220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_178cae5a-2137-4be3-b0b7-ef646fc54a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a9177d6f-ff66-4874-b7f4-82d92ded1220" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_178cae5a-2137-4be3-b0b7-ef646fc54a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_206171eb-7968-4600-a5f6-5a11230281d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a9177d6f-ff66-4874-b7f4-82d92ded1220" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_206171eb-7968-4600-a5f6-5a11230281d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_362b45c8-6856-4f13-aaa3-529478a29b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a9177d6f-ff66-4874-b7f4-82d92ded1220" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_362b45c8-6856-4f13-aaa3-529478a29b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_d1186563-9508-47f9-b316-4ac4876643e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a9177d6f-ff66-4874-b7f4-82d92ded1220" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_d1186563-9508-47f9-b316-4ac4876643e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_cb31bba9-b306-41fd-8f34-82e1c130902f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a9177d6f-ff66-4874-b7f4-82d92ded1220" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_cb31bba9-b306-41fd-8f34-82e1c130902f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_10dee019-89dd-4727-a81c-9345d7d610b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a9177d6f-ff66-4874-b7f4-82d92ded1220" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_10dee019-89dd-4727-a81c-9345d7d610b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#StockholdersEquityStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8615ea7d-b546-42ff-9923-b6e8e8cfc3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_95763f0d-6665-41a1-bae2-2eafe7352309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8615ea7d-b546-42ff-9923-b6e8e8cfc3a0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_95763f0d-6665-41a1-bae2-2eafe7352309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_42aa37b1-e4d4-4d82-a7bb-af0c1939877f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_95763f0d-6665-41a1-bae2-2eafe7352309" xlink:to="loc_us-gaap_AwardTypeAxis_42aa37b1-e4d4-4d82-a7bb-af0c1939877f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f907d249-c2f6-4a1a-be10-86c2b6f38297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_42aa37b1-e4d4-4d82-a7bb-af0c1939877f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f907d249-c2f6-4a1a-be10-86c2b6f38297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f19ad6a5-72b4-410f-86e7-a4781f009dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f907d249-c2f6-4a1a-be10-86c2b6f38297" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f19ad6a5-72b4-410f-86e7-a4781f009dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5e20b4d8-d77d-4831-ad59-1ee08403b9e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_95763f0d-6665-41a1-bae2-2eafe7352309" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5e20b4d8-d77d-4831-ad59-1ee08403b9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5634452d-9dee-40a9-bf36-07d7ca6a5457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5e20b4d8-d77d-4831-ad59-1ee08403b9e0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5634452d-9dee-40a9-bf36-07d7ca6a5457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7a815354-9679-456c-ae0d-d6af5837b60a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5634452d-9dee-40a9-bf36-07d7ca6a5457" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7a815354-9679-456c-ae0d-d6af5837b60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_62b2e109-d488-4b89-8a86-9b89f970d0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5634452d-9dee-40a9-bf36-07d7ca6a5457" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_62b2e109-d488-4b89-8a86-9b89f970d0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15c9a475-d119-4686-862c-9e075ba7fe67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_95763f0d-6665-41a1-bae2-2eafe7352309" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15c9a475-d119-4686-862c-9e075ba7fe67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6838c07d-a526-43b7-861e-c99415a48a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15c9a475-d119-4686-862c-9e075ba7fe67" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6838c07d-a526-43b7-861e-c99415a48a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_343b9c27-dd1f-4df7-89c3-bd1be2e02f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15c9a475-d119-4686-862c-9e075ba7fe67" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_343b9c27-dd1f-4df7-89c3-bd1be2e02f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_53e7cdfd-caf9-4e83-8d77-1506f4a834ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15c9a475-d119-4686-862c-9e075ba7fe67" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_53e7cdfd-caf9-4e83-8d77-1506f4a834ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8bfd6294-6f8f-4552-a0b9-b3e00788867f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15c9a475-d119-4686-862c-9e075ba7fe67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8bfd6294-6f8f-4552-a0b9-b3e00788867f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7792726a-5a07-4900-a671-61e24d514f74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15c9a475-d119-4686-862c-9e075ba7fe67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7792726a-5a07-4900-a671-61e24d514f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#StockholdersEquityStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_3b040749-ebc4-4032-9305-1d514c016fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c1ec5c-65c9-4395-af13-1e7552d9d81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3b040749-ebc4-4032-9305-1d514c016fe2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c1ec5c-65c9-4395-af13-1e7552d9d81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d66e832a-8f0e-4c76-b41e-88555c055262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c1ec5c-65c9-4395-af13-1e7552d9d81d" xlink:to="loc_us-gaap_PlanNameAxis_d66e832a-8f0e-4c76-b41e-88555c055262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_771251d2-98e7-4dad-84bf-4a6dd66033f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d66e832a-8f0e-4c76-b41e-88555c055262" xlink:to="loc_us-gaap_PlanNameDomain_771251d2-98e7-4dad-84bf-4a6dd66033f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2021Member_fd2c70d3-7177-45ae-82bb-6bc2936131f8" xlink:href="crdf-20210930.xsd#crdf_EquityIncentivePlan2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_771251d2-98e7-4dad-84bf-4a6dd66033f3" xlink:to="loc_crdf_EquityIncentivePlan2021Member_fd2c70d3-7177-45ae-82bb-6bc2936131f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3df8a092-b6ca-4905-9530-d18a8bec942f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c1ec5c-65c9-4395-af13-1e7552d9d81d" xlink:to="loc_us-gaap_AwardTypeAxis_3df8a092-b6ca-4905-9530-d18a8bec942f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7bde6f-4fc9-4995-8d6a-fcd54854a3d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3df8a092-b6ca-4905-9530-d18a8bec942f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7bde6f-4fc9-4995-8d6a-fcd54854a3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_23e432e3-86ac-4d15-a3fa-07c8d38786bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7bde6f-4fc9-4995-8d6a-fcd54854a3d9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_23e432e3-86ac-4d15-a3fa-07c8d38786bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_InducementGrantStockOptionsMember_4ea319b5-1358-47c7-a07b-45c5c4331da0" xlink:href="crdf-20210930.xsd#crdf_InducementGrantStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7bde6f-4fc9-4995-8d6a-fcd54854a3d9" xlink:to="loc_crdf_InducementGrantStockOptionsMember_4ea319b5-1358-47c7-a07b-45c5c4331da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c1ec5c-65c9-4395-af13-1e7552d9d81d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9b9abe0a-647d-4338-92c8-4b9767fd3281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9b9abe0a-647d-4338-92c8-4b9767fd3281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e6f906fe-a211-4829-9e12-a7db42086daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9b9abe0a-647d-4338-92c8-4b9767fd3281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e6f906fe-a211-4829-9e12-a7db42086daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6b7b4bf2-6e18-4522-8760-4826874bea6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9b9abe0a-647d-4338-92c8-4b9767fd3281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6b7b4bf2-6e18-4522-8760-4826874bea6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66a0cb8d-7539-4da0-8d49-a12e3502beb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9b9abe0a-647d-4338-92c8-4b9767fd3281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66a0cb8d-7539-4da0-8d49-a12e3502beb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2d7b5612-a050-4b24-abd2-abe93135af6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9b9abe0a-647d-4338-92c8-4b9767fd3281" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2d7b5612-a050-4b24-abd2-abe93135af6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6b635b6b-6c62-44a4-b9ca-039eabf188fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6b635b6b-6c62-44a4-b9ca-039eabf188fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59b7fb9b-43cf-42f1-bd83-a3ee48fe5d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6b635b6b-6c62-44a4-b9ca-039eabf188fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59b7fb9b-43cf-42f1-bd83-a3ee48fe5d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75547163-524e-411b-9339-16941770d1ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6b635b6b-6c62-44a4-b9ca-039eabf188fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75547163-524e-411b-9339-16941770d1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_54095d5b-779e-4ec1-9719-8ce84c679827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6b635b6b-6c62-44a4-b9ca-039eabf188fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_54095d5b-779e-4ec1-9719-8ce84c679827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_e486dda0-3d67-4f9f-b264-bee1233979ce" xlink:href="crdf-20210930.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6b635b6b-6c62-44a4-b9ca-039eabf188fb" xlink:to="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_e486dda0-3d67-4f9f-b264-bee1233979ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ffd25437-7bbc-45a6-b9e4-5edf47069c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6b635b6b-6c62-44a4-b9ca-039eabf188fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ffd25437-7bbc-45a6-b9e4-5edf47069c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e72f8f1e-2c68-4184-8018-571548f32371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e72f8f1e-2c68-4184-8018-571548f32371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_081ab2ee-42fa-417f-a276-f059a9298dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_081ab2ee-42fa-417f-a276-f059a9298dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_994697f8-cf1d-4189-abc4-2048a708a960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_994697f8-cf1d-4189-abc4-2048a708a960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5479c13-5a3f-47bc-9ad5-9e6f3b722af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_994697f8-cf1d-4189-abc4-2048a708a960" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5479c13-5a3f-47bc-9ad5-9e6f3b722af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_595fa5c5-b150-4cbd-b8bd-502c2c1c2baf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_994697f8-cf1d-4189-abc4-2048a708a960" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_595fa5c5-b150-4cbd-b8bd-502c2c1c2baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ace62d3-bc75-421d-bb57-fdce8b53bd1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_994697f8-cf1d-4189-abc4-2048a708a960" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ace62d3-bc75-421d-bb57-fdce8b53bd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_adfea892-ac0d-4b3d-84a1-8817935e4123" xlink:href="crdf-20210930.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_994697f8-cf1d-4189-abc4-2048a708a960" xlink:to="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_adfea892-ac0d-4b3d-84a1-8817935e4123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1906e382-5dbb-4151-8cf0-c1d79b59e213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_994697f8-cf1d-4189-abc4-2048a708a960" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1906e382-5dbb-4151-8cf0-c1d79b59e213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6a4d1f14-40d0-4b5a-b24c-6539f894cb90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6a4d1f14-40d0-4b5a-b24c-6539f894cb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9fd47669-095c-44ca-8e1e-67dbdd05cb8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9fd47669-095c-44ca-8e1e-67dbdd05cb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_28f3ac9b-0895-4815-91bf-7c4612483ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_28f3ac9b-0895-4815-91bf-7c4612483ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4ccf8c60-c746-420b-a517-19a6745d6a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_28f3ac9b-0895-4815-91bf-7c4612483ff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4ccf8c60-c746-420b-a517-19a6745d6a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5c0ccfda-bb55-4b37-bcc8-adc6361e5a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_28f3ac9b-0895-4815-91bf-7c4612483ff3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5c0ccfda-bb55-4b37-bcc8-adc6361e5a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2acaee1d-4b53-437e-a880-f2b2f93a8a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_28f3ac9b-0895-4815-91bf-7c4612483ff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2acaee1d-4b53-437e-a880-f2b2f93a8a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f1ba1b0f-6915-4dc3-a0d9-e21aad7203a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f1ba1b0f-6915-4dc3-a0d9-e21aad7203a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7cd18053-bd8b-4821-9702-a6081ae4416f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7cd18053-bd8b-4821-9702-a6081ae4416f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_93474808-463c-45d1-84db-7e50516b55b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_281f2dfc-18d1-4f0d-abe1-75ed6e48df71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_93474808-463c-45d1-84db-7e50516b55b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#StockholdersEquityRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7009dc23-745e-4301-a980-cfbc41509f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f03dd704-c48c-4f9f-850f-1c6b64cfb6b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7009dc23-745e-4301-a980-cfbc41509f1d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f03dd704-c48c-4f9f-850f-1c6b64cfb6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7931be6e-b66c-46dd-80f8-e682a6917c62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f03dd704-c48c-4f9f-850f-1c6b64cfb6b2" xlink:to="loc_us-gaap_AwardTypeAxis_7931be6e-b66c-46dd-80f8-e682a6917c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57ed280a-792a-4062-9c81-9d8bb5f8f706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7931be6e-b66c-46dd-80f8-e682a6917c62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57ed280a-792a-4062-9c81-9d8bb5f8f706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a9c53003-afe8-495a-a9c3-767313a3daa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57ed280a-792a-4062-9c81-9d8bb5f8f706" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a9c53003-afe8-495a-a9c3-767313a3daa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6826854e-1a49-4644-8a4a-6ab422bf4f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f03dd704-c48c-4f9f-850f-1c6b64cfb6b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6826854e-1a49-4644-8a4a-6ab422bf4f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86da1e92-808a-4f14-b2d9-4c47db56b948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6826854e-1a49-4644-8a4a-6ab422bf4f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86da1e92-808a-4f14-b2d9-4c47db56b948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e7e6c145-f048-4ea1-a78e-c7a30ae8400b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86da1e92-808a-4f14-b2d9-4c47db56b948" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e7e6c145-f048-4ea1-a78e-c7a30ae8400b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_78397d21-1866-44f8-9d99-9fb94d46371c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86da1e92-808a-4f14-b2d9-4c47db56b948" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_78397d21-1866-44f8-9d99-9fb94d46371c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40fff31e-e38d-4ff4-972d-1f6670a223ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86da1e92-808a-4f14-b2d9-4c47db56b948" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40fff31e-e38d-4ff4-972d-1f6670a223ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a191db9-ac6d-41e1-a3f0-31fb5935b8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6826854e-1a49-4644-8a4a-6ab422bf4f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a191db9-ac6d-41e1-a3f0-31fb5935b8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0aa26ff1-baeb-4a21-93f1-62420d9392ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a191db9-ac6d-41e1-a3f0-31fb5935b8ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0aa26ff1-baeb-4a21-93f1-62420d9392ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7edeb28f-0862-444c-b5f0-d3b01c6ca236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a191db9-ac6d-41e1-a3f0-31fb5935b8ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7edeb28f-0862-444c-b5f0-d3b01c6ca236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a0985cce-077d-4ddd-bb46-1a3c147ed754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4a191db9-ac6d-41e1-a3f0-31fb5935b8ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a0985cce-077d-4ddd-bb46-1a3c147ed754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_f03ad61c-350f-49c4-8d1b-d76ba7088b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6826854e-1a49-4644-8a4a-6ab422bf4f1e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_f03ad61c-350f-49c4-8d1b-d76ba7088b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b28203ea-b617-49e4-96aa-479030706b55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6826854e-1a49-4644-8a4a-6ab422bf4f1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b28203ea-b617-49e4-96aa-479030706b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#StockholdersEquityWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_355590a3-2a48-490b-a661-598a39e7eccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsAndRightsRollForward_3df03390-d150-4524-bb94-577f0a40af5e" xlink:href="crdf-20210930.xsd#crdf_WarrantsAndRightsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_355590a3-2a48-490b-a661-598a39e7eccb" xlink:to="loc_crdf_WarrantsAndRightsRollForward_3df03390-d150-4524-bb94-577f0a40af5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_af5b681e-fba9-4c09-9377-46e76bcabb6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_3df03390-d150-4524-bb94-577f0a40af5e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_af5b681e-fba9-4c09-9377-46e76bcabb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberExercised_ff0a7233-eb8f-4a2c-9c39-a7967fa1d81a" xlink:href="crdf-20210930.xsd#crdf_ClassOfWarrantOrRightNumberExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_3df03390-d150-4524-bb94-577f0a40af5e" xlink:to="loc_crdf_ClassOfWarrantOrRightNumberExercised_ff0a7233-eb8f-4a2c-9c39-a7967fa1d81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_213a7fb8-0b1b-4c43-a8d5-c37c53d5d3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_3df03390-d150-4524-bb94-577f0a40af5e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_213a7fb8-0b1b-4c43-a8d5-c37c53d5d3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_9e0fe7f2-569d-4ee6-a42b-253066193d52" xlink:href="crdf-20210930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_355590a3-2a48-490b-a661-598a39e7eccb" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_9e0fe7f2-569d-4ee6-a42b-253066193d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_20097688-2afa-411e-bf19-3ef88aa8b773" xlink:href="crdf-20210930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_9e0fe7f2-569d-4ee6-a42b-253066193d52" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_20097688-2afa-411e-bf19-3ef88aa8b773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_8d2d1b9f-8386-4b36-8a30-e0905d08b8fe" xlink:href="crdf-20210930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_9e0fe7f2-569d-4ee6-a42b-253066193d52" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_8d2d1b9f-8386-4b36-8a30-e0905d08b8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_bd34a408-ae5f-4642-bd9a-7c90a5449d7a" xlink:href="crdf-20210930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_9e0fe7f2-569d-4ee6-a42b-253066193d52" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_bd34a408-ae5f-4642-bd9a-7c90a5449d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_7fc2ece4-e83e-4cdd-a4af-1620d7ff7067" xlink:href="crdf-20210930.xsd#crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_355590a3-2a48-490b-a661-598a39e7eccb" xlink:to="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_7fc2ece4-e83e-4cdd-a4af-1620d7ff7067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_8bbb90d9-eb51-4571-bb27-bbf95ec5978c" xlink:href="crdf-20210930.xsd#crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_7fc2ece4-e83e-4cdd-a4af-1620d7ff7067" xlink:to="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_8bbb90d9-eb51-4571-bb27-bbf95ec5978c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_16a02948-31cf-46dc-95e4-08025614d8de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5b7e9f69-2a61-407f-86be-5eb6381feab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_16a02948-31cf-46dc-95e4-08025614d8de" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5b7e9f69-2a61-407f-86be-5eb6381feab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bad6c08f-fed1-44d0-9fc9-841fa8f81f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5b7e9f69-2a61-407f-86be-5eb6381feab9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bad6c08f-fed1-44d0-9fc9-841fa8f81f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6d14cd60-c824-48d4-b0f8-a89f435fde05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bad6c08f-fed1-44d0-9fc9-841fa8f81f40" xlink:to="loc_us-gaap_ClassOfStockDomain_6d14cd60-c824-48d4-b0f8-a89f435fde05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember_59cd4b56-1fdc-419f-9935-4ebc03c06e4f" xlink:href="crdf-20210930.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6d14cd60-c824-48d4-b0f8-a89f435fde05" xlink:to="loc_crdf_SeriesAConvertiblePreferredStockMember_59cd4b56-1fdc-419f-9935-4ebc03c06e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember_89a9b14e-9e1d-403a-a4af-54e2a9f403d0" xlink:href="crdf-20210930.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6d14cd60-c824-48d4-b0f8-a89f435fde05" xlink:to="loc_crdf_SeriesBConvertiblePreferredStockMember_89a9b14e-9e1d-403a-a4af-54e2a9f403d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_5cf321ca-ccb0-44b1-8e21-9488d53053e0" xlink:href="crdf-20210930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6d14cd60-c824-48d4-b0f8-a89f435fde05" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_5cf321ca-ccb0-44b1-8e21-9488d53053e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_c7fc43d7-ae47-4547-8f3c-bf986ee5e58f" xlink:href="crdf-20210930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6d14cd60-c824-48d4-b0f8-a89f435fde05" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_c7fc43d7-ae47-4547-8f3c-bf986ee5e58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_39f73c90-f37c-4c4c-875a-9f80f44186f3" xlink:href="crdf-20210930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6d14cd60-c824-48d4-b0f8-a89f435fde05" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_39f73c90-f37c-4c4c-875a-9f80f44186f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_269f8c85-5099-47c7-92b5-b73e343b0388" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5b7e9f69-2a61-407f-86be-5eb6381feab9" xlink:to="loc_us-gaap_ClassOfStockLineItems_269f8c85-5099-47c7-92b5-b73e343b0388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_03cda905-719a-4785-ab2d-28264bbd45b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_269f8c85-5099-47c7-92b5-b73e343b0388" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_03cda905-719a-4785-ab2d-28264bbd45b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ccdc128c-a968-4780-a593-bd39f5027959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_269f8c85-5099-47c7-92b5-b73e343b0388" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ccdc128c-a968-4780-a593-bd39f5027959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_3e4502cb-ab77-43ad-b9de-3254e3def20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_269f8c85-5099-47c7-92b5-b73e343b0388" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_3e4502cb-ab77-43ad-b9de-3254e3def20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2f82219e-7512-4ab1-ad3b-7ccfd0d159a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_269f8c85-5099-47c7-92b5-b73e343b0388" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2f82219e-7512-4ab1-ad3b-7ccfd0d159a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="crdf-20210930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_faff97be-3371-46e7-a2b0-8fec8d8bc791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e95825b4-d40b-4546-903c-0406e71947e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_faff97be-3371-46e7-a2b0-8fec8d8bc791" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e95825b4-d40b-4546-903c-0406e71947e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a9058416-e25b-4196-950f-9e42f93ccc2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_8c51a0ab-8c22-4cdf-a6a3-58725b4c47bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a9058416-e25b-4196-950f-9e42f93ccc2d" xlink:to="loc_us-gaap_OtherCommitmentsTable_8c51a0ab-8c22-4cdf-a6a3-58725b4c47bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1c06a68e-2881-46a0-b7e9-32e9863d9d59" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8c51a0ab-8c22-4cdf-a6a3-58725b4c47bc" xlink:to="loc_srt_CounterpartyNameAxis_1c06a68e-2881-46a0-b7e9-32e9863d9d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4e3bf3a-bef1-4ae0-8740-d489ca850e06" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1c06a68e-2881-46a0-b7e9-32e9863d9d59" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4e3bf3a-bef1-4ae0-8740-d489ca850e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_NorvianoMember_5c859eeb-a57a-4289-8017-9edb182981ef" xlink:href="crdf-20210930.xsd#crdf_NorvianoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4e3bf3a-bef1-4ae0-8740-d489ca850e06" xlink:to="loc_crdf_NorvianoMember_5c859eeb-a57a-4289-8017-9edb182981ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_ae4c0ac9-b9a0-4eb5-8199-17b31197a0cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8c51a0ab-8c22-4cdf-a6a3-58725b4c47bc" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_ae4c0ac9-b9a0-4eb5-8199-17b31197a0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_6965b963-e8d5-4ad4-a4f4-31948e6c47f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ae4c0ac9-b9a0-4eb5-8199-17b31197a0cb" xlink:to="loc_us-gaap_PurchaseObligation_6965b963-e8d5-4ad4-a4f4-31948e6c47f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="crdf-20210930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5f9609eb-1c10-4796-a190-805388490dc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_be0d7065-64de-400a-a319-ef55680226c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5f9609eb-1c10-4796-a190-805388490dc9" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_be0d7065-64de-400a-a319-ef55680226c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="crdf-20210930.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_bc06c584-c891-4eb6-a9f6-b18e41145b22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_583aa8fd-3583-4d80-b717-17e1539dda2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_bc06c584-c891-4eb6-a9f6-b18e41145b22" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_583aa8fd-3583-4d80-b717-17e1539dda2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19f7382f-95fe-485b-88a1-677dc3ce91d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_583aa8fd-3583-4d80-b717-17e1539dda2d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19f7382f-95fe-485b-88a1-677dc3ce91d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_642245c9-4a13-4e08-bfef-9476dd59839b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19f7382f-95fe-485b-88a1-677dc3ce91d3" xlink:to="loc_us-gaap_RelatedPartyDomain_642245c9-4a13-4e08-bfef-9476dd59839b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_f4f0aef1-c5b3-491e-8b35-0ef6baac2c6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_642245c9-4a13-4e08-bfef-9476dd59839b" xlink:to="loc_srt_DirectorMember_f4f0aef1-c5b3-491e-8b35-0ef6baac2c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAffiliatesMember_f74a725e-e6b3-44d9-a56b-36fc105200a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAffiliatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_642245c9-4a13-4e08-bfef-9476dd59839b" xlink:to="loc_us-gaap_OtherAffiliatesMember_f74a725e-e6b3-44d9-a56b-36fc105200a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_bded4fa8-196a-4b15-a672-90edb9762d78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_583aa8fd-3583-4d80-b717-17e1539dda2d" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_bded4fa8-196a-4b15-a672-90edb9762d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_96ac9a3c-6b5d-4e7d-99be-3bbbf157eaa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bded4fa8-196a-4b15-a672-90edb9762d78" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_96ac9a3c-6b5d-4e7d-99be-3bbbf157eaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7cdfea1c-589d-4b30-8300-03667c1bf3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bded4fa8-196a-4b15-a672-90edb9762d78" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7cdfea1c-589d-4b30-8300-03667c1bf3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2d9c4726-ce5a-467a-bfb1-553f07e9e72f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bded4fa8-196a-4b15-a672-90edb9762d78" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2d9c4726-ce5a-467a-bfb1-553f07e9e72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_339d299c-3ee3-4d20-af15-c0c5c19601d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bded4fa8-196a-4b15-a672-90edb9762d78" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_339d299c-3ee3-4d20-af15-c0c5c19601d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/COVID19" xlink:type="simple" xlink:href="crdf-20210930.xsd#COVID19"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/COVID19" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_6ffddf56-78cd-473c-ad90-1ce8f4829551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_5d802be4-407e-42a0-afae-c0d6c17601ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_6ffddf56-78cd-473c-ad90-1ce8f4829551" xlink:to="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_5d802be4-407e-42a0-afae-c0d6c17601ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>crdf-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:crdf="http://www.cardiffoncology.com/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="crdf-20210930.xsd" xlink:type="simple"/>
    <context id="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i687be38fd69743e5adc911fcb3916233_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="i5536a0b2fc2740479fff4987362a1f5e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8176bd16da194dae836e30659930f9a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic0d1b29ac93e4d80933267bf7ecf68b5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iee5016562f414703bd929a2aa895f388_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie19a2c1f7f0b479188b45d6f374dbc81_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia35d15a9dfb646fcbffcffbb9d8262b1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8da7726f257f43acb1bea9b40eef263e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2cf61f0afd274f019119b3ea148e5dd3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibcfb466ee9f44377b4e807b87d71fd6a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3c1a472218714bdea2c26e2f2f2bc0a7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i17d10d73626940a1bfac19a0e15cf9bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6ed485db45c4a5f8022e1d59b12bf4d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice871a4562a84cd4b52a4356d2cb860e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb627674086848deba17572418728d83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5d058c8bebe4a3a9d2336d08237e91c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ca2109088ac4793a57a5fce35eb3903_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i10e530a8190d4a178d02e013246439d8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib5c1a7cba4434a29a666db82f58a89f0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie7083bc457c04ea7b4169c892901eaf8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i205895823e59424a919b3d93617d9f2c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i482f9e2b8aa14c00bc8e55d73914ccd7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7880684c50674dbb8cfd7f810fc1727a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6eefd6a8f9ad4956b669740bb2b8c353_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5a0df33fbbec49a5a57d580b1dcf380b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibd12c54fcda54b7ebf4612de0f518a99_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i71acb7a4b79649b297dc1e8c8c73d504_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4e8063e7fb6749e0af8bd1ecebda0314_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib30b6ac5d0cd4c369a9097268eb12984_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i24420ff79ce74c9b9b895204b192740b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia3282128780c4055854a3cc8fbe4a2e0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i41602febb1074927adedec6da8eb37fe_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2465b36c344b4703902f0880f5e52116_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if9b018ac82a04fb590b1485d91230d8d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7ca563e0d06f4599a46a722d3581dd74_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if15e882bdfea4fdf952e43b08bc2429b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i350d28ef78674e3eab8458411c7fcc81_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idf1c65b7a7224893adb36ad9e8cbe745_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic5336d0a252e4aeb98ca683a43ba06b0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5824d16b9ba441788705b462bc177803_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i33e4526f7e164ab8b705c8f15dd1b690_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia14d6cd1be5f488284a0548acc13b622_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i402f50ca14e9498daade666a2aba16c6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic553804c0eaf41af8f0aea771674f3de_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i56cfeedf0a7846a480b68514e6ec597c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i583e90cffdc74283ad12fcd0e679a613_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7fb9b1347f54faaa7e69ff2ccf6a961_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i33912183705e412b83ed2cef39eddc1c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic25a7e642c104708a790b647db5d1ded_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7086816a72204fa58a1df8fa6c35a63a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ied522f508b844f94be0b94767cf40167_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9d4805fa04ec446eab0d6af2de913c7c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i45e23d0997d94ed9a6bbb2f8fc1ee85e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib94e5739ad98459497e72c9a6bc0ad84_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i83bc7c42c1824b15a08376355aa11ba3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3aa726d5321245c1a96ba3990871ca22_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf57c9859a8a4e38b67c19c2be236a90_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i631d652218464d15843c3a80ff37978c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i953e77c8d38e45e6974947b84da4f172_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c0e2ceae22248b4a0ebd0aa20fa60c6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iff0a01a8a61a458184bb5efcbdd6cdae_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i98824144f8e24c5cad08193a1247420c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="idd2c102f2b6845ce95560b93eba83063_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i451d0811b3544bcc912debf2a8ede85a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2cd86fa1857349e7b73861b629a3a124_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i49c8e30388454e01b1713f33c031e81a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icac2c0c6030c476080cddc898da2fdbe_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icaebc49a046040e29e5e4565fd900bcb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i63aaf8a8792b4035ba42f8b374bd567e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4c0e65a2de674c8a814d4c385ed678a6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie5a2c6673bb34fcfaba41b7f80484177_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i110b9bf586124339b177542a41284804_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i18b0e382e0084fe29c322a52a6d9fb60_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i28dd1563898f43d9b46b76dc77925f8e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i449d2f3eb8d0492f8052bba28b62b75d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic80c59f86e5f4a4186743622863a59c7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2636d69182a44bceacd8ee49296aa242_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib95b420a99f04c7ea8d5bc830d3e1aba_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i205347e8f5484902aba963f9ad58ff6a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2f820ff8f6c24d05b3ffd3339f0dcfc9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1e7e9d9d6bd7457098d60b651db0d39f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ieb79d8dc23ad4047a11793096554a73c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibfabfd86abc84c9d8332a7d6522f0b05_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0d9ab8d6d1f3471aada01b6d9a78f35d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iefd2c993874045f0903171fafd6a6737_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i02b12865eb164c1b8daa72971befc365_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7223f8f5e4b7451fac6e9a53f511b618_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibb8b40a3759d4dd8bdff04839d6af29e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i60b2d2a3f17d4b329211ee5e90f04d9c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia6b51a15c074437984b0293d4935aae9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i793b333bdcf34df8a736118d629cb3b7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8768b38297214afab61b468bbf429f52_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3a7ab6cbc6374029b4bffd3ec9b17e0c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie26a981245d5493394cff84a3e0e6e70_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i775faff3942e4e5db3e5bd022093d60f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i81e14a5109df413e81014c0b81871037_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i51efe940143345028a304e5a815b9230_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if45c6805e8814c47933df9000082c117_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i057b4c0f72d44fdb8719e1f993ada81b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i41cb574ec6224df9954670aecbbdd57c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i17ac44632d4944509820a9395d78c529_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i55b121d890664785a96f2abd68d7743a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4778f546e098429f8ad5e7ca4beac4b6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7cd4aae3ff4246df84edcf2ab4da4c2b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5afbd3931f114b889cf2b6d1fcba9d91_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i472a131094f2474fb3218a9b6bc0594c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if4544f5428574ef481cdcbd193499f68_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3bc75745225b41fda9b79e00c8ab8c58_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i21f389c33c2b4cb0969bd99011bcb8db_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie73becd6b06646ffad08290d5060d468_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5c421333d9e842cd938364a79a347e01_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia4871ed60f064988846d5339b4cefb37_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7ab1f91262aa4961bfa27744b525f31a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7a924190f51c43a6b7d3270fde532fa2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0f837af10c4e49b681e48bb6553d03bb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibc20b1e7fdcf4fb4b59ce226be19d676_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3cac633b9fd54f2a99fe41969f58f594_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie508430c486f4b33b819c76634f5166c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2272875d1e6040bbbc4cb41775efc0c5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibcadbd307c7048f089ba63bc4e00d913_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iab14befe92264008986e1a141957af7d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9ffd53bdfd4d459c8b703013a42d0264_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia92b222fd62f45f2b838481f5c639808_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if41d19fc393f4c7c97eb7bcda789a9d9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id79faeb4f57d4754840ae281b5c51f1c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iec2c0b1298ef43bd8a6cf6425715b928_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic693b77303c24a2a99b2842d76d72241_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i81b0c6cd52a849caa99be52f924b86e2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8a9858e566ca4451af2bd491f1fdcdad_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i065815c78e2d4c5cb9a8ed1ec7b1f4db_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iddf531bc123047f2adcdb4ad64487d5d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4ce0447ee3b24f7b8e5c636200fa056d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i00578720dda04f5e803f8dd40e53c600_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if3c645e1dbc2452aa3d3d3e63a2097ab_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib90db4c568644361b2954142f5e9ef53_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4f802e75c98e40ab9791dea64340ce78_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i91b041904ffe4c919883330668092c9b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ica2abb6ba5634bf2bf4bf896d7c9258c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6ffcbb6630ed443ea2e088b433bc9ce4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3bc267f79c2a489989a67cdc20d3a3c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e6e261cb9904caaadea9698ea51a5af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0222ae72231f44db9f7d8ea289ba7e70_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85d1e68d697c4ef0aff6b17bcd0598d3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb4ce146f5434b44a3a5c1272c9610ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86124e9d3ce549fb84e7bdc9a8ebe5d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i813279dffe5742cdb683aadf13c65b58_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a78ea25d06f4f24a1e99abe072332f0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i62c3a0c6662345618211a584192ca26a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib20f35230bce4c59b8a12b5a5680b915_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i31763bf591274c6bb305e9bff5fff3d0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9e4bc90bddda41caa182ab326e680cfd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i96238e9478424ff983eea316b3b6d48c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i15293ce702ad4f1994f5e08e17c540fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81df56d144dd4aef8aa1484cbced739d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie267b2ad37e64532bdf3ce1ab2728c95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e08014d936d49259c36229cca64a87f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4c2c267750ac4a1f8c2d127cc7cb6594_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb7822e6be894e0796c8f0e8eac7e29a_D20220101-20270228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2027-02-28</endDate>
        </period>
    </context>
    <context id="ide4c82a6d8fc4a50b3c355ad46b5663c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2c7f42dfef2c4958ba29b2e28bb9b35d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i27c1821fc9ab463284b24faa6a39aeca_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i81c4317e30404c12b737872399063ecb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id32688583be64531a4c3b6f8dda463e1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i870cb7768ebe4cd9a47cae43d43fa560_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22ae9743fe9e485bb2f97b84bd14ef48_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i93a076cf959748b68d0895f7a702037c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i577dc0d878144b149b1dd7752563c6fe_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if1e8bf7f73344b78ab04d1ba7ddea8a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2f22ed10e3b4e019378ae1db12695ed_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iebfd4c8685c349cca9ac74c079a51df8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a2fc422184c4397bfd8fde6fbfdd4f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb2a438ab8374c9284bc780389cd9e66_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b6a8197ab2846cf8242cf259266a02c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i39e92eec12814d63b23dec15ee3a82e2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i951a79658a174acdabb183cc6c576e38_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i44d179594bba4e1dad1a989df3916c06_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7c42cef5a93d477d8d01cdeb0d9a6497_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0f4bdbe2cd9a4216b241d6c0f58f92af_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9dd0cbb07f2c48e9809d2340ba480ed4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iec5f94b33da24052af9749b10b28f208_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i429dafc4192b4a51aac45b680a2ebe82_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i918a2f804e04472a831f145c622bff4c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7ec0a3e52eaa44bfbbe255b9105dd595_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia67d1806a46a419689781a32baf40aff_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idd65b030d4494709b2f9be0748ec2b5f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crdf:InducementGrantStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3e1d4f2076ee4dce9307fbd38c110992_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6cf797ce4852460992cc81f91f71ee21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i419dd88bc1ef4b699ca582afa2243156_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i967f68e7c70142858d962d262e96d5a5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i53d86dcdd30e4e97a88db626c3ce171f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9e7dd4c9b04a4f348fa618cc15a91b23_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7086b0baa05e4031aa8f4f411b551b42_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id64a71bd7b9f42509949a24fc02bdde8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id69610f358d94455a4cc69212cec3ba1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8110c72e246c4d70b73aed2bc0bde2d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7451a3efe7274af285d44ebc3dd77d40_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9eff0db6959b461584bc397787961a0d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e88f2da585d4200bcee660bbd23922a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i38a9fc7a1cf3406fa656608bfd2022aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90efb04788c94a62b210da8a40d1537a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9421b674007949588bce3135aff1f1ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6585aa9e614148a98914993084f4d834_I20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crdf:NorvianoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="ide58ed83af2b4d2ebaccb755576f716c_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i18a95e66b28b495995cc5b43de061428_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i23b7b762231f4268ada27fef1b3fbde1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8d5c6bcbeb3143e6819f6adceffa7b49_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7613ce60f5ae411799a4b34ca529c402_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i16cbd98a78db40d8a92555d8d4608ec6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="lease">
        <measure>crdf:lease</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80L2ZyYWc6MjhiNDQxOGFmMjYxNGE5MzhiNDIyMDRkOTQwYmMwM2EvdGFibGU6ZTg4YmM4YjEyMmE3NGRjN2I0ODcwNzlmNzA2MzY0MzYvdGFibGVyYW5nZTplODhiYzhiMTIyYTc0ZGM3YjQ4NzA3OWY3MDYzNjQzNl80LTEtMS0xLTY2NTU_35e930ed-40cf-479e-b0a7-def921c866bf">0001213037</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80L2ZyYWc6MjhiNDQxOGFmMjYxNGE5MzhiNDIyMDRkOTQwYmMwM2EvdGFibGU6ZTg4YmM4YjEyMmE3NGRjN2I0ODcwNzlmNzA2MzY0MzYvdGFibGVyYW5nZTplODhiYzhiMTIyYTc0ZGM3YjQ4NzA3OWY3MDYzNjQzNl83LTEtMS0xLTY2NTU_84e4d94a-f07d-4152-8b93-a5d19c2be0ac">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80L2ZyYWc6MjhiNDQxOGFmMjYxNGE5MzhiNDIyMDRkOTQwYmMwM2EvdGFibGU6ZTg4YmM4YjEyMmE3NGRjN2I0ODcwNzlmNzA2MzY0MzYvdGFibGVyYW5nZTplODhiYzhiMTIyYTc0ZGM3YjQ4NzA3OWY3MDYzNjQzNl84LTEtMS0xLTY2NTU_b98ee63b-cbec-4550-87c1-98460223acbb">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80L2ZyYWc6MjhiNDQxOGFmMjYxNGE5MzhiNDIyMDRkOTQwYmMwM2EvdGFibGU6ZTg4YmM4YjEyMmE3NGRjN2I0ODcwNzlmNzA2MzY0MzYvdGFibGVyYW5nZTplODhiYzhiMTIyYTc0ZGM3YjQ4NzA3OWY3MDYzNjQzNl8xMi0xLTEtMS02NjU1_93267302-deba-440f-b6ff-638ebbdc7c15">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80L2ZyYWc6MjhiNDQxOGFmMjYxNGE5MzhiNDIyMDRkOTQwYmMwM2EvdGFibGU6ZTg4YmM4YjEyMmE3NGRjN2I0ODcwNzlmNzA2MzY0MzYvdGFibGVyYW5nZTplODhiYzhiMTIyYTc0ZGM3YjQ4NzA3OWY3MDYzNjQzNl8xMy0xLTEtMS02NjU1_3cb94fc3-287e-4c8b-9e38-1525b4ca4f5b">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xODU3_058e1437-8cc9-4c73-b36a-c0b7e3345011">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6MmVjNTE5YmNkN2JhNGY5ZjhmZjg2NGFlNjVmN2ZlZGQvdGFibGVyYW5nZToyZWM1MTliY2Q3YmE0ZjlmOGZmODY0YWU2NWY3ZmVkZF8wLTAtMS0xLTY2NTU_a4d08a35-c022-4c63-964c-88567387e542">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xMzc_2e226bb8-a66b-478f-bd6f-b53a53ad1530">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Y2IyNjVmZTFiYTM1NDA2OWI0OTIxYmFkMGE4ZDY4ZDYvdGFibGVyYW5nZTpjYjI2NWZlMWJhMzU0MDY5YjQ5MjFiYWQwYThkNjhkNl8wLTAtMS0xLTY2NTU_dbf12117-20aa-4811-acc8-223ef2d34019">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xODU4_95e69c3d-1d62-4bed-9e52-1151b8c97465">001-35558</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xODYw_a6fea90d-3dab-45be-bfc7-a382ebc77eea">CARDIFF ONCOLOGY,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV8wLTAtMS0xLTY2NTU_59cea0bd-a396-4539-9eb3-3a9c057d68b3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV8wLTItMS0xLTY2NTU_7eb565f3-3326-4242-a262-842b16ed3a49">27-2004382</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV8zLTAtMS0xLTY2NTUvdGV4dHJlZ2lvbjpmY2M4YTA2NjExYWQ0ZTkyYTQ4ZTI5YzBjNWVhZGU1NV80_f83a65da-4a02-4d52-a3c4-ed8b7cbab764">11055 Flintkote Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV8zLTAtMS0xLTY2NTUvdGV4dHJlZ2lvbjpmY2M4YTA2NjExYWQ0ZTkyYTQ4ZTI5YzBjNWVhZGU1NV84_6c3b65dd-df83-420d-8471-483c0e68c104">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV8zLTAtMS0xLTY2NTUvdGV4dHJlZ2lvbjpmY2M4YTA2NjExYWQ0ZTkyYTQ4ZTI5YzBjNWVhZGU1NV8xMg_6652b31a-acea-4f60-a364-79d536049546">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV8zLTItMS0xLTY2NTU_8c929af1-7c6e-4a32-9acf-7c9a2e4e88d0">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV82LTAtMS0xLTY2NTUvdGV4dHJlZ2lvbjo4N2ZjODIyODY5NjI0MGZhYTNhYTMwMDM4YmMzOGEzZl81_17a836f3-0ac5-44b7-89b5-8c018675c8cf">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Mjg4MmE3MDMxM2NjNGFiMWFmM2FhYjQ5ZDE4YTEzOTkvdGFibGVyYW5nZToyODgyYTcwMzEzY2M0YWIxYWYzYWFiNDlkMThhMTM5OV82LTAtMS0xLTY2NTUvdGV4dHJlZ2lvbjo4N2ZjODIyODY5NjI0MGZhYTNhYTMwMDM4YmMzOGEzZl85_297bc75a-5631-4be6-9519-4902f86a3444">952-7570</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6MDc5NGY2ZWVlNmYzNDE1YjgzMTQ4OGViNGJlYmQyZmMvdGFibGVyYW5nZTowNzk0ZjZlZWU2ZjM0MTViODMxNDg4ZWI0YmViZDJmY18xLTAtMS0xLTY2NTU_84a1b293-306b-497f-822a-e97f2d971a66">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6MDc5NGY2ZWVlNmYzNDE1YjgzMTQ4OGViNGJlYmQyZmMvdGFibGVyYW5nZTowNzk0ZjZlZWU2ZjM0MTViODMxNDg4ZWI0YmViZDJmY18xLTItMS0xLTY2NTU_4ecf7ff0-8f34-4737-957b-8cbf90dde446">CRDF</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xODYx_e4164388-1830-494b-b619-4accc003166f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xODU1_aae23b33-d0de-4aa2-89a2-a3186953a1cf">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Y2Q3NmM2NGQwYjdhNGMyZmE0OGIyZWM5NTkzYWU4NDgvdGFibGVyYW5nZTpjZDc2YzY0ZDBiN2E0YzJmYTQ4YjJlYzk1OTNhZTg0OF8wLTQtMS0xLTY2NTUvdGV4dHJlZ2lvbjo0NjI1YzdjYTdmNjQ0ZDY5OGUwMmFmODU3MmM4ODk5ZV80_74f4852d-8d1c-433e-a855-667e36234d79">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Y2Q3NmM2NGQwYjdhNGMyZmE0OGIyZWM5NTkzYWU4NDgvdGFibGVyYW5nZTpjZDc2YzY0ZDBiN2E0YzJmYTQ4YjJlYzk1OTNhZTg0OF8wLTYtMS0xLTY2NTUvdGV4dHJlZ2lvbjpmODA5ZWIxNzg0MGM0YTBhYmRjN2FhNjg5NTYyYWVmM18zMA_c5bb16a9-91a1-4ab5-93b0-7bf60ec64584">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGFibGU6Y2Q3NmM2NGQwYjdhNGMyZmE0OGIyZWM5NTkzYWU4NDgvdGFibGVyYW5nZTpjZDc2YzY0ZDBiN2E0YzJmYTQ4YjJlYzk1OTNhZTg0OF8wLTgtMS0xLTY2NTUvdGV4dHJlZ2lvbjpjN2EzNDk2YjFlNjc0ZTQ3OGRkMGQzYzE1ZjAwYzFmNF8yOA_2b65cad5-1266-4ea7-beb4-d3dcf595afa1">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xODU2_898ce5cf-4f23-4fd6-894e-750e74c097de">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i687be38fd69743e5adc911fcb3916233_I20211029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xL2ZyYWc6NmQxY2I1Nzg2ZDhjNDM3Mjg5YTIxMjUyNzg4MGM1ZmYvdGV4dHJlZ2lvbjo2ZDFjYjU3ODZkOGM0MzcyODlhMjEyNTI3ODgwYzVmZl8xODA1_8dbd1e72-0b4d-47d2-9edc-4501dcb0c75c"
      unitRef="shares">39552129</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMy0xLTEtMS02NjU1_a684fb54-9925-4b08-8490-f04181c1e116"
      unitRef="usd">13165000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMy0zLTEtMS02NjU1_20338b4c-7300-42a7-bb14-d9291a194c3e"
      unitRef="usd">130981000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNC0xLTEtMS02NjU1_6229d7d0-e01c-4a8f-976e-8a8014c9e27e"
      unitRef="usd">120882000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNC0zLTEtMS02NjU1_71dda192-1bef-4308-8a77-df8c31053f37"
      unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNS0xLTEtMS02NjU1_67f6c8b6-f3af-4b73-9912-13d95f1505d4"
      unitRef="usd">395000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNS0zLTEtMS02NjU1_fcccb547-9ac3-4d3d-993a-776912a8329c"
      unitRef="usd">320000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNi0xLTEtMS02NjU1_37780a46-8975-440a-adb8-e084dca5914b"
      unitRef="usd">3327000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNi0zLTEtMS02NjU1_77ee5a26-5447-4a6d-b77a-8e9d6523220c"
      unitRef="usd">2055000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNy0xLTEtMS02NjU1_abf69443-2975-479f-989f-d5519ef5c416"
      unitRef="usd">137769000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNy0zLTEtMS02NjU1_3fb3f93b-68ab-49a0-9d54-78c42ee1f55e"
      unitRef="usd">133356000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfOC0xLTEtMS02NjU1_4e6a7dfd-1ccc-4404-a03e-7bf9f27f06ae"
      unitRef="usd">383000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfOC0zLTEtMS02NjU1_f488436f-6f6b-4d58-999f-122e344d7031"
      unitRef="usd">624000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTAtMS0xLTEtNjY1NQ_ffac4ffd-3cdb-4809-87fd-886fff0fa83d"
      unitRef="usd">3017000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTAtMy0xLTEtNjY1NQ_41062b73-de7f-4333-bcc2-a25772852934"
      unitRef="usd">343000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTEtMS0xLTEtNjY1NQ_92de58a9-c217-415d-89bc-4498ad98e3e8"
      unitRef="usd">143000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTEtMy0xLTEtNjY1NQ_ebc5040a-b40a-413a-8ab6-97274191a50d"
      unitRef="usd">404000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTItMS0xLTEtNjY1NQ_85d93463-62d0-4a6f-9579-47202cc28fa9"
      unitRef="usd">141312000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTItMy0xLTEtNjY1NQ_aa6ac707-cf2d-416c-b0ee-df8ae69dc441"
      unitRef="usd">134727000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTYtMS0xLTEtNjY1NQ_df644028-4471-4fe6-b867-418086754d03"
      unitRef="usd">396000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTYtMy0xLTEtNjY1NQ_3001630d-9629-4f59-a66d-2146a45a134a"
      unitRef="usd">1366000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTctMS0xLTEtNjY1NQ_cc821974-ac34-4cbe-b587-df3b3018a6d9"
      unitRef="usd">4010000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTctMy0xLTEtNjY1NQ_ee1509ce-ab13-4dbd-8eaf-3384cc81b102"
      unitRef="usd">3851000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTktMS0xLTEtNjY1NQ_deab76f8-97b4-415a-aa57-e3e302f0b0f9"
      unitRef="usd">594000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMTktMy0xLTEtNjY1NQ_67e1735b-3a4f-4909-8aaa-29bc428f32df"
      unitRef="usd">860000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjAtMS0xLTEtNjY1NQ_51457a0d-e544-4d0e-897e-a525a3e28fba"
      unitRef="usd">42000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjAtMy0xLTEtNjY1NQ_584c5a4d-d4cd-48af-9e02-3ce5a7e81623"
      unitRef="usd">42000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjItMS0xLTEtNjY1NQ_873efcbb-149f-4e3c-bc12-85c3ea9f9e85"
      unitRef="usd">5042000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjItMy0xLTEtNjY1NQ_b74ffb0b-5737-48d7-b887-23784f6d7b4a"
      unitRef="usd">6119000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjMtMS0xLTEtNjY1NQ_39670048-cd44-4053-a759-327a8867ff66"
      unitRef="usd">5000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjMtMy0xLTEtNjY1NQ_79bcfc50-1d47-4436-a497-b8d7290af1ec"
      unitRef="usd">285000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjUtMS0xLTEtNjY1NQ_6bf30560-9bcd-4f54-9587-e401f6cae107"
      unitRef="usd">2691000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjUtMy0xLTEtNjY1NQ_b8d849b9-3d35-4c89-8cab-3df32f563b20"
      unitRef="usd">9000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjctMS0xLTEtNjY1NQ_4f75aec2-110a-4856-aca2-f5d001be3564"
      unitRef="usd">30000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjctMy0xLTEtNjY1NQ_e0f20acb-bb54-4fc1-a683-07f9bcaeb8f7"
      unitRef="usd">156000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjgtMS0xLTEtNjY1NQ_dd0a1060-7d64-4b68-99aa-55242d3d5d23"
      unitRef="usd">7768000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMjgtMy0xLTEtNjY1NQ_355e687d-0ba8-42ce-bf37-c3d3c80ac477"
      unitRef="usd">6569000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzAtMS0xLTEtNjY1NQ_7fe736fb-cb5b-47bb-937d-924f3504eef3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzAtMy0xLTEtNjY1NQ_60b76554-a75d-40c4-b369-faf4ddb06265"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzMtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjUxNTE3NDA0ZDZmMzQzMzY4M2RkZGI0MGYxOWZmZDk3XzIx_4faf658b-8474-4190-801c-228845eaba7b"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzMtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjUxNTE3NDA0ZDZmMzQzMzY4M2RkZGI0MGYxOWZmZDk3XzIx_b9ef40a2-5f33-405f-8ea0-2a960275851e"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzMtMS0xLTEtNjY1NQ_ce1ce1aa-cf9f-4389-b18b-f9e47cd83b03"
      unitRef="usd">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzMtMy0xLTEtNjY1NQ_fca953a9-3504-438c-b1aa-b609f7e53992"
      unitRef="usd">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzE5_4523fb31-5caf-46e9-bcd1-999ed942a423"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzE5_da1bd84f-fe59-4a28-bc6f-8f260caf8268"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzMz_75584db5-1443-4d73-b78c-2a8c64e242d3"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzMz_79c5240e-9ba0-4e57-a7fc-7c283e37723f"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzU1_19a144ec-3149-43f4-aec6-85f6c3d6e12f"
      unitRef="shares">39552000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzU1_7e2bc85f-7972-45bc-8073-ca5083e79978"
      unitRef="shares">39552000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzYy_21ee8c9d-c29e-4f55-ae5b-01e8dcb0ce37"
      unitRef="shares">36781000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjhjNzUyZWE0NDFiYjQwYzY5OTRmNzE0M2UyMTJiZTlmXzYy_54e47fb5-dae7-442a-8b58-ed5ed9889165"
      unitRef="shares">36781000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMS0xLTEtNjY1NQ_ee662fcc-a97c-4f50-a9fa-7eae43a50280"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzQtMy0xLTEtNjY1NQ_771ebead-ae30-44e8-a187-b40142797767"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzUtMS0xLTEtNjY1NQ_c46ae29d-8022-4ae8-aac2-bdd34e20f847"
      unitRef="usd">384551000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzUtMy0xLTEtNjY1NQ_55287873-a10f-4a48-ac4b-b39d92ef0c8b"
      unitRef="usd">361819000</us-gaap:AdditionalPaidInCapital>
    <crdf:ServiceReceivable
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzYtMS0xLTEtNjY1NQ_49b86e05-0a7a-4d0f-86d3-bc2137d82208"
      unitRef="usd">666000</crdf:ServiceReceivable>
    <crdf:ServiceReceivable
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzYtMy0xLTEtNjY1NQ_91802da8-7b09-4354-b5d5-60cd78a3cbd0"
      unitRef="usd">2171000</crdf:ServiceReceivable>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzctMS0xLTEtNjY1NQ_a8941083-ddbb-4d17-80c8-3e7f3cfc5c89"
      unitRef="usd">16000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzctMy0xLTEtNjY1NQ_063d8cc3-3d2b-4b9b-8e57-3654fd628f05"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzgtMS0xLTEtNjY1NQ_56a251fe-6403-4060-955c-722a14830ddd"
      unitRef="usd">-250362000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzgtMy0xLTEtNjY1NQ_4b6398c8-7b38-44cd-9ac2-cc679fe85b14"
      unitRef="usd">-231495000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzktMS0xLTEtNjY1NQ_fe812b09-9234-4bd3-a853-0ac92608628b"
      unitRef="usd">133544000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfMzktMy0xLTEtNjY1NQ_8c428b12-ad39-49bf-951d-88788be3705e"
      unitRef="usd">128158000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNDAtMS0xLTEtNjY1NQ_e123f17c-7689-4d81-b8aa-35890c9b43d5"
      unitRef="usd">141312000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xNi9mcmFnOjM0NTFmOWM4ZmNkMzQ0NGJiYmNhNDgxNjQwMjY5YTBjL3RhYmxlOmE3ZTk1OGY2YjNlNzRhYmJhZjE1MTUzMjNhNjgzNmM4L3RhYmxlcmFuZ2U6YTdlOTU4ZjZiM2U3NGFiYmFmMTUxNTMyM2E2ODM2YzhfNDAtMy0xLTEtNjY1NQ_01131029-b438-4eb0-a8db-57d0d63104a7"
      unitRef="usd">134727000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMy0xLTEtMS02NjU1_e24df43b-d7b6-4037-ae96-03727b903329"
      unitRef="usd">86000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMy0zLTEtMS02NjU1_601c97dd-7a46-4970-b50f-3fdd60cda5d6"
      unitRef="usd">136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMy01LTEtMS02NjU1_9968d32e-b5c0-4c0b-b94e-2f8def4d7bb3"
      unitRef="usd">226000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMy03LTEtMS02NjU1_8e08f3bc-17cc-4574-a8f6-46d48246270f"
      unitRef="usd">247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfNS0xLTEtMS02NjU1_59342ff5-d373-47c4-9c41-a9547d27ed39"
      unitRef="usd">86000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfNS0zLTEtMS02NjU1_2b6eb4ea-99bd-4de0-909f-d866c7b568d5"
      unitRef="usd">136000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfNS01LTEtMS02NjU1_a4d9b7b4-4f4f-4c35-a25f-d9306fb90b44"
      unitRef="usd">226000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfNS03LTEtMS02NjU1_118cfafc-859e-433e-8ca9-932d40b409d1"
      unitRef="usd">247000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOC0xLTEtMS02NjU1_4773837b-9aa3-4a56-b4e5-975ae8c4414a"
      unitRef="usd">4154000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOC0zLTEtMS02NjU1_e0ce1241-4cbf-48db-a422-ca2a0f45852b"
      unitRef="usd">2855000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOC01LTEtMS02NjU1_24011992-7716-45e2-8558-2060bd3202bd"
      unitRef="usd">11552000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOC03LTEtMS02NjU1_69acf749-6fa3-4590-a68f-ee4fc407756e"
      unitRef="usd">8036000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOS0xLTEtMS02NjU1_0807db0d-65d7-4272-ae47-18d8c3f1699a"
      unitRef="usd">2930000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOS0zLTEtMS02NjU1_85477f69-63a5-4fdf-8177-433701ab7b14"
      unitRef="usd">1644000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOS01LTEtMS02NjU1_4865d4bc-36d5-40e7-b2a6-3717c7578858"
      unitRef="usd">8003000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfOS03LTEtMS02NjU1_fbd907e0-a689-4472-8522-874b827bdbee"
      unitRef="usd">4800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTItMS0xLTEtNjY1NQ_5ce43461-32eb-46f0-a908-aff8732925c4"
      unitRef="usd">7084000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTItMy0xLTEtNjY1NQ_e9bc0fca-36c2-49de-9841-1d31353364c7"
      unitRef="usd">4499000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTItNS0xLTEtNjY1NQ_d5beec81-64ae-45c4-a6c9-716ea6eaa49f"
      unitRef="usd">19555000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTItNy0xLTEtNjY1NQ_76220de6-df1b-4c2f-8cac-f9f5da05c5c4"
      unitRef="usd">12836000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTQtMS0xLTEtNjY1NQ_d4637095-ebe0-4f79-b730-0bd82736dc02"
      unitRef="usd">-6998000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTQtMy0xLTEtNjY1NQ_ef47adc8-d94b-45f4-ae54-daf5a9309bda"
      unitRef="usd">-4363000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTQtNS0xLTEtNjY1NQ_d0825783-0db5-4930-b026-6223ae9d321b"
      unitRef="usd">-19329000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTQtNy0xLTEtNjY1NQ_df3c3672-bd07-42d0-b2de-5fe87f136d2f"
      unitRef="usd">-12589000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTYtMS0xLTEtNjY1NQ_827b05de-5e68-43af-a045-6470b398a04b"
      unitRef="usd">70000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTYtMy0xLTEtNjY1NQ_380e2c32-f243-460c-9a2f-e1ff95cc3f44"
      unitRef="usd">16000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTYtNS0xLTEtNjY1NQ_ef24d32a-7e87-40f9-964e-fb8863621926"
      unitRef="usd">185000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTYtNy0xLTEtNjY1NQ_6eccb3df-b975-48ee-851b-3d085519af8b"
      unitRef="usd">67000</us-gaap:InterestIncomeOperating>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTgtMS0xLTEtNjY1NQ_055e140c-475b-4747-93e1-e251ec2dbe48"
      unitRef="usd">12000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTgtMy0xLTEtNjY1NQ_c3d56326-231c-4afb-8e7c-372989badff2"
      unitRef="usd">-144000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTgtNS0xLTEtNjY1NQ_e389c28a-0717-419f-8480-997f51dfe2d7"
      unitRef="usd">280000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMTgtNy0xLTEtNjY1NQ_1626f316-c469-4422-ac03-edaf5990ec5f"
      unitRef="usd">-186000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjAtMS0xLTEtNjY1NQ_25270158-95a8-4ab3-953a-27b371480573"
      unitRef="usd">3000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjAtMy0xLTEtNjY1NQ_2cb88ad9-454e-4396-8c2b-f14022c4dca4"
      unitRef="usd">-6000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjAtNS0xLTEtNjY1NQ_9fe2100c-24db-4ff7-88d6-d7ec9cd3baea"
      unitRef="usd">15000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjAtNy0xLTEtNjY1NQ_7c135862-1bcb-456a-9ce4-76d5742cc293"
      unitRef="usd">-2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjEtMS0xLTEtNjY1NQ_32097d79-e395-43ce-80f0-c65f2cd9f6d8"
      unitRef="usd">-6913000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjEtMy0xLTEtNjY1NQ_7f30d0d2-8025-4614-8762-a96830c2793b"
      unitRef="usd">-4497000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjEtNS0xLTEtNjY1NQ_519a16a2-8123-4595-a637-117532f1b66e"
      unitRef="usd">-18849000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjEtNy0xLTEtNjY1NQ_b9a03efa-e6bb-4049-b376-1a134289aaeb"
      unitRef="usd">-12710000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjMtMS0xLTEtNjY1NQ_f564ab75-18db-461e-9d36-3fc4fbc5c1ba"
      unitRef="usd">6000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjMtMy0xLTEtNjY1NQ_bd2103fe-a69c-46d8-b6c8-c7f162b8c786"
      unitRef="usd">6000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjMtNS0xLTEtNjY1NQ_93e4ec2e-54e9-4f50-b516-96dcf9a2b1ef"
      unitRef="usd">18000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjMtNy0xLTEtNjY1NQ_a7690b39-19ed-46d7-9972-2ee83673f388"
      unitRef="usd">18000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ic0d1b29ac93e4d80933267bf7ecf68b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjYtMS0xLTEtNjY1NQ_62e511e9-acc6-41dc-8652-233d39afaeaa"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="iee5016562f414703bd929a2aa895f388_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjYtMy0xLTEtNjY1NQ_f80731e0-3825-4553-91fa-c83c881dbce6"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ie19a2c1f7f0b479188b45d6f374dbc81_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjYtNS0xLTEtNjY1NQ_bb6cc246-0ff3-4785-9a2a-95edf74eccb2"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ia35d15a9dfb646fcbffcffbb9d8262b1_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjYtNy0xLTEtNjY1NQ_c850b905-1db5-47da-87f5-83cb9bccc025"
      unitRef="usd">602000</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i8da7726f257f43acb1bea9b40eef263e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjctMS0xLTEtNjY1NQ_8430ab25-c263-4759-a69f-bab42db056dd"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i2cf61f0afd274f019119b3ea148e5dd3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjctMy0xLTEtNjY1NQ_18f1e1bf-e92c-4a77-9376-2fe71828d473"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ibcfb466ee9f44377b4e807b87d71fd6a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjctNS0xLTEtNjY1NQ_52c9b1e9-c51d-46cf-84ee-bdeac7d6ed9f"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i3c1a472218714bdea2c26e2f2f2bc0a7_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjctNy0xLTEtNjY1NQ_d127be50-ad9b-4144-8b0e-71a2f1049ad6"
      unitRef="usd">2665000</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjktMS0xLTEtNjY1NQ_1a8393df-6302-4ad3-9740-4f44175a33b9"
      unitRef="usd">-6919000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjktMy0xLTEtNjY1NQ_5ab607b5-2932-40bc-9001-96a23d9fb6f2"
      unitRef="usd">-4503000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjktNS0xLTEtNjY1NQ_da17d7fa-8fb1-4314-b782-8ff856bfea4c"
      unitRef="usd">-18867000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMjktNy0xLTEtNjY1NQ_c545c291-c20d-44e3-b9cd-39f38256c781"
      unitRef="usd">-15995000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtMS0xLTEtNjY1NQ_8dbfc723-92fe-40cf-b781-0bb078517360"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtMS0xLTEtNjY1NQ_dbedc34d-3626-4b98-8646-c941baf3689e"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtMy0xLTEtNjY1NQ_7b57aa0d-93e1-4d45-8a77-c3d88ae93ffd"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtMy0xLTEtNjY1NQ_fadfa83b-ceee-4fdb-93fa-1ccf23944b3b"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtNS0xLTEtNjY1NQ_0f95e248-c8e1-438e-af47-2504d0088930"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtNS0xLTEtNjY1NQ_bae2ffad-eaa2-445f-8c31-278560f58724"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtNy0xLTEtNjY1NQ_5c359fbb-9d96-4215-9186-dce7056bcc07"
      unitRef="usdPerShare">-1.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzEtNy0xLTEtNjY1NQ_9e3b6058-2fb0-4a0b-9c21-65d39f3b3d0f"
      unitRef="usdPerShare">-1.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtMS0xLTEtNjY1NQ_59c677ab-eb95-4f79-b853-7c3484c69871"
      unitRef="shares">39552000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtMS0xLTEtNjY1NQ_b2e06aea-13f4-4fbe-8fa1-b72b7c09a7e5"
      unitRef="shares">39552000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtMy0xLTEtNjY1NQ_2ddf5405-b9ae-4ee2-bc70-81581ec718b2"
      unitRef="shares">23341000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtMy0xLTEtNjY1NQ_f40635a3-4353-4152-8bd5-d00f36b4c64d"
      unitRef="shares">23341000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtNS0xLTEtNjY1NQ_15f4919a-08ac-456e-9552-a086cc15541d"
      unitRef="shares">38501000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtNS0xLTEtNjY1NQ_da06ddf9-3020-49c0-9ec7-e31eb8e2b135"
      unitRef="shares">38501000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtNy0xLTEtNjY1NQ_2f844085-0d46-4ff9-877f-0e5ca1b416e5"
      unitRef="shares">15942000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8xOS9mcmFnOmIzZDA5Y2ExNzFiNTQzODBhZmNlYzM3ZDYyNTIzZDA3L3RhYmxlOjliMjlmYzUzYmVlZTRjM2Y5MjdiZjdlMDkwNmIzMTU1L3RhYmxlcmFuZ2U6OWIyOWZjNTNiZWVlNGMzZjkyN2JmN2UwOTA2YjMxNTVfMzQtNy0xLTEtNjY1NQ_dd31cd78-729d-4f70-bebd-0be52d578f0c"
      unitRef="shares">15942000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMi0xLTEtMS02NjU1_5fbc5690-dbda-4b25-80c5-2aaedf1c45fb"
      unitRef="usd">-6913000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMi0zLTEtMS02NjU1_3140e15b-673d-4f90-ac51-1f1a6614d87d"
      unitRef="usd">-4497000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMi01LTEtMS02NjU1_9eadf5ff-de9f-410d-a004-bd2bf7fbf028"
      unitRef="usd">-18849000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMi03LTEtMS02NjU1_feb76fbd-44d0-43bc-9f8f-105effc0c8b5"
      unitRef="usd">-12710000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNC0xLTEtMS02NjU1_1cc1c504-7f92-43ba-af61-7ca29f50db97"
      unitRef="usd">26000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNC0zLTEtMS02NjU1_451bc017-23c1-42c7-93e0-274b8db917a2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNC01LTEtMS02NjU1_79dc4341-ee87-4326-8273-b821884b3648"
      unitRef="usd">16000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNC03LTEtMS02NjU1_00baa0f8-075e-4538-bd4e-dc2f50244a52"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNS0xLTEtMS02NjU1_83ddb908-4235-4a3b-b789-900452a7bc01"
      unitRef="usd">-6887000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNS0zLTEtMS02NjU1_d5cc6125-0a91-471d-9c40-800f179c6b15"
      unitRef="usd">-4497000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNS01LTEtMS02NjU1_23e80159-a214-41cd-9838-435add03ef2c"
      unitRef="usd">-18833000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNS03LTEtMS02NjU1_42280265-7f9a-47b6-8027-db5119b19395"
      unitRef="usd">-12710000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNy0xLTEtMS02NjU1_425da13d-3f2e-471d-b1df-32291e52a197"
      unitRef="usd">6000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNy0zLTEtMS02NjU1_273964a1-3f19-4950-901f-3198fc2fadbb"
      unitRef="usd">6000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNy01LTEtMS02NjU1_c2d828c5-719c-4ce3-9219-a16e96247ee5"
      unitRef="usd">18000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfNy03LTEtMS02NjU1_5b590859-50d5-4b85-8637-29d54c434559"
      unitRef="usd">18000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ic0d1b29ac93e4d80933267bf7ecf68b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTAtMS0xLTEtNjY1NQ_64cf9397-692d-4758-a897-6c2b38f4e8d6"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="iee5016562f414703bd929a2aa895f388_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTAtMy0xLTEtNjY1NQ_5a379a86-1d40-4b88-89a0-0dd894fd435b"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ie19a2c1f7f0b479188b45d6f374dbc81_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTAtNS0xLTEtNjY1NQ_ab727028-4539-45fd-bf0a-fbfe82422f61"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ia35d15a9dfb646fcbffcffbb9d8262b1_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTAtNy0xLTEtNjY1NQ_0b874777-4abf-4b0a-97c8-cc6b47e32498"
      unitRef="usd">602000</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i8da7726f257f43acb1bea9b40eef263e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTEtMS0xLTEtNjY1NQ_f850c80f-7ce5-46d2-b40c-92d1583765e8"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i2cf61f0afd274f019119b3ea148e5dd3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTEtMy0xLTEtNjY1NQ_67b37e40-26b3-4f0c-9892-e7a5c63ca8ca"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ibcfb466ee9f44377b4e807b87d71fd6a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTEtNS0xLTEtNjY1NQ_bad34168-8533-44ad-b359-56add1d74ecf"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i3c1a472218714bdea2c26e2f2f2bc0a7_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTEtNy0xLTEtNjY1NQ_8084bfcd-5a70-4b82-8b58-c6811fb43f46"
      unitRef="usd">2665000</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTMtMS0xLTEtNjY1NQ_a1ad04e0-3994-4259-8236-51c4cf572ed3"
      unitRef="usd">-6893000</crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic>
    <crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTMtMy0xLTEtNjY1NQ_3c4272c2-ac68-4e66-afe5-6fffd243be69"
      unitRef="usd">-4503000</crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic>
    <crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTMtNS0xLTEtNjY1NQ_d3e54c83-d59b-4cd9-8b35-6974601449d3"
      unitRef="usd">-18851000</crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic>
    <crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yMi9mcmFnOmRiNmJmNTY2ZmUyMDQ2NjliNjdiNTA5NGIxNTIyODhlL3RhYmxlOjQyNjliOTM0MGRkNDRkODRhODliZmJhMzM0MTIwZmFjL3RhYmxlcmFuZ2U6NDI2OWI5MzQwZGQ0NGQ4NGE4OWJmYmEzMzQxMjBmYWNfMTMtNy0xLTEtNjY1NQ_d1e861ed-cfa5-4277-a418-a59c7b50fe40"
      unitRef="usd">-15995000</crdf:ComprehensiveIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:SharesIssued
      contextRef="i17d10d73626940a1bfac19a0e15cf9bf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS0xLTEtMS02NjU1_bb2107fe-0221-4c88-ad73-5044de68fb53"
      unitRef="shares">716000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i17d10d73626940a1bfac19a0e15cf9bf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS0zLTEtMS02NjU1_72b87635-4237-4eef-8132-8b13c205c5b9"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ic6ed485db45c4a5f8022e1d59b12bf4d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS01LTEtMS02NjU1_c977f888-c44f-4e09-b8cb-e3c8efbb2c1b"
      unitRef="shares">36781000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ic6ed485db45c4a5f8022e1d59b12bf4d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS03LTEtMS02NjU1_6184ca49-79af-4f7c-bc9d-0027241fc03e"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice871a4562a84cd4b52a4356d2cb860e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS05LTEtMS02NjU1_491afe7c-84ac-4fb5-bff1-94776447fdc3"
      unitRef="usd">361819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieb627674086848deba17572418728d83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS0xMS0xLTEtNjY1NQ_9c05e733-372e-4ff4-a859-97730fcd20a9"
      unitRef="usd">-2171000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5d058c8bebe4a3a9d2336d08237e91c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS0xMy0xLTEtNjY1NQ_a13278c1-17cc-4c4e-9a75-7113a748c2e3"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ca2109088ac4793a57a5fce35eb3903_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS0xNS0xLTEtNjY1NQ_398d9917-f6db-473a-a482-3db23278971a"
      unitRef="usd">-231495000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMS0xNy0xLTEtNjY1NQ_66a97bf0-39e8-44ae-9ca9-7dfc22f67632"
      unitRef="usd">128158000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i10e530a8190d4a178d02e013246439d8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMi05LTEtMS02NjU1_0918c7bb-5f7f-4c3e-b068-74a6dcc95556"
      unitRef="usd">268000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib5c1a7cba4434a29a666db82f58a89f0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMi0xNy0xLTEtNjY1NQ_807eb210-ec13-4db5-ac49-551ca8d49c4a"
      unitRef="usd">268000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <crdf:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="ie7083bc457c04ea7b4169c892901eaf8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfNC01LTEtMS02NjU1_ade5c510-bb39-4390-98c7-2ba18a61dd87"
      unitRef="shares">771000</crdf:StockIssuedDuringPeriodSharesWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i10e530a8190d4a178d02e013246439d8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfNC05LTEtMS02NjU1_5c7fd151-aea0-4ff5-9e01-0da4677189e2"
      unitRef="usd">1263000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ib5c1a7cba4434a29a666db82f58a89f0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfNC0xNy0xLTEtNjY1NQ_bac5e5ec-c421-44c2-b530-8030520b8e14"
      unitRef="usd">1263000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i205895823e59424a919b3d93617d9f2c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfNi0xMy0xLTEtNjY1NQ_5c9786c5-73e4-4881-af9e-f3cf2e613b1f"
      unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib5c1a7cba4434a29a666db82f58a89f0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfNi0xNy0xLTEtNjY1NQ_32e6926e-6af8-4e8a-ba84-00f6e84ba5d7"
      unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsPreferredStock
      contextRef="i482f9e2b8aa14c00bc8e55d73914ccd7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfNy0xNS0xLTEtNjY1NQ_58ca9d19-2936-4c59-9183-e295df65e721"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="ib5c1a7cba4434a29a666db82f58a89f0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfNy0xNy0xLTEtNjY1NQ_9f29954b-af82-4581-bf35-4b744d7e3223"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i7880684c50674dbb8cfd7f810fc1727a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfOC0xMS0xLTEtNjY1NQ_05d5a89f-bfd3-4c31-8d72-302bfe46134e"
      unitRef="usd">380000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="ib5c1a7cba4434a29a666db82f58a89f0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfOC0xNy0xLTEtNjY1NQ_9b9d3bba-8c0a-4e90-ba80-f5382e432879"
      unitRef="usd">380000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="i482f9e2b8aa14c00bc8e55d73914ccd7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfOS0xNS0xLTEtNjY1NQ_27c89d6d-1ab4-4956-ba23-9f1c519b3559"
      unitRef="usd">-5179000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib5c1a7cba4434a29a666db82f58a89f0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfOS0xNy0xLTEtNjY1NQ_4605c802-b6ba-4ca5-b793-f7c68c929712"
      unitRef="usd">-5179000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i6eefd6a8f9ad4956b669740bb2b8c353_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtMS0xLTEtNjY1NQ_5473b37a-5fa3-4d55-b861-06780b8db57c"
      unitRef="shares">716000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i6eefd6a8f9ad4956b669740bb2b8c353_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtMy0xLTEtNjY1NQ_8592fce4-c585-44cb-9ae3-b90f2a084d83"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i5a0df33fbbec49a5a57d580b1dcf380b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtNS0xLTEtNjY1NQ_8aca48bc-dc65-4b75-bddc-478fbb5bcbd1"
      unitRef="shares">37552000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i5a0df33fbbec49a5a57d580b1dcf380b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtNy0xLTEtNjY1NQ_2a3ee6c6-e9f2-46e4-ba15-e9cfd8619371"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibd12c54fcda54b7ebf4612de0f518a99_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtOS0xLTEtNjY1NQ_ff37cd90-f695-4b3e-aa64-7ffb2a8009f8"
      unitRef="usd">363350000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i71acb7a4b79649b297dc1e8c8c73d504_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtMTEtMS0xLTY2NTU_c7eb2d65-5e30-49a9-871a-b49c6a08840e"
      unitRef="usd">-1791000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e8063e7fb6749e0af8bd1ecebda0314_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtMTMtMS0xLTY2NTU_bef21507-99de-413d-aa8f-ce9f74dd6ef4"
      unitRef="usd">-67000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib30b6ac5d0cd4c369a9097268eb12984_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtMTUtMS0xLTY2NTU_c38972c2-140b-4c26-bdd4-ef214e49077a"
      unitRef="usd">-236680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i24420ff79ce74c9b9b895204b192740b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTAtMTctMS0xLTY2NTU_75d45995-0301-4d84-a20b-5332de520d33"
      unitRef="usd">124817000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia3282128780c4055854a3cc8fbe4a2e0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTEtOS0xLTEtNjY1NQ_b06f6500-8ba5-47fd-b57f-491bdb85dbec"
      unitRef="usd">1036000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i41602febb1074927adedec6da8eb37fe_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTEtMTctMS0xLTY2NTU_27a155bf-6b2d-4b69-8c90-85f029311ce8"
      unitRef="usd">1036000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2465b36c344b4703902f0880f5e52116_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItNS0xLTEtNjY1NQ_7234ddc5-b679-4fc0-a393-e948e7d69e05"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia3282128780c4055854a3cc8fbe4a2e0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItOS0xLTEtNjY1NQ_1b881f8f-1dfb-4cc2-a134-d47449a4a1f3"
      unitRef="usd">19225000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i41602febb1074927adedec6da8eb37fe_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItMTctMS0xLTY2NTU_59530542-f04c-47ab-b223-2db7c69d1645"
      unitRef="usd">19225000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if9b018ac82a04fb590b1485d91230d8d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTMtMTMtMS0xLTY2NTU_5a4e688a-4ce5-4d56-933d-5d790c280bf3"
      unitRef="usd">57000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i41602febb1074927adedec6da8eb37fe_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTMtMTctMS0xLTY2NTU_f7a7cf50-9773-4ea5-8f18-bff3721b756a"
      unitRef="usd">57000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsPreferredStock
      contextRef="i7ca563e0d06f4599a46a722d3581dd74_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTQtMTUtMS0xLTY2NTU_ea5cb9ae-1beb-4a05-95e2-39ce4f40d37a"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="i41602febb1074927adedec6da8eb37fe_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTQtMTctMS0xLTY2NTU_2aedb09a-5679-43b0-bf89-935ecd903bac"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="if15e882bdfea4fdf952e43b08bc2429b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTUtMTEtMS0xLTY2NTU_2aaa62dc-45d2-48bd-b180-3f5021f80cfa"
      unitRef="usd">546000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i41602febb1074927adedec6da8eb37fe_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTUtMTctMS0xLTY2NTU_b8a8db7a-2e9f-422f-950a-902ed4127543"
      unitRef="usd">546000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="i7ca563e0d06f4599a46a722d3581dd74_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTYtMTUtMS0xLTY2NTU_920faad8-2a96-4d4a-b35b-d94c4acf93b9"
      unitRef="usd">-6757000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i41602febb1074927adedec6da8eb37fe_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTYtMTctMS0xLTY2NTU_44044422-2028-49a1-bb61-32ee46cceef7"
      unitRef="usd">-6757000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i350d28ef78674e3eab8458411c7fcc81_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctMS0xLTEtNjY1NQ_656085ce-6e5c-4321-a20d-047c5717786d"
      unitRef="shares">716000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i350d28ef78674e3eab8458411c7fcc81_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctMy0xLTEtNjY1NQ_b6a0a902-6848-458c-bb76-9f4a01fb592f"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="idf1c65b7a7224893adb36ad9e8cbe745_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctNS0xLTEtNjY1NQ_e58fc72b-8855-43fe-a8a3-9ceb8ab49284"
      unitRef="shares">39552000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="idf1c65b7a7224893adb36ad9e8cbe745_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctNy0xLTEtNjY1NQ_f400d94d-9edf-478b-90d7-e9d647edc207"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5336d0a252e4aeb98ca683a43ba06b0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctOS0xLTEtNjY1NQ_87da8aa9-4718-44a2-8f6c-4f28c6354fb1"
      unitRef="usd">383611000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5824d16b9ba441788705b462bc177803_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctMTEtMS0xLTY2NTU_c6ce005a-b53b-408e-840c-d5d33f3bbfa9"
      unitRef="usd">-1245000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i33e4526f7e164ab8b705c8f15dd1b690_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctMTMtMS0xLTY2NTU_4b00415d-069e-4f41-9be3-34e7f6091341"
      unitRef="usd">-10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia14d6cd1be5f488284a0548acc13b622_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctMTUtMS0xLTY2NTU_caa095ab-ab97-458a-9bac-2dbd8f1c3b60"
      unitRef="usd">-243443000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i402f50ca14e9498daade666a2aba16c6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTctMTctMS0xLTY2NTU_17fdb243-578e-47f2-b9e2-7f98b0c57cb5"
      unitRef="usd">138918000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic553804c0eaf41af8f0aea771674f3de_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTgtOS0xLTEtMjAyMjI_9102dd6c-f429-42c6-911e-cfdcc9539673"
      unitRef="usd">940000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTgtMTctMS0xLTIwMjI5_4dd32a7a-f99a-459c-8cc0-40eeb5703ecf"
      unitRef="usd">940000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i56cfeedf0a7846a480b68514e6ec597c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTktMTMtMS0xLTIwMjIy_3f60d6fd-8477-472d-a057-26e8c47e6117"
      unitRef="usd">26000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTktMTctMS0xLTIwMjI5_0339b283-c11c-4692-ad34-98eadd43cc5e"
      unitRef="usd">26000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsPreferredStock
      contextRef="i583e90cffdc74283ad12fcd0e679a613_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjAtMTUtMS0xLTIwMjIy_c8180f4c-4cc1-4405-8b53-ad29550c0a63"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjAtMTctMS0xLTIwMjI5_e82814c9-52ef-4b37-8bc4-0431509a2552"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="ia7fb9b1347f54faaa7e69ff2ccf6a961_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjEtMTEtMS0xLTIwMjIy_f37a4b64-1399-40e8-9374-7bb9fc44df0d"
      unitRef="usd">579000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjEtMTctMS0xLTIwMjI5_f12a90e1-4c52-40e7-b235-cb463ce53190"
      unitRef="usd">579000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="i583e90cffdc74283ad12fcd0e679a613_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjItMTUtMS0xLTIwMjIy_99610928-ebd5-4c45-a5d2-9f4f84faa84b"
      unitRef="usd">-6913000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjItMTctMS0xLTIwMjI5_4a6360e0-55fd-4579-8d24-4e8c69abacd5"
      unitRef="usd">-6913000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i33912183705e412b83ed2cef39eddc1c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtMS0xLTEtMjEwMTE_e599ff38-c06a-4b00-8503-2561c6dbe950"
      unitRef="shares">716000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i33912183705e412b83ed2cef39eddc1c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtMy0xLTEtMjEwMTE_6b6de2cd-b380-4a07-9cf1-a1dcc9a9211a"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ic25a7e642c104708a790b647db5d1ded_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtNS0xLTEtMjEwMTE_227f0299-af93-4b0b-9b87-2da4b5dd6f51"
      unitRef="shares">39552000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ic25a7e642c104708a790b647db5d1ded_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtNy0xLTEtMjEwMTE_2099683f-e01b-4733-801e-989f9b00b321"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7086816a72204fa58a1df8fa6c35a63a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtOS0xLTEtMjEwMTE_31fb1b5a-f953-41e2-ad2c-dac8491bd8c9"
      unitRef="usd">384551000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied522f508b844f94be0b94767cf40167_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtMTEtMS0xLTIxMDEx_9447970c-db9c-460a-a275-f0c3069560bb"
      unitRef="usd">-666000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9d4805fa04ec446eab0d6af2de913c7c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtMTMtMS0xLTIxMDEx_7583f273-86ae-4563-9792-5d9de0e91feb"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i45e23d0997d94ed9a6bbb2f8fc1ee85e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtMTUtMS0xLTIxMDEx_31584136-3e98-4169-be1a-c656edcb6cdc"
      unitRef="usd">-250362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMjMtMTctMS0xLTIxMDEx_2bdccc67-73d5-4d56-9fe7-adce16d25194"
      unitRef="usd">133544000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i41602febb1074927adedec6da8eb37fe_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMTIz_9ea76d1d-be5b-431b-89d4-9c4c6eb4edd6"
      unitRef="usd">800000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SharesIssued
      contextRef="ib94e5739ad98459497e72c9a6bc0ad84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS0xLTEtMS02NjU1_664f71bc-c61a-4cb6-97a2-ba760fb57fd4"
      unitRef="shares">61000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ib94e5739ad98459497e72c9a6bc0ad84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS0zLTEtMS02NjU1_79d225fb-539f-477d-845c-6babd15ed16b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i83bc7c42c1824b15a08376355aa11ba3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS01LTEtMS02NjU1_c13a4ef2-dfcc-47c2-b081-563a3739d110"
      unitRef="shares">8594000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i83bc7c42c1824b15a08376355aa11ba3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS03LTEtMS02NjU1_8a427627-41e3-4038-9ac0-a6f78aa391fd"
      unitRef="usd">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3aa726d5321245c1a96ba3990871ca22_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS05LTEtMS02NjU1_e1a00579-5572-46d4-8665-81722876eeff"
      unitRef="usd">217172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icf57c9859a8a4e38b67c19c2be236a90_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS0xMS0xLTEtNjY1NQ_9b1563d8-3d7a-470b-b578-510d7f67593f"
      unitRef="usd">-972000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i631d652218464d15843c3a80ff37978c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS0xMy0xLTEtNjY1NQ_aaaca603-196f-41d5-b7cd-f170e596fdc8"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i953e77c8d38e45e6974947b84da4f172_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS0xNS0xLTEtNjY1NQ_f2fccea7-ea56-4307-ad67-f75b53b90f7b"
      unitRef="usd">-208898000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c0e2ceae22248b4a0ebd0aa20fa60c6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMS0xNy0xLTEtNjY1NQ_7673c9ca-f66a-494f-899e-8173956a4cbb"
      unitRef="usd">7310000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iff0a01a8a61a458184bb5efcbdd6cdae_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMi05LTEtMS02NjU1_5119c6a5-3412-41ae-a80c-c7ce406348c8"
      unitRef="usd">177000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMi0xNy0xLTEtNjY1NQ_fd7c2bde-dbea-4efa-b8f0-67278f9cc601"
      unitRef="usd">177000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <crdf:SaleOfStockCommonAndWarrantsNetShares
      contextRef="i98824144f8e24c5cad08193a1247420c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMy01LTEtMS02NjU1_bb9be4fc-3762-46b7-a236-1a31d1a06d9c"
      unitRef="shares">-800000</crdf:SaleOfStockCommonAndWarrantsNetShares>
    <crdf:SaleOfStockValueCommonAndWarrantsNet
      contextRef="iff0a01a8a61a458184bb5efcbdd6cdae_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMy05LTEtMS02NjU1_8689fef9-a6dd-4dea-8ce1-5b621a48c4f1"
      unitRef="usd">-1000000</crdf:SaleOfStockValueCommonAndWarrantsNet>
    <crdf:SaleOfStockValueCommonAndWarrantsNet
      contextRef="ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMy0xNy0xLTEtNjY1NQ_a1ecbb7e-9b3b-48f4-9416-5835b07b2a5e"
      unitRef="usd">-1000000</crdf:SaleOfStockValueCommonAndWarrantsNet>
    <crdf:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i98824144f8e24c5cad08193a1247420c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNC01LTEtMS02NjU1_bb9acb11-89f6-4c7c-b616-ba1bd1176ba9"
      unitRef="shares">1610000</crdf:StockIssuedDuringPeriodSharesWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="iff0a01a8a61a458184bb5efcbdd6cdae_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNC05LTEtMS02NjU1_d4d8cea1-2ea1-41a6-beee-c9331c5c3cd1"
      unitRef="usd">1456000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNC0xNy0xLTEtNjY1NQ_92875080-b636-4c6e-804c-ec637318419a"
      unitRef="usd">1456000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased
      contextRef="i98824144f8e24c5cad08193a1247420c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNS01LTEtMS02NjU1_62716f65-e18b-49a6-88a5-ab2c0109d191"
      unitRef="shares">7000</crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased>
    <us-gaap:DividendsPreferredStock
      contextRef="idd2c102f2b6845ce95560b93eba83063_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNi0xNS0xLTEtNjY1NQ_5446dcb4-fee1-4c09-b62c-1c1628cd50f0"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNi0xNy0xLTEtNjY1NQ_5bbb0f23-e915-41a1-8a0d-1d7ecd5dcfeb"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i451d0811b3544bcc912debf2a8ede85a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNy0xMS0xLTEtNjY1NQ_874ffcc5-aca3-4f50-ab0c-25e519c056e7"
      unitRef="usd">293000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfNy0xNy0xLTEtNjY1NQ_37a42f90-8c82-4420-9e40-a55443790ae9"
      unitRef="usd">293000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="idd2c102f2b6845ce95560b93eba83063_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOC0xNS0xLTEtNjY1NQ_abb505c5-381c-4667-8ab2-c66d66968c8a"
      unitRef="usd">-4089000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOC0xNy0xLTEtNjY1NQ_3b5e2674-60c0-43df-944e-539be20b1b4e"
      unitRef="usd">-4089000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i2cd86fa1857349e7b73861b629a3a124_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS0xLTEtMS02NjU1_b5637034-d920-4a2a-b6c4-cc2dfab62148"
      unitRef="shares">61000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i2cd86fa1857349e7b73861b629a3a124_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS0zLTEtMS02NjU1_da35b6a1-787c-407e-8f8d-6c6e3a2b3fe3"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i49c8e30388454e01b1713f33c031e81a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS01LTEtMS02NjU1_fb42161b-dec8-48a7-b11a-6a1461b6a7f4"
      unitRef="shares">11011000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i49c8e30388454e01b1713f33c031e81a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS03LTEtMS02NjU1_3efdc5da-bf08-47c8-8ae9-64b786bdc62f"
      unitRef="usd">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icac2c0c6030c476080cddc898da2fdbe_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS05LTEtMS02NjU1_55cdcf81-c351-4522-a525-d9c7a94a751f"
      unitRef="usd">219805000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icaebc49a046040e29e5e4565fd900bcb_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS0xMS0xLTEtNjY1NQ_85b12796-898f-4989-baf0-be118175a0e5"
      unitRef="usd">-679000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63aaf8a8792b4035ba42f8b374bd567e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS0xMy0xLTEtNjY1NQ_2a94a42d-8bef-4ea7-b973-256b6b9fbaa9"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c0e65a2de674c8a814d4c385ed678a6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS0xNS0xLTEtNjY1NQ_daa18449-a752-4a84-8438-2cc97587a957"
      unitRef="usd">-212993000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5a2c6673bb34fcfaba41b7f80484177_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfOS0xNy0xLTEtNjY1NQ_afe0c5f4-4d21-423d-8a9f-500b75765777"
      unitRef="usd">6141000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i110b9bf586124339b177542a41284804_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTAtOS0xLTEtNjY1NQ_043a8246-1f43-4938-9b22-93e080742f9d"
      unitRef="usd">282000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTAtMTctMS0xLTY2NTU_a8a5e2af-8b1f-4ab5-a308-9bcb7f89714c"
      unitRef="usd">282000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i18b0e382e0084fe29c322a52a6d9fb60_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTEtMS0xLTEtNjY1NQ_8bdcda0e-6034-4244-acaa-077a0e16b884"
      unitRef="shares">155000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i28dd1563898f43d9b46b76dc77925f8e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTEtNS0xLTEtNjY1NQ_19b13695-b291-49af-9409-d4bf84a62003"
      unitRef="shares">603000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i110b9bf586124339b177542a41284804_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTEtOS0xLTEtNjY1NQ_9a32f22b-3d70-48e3-a818-6f90b8378f2b"
      unitRef="usd">2292000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i449d2f3eb8d0492f8052bba28b62b75d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTEtMTEtMS0xLTY2NTU_845576a5-1809-472b-830e-b87802b97169"
      unitRef="usd">-2300000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTEtMTctMS0xLTY2NTU_f39bb0c8-7c68-436d-8aa5-5ad3d1c59fee"
      unitRef="usd">-8000</us-gaap:StockIssuedDuringPeriodValueOther>
    <crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="ic80c59f86e5f4a4186743622863a59c7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTItOS0xLTEtNjY1NQ_229be52d-ad9b-49ed-8b67-b9249f36f8d6"
      unitRef="usd">602000</crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="i2636d69182a44bceacd8ee49296aa242_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTItMTUtMS0xLTY2NTU_5ef97e18-046f-4b7f-bf43-ee770b2433aa"
      unitRef="usd">-602000</crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="ib95b420a99f04c7ea8d5bc830d3e1aba_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTMtOS0xLTEtNjY1NQ_53f9be33-8a59-4fb1-a09c-1d8f60058c84"
      unitRef="usd">2665000</crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="i205347e8f5484902aba963f9ad58ff6a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTMtMTUtMS0xLTY2NTU_05110476-e646-4d08-a6ab-93f6fea8872b"
      unitRef="usd">-2665000</crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i18b0e382e0084fe29c322a52a6d9fb60_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMS0xLTEtNjY1NQ_2cb15daf-5623-463f-b164-40c2c32e26af"
      unitRef="shares">866000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i18b0e382e0084fe29c322a52a6d9fb60_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMy0xLTEtNjY1NQ_0c21b0be-0a08-4608-bbad-fb219c020305"
      unitRef="usd">1000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i28dd1563898f43d9b46b76dc77925f8e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtNS0xLTEtNjY1NQ_c480c886-f66a-4315-9261-61b886b3ff94"
      unitRef="shares">4689000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i28dd1563898f43d9b46b76dc77925f8e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtNy0xLTEtNjY1NQ_f2aa8f4b-04f8-4b63-911b-932ff2860817"
      unitRef="usd">1000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i110b9bf586124339b177542a41284804_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtOS0xLTEtNjY1NQ_bce4f6d3-de3c-4401-99d8-dad63b036878"
      unitRef="usd">17277000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMTctMS0xLTY2NTU_250d4afb-d517-49b4-ae52-055936d7d7c9"
      unitRef="usd">17279000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <crdf:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i28dd1563898f43d9b46b76dc77925f8e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTUtNS0xLTEtNjY1NQ_5f93d3d2-1100-4060-bdef-868b8ff6aebc"
      unitRef="shares">3473000</crdf:StockIssuedDuringPeriodSharesWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i110b9bf586124339b177542a41284804_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTUtOS0xLTEtNjY1NQ_7b10faad-6e43-40ae-ac9a-85ace846f59e"
      unitRef="usd">4605000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTUtMTctMS0xLTY2NTU_bb730793-e889-49cc-9f9f-6825ce3ce0f5"
      unitRef="usd">4605000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased
      contextRef="i28dd1563898f43d9b46b76dc77925f8e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTYtNS0xLTEtNjY1NQ_01188eea-d65c-48a6-9842-6fd7db1ded01"
      unitRef="shares">2000</crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i2f820ff8f6c24d05b3ffd3339f0dcfc9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTctMS0xLTEtNjY1NQ_30d1624f-c8ce-4123-8754-e1bd86915cfe"
      unitRef="shares">-155000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i1e7e9d9d6bd7457098d60b651db0d39f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTctNS0xLTEtNjY1NQ_105b317a-1cbd-439f-98f2-6d6ddec12033"
      unitRef="shares">1547000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DividendsPreferredStock
      contextRef="ieb79d8dc23ad4047a11793096554a73c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTgtMTUtMS0xLTY2NTU_a66489fb-82c2-4ad7-bd78-0e78d304fcaf"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTgtMTctMS0xLTY2NTU_690c5cba-2fe9-427b-b5d5-3f61fcf55dd4"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i449d2f3eb8d0492f8052bba28b62b75d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTktMTEtMS0xLTY2NTU_dc0064e8-8b7b-4ec5-9f15-e6b0f1f5cef0"
      unitRef="usd">213000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTktMTctMS0xLTY2NTU_7d7c3056-f61a-47e8-9fc6-b4fb4d475df0"
      unitRef="usd">213000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="ieb79d8dc23ad4047a11793096554a73c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjAtMTUtMS0xLTY2NTU_107adca0-8073-44b3-a8b9-b4988c1bd2e5"
      unitRef="usd">-4124000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjAtMTctMS0xLTY2NTU_af355baf-67d3-4f5f-b896-fe2939686f0b"
      unitRef="usd">-4124000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ibfabfd86abc84c9d8332a7d6522f0b05_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtMS0xLTEtNjY1NQ_5da2babe-e3f9-4d87-b3c5-c92ee938d518"
      unitRef="shares">927000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ibfabfd86abc84c9d8332a7d6522f0b05_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtMy0xLTEtNjY1NQ_6993acf2-eb3f-461e-9aed-769b172dda34"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i0d9ab8d6d1f3471aada01b6d9a78f35d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtNS0xLTEtNjY1NQ_31de97ba-ab6f-421d-86ed-c668e44fbfee"
      unitRef="shares">21325000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0d9ab8d6d1f3471aada01b6d9a78f35d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtNy0xLTEtNjY1NQ_dc81cd6c-76d0-454e-8231-02db961245e9"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iefd2c993874045f0903171fafd6a6737_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtOS0xLTEtNjY1NQ_c4653ef3-9772-4ed0-a233-1d92218f075d"
      unitRef="usd">247528000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i02b12865eb164c1b8daa72971befc365_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtMTEtMS0xLTY2NTU_36d2d961-e09b-49db-95f6-1fe942aa722a"
      unitRef="usd">-2766000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7223f8f5e4b7451fac6e9a53f511b618_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtMTMtMS0xLTY2NTU_078ec2fd-030b-4a4b-9c92-59f93ce8974a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb8b40a3759d4dd8bdff04839d6af29e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtMTUtMS0xLTY2NTU_aa64409e-8fc4-4e82-afc1-bdecdf1c6109"
      unitRef="usd">-220390000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60b2d2a3f17d4b329211ee5e90f04d9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjEtMTctMS0xLTY2NTU_1ede8dc7-1826-4d18-af4a-192d2da648b9"
      unitRef="usd">24382000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia6b51a15c074437984b0293d4935aae9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjItOS0xLTEtNjc2Mg_b93a2ca1-ab57-4a2d-b2c4-f3836f3b9c5f"
      unitRef="usd">362000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjItMTctMS0xLTY3NjI_fc6ae462-d52f-4ce2-9c3c-e9970dd8bc3a"
      unitRef="usd">362000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <crdf:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i793b333bdcf34df8a736118d629cb3b7_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjMtNS0xLTEtNjg2MQ_c925f0ad-29ae-4538-8a0e-cc25d210edf0"
      unitRef="shares">4957000</crdf:StockIssuedDuringPeriodSharesWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i793b333bdcf34df8a736118d629cb3b7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjMtNy0xLTEtNjg2MQ_592fbbcd-fed8-416c-849a-fa6b5914ca6d"
      unitRef="usd">1000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ia6b51a15c074437984b0293d4935aae9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjMtOS0xLTEtNjg2MQ_44b0f88b-b0c1-4e53-9dee-0d38300e8880"
      unitRef="usd">12910000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjMtMTctMS0xLTY4NjE_ebaa412b-9512-49dc-8dd7-dce694897c69"
      unitRef="usd">12911000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i793b333bdcf34df8a736118d629cb3b7_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjQtNS0xLTEtMjEwNjQ_6cecdc03-6619-486a-a211-6981e79b6e71"
      unitRef="shares">3000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia6b51a15c074437984b0293d4935aae9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjQtOS0xLTEtMjEwNjQ_f633d5f6-cc5f-4d2f-b25b-3d0774fe08c5"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjQtMTctMS0xLTIxMDY0_0ca6e876-7b10-4a49-9e31-ad6b4b8d9bdf"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased
      contextRef="i793b333bdcf34df8a736118d629cb3b7_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjUtNS0xLTEtNjg3NQ_1ef20895-3749-4435-b3be-751b9002489c"
      unitRef="shares">1000</crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased>
    <us-gaap:DividendsPreferredStock
      contextRef="i8768b38297214afab61b468bbf429f52_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjYtMTUtMS0xLTY4OTc_fe4d3395-6c5e-4c7c-a107-627f1f7c6d36"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjYtMTctMS0xLTY4OTc_a1307de2-9337-4ddf-bf3d-35ade8d34c3e"
      unitRef="usd">6000</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i3a7ab6cbc6374029b4bffd3ec9b17e0c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjctMTEtMS0xLTY5MDk_69a08848-3aef-44c2-b8ac-36fd8383d64d"
      unitRef="usd">362000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjctMTctMS0xLTY5MDk_5b82c423-4e41-4e8b-8148-750146293c93"
      unitRef="usd">362000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="i8768b38297214afab61b468bbf429f52_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjgtMTUtMS0xLTY5MzM_7abd4561-23c7-4bcd-b74b-4dc353719f94"
      unitRef="usd">-4497000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjgtMTctMS0xLTY5MzM_753ade59-1578-430d-a3d1-ad54254ae288"
      unitRef="usd">-4497000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ie26a981245d5493394cff84a3e0e6e70_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktMS0xLTEtNjk0NQ_c9e851e3-d25b-4071-a698-16c5300935a8"
      unitRef="shares">927000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ie26a981245d5493394cff84a3e0e6e70_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktMy0xLTEtNjk0OA_5358590a-3820-4c47-bcc2-5fa0a441e806"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i775faff3942e4e5db3e5bd022093d60f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktNS0xLTEtMjEwMDk_026db4f6-dafb-4f08-9ff2-d7edaef2af91"
      unitRef="shares">26286000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i775faff3942e4e5db3e5bd022093d60f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktNy0xLTEtMjEwMDk_0ae79145-67bf-40c2-a80a-20cf8b88846a"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i81e14a5109df413e81014c0b81871037_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktOS0xLTEtMjEwMDk_7c0c98e5-fb37-49fa-a691-7553615618d6"
      unitRef="usd">260807000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i51efe940143345028a304e5a815b9230_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktMTEtMS0xLTIxMDA5_dd1bf80f-7614-412a-bd75-eecb94e2fe4b"
      unitRef="usd">-2404000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if45c6805e8814c47933df9000082c117_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktMTMtMS0xLTIxMDA5_ed3219f3-0f1b-4f81-9594-90c3a5bd41b0"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i057b4c0f72d44fdb8719e1f993ada81b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktMTUtMS0xLTIxMDA5_e765d1cf-77cc-4d9f-a3aa-366f862c13c9"
      unitRef="usd">-224893000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i41cb574ec6224df9954670aecbbdd57c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMjktMTctMS0xLTIxMDA5_0a017562-cb42-40bf-bf6a-d1b204c64b5b"
      unitRef="usd">33521000</us-gaap:StockholdersEquity>
    <crdf:CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment
      contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMjIz_925c7062-640d-4e89-a0ce-01899019ffc9"
      unitRef="usd">600000</crdf:CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment>
    <crdf:WarrantsFairValue
      contextRef="ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzIx_bf62510d-e195-48d4-aef2-348d18456f35"
      unitRef="usd">400000</crdf:WarrantsFairValue>
    <us-gaap:NetIncomeLoss
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMy0xLTEtMS02NjU1_822454bb-7e24-46fe-b3f8-2f1eaa5bf277"
      unitRef="usd">-18849000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMy0zLTEtMS02NjU1_99da45c7-cfe8-4919-9200-fceac59e3fef"
      unitRef="usd">-12710000</us-gaap:NetIncomeLoss>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNS0xLTEtMS02NjU1_5bd69d19-ec60-4615-9ba3-42fe4c5f51bc"
      unitRef="usd">-1000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNS0zLTEtMS02NjU1_14a88f5f-e8cb-4611-95af-d59561830117"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNi0xLTEtMS02NjU1_3130df22-15ee-4ce2-8c67-a8a607d440ad"
      unitRef="usd">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNi0zLTEtMS02NjU1_49efd1d1-a743-43ab-ac10-b7c64abeca76"
      unitRef="usd">34000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNy0xLTEtMS02NjU1_1620803f-16b0-4db0-9d75-be70a49806fa"
      unitRef="usd">338000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNy0zLTEtMS02NjU1_5df42498-48f5-41c5-8242-295987c21675"
      unitRef="usd">349000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfOC0xLTEtMS02NjU1_46b8e457-195f-4a11-96a7-b76af7989110"
      unitRef="usd">2244000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfOC0zLTEtMS02NjU1_7164c63c-468b-4081-b10b-bad2654a8e0d"
      unitRef="usd">821000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTMtMS0xLTEtNjY1NQ_e88285d2-d1e3-4abd-ba8a-f713cee534a2"
      unitRef="usd">-1160000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTMtMy0xLTEtNjY1NQ_753983fe-afb4-429f-8654-25c9093d8c93"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTYtMS0xLTEtNjY1NQ_4fa2c931-7d50-4ec3-8847-a0ab9c3a999f"
      unitRef="usd">280000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTYtMy0xLTEtNjY1NQ_7535a7a1-c20e-4b7a-8b36-c1b9f513e9be"
      unitRef="usd">-186000</us-gaap:UnrealizedGainLossOnDerivatives>
    <crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTctMS0xLTEtNjY1NQ_602a993f-1696-4e9f-b75e-227730e60eb9"
      unitRef="usd">1505000</crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived>
    <crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTctMy0xLTEtNjY1NQ_3a3fdd04-55d5-4030-826e-7272d6dbebd7"
      unitRef="usd">868000</crdf:ReleaseOfClinicalTrialFundingCommitmentForServicesReceived>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTktMS0xLTEtNjY1NQ_0485aaf3-38ed-4110-b01c-611bad32c189"
      unitRef="usd">-261000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMTktMy0xLTEtNjY1NQ_57994ce0-3bc8-41ed-8ae2-317d399421c9"
      unitRef="usd">-2000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjAtMS0xLTEtNjY1NQ_723cf002-d5bf-4007-b8cf-97a15a16aa96"
      unitRef="usd">74000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjAtMy0xLTEtNjY1NQ_3c482417-f2b7-4260-97da-9a23f0e0c5d5"
      unitRef="usd">1000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjEtMS0xLTEtNjY1NQ_d6fb3119-5d5b-41da-b3e4-e6353bba896c"
      unitRef="usd">741000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjEtMy0xLTEtNjY1NQ_3b96a056-7ffc-4410-9943-4e0b6d5c2047"
      unitRef="usd">624000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjItMS0xLTEtNjY1NQ_273ed4df-24ba-4121-8b40-d5bdd6072669"
      unitRef="usd">-386000</crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjItMy0xLTEtNjY1NQ_4858db91-d561-4a66-881f-707fd9d140d0"
      unitRef="usd">-240000</crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjMtMS0xLTEtNjY1NQ_31fd8f22-0632-4eae-9b33-3b87f6ed7caa"
      unitRef="usd">-830000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjMtMy0xLTEtNjY1NQ_6c69434a-0ccc-44ad-bc99-29622f19e7e8"
      unitRef="usd">320000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <crdf:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjQtMS0xLTEtNjY1NQ_9ef196f7-0bc9-4b4f-a61d-5d8e2f0a15c1"
      unitRef="usd">-645000</crdf:IncreaseDecreaseInOperatingLeaseLiability>
    <crdf:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjQtMy0xLTEtNjY1NQ_d34bba15-81a0-4cd9-aa3c-1c2a4f48c4a7"
      unitRef="usd">-636000</crdf:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjUtMS0xLTEtNjY1NQ_219b036d-5a45-43f0-b9b1-ad232af414a8"
      unitRef="usd">-126000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjUtMy0xLTEtNjY1NQ_9f228ca0-74bd-4693-b645-603285780742"
      unitRef="usd">-40000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjYtMS0xLTEtNjY1NQ_ee520244-a23c-48d1-9781-9b6ecefd4ca9"
      unitRef="usd">-15650000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMjYtMy0xLTEtNjY1NQ_8a8d15c9-3bf4-4507-b45b-fd5651ee52a1"
      unitRef="usd">-11191000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzAtMS0xLTEtNjY1NQ_07c83fda-41a7-4054-a5fe-dc6640b9e8a4"
      unitRef="usd">98000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzAtMy0xLTEtNjY1NQ_594b4bc6-cf15-40c2-a405-0c90e1d9304d"
      unitRef="usd">154000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzEtMS0xLTEtNjY1NQ_082ec3ef-2c4e-4bc6-8b99-ef56610111e2"
      unitRef="usd">15101000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzEtMy0xLTEtNjY1NQ_c5fc9f14-6f0e-4e45-bde8-6705876c925c"
      unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzItMS0xLTEtNjY1NQ_0639e6cb-a38b-4974-bdec-2a75be8ed34c"
      unitRef="usd">146632000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzItMy0xLTEtNjY1NQ_17fd6a02-47fb-4900-897c-c60e76006cb1"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzMtMS0xLTEtNjY1NQ_06c8de99-0230-470d-9494-1e9388903d0b"
      unitRef="usd">8975000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzMtMy0xLTEtNjY1NQ_bee10c07-4f8b-41a5-8c13-b34a4a0876ca"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzQtMS0xLTEtNjY1NQ_b4f8c18f-3418-423a-bc6a-0cdcbfa1058f"
      unitRef="usd">-122654000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzQtMy0xLTEtNjY1NQ_a5d872e3-85f4-4e8c-aabd-bc2f92697ec7"
      unitRef="usd">-154000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzctMC0xLTEtNjY1NS90ZXh0cmVnaW9uOmZlZDY4ZDRkODczYzRiYjc4MDFjNDRjNDMzZGJmNzdmXzkw_5899e386-72fe-4304-8575-2260b3e31dc2"
      unitRef="usd">776000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzctMC0xLTEtNjY1NS90ZXh0cmVnaW9uOmZlZDY4ZDRkODczYzRiYjc4MDFjNDRjNDMzZGJmNzdmXzk3_6bd85a92-8b2a-43f8-80dc-b22bbc69fb56"
      unitRef="usd">634000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzctMS0xLTEtNjY1NQ_78edbe38-6f1e-4922-87c2-dea6ec714dec"
      unitRef="usd">19225000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzctMy0xLTEtNjY1NQ_c7395a6f-be6e-434b-8667-2ee6915bac00"
      unitRef="usd">18279000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzktMS0xLTEtNjY1NQ_cf72558d-63cb-4a2b-b2b8-748d3875e7c1"
      unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfMzktMy0xLTEtNjY1NQ_889bab33-9565-4e55-9cf0-152014b9cc85"
      unitRef="usd">-8000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDAtMS0xLTEtNjY1NQ_f6087eae-77d9-438a-bb9f-dd53a8e10eea"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDAtMy0xLTEtNjY1NQ_879d1c3f-6396-414d-a0f6-e15e166e48b7"
      unitRef="usd">7000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDEtMS0xLTEtNjY1NQ_7abe9451-5f92-4044-9550-d9a498049f1a"
      unitRef="usd">1263000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDEtMy0xLTEtNjY1NQ_f249aff4-18f1-4e6e-938c-41978e70f83d"
      unitRef="usd">18972000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDMtMS0xLTEtNjY1NQ_ff6707d9-0a06-4351-9180-b9b17776d3c0"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDMtMy0xLTEtNjY1NQ_3daa1abd-0f10-436b-b578-4f16e7b79a03"
      unitRef="usd">305000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDctMS0xLTEtNjY1NQ_db22e757-3422-483c-9ef4-09045da822a1"
      unitRef="usd">20488000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDctMy0xLTEtNjY1NQ_50f8b2c9-1e56-4276-9009-0f3f63ffdceb"
      unitRef="usd">37555000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDktMS0xLTEtNjY1NQ_959acc64-9bac-4fa3-9cb5-898bc91b2240"
      unitRef="usd">-117816000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNDktMy0xLTEtNjY1NQ_da3c862f-5f68-4683-804f-134b6163cb44"
      unitRef="usd">26210000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNTAtMS0xLTEtNjY1NQ_45ca21de-6e57-4017-a6bd-ac8bd693f1ef"
      unitRef="usd">130981000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4c0e2ceae22248b4a0ebd0aa20fa60c6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNTAtMy0xLTEtNjY1NQ_d1618dca-088c-4cf8-af7d-30e393161c23"
      unitRef="usd">10195000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNTEtMS0xLTEtNjY1NQ_3d340e2b-31ac-4637-954d-9f89b8464248"
      unitRef="usd">13165000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i41cb574ec6224df9954670aecbbdd57c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNTEtMy0xLTEtNjY1NQ_f015265d-48ae-497f-ab3c-6e17a8862729"
      unitRef="usd">36405000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNTQtMS0xLTEtNjY1NQ_c4c9a19c-62d8-42ce-bad9-855f432b4156"
      unitRef="usd">1000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNTQtMy0xLTEtNjY1NQ_f91ded16-74db-4363-af9d-2234f8d31135"
      unitRef="usd">1000</us-gaap:IncomeTaxesPaid>
    <crdf:PreferredStockDividendAccrued
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjAtMS0xLTEtNjY1NQ_a7030e9e-7a16-40ae-b410-00a2a79ca2cd"
      unitRef="usd">18000</crdf:PreferredStockDividendAccrued>
    <crdf:PreferredStockDividendAccrued
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjAtMy0xLTEtNjY1NQ_104084f2-84e1-4021-ac76-b9cb787363cf"
      unitRef="usd">18000</crdf:PreferredStockDividendAccrued>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ie19a2c1f7f0b479188b45d6f374dbc81_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjMtMS0xLTEtNjY1NQ_c017a6c6-bdbe-4419-a85c-2ad5ff03031b"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ia35d15a9dfb646fcbffcffbb9d8262b1_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjMtMy0xLTEtNjY1NQ_d1e583c4-88fc-4b83-b441-54606ee8fa41"
      unitRef="usd">602000</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ibcfb466ee9f44377b4e807b87d71fd6a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjQtMS0xLTEtNjY1NQ_e7eb4503-943c-4ffb-a830-9bf395ad8d10"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i3c1a472218714bdea2c26e2f2f2bc0a7_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjQtMy0xLTEtNjY1NQ_f6a4a943-fd09-4cf2-9ac1-dde715010ba8"
      unitRef="usd">2665000</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment
      contextRef="ie19a2c1f7f0b479188b45d6f374dbc81_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjYtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjgyNmY3MDk5NDQxOTRjZTVhYTEwZTQ2MGI4YmE0NTVkXzEwOTk1MTE2Mjc5NDk_78c1de96-02bd-4f54-97d9-a6a2b9ffd8a9"
      unitRef="usd">0</crdf:DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment>
    <crdf:DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment
      contextRef="ia35d15a9dfb646fcbffcffbb9d8262b1_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjYtMC0xLTEtNjY1NS90ZXh0cmVnaW9uOjgyNmY3MDk5NDQxOTRjZTVhYTEwZTQ2MGI4YmE0NTVkXzE1NQ_efea714d-584d-426e-851e-9f77735c5192"
      unitRef="usd">488000</crdf:DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment>
    <crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment
      contextRef="ie19a2c1f7f0b479188b45d6f374dbc81_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjYtMS0xLTEtNjY1NQ_98f90610-541e-4082-9d8d-f79747119247"
      unitRef="usd">0</crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment>
    <crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment
      contextRef="ia35d15a9dfb646fcbffcffbb9d8262b1_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8zMS9mcmFnOmU1ZGQ4ZDk1NGIzYjQzM2Y5NTE5ODQyYjhlNjRiYzg4L3RhYmxlOjdmZDZiZGI3MzI5ZTQyMjNhNWY1MTkyN2IxOTFhMDQxL3RhYmxlcmFuZ2U6N2ZkNmJkYjczMjllNDIyM2E1ZjUxOTI3YjE5MWEwNDFfNjYtMy0xLTEtNjY1NQ_819c624d-ce54-46af-83c1-0984fb06442a"
      unitRef="usd">2300000</crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80MC9mcmFnOjIzYTg5YWFlYWVkMzRiZGU4Y2I0M2MxZTI0ZTg3ODY4L3RleHRyZWdpb246MjNhODlhYWVhZWQzNGJkZThjYjQzYzFlMjRlODc4NjhfMzExNg_cf6b9af6-e9ee-4282-9a26-a27a12b8e47d">Organization and Basis of Presentation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Organization and Overview&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiff Oncology, Inc. (&#x201c;Cardiff Oncology&#x201d; or the &#x201c;Company&#x201d;) headquartered in San Diego, California, is a clinical-stage oncology company with the mission of developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need, including KRAS-mutated metastatic colorectal cancer, metastatic pancreatic cancer and metastatic castration-resistant prostate cancer. The Company's common stock is listed on the Nasdaq Capital Market under the ticker symbol "CRDF".&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and the rules&#160;and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) related to a quarterly report on Form&#160;10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules&#160;and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company&#x2019;s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December&#160;31, 2020 included in the Company&#x2019;s annual report on Form&#160;10-K filed with the SEC on February&#160;25, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred net losses since its inception and has negative operating cash flows. As of September&#160;30, 2021, the Company had $134.0&#160;million in cash, cash equivalents and short-term investments and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#x2019;s stockholders may experience additional dilution. The economic effects of COVID-19 could also have an adverse effect on the Company's ability to raise additional capital. See Note 10 to the condensed financial statements for further information.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80MC9mcmFnOjIzYTg5YWFlYWVkMzRiZGU4Y2I0M2MxZTI0ZTg3ODY4L3RleHRyZWdpb246MjNhODlhYWVhZWQzNGJkZThjYjQzYzFlMjRlODc4NjhfMjI1Nw_7908e06c-31c8-4fd8-af5c-bbcc281cc2c7"
      unitRef="usd">134000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RleHRyZWdpb246MGI3YjUyMGU3MTc0NGVjN2JlYTRkNTQxY2QzZjljMDRfNDQyMA_8c8c261d-08b7-44b0-89d5-8462dabd9f3b">Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2021, there have been no changes to the Company&#x2019;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, other than the addition of investment securities as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All investments have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#x2019;s ability to liquidate the investment for use in operations within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#x2019;s investment holdings are in the form of debt securities or certificates of deposit, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,920,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,548,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,742,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,844,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncement Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04 ("ASU 2021-04), Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RleHRyZWdpb246MGI3YjUyMGU3MTc0NGVjN2JlYTRkNTQxY2QzZjljMDRfNDQyMg_7a9f77c0-ef1f-4b04-b922-f5a624a63892">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All investments have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#x2019;s ability to liquidate the investment for use in operations within the next 12 months.&lt;/span&gt;&lt;/div&gt;Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#x2019;s investment holdings are in the form of debt securities or certificates of deposit, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RleHRyZWdpb246MGI3YjUyMGU3MTc0NGVjN2JlYTRkNTQxY2QzZjljMDRfNDQxOA_4c1cc438-382e-4a86-8246-31600e080aa1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RleHRyZWdpb246MGI3YjUyMGU3MTc0NGVjN2JlYTRkNTQxY2QzZjljMDRfNDQxOQ_dbe423f4-54ec-46fa-a205-a4099de8e3e6">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,920,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,548,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,742,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,844,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i17ac44632d4944509820a9395d78c529_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfMi0xLTEtMS02NjU1_7e524171-e783-443d-8b35-0d5f00b7b295"
      unitRef="shares">3566832</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i55b121d890664785a96f2abd68d7743a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfMi0zLTEtMS02NjU1_ee8420c8-799b-4284-bf5f-73a2b533b6d6"
      unitRef="shares">1920706</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4778f546e098429f8ad5e7ca4beac4b6_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfMy0xLTEtMS02NjU1_d7f586d5-5ecd-479d-ba91-a06c6a3a2d54"
      unitRef="shares">4490159</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7cd4aae3ff4246df84edcf2ab4da4c2b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfMy0zLTEtMS02NjU1_b2736a70-b390-45ef-9b93-61753140cea3"
      unitRef="shares">7373351</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5afbd3931f114b889cf2b6d1fcba9d91_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfNC0xLTEtMS02NjU1_724e283a-0a71-4bdf-8629-8d76c37c9d2d"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i472a131094f2474fb3218a9b6bc0594c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfNC0zLTEtMS02NjU1_06894c5c-1e30-4bf1-9d02-27b64590cdc7"
      unitRef="shares">991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if4544f5428574ef481cdcbd193499f68_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfNS0xLTEtMS02NjU1_a27fcb85-5376-41c1-83cf-d30264004260"
      unitRef="shares">877</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3bc75745225b41fda9b79e00c8ab8c58_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfNS0zLTEtMS02NjU1_de644100-8715-46b9-9460-2d68ef4c5b8c"
      unitRef="shares">877</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i21f389c33c2b4cb0969bd99011bcb8db_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfNy0xLTEtMS02NjU1_34fa1911-81ee-4f30-a6f7-f7ff2b7815c8"
      unitRef="shares">2684607</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie73becd6b06646ffad08290d5060d468_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfNy0zLTEtMS02NjU1_1cbe8784-a24f-46c1-ae49-cbb2e189ec50"
      unitRef="shares">3548459</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfOC0xLTEtMS02NjU1_164c5196-1fd4-404e-86ee-c6bb86a9b401"
      unitRef="shares">10742475</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RhYmxlOmY1NTQyODE2MzAwODQwMDBhMjRjYzczMDQwZWJkMTY1L3RhYmxlcmFuZ2U6ZjU1NDI4MTYzMDA4NDAwMGEyNGNjNzMwNDBlYmQxNjVfOC0zLTEtMS02NjU1_e076682c-b433-49d1-b2f6-3e9b6e2118b6"
      unitRef="shares">12844384</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80My9mcmFnOjBiN2I1MjBlNzE3NDRlYzdiZWE0ZDU0MWNkM2Y5YzA0L3RleHRyZWdpb246MGI3YjUyMGU3MTc0NGVjN2JlYTRkNTQxY2QzZjljMDRfNDQxMQ_940c9aa1-6182-435b-b312-38249a270e95">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncement Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04 ("ASU 2021-04), Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RleHRyZWdpb246MGE2OGE0MTI4NTllNDRkMjgxYzRkOGYzNmVjNTcxZWVfMTEwMw_8fd72eff-537f-4d59-87b2-4ce38b725ebc">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September&#160;30, 2021 and December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total included in cash and cash equivalents (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale investments (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;Included as a component of cash and cash equivalents on the accompanying condensed balance sheets. Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) Included in short-term investments in the accompanying condensed balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, all assets and liabilities for which the fair value &lt;/span&gt;&lt;/div&gt;measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 6 to the condensed financial statements for further information.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RleHRyZWdpb246MGE2OGE0MTI4NTllNDRkMjgxYzRkOGYzNmVjNTcxZWVfMTEwNA_2866c984-53b8-40f4-a7ba-ec4e7c7a4468">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September&#160;30, 2021 and December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total included in cash and cash equivalents (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale investments (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;Included as a component of cash and cash equivalents on the accompanying condensed balance sheets. Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) Included in short-term investments in the accompanying condensed balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, all assets and liabilities for which the fair value &lt;/span&gt;&lt;/div&gt;measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 6 to the condensed financial statements for further information.</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5c421333d9e842cd938364a79a347e01_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMy0xLTEtMS02NjU1_d2b498e2-b70b-4ad6-9a70-1d54bed315d2"
      unitRef="usd">12650000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia4871ed60f064988846d5339b4cefb37_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMy0zLTEtMS02NjU1_45d64a8a-591a-4ad5-89b4-2c6738bd83fa"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7ab1f91262aa4961bfa27744b525f31a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMy01LTEtMS02NjU1_818308dd-1c06-45a1-b0e1-1a557ffc0a1b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7a924190f51c43a6b7d3270fde532fa2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMy03LTEtMS02NjU1_3190e82f-5074-4436-8f31-d8fbd42c5169"
      unitRef="usd">12650000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0f837af10c4e49b681e48bb6553d03bb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfNS0xLTEtMS02NjU1_b7495227-4fb2-4c3e-b46a-91a51c7d1aa1"
      unitRef="usd">12650000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibc20b1e7fdcf4fb4b59ce226be19d676_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfNS0zLTEtMS02NjU1_0ac0ecdf-55e5-4e1c-a839-cfa521104111"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3cac633b9fd54f2a99fe41969f58f594_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfNS01LTEtMS02NjU1_fe78529b-c3d9-4df9-8611-c56902843a02"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie508430c486f4b33b819c76634f5166c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfNS03LTEtMS02NjU1_1bc02c6f-21ce-4fa6-a27f-539c11d7a5c3"
      unitRef="usd">12650000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2272875d1e6040bbbc4cb41775efc0c5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOC0xLTEtMS02NjU1_6b9e29f3-29c1-49c4-814f-a94556572f93"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibcadbd307c7048f089ba63bc4e00d913_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOC0zLTEtMS02NjU1_c7bf91ff-69d1-4997-b99f-c26a617caa5b"
      unitRef="usd">2610000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iab14befe92264008986e1a141957af7d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOC01LTEtMS02NjU1_f93ceb16-6cb8-4c8c-b944-a79dc29cd0ed"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ffd53bdfd4d459c8b703013a42d0264_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOC03LTEtMS02NjU1_a1a2f926-e237-43af-ba19-d23bc51ae678"
      unitRef="usd">2610000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia92b222fd62f45f2b838481f5c639808_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOS0xLTEtMS02NjU1_a28df43a-eef8-40b5-82ef-a7d1e7199588"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if41d19fc393f4c7c97eb7bcda789a9d9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOS0zLTEtMS02NjU1_b3bf8b6b-9e3e-4a93-b53d-26418812c755"
      unitRef="usd">77910000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id79faeb4f57d4754840ae281b5c51f1c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOS01LTEtMS02NjU1_456a1cdb-60a0-4fb8-820b-ab504d9f3843"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec2c0b1298ef43bd8a6cf6425715b928_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfOS03LTEtMS02NjU1_f2b27fa0-1ddd-4938-8706-b5638051b365"
      unitRef="usd">77910000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic693b77303c24a2a99b2842d76d72241_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTAtMS0xLTEtNjY1NQ_07941594-7f2c-4703-bd26-5d257118bf07"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81b0c6cd52a849caa99be52f924b86e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTAtMy0xLTEtNjY1NQ_b4bc98d3-1686-4c21-932c-ab10053ee145"
      unitRef="usd">12436000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a9858e566ca4451af2bd491f1fdcdad_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTAtNS0xLTEtNjY1NQ_2d717ac6-a995-419d-b61b-4fe97be52d10"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i065815c78e2d4c5cb9a8ed1ec7b1f4db_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTAtNy0xLTEtNjY1NQ_ee39270e-bec6-439a-935f-12fbddf8770f"
      unitRef="usd">12436000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iddf531bc123047f2adcdb4ad64487d5d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTEtMS0xLTEtNjY1NQ_5f5f26d9-ff59-4016-85aa-a915ebe1d92d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4ce0447ee3b24f7b8e5c636200fa056d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTEtMy0xLTEtNjY1NQ_be44518c-09ed-47d1-8fe0-71fe2d963948"
      unitRef="usd">732000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00578720dda04f5e803f8dd40e53c600_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTEtNS0xLTEtNjY1NQ_72d52678-42fb-4491-b700-f1556c478846"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if3c645e1dbc2452aa3d3d3e63a2097ab_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTEtNy0xLTEtNjY1NQ_967cc1a9-6d05-46e3-9bb7-b9ec1eea3ef6"
      unitRef="usd">732000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib90db4c568644361b2954142f5e9ef53_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTItMS0xLTEtNjY1NQ_493fc779-4cfb-4bea-8718-216cfcbfbabb"
      unitRef="usd">27194000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4f802e75c98e40ab9791dea64340ce78_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTItMy0xLTEtNjY1NQ_20c1482d-2697-45cd-a8ed-82362df20bf8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i91b041904ffe4c919883330668092c9b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTItNS0xLTEtNjY1NQ_58326bfe-b0b8-4039-a05d-cde4e899c1c7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica2abb6ba5634bf2bf4bf896d7c9258c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTItNy0xLTEtNjY1NQ_1ab8cd15-6012-4c95-9db9-f9ed5d57b36e"
      unitRef="usd">27194000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0f837af10c4e49b681e48bb6553d03bb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTMtMS0xLTEtNjY1NQ_891e8196-36a9-497c-a530-fe23440e20ef"
      unitRef="usd">27194000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc20b1e7fdcf4fb4b59ce226be19d676_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTMtMy0xLTEtNjY1NQ_ec1a9d6a-533b-4ac1-bde1-95e6c42ae2a3"
      unitRef="usd">93688000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3cac633b9fd54f2a99fe41969f58f594_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTMtNS0xLTEtNjY1NQ_ee613028-3fe2-44f6-a1b1-8840b6d9c1f2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie508430c486f4b33b819c76634f5166c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTMtNy0xLTEtNjY1NQ_7d7e9cbb-2e5a-4a6e-868a-a3f86c13dae9"
      unitRef="usd">120882000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0f837af10c4e49b681e48bb6553d03bb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTUtMS0xLTEtNjY1NQ_e7dbb24b-885a-4212-ae51-0c0a28937440"
      unitRef="usd">39844000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibc20b1e7fdcf4fb4b59ce226be19d676_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTUtMy0xLTEtNjY1NQ_3c407e54-ec7d-49f2-aa12-34f9a3551551"
      unitRef="usd">93688000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3cac633b9fd54f2a99fe41969f58f594_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTUtNS0xLTEtNjY1NQ_b1d95fc1-60e9-426f-baea-a08ecf732f4f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie508430c486f4b33b819c76634f5166c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTUtNy0xLTEtNjY1NQ_cf1c6c2a-984d-482b-86b2-8472967f1b9d"
      unitRef="usd">133532000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i0f837af10c4e49b681e48bb6553d03bb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTctMS0xLTEtNjY1NQ_0504ec86-86c4-4b3f-8006-05ec85502785"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ibc20b1e7fdcf4fb4b59ce226be19d676_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTctMy0xLTEtNjY1NQ_ecb4c9f7-57a3-4ab9-9d74-87265a61789d"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i3cac633b9fd54f2a99fe41969f58f594_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTctNS0xLTEtNjY1NQ_400aef38-8e54-4790-ad48-e20c42acfac5"
      unitRef="usd">5000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ie508430c486f4b33b819c76634f5166c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTctNy0xLTEtNjY1NQ_3350993b-8659-49fb-aaf2-aff8ec48d401"
      unitRef="usd">5000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0f837af10c4e49b681e48bb6553d03bb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTgtMS0xLTEtNjY1NQ_72141c62-7d85-45c2-a37c-d801bc445948"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibc20b1e7fdcf4fb4b59ce226be19d676_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTgtMy0xLTEtNjY1NQ_63dddb58-358f-4066-99d2-cda549bcef3b"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3cac633b9fd54f2a99fe41969f58f594_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTgtNS0xLTEtNjY1NQ_1a4fd038-9845-4d96-b3a7-1176d58cf1b7"
      unitRef="usd">5000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie508430c486f4b33b819c76634f5166c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjkzOTk0Mjg4MmVhOTRmNWFhYTU0NGY2OTQ4YTU1MmYyL3RhYmxlcmFuZ2U6OTM5OTQyODgyZWE5NGY1YWFhNTQ0ZjY5NDhhNTUyZjJfMTgtNy0xLTEtNjY1NQ_f3ea467e-791c-42ca-a0d0-5e95739cdfc7"
      unitRef="usd">5000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6ffcbb6630ed443ea2e088b433bc9ce4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMy0xLTEtMS02NjU1_4db24a5e-62e1-4d81-bfab-23f6813dd81f"
      unitRef="usd">129988000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3bc267f79c2a489989a67cdc20d3a3c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMy0zLTEtMS02NjU1_f63acfb5-2806-4e40-b47d-e7e0bf3f587d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1e6e261cb9904caaadea9698ea51a5af_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMy01LTEtMS02NjU1_3fd574e6-02a2-453c-b271-5911bd7c98a0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0222ae72231f44db9f7d8ea289ba7e70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMy03LTEtMS02NjU1_cd85b4cb-2b08-4966-b586-903bfcbbd482"
      unitRef="usd">129988000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i85d1e68d697c4ef0aff6b17bcd0598d3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfNy0xLTEtMS02NjU1_3cc6b48c-c2ed-4a95-8a29-150537ea9811"
      unitRef="usd">129988000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifb4ce146f5434b44a3a5c1272c9610ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfNy0zLTEtMS02NjU1_2dad7502-fc48-4091-91af-31078e1df440"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i86124e9d3ce549fb84e7bdc9a8ebe5d8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfNy01LTEtMS02NjU1_e691d063-8aa7-4c02-8310-d300c47b9c29"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i813279dffe5742cdb683aadf13c65b58_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfNy03LTEtMS02NjU1_afa742dc-01b1-422b-882b-a6cbb13ff496"
      unitRef="usd">129988000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i85d1e68d697c4ef0aff6b17bcd0598d3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfOS0xLTEtMS02NjU1_f3b3a08a-40c9-4ef8-b73c-0485a6da58d5"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ifb4ce146f5434b44a3a5c1272c9610ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfOS0zLTEtMS02NjU1_28d6230e-2b11-48da-a92c-c2fc80e1c06d"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i86124e9d3ce549fb84e7bdc9a8ebe5d8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfOS01LTEtMS02NjU1_70695e50-bb5b-458d-902c-abee55536675"
      unitRef="usd">285000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i813279dffe5742cdb683aadf13c65b58_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfOS03LTEtMS02NjU1_5e0bbacb-b3a8-4ebe-98e4-1f2150d2cefc"
      unitRef="usd">285000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i85d1e68d697c4ef0aff6b17bcd0598d3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMTAtMS0xLTEtNjY1NQ_d24110b4-79c4-467e-84bf-6b0e7e3acf8a"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ifb4ce146f5434b44a3a5c1272c9610ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMTAtMy0xLTEtNjY1NQ_8837ac86-68df-4da5-930d-a1ea915d33fa"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i86124e9d3ce549fb84e7bdc9a8ebe5d8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMTAtNS0xLTEtNjY1NQ_ada60f11-96e0-4b28-9e8e-e6ee0778104d"
      unitRef="usd">285000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i813279dffe5742cdb683aadf13c65b58_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80Ni9mcmFnOjBhNjhhNDEyODU5ZTQ0ZDI4MWM0ZDhmMzZlYzU3MWVlL3RhYmxlOjZmZWU2ODE3NWVhZDRlMjhiNzNlOTZjODJkOTBmMmU4L3RhYmxlcmFuZ2U6NmZlZTY4MTc1ZWFkNGUyOGI3M2U5NmM4MmQ5MGYyZThfMTAtNy0xLTEtNjY1NQ_0663367d-8aab-43fb-a3ae-653d74c8656b"
      unitRef="usd">285000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RleHRyZWdpb246MTczM2YxNjZiODQ3NDYzN2JmNmY5N2FiMGNlZTUxNjRfMTcx_032792c6-18c7-4845-a638-a029e3cee5ac">Supplementary Balance Sheet Information&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments available for sale consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#x2014;accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RleHRyZWdpb246MTczM2YxNjZiODQ3NDYzN2JmNmY5N2FiMGNlZTUxNjRfMTY2_864e4974-1cab-45e3-89ae-3bc6299a91bf">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments available for sale consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1a78ea25d06f4f24a1e99abe072332f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMi0xLTEtMS02NjU1_6b081169-ef1f-45ca-a4d1-4fa17cebd608"
      unitRef="usd">2609000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1a78ea25d06f4f24a1e99abe072332f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMi0zLTEtMS02NjU1_4d966a3a-a09e-44c3-8a48-84939b867d48"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1a78ea25d06f4f24a1e99abe072332f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMi01LTEtMS02NjU1_acf5d47e-5e04-441e-8afe-15bedc40acda"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1a78ea25d06f4f24a1e99abe072332f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMi03LTEtMS02NjU1_45aa9740-40c5-4383-9923-f5cb2769852f"
      unitRef="usd">2610000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i62c3a0c6662345618211a584192ca26a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMy0xLTEtMS02NjU1_0d60c855-6386-47d2-967d-f5e7fc097305"
      unitRef="usd">77901000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i62c3a0c6662345618211a584192ca26a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMy0zLTEtMS02NjU1_77f71843-b534-4319-bed9-294569c2dafe"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i62c3a0c6662345618211a584192ca26a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMy01LTEtMS02NjU1_d28568dc-709f-4d44-92b2-a696b980359f"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i62c3a0c6662345618211a584192ca26a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfMy03LTEtMS02NjU1_0e655f9e-92bd-4367-b910-3d548bda8d5f"
      unitRef="usd">77910000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib20f35230bce4c59b8a12b5a5680b915_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNC0xLTEtMS02NjU1_622c3b24-730b-4da9-82bc-08fc87a2f55b"
      unitRef="usd">12434000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib20f35230bce4c59b8a12b5a5680b915_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNC0zLTEtMS02NjU1_c749b4df-aaf3-49f2-a615-67647e4136ce"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib20f35230bce4c59b8a12b5a5680b915_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNC01LTEtMS02NjU1_6641f44b-71f4-4332-9f1e-a20960c8d5c0"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib20f35230bce4c59b8a12b5a5680b915_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNC03LTEtMS02NjU1_73398c7a-f745-48d7-93c6-1fb780d44562"
      unitRef="usd">12436000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i31763bf591274c6bb305e9bff5fff3d0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNS0xLTEtMS02NjU1_3d4447f7-ea33-4143-ba42-0c9873181a6e"
      unitRef="usd">732000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i31763bf591274c6bb305e9bff5fff3d0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNS0zLTEtMS02NjU1_68f7c4cd-5932-41be-bd62-9b971c83d2dd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i31763bf591274c6bb305e9bff5fff3d0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNS01LTEtMS02NjU1_90ec0ee1-1112-4193-8f2e-a406e48ba3f5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i31763bf591274c6bb305e9bff5fff3d0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNS03LTEtMS02NjU1_c767e7be-afef-4688-bc1a-aa8ae6834438"
      unitRef="usd">732000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9e4bc90bddda41caa182ab326e680cfd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNi0xLTEtMS02NjU1_421694aa-aaec-4c96-84c0-5b3a4c02a705"
      unitRef="usd">27190000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9e4bc90bddda41caa182ab326e680cfd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNi0zLTEtMS02NjU1_5e6eef29-dd9f-4497-b484-e55993c99fad"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9e4bc90bddda41caa182ab326e680cfd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNi01LTEtMS02NjU1_a337b2e7-bf32-42a7-8b19-a79425ef12d5"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9e4bc90bddda41caa182ab326e680cfd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNi03LTEtMS02NjU1_c1a75755-2d63-446c-8751-13c7fb8c55a1"
      unitRef="usd">27194000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNy0xLTEtMS02NjU1_08010def-7944-41f5-9a71-0bdc1d3cb736"
      unitRef="usd">120866000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNy0zLTEtMS02NjU1_3b99d2fe-263a-4661-9dbf-5601172a8eb7"
      unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNy01LTEtMS02NjU1_9f56338d-af37-4bec-b4fd-88ea3c834a1d"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOjk2OGRhYmM0ODMwMTRjYzVhYzMwZTllODA0YjM4MjViL3RhYmxlcmFuZ2U6OTY4ZGFiYzQ4MzAxNGNjNWFjMzBlOWU4MDRiMzgyNWJfNy03LTEtMS02NjU1_814651b3-6a0b-4256-8417-e6638fd671ee"
      unitRef="usd">120882000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RleHRyZWdpb246MTczM2YxNjZiODQ3NDYzN2JmNmY5N2FiMGNlZTUxNjRfMTY3_5936da55-1689-4d25-9c90-38f2e016b673">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#x2014;accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i96238e9478424ff983eea316b3b6d48c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfMS0xLTEtMS02NjU1_42950f85-3912-4d04-ad31-4e6a48971d1d"
      unitRef="usd">866000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i15293ce702ad4f1994f5e08e17c540fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfMS0zLTEtMS02NjU1_0ae7bfbb-29bc-44a0-84e3-c54d9e9916fe"
      unitRef="usd">798000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i81df56d144dd4aef8aa1484cbced739d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfMi0xLTEtMS02NjU1_526715a6-7df2-4613-a467-05f8bc749cf8"
      unitRef="usd">1962000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie267b2ad37e64532bdf3ce1ab2728c95_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfMi0zLTEtMS02NjU1_1e15d8cb-9b78-4ccc-b9bd-15d0b72a1081"
      unitRef="usd">1962000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9e08014d936d49259c36229cca64a87f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfMy0xLTEtMS02NjU1_304d057b-29f1-432f-bfaf-1c80b31452aa"
      unitRef="usd">884000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4c2c267750ac4a1f8c2d127cc7cb6594_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfMy0zLTEtMS02NjU1_d3189924-3520-4edb-8325-2c291df6d514"
      unitRef="usd">868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfNC0xLTEtMS02NjU1_1666dc3e-813b-447f-aaa0-4491904dfa9d"
      unitRef="usd">3712000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfNC0zLTEtMS02NjU1_023cb2a7-67b6-4e05-b572-d4bf09fbfe07"
      unitRef="usd">3628000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfNS0xLTEtMS02NjU1_5e97384f-5c7c-4e62-a691-b47f8c5cf3ba"
      unitRef="usd">3329000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfNS0zLTEtMS02NjU1_2f6ba3ed-dff4-4549-817b-db1bb54ded98"
      unitRef="usd">3004000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfNi0xLTEtMS02NjU1_44e949c4-eb47-4a51-95e3-1e0839e90758"
      unitRef="usd">383000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl80OS9mcmFnOjE3MzNmMTY2Yjg0NzQ2MzdiZjZmOTdhYjBjZWU1MTY0L3RhYmxlOmYzZDUzMTJiNGM0MTRmOWM5ZWY3ZDA0MjJhZGZiNjU2L3RhYmxlcmFuZ2U6ZjNkNTMxMmI0YzQxNGY5YzllZjdkMDQyMmFkZmI2NTZfNi0zLTEtMS02NjU1_6c770cd9-8008-423a-a6d7-83a48a82386e"
      unitRef="usd">624000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTUxMg_09147319-238f-4a96-96a4-6bafd5163a42">Leases&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;As a lessee, the Company&#x2019;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Master Facility Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently occupies 9,500 square feet of office and lab space in San Diego. During July 2021, the Company entered into an amended lease agreement to increase its occupied space to 12,300 square feet which commences on January 1, 2022 and expires on February 28, 2027. Under the current master facility lease, which expires on December 31, 2021, the Company leases 26,100 square feet of office and lab space. This includes 16,600 square feet of space that is subleased to third parties, all of which expires on December 31, 2021. The minimum monthly rent under the amended lease is $55,000 with an annual rent escalation of 3% per year beginning on January 1, 2022. Through December 31, 2021 rent payments are approximately $80,000 per month. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facility Subleases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under three separate sublease agreements, which all expire on December 31, 2021. The Company as a sublessor is leasing approximately 16,600 square feet of space to third parties as of September 30, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:33.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Sublease Income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Net Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the nine months ended September 31, 2021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTUzMQ_33fc412f-a567-4dbf-8fd2-c1245aeeebc8">Leases&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;As a lessee, the Company&#x2019;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Master Facility Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently occupies 9,500 square feet of office and lab space in San Diego. During July 2021, the Company entered into an amended lease agreement to increase its occupied space to 12,300 square feet which commences on January 1, 2022 and expires on February 28, 2027. Under the current master facility lease, which expires on December 31, 2021, the Company leases 26,100 square feet of office and lab space. This includes 16,600 square feet of space that is subleased to third parties, all of which expires on December 31, 2021. The minimum monthly rent under the amended lease is $55,000 with an annual rent escalation of 3% per year beginning on January 1, 2022. Through December 31, 2021 rent payments are approximately $80,000 per month. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facility Subleases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under three separate sublease agreements, which all expire on December 31, 2021. The Company as a sublessor is leasing approximately 16,600 square feet of space to third parties as of September 30, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:33.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Sublease Income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Net Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the nine months ended September 31, 2021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <crdf:LessorNumberOfSubleases
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMjY2_453b22e8-26ab-4c1b-aab8-5b72d820f241"
      unitRef="lease">3</crdf:LessorNumberOfSubleases>
    <crdf:LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTA5OTUxMTYzNzM1Mw_e8f50e3f-c7d4-4116-a98a-0e8d4f391f91"
      unitRef="sqft">9500</crdf:LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany>
    <crdf:LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease
      contextRef="ieb7822e6be894e0796c8f0e8eac7e29a_D20220101-20270228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTA5OTUxMTYzNzM2MQ_f8da2b7e-2201-4c9c-94d9-7b88c82c1114"
      unitRef="sqft">12300</crdf:LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease>
    <crdf:LesseeOperatingLeaseAreaOfLease
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTA5OTUxMTYzNzM2NQ_9cb73d2c-0364-4001-944a-e64d226bf81e"
      unitRef="sqft">26100</crdf:LesseeOperatingLeaseAreaOfLease>
    <crdf:LessorAreaOfSublease
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTA5OTUxMTYzNzM2OA_5e9a72ca-fe1f-4032-8225-12832fcae247"
      unitRef="sqft">16600</crdf:LessorAreaOfSublease>
    <crdf:LesseeOperatingLeaseMonthlyRentPayment
      contextRef="ide4c82a6d8fc4a50b3c355ad46b5663c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTY0OTI2NzQ0NTE4OA_e4f06b3c-9037-4474-af78-4d00d7968238"
      unitRef="usd">55000</crdf:LesseeOperatingLeaseMonthlyRentPayment>
    <crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage
      contextRef="ieb7822e6be894e0796c8f0e8eac7e29a_D20220101-20270228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTY0OTI2NzQ0NTIyNg_7398aec1-58ad-4694-b943-b975f5ec5ef5"
      unitRef="number">0.03</crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage>
    <crdf:LesseeOperatingLeaseMonthlyRentPayment
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfNjEz_e38e3818-2e7d-419a-84f2-dbf7911f7c3c"
      unitRef="usd">80000</crdf:LesseeOperatingLeaseMonthlyRentPayment>
    <crdf:LessorNumberOfSubleases
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTEwMg_91558be5-1fd0-44ff-8221-3cfef04391ff"
      unitRef="lease">3</crdf:LessorNumberOfSubleases>
    <crdf:LessorAreaOfSublease
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTY0OTI2NzQ0ODIzMg_be9e037e-52f4-46b9-8f35-34e9787876fa"
      unitRef="sqft">16600</crdf:LessorAreaOfSublease>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTUyMA_dc9966ad-0e95-4b92-bea1-ae747d105057">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMi0xLTEtMS02NjU1_67507869-862b-4d8e-a8cc-26f8ede2dc29"
      unitRef="usd">281000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMi0zLTEtMS02NjU1_62ab36bf-689b-4ae8-8642-075878387a0e"
      unitRef="usd">99000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMi01LTEtMS02NjU1_8dc28686-0e46-4960-9de8-5f60814b3936"
      unitRef="usd">468000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMi03LTEtMS02NjU1_f1a9d078-8c3e-4f26-b7ee-0b5be3fe92e5"
      unitRef="usd">345000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMy0xLTEtMS02NjU1_ce9f503b-3ec0-4603-a3b2-4e4ba3dac477"
      unitRef="usd">101000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMy0zLTEtMS02NjU1_6026ea41-e9f4-4132-9c3a-30bfa8ffbce4"
      unitRef="usd">73000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMy01LTEtMS02NjU1_a1fc4b2b-8b8f-4a38-b500-970cbf93e59c"
      unitRef="usd">303000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfMy03LTEtMS02NjU1_0e26e9d1-f761-4d9c-bfd8-3a6e9d9c0bd2"
      unitRef="usd">218000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfNC0xLTEtMS02NjU1_e9ad3643-50fc-4025-9d0d-b790cf5f8e1e"
      unitRef="usd">180000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfNC0zLTEtMS02NjU1_7d094e8e-759a-4e0c-b845-4e656f041c47"
      unitRef="usd">26000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfNC01LTEtMS02NjU1_5c6a1149-3c6a-4807-b741-b873c75f4797"
      unitRef="usd">165000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmMxNDBmYzZhNmFhNDQwY2M5ZmRlNzM2ZDFlYzAzZDE0L3RhYmxlcmFuZ2U6YzE0MGZjNmE2YWE0NDBjYzlmZGU3MzZkMWVjMDNkMTRfNC03LTEtMS02NjU1_cf100626-202f-42b9-b073-b1f48e50300e"
      unitRef="usd">127000</us-gaap:LeaseCost>
    <crdf:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTUyMw_abe19a9a-15a3-4195-99eb-a3ba9a014f3f">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</crdf:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfMS0xLTEtMS02NjU1_19089f5b-5105-424b-867a-44573081e0ff"
      unitRef="usd">3017000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfMS0zLTEtMS02NjU1_4d23dc60-1e7b-42e7-916f-4bbf01ee14b3"
      unitRef="usd">343000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfMy0xLTEtMS02NjU1_d347074f-dc93-4d14-8c3f-adfcc5d2c21e"
      unitRef="usd">594000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfMy0zLTEtMS02NjU1_e83f0902-882c-4ccd-a556-37f34460d726"
      unitRef="usd">860000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfNC0xLTEtMS02NjU1_c2056591-37ff-406b-87a7-d2731d2137ea"
      unitRef="usd">2691000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfNC0zLTEtMS02NjU1_a1f42100-edac-4068-936e-28fa69b9796e"
      unitRef="usd">9000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfNS0xLTEtMS02NjU1_23fd69f9-2a65-47ce-9c7c-65369fd192ea"
      unitRef="usd">3285000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfNS0zLTEtMS02NjU1_8589a702-dabb-4ab1-87ff-be45ed0fa1d3"
      unitRef="usd">869000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfNy0xLTEtMS02NjU1_09eb92cd-cde3-463e-b6cd-b64dc5492458">P5Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfNy0zLTEtMS02NjU1_43d44844-ecf2-4b4f-8306-84ce01cb1adf">P1Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfOC0xLTEtMS02NjU1_89e44826-04c5-412a-91cd-75a43e586309"
      unitRef="number">0.070</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOmU3MGJjYmZjMGZjYjQ2MzFiZmVhZDJmZWFjZWU1NTk1L3RhYmxlcmFuZ2U6ZTcwYmNiZmMwZmNiNDYzMWJmZWFkMmZlYWNlZTU1OTVfOC0zLTEtMS02NjU1_6e5096c3-e2e6-4657-9666-3f0d4b4bdbc8"
      unitRef="number">0.065</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfMy0xLTEtMS02NjU1_417d1888-14fb-4976-aa6c-ef53d4bd67e5"
      unitRef="usd">243000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfMy0zLTEtMS02NjU1_63557e59-1421-407d-a611-088a0ce08b97"
      unitRef="usd">237000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfMy01LTEtMS02NjU1_8ae4006d-93a3-4e6e-a2f4-a05d5713083b"
      unitRef="usd">726000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfMy03LTEtMS02NjU1_645117d2-c193-4920-87d3-2788e7d18aaa"
      unitRef="usd">706000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfNS0xLTEtMS0xOTc5MA_778a72d6-a7c3-4f24-a506-a458de5e597d"
      unitRef="usd">3061000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfNS0zLTEtMS0xOTc5MA_1edf2a94-7fb7-45c0-86e6-95f9fb90c53a"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfNS01LTEtMS0xOTc5MA_165a57c8-87ba-4efa-b729-dd8ab971e91f"
      unitRef="usd">3061000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjc3MjE5MDEyMTAxNDQ3NjA5OTkyZjE5ZjY1MDhhMjliL3RhYmxlcmFuZ2U6NzcyMTkwMTIxMDE0NDc2MDk5OTJmMTlmNjUwOGEyOWJfNS03LTEtMS0xOTc5MA_75b9e242-59da-45f5-aa9f-12199d5d2350"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RleHRyZWdpb246NTA2ZmUwZDYzZGU0NDI5MGJmMDYwMDdmN2ZmYTkxY2ZfMTUxNQ_e0a7bd5c-ba7f-4bfa-b8d0-dd75ad6e426b">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:33.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Sublease Income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Net Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the nine months ended September 31, 2021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfMy0xLTEtMS02NjU1_bfc8fb3e-120e-43e8-81d2-71c9790a6b6b"
      unitRef="usd">163000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfMy0zLTEtMS02NjU1_04410116-d643-4ba0-b07e-cb252fac1ab1"
      unitRef="usd">101000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear>
    <crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfMy01LTEtMS02NjU1_53c75410-e1e1-4752-9db5-98cd053408e8"
      unitRef="usd">62000</crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNC0xLTEtMS02NjU1_4f5b8181-7219-4f3a-9199-05b0829ba190"
      unitRef="usd">610000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNC0zLTEtMS02NjU1_e66c12b3-9c3c-4fcf-85fd-5a38b6c42653"
      unitRef="usd">0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNC01LTEtMS02NjU1_86afae18-ff6a-4c63-91c5-06a99d46b48e"
      unitRef="usd">610000</crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNS0xLTEtMS02NjU1_093b2d27-4793-4d89-8b1d-c9a80d468203"
      unitRef="usd">737000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNS0zLTEtMS02NjU1_762d5900-8615-4dd1-85d6-fca2ca9f583c"
      unitRef="usd">0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNS01LTEtMS02NjU1_c880adf5-6702-448a-a3ab-5dd7ace03599"
      unitRef="usd">737000</crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNi0xLTEtMS02NjU1_0c5412de-c2af-4284-91c8-6922de33eb1d"
      unitRef="usd">754000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNi0zLTEtMS02NjU1_856f9c68-f076-4c4a-b978-1a0775ee5304"
      unitRef="usd">0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNi01LTEtMS02NjU1_2d275ce6-1a34-454b-9239-96c0ec11121c"
      unitRef="usd">754000</crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNy0xLTEtMS0xOTg1MQ_9d72b117-4e90-4351-8726-ae0a6652a3db"
      unitRef="usd">775000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNy0zLTEtMS0xOTg1MQ_45af9466-651b-48a8-be66-ece00b7fbf8a"
      unitRef="usd">0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNy01LTEtMS0xOTg1MQ_18dfdd9f-2ed5-49c3-8407-980ace3b399f"
      unitRef="usd">775000</crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour>
    <crdf:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfOS0xLTEtMS0xOTg1OQ_5d78f21c-ec76-41ed-9e6e-02227f065aa2"
      unitRef="usd">933000</crdf:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <crdf:LessorOperatingLeasePaymentToBeReceivedAfterYearFour
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfOS0zLTEtMS0xOTg1OQ_d03fd012-1062-4e73-9e70-a93002ae0bd9"
      unitRef="usd">0</crdf:LessorOperatingLeasePaymentToBeReceivedAfterYearFour>
    <crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfOS01LTEtMS0xOTg1OQ_17bc428c-2d07-4046-8b16-e967bab212c7"
      unitRef="usd">933000</crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNy0xLTEtMS02NjU1_62d5c064-8fef-4ce9-be58-16f0582ab718"
      unitRef="usd">3972000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNy0zLTEtMS02NjU1_3bace139-11c4-44e7-8fb0-6555cf36dbc5"
      unitRef="usd">101000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfNy01LTEtMS02NjU1_43af959b-2a4b-42ca-b4cc-ebf2370d5b83"
      unitRef="usd">3871000</crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfOC0xLTEtMS02NjU1_a11830e0-62b5-4775-bf61-4ba84561f644"
      unitRef="usd">687000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81Mi9mcmFnOjUwNmZlMGQ2M2RlNDQyOTBiZjA2MDA3ZjdmZmE5MWNmL3RhYmxlOjkyMjVjNjZjMTYzNzQxOWI4MmNlMGU1MDcwNGRlZjViL3RhYmxlcmFuZ2U6OTIyNWM2NmMxNjM3NDE5YjgyY2UwZTUwNzA0ZGVmNWJfOS0xLTEtMS02NjU1_a982f2be-deeb-41cc-ad9f-83b0813ff17e"
      unitRef="usd">3285000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RleHRyZWdpb246YzYwNjYxOTIwYWU1NDQ1NWIzNWJkZDkyNTc2Yzc3ZGNfMTUyNg_727d8fcb-2dc4-45d6-9e02-38be84265467">Derivative Financial Instruments &#x2014; Warrants&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon the Company&#x2019;s analysis of the criteria contained in ASC Topic 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 815-40&#x201d;) or ASC Topic 480-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 480-10&#x201d;), Cardiff Oncology determined that certain warrants issued in connection with the execution of certain equity financings must be recorded as derivative liabilities.&#160;In accordance with ASC 815-40 and ASC 480-10, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company&#x2019;s condensed statements of operations.&#160;The Company estimates the fair value of these warrants using the Black-Scholes option pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used to determine the fair value of the warrants using the Black-Scholes option pricing model were:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected warrant term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility is based on historical volatility of Cardiff Oncology&#x2019;s common stock.&#160;The warrants have a transferability provision, accordingly, Cardiff Oncology used the remaining contractual term as the expected term of the warrants.&#160;The risk-free rate is based on the U.S.&#160;Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of changes in the Company&#x2019;s derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except for number of warrants)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;Instrument&lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants during the period recognized as a gain in the condensed statements of operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i2c7f42dfef2c4958ba29b2e28bb9b35d_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RleHRyZWdpb246YzYwNjYxOTIwYWU1NDQ1NWIzNWJkZDkyNTc2Yzc3ZGNfMTUyNw_94c786c0-387b-4244-8e83-05a307328f8b">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used to determine the fair value of the warrants using the Black-Scholes option pricing model were:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected warrant term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <crdf:EstimatedFairValueOfWarrant
      contextRef="i27c1821fc9ab463284b24faa6a39aeca_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfMS0xLTEtMS02NjU1_9ca91e54-2de9-448f-be51-027097b81f3a"
      unitRef="usdPerShare">6.66</crdf:EstimatedFairValueOfWarrant>
    <crdf:EstimatedFairValueOfWarrant
      contextRef="i81c4317e30404c12b737872399063ecb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfMS0zLTEtMS02NjU1_9c98cd67-23e3-4216-ac1e-f968fb1e4b0b"
      unitRef="usdPerShare">17.99</crdf:EstimatedFairValueOfWarrant>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="id32688583be64531a4c3b6f8dda463e1_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfMi0xLTEtMS02NjU1_83738741-9812-4b07-be6d-0521a0463174">P1Y3M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i870cb7768ebe4cd9a47cae43d43fa560_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfMi0zLTEtMS02NjU1_4543b61b-2e59-4d20-a707-25f8bff60695">P2Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i22ae9743fe9e485bb2f97b84bd14ef48_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfMy0xLTEtMS02NjU1_6314e2e7-5b61-467a-ba8f-bd6a284d1088"
      unitRef="number">0.0015</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i93a076cf959748b68d0895f7a702037c_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfMy0zLTEtMS02NjU1_315a5ade-423f-4e7f-958d-8d5cb3be4967"
      unitRef="number">0.0013</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i577dc0d878144b149b1dd7752563c6fe_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfNC0xLTEtMS02NjU1_863d60d2-3975-438b-9e17-d0313920fda2"
      unitRef="number">1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="if1e8bf7f73344b78ab04d1ba7ddea8a2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfNC0zLTEtMS02NjU1_b5616d7b-7b89-427a-b990-1627d5095a45"
      unitRef="number">1.16</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="id2f22ed10e3b4e019378ae1db12695ed_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfNS0xLTEtMS02NjU1_b55aa903-39bd-48cf-a28e-59c3b30946be"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="iebfd4c8685c349cca9ac74c079a51df8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjFiZjFhN2UwZDYwMzQ5NjdhZGVlMjQzMDlhMzNkYjA4L3RhYmxlcmFuZ2U6MWJmMWE3ZTBkNjAzNDk2N2FkZWUyNDMwOWEzM2RiMDhfNS0zLTEtMS02NjU1_71e13688-2a89-42a0-9bb6-c220d66e6cc5"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <crdf:ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock
      contextRef="i2c7f42dfef2c4958ba29b2e28bb9b35d_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RleHRyZWdpb246YzYwNjYxOTIwYWU1NDQ1NWIzNWJkZDkyNTc2Yzc3ZGNfMTUxNw_f48739c5-a458-4b04-9b81-efe151dd17c6">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of changes in the Company&#x2019;s derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except for number of warrants)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;Instrument&lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants during the period recognized as a gain in the condensed statements of operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</crdf:ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2a2fc422184c4397bfd8fde6fbfdd4f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjAxZGE0Yjg2MTA1NTRiZDk5YTE0MDc5YTg5NzBjMDllL3RhYmxlcmFuZ2U6MDFkYTRiODYxMDU1NGJkOTlhMTQwNzlhODk3MGMwOWVfMi00LTEtMS02NjU1_1485aa52-6e1b-4c33-aad5-33b593f4530e"
      unitRef="shares">64496</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i2a2fc422184c4397bfd8fde6fbfdd4f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjAxZGE0Yjg2MTA1NTRiZDk5YTE0MDc5YTg5NzBjMDllL3RhYmxlcmFuZ2U6MDFkYTRiODYxMDU1NGJkOTlhMTQwNzlhODk3MGMwOWVfMi02LTEtMS02NjU1_d239881f-64ff-41b4-8565-7d069b265e26"
      unitRef="usd">285000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ifb2a438ab8374c9284bc780389cd9e66_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjAxZGE0Yjg2MTA1NTRiZDk5YTE0MDc5YTg5NzBjMDllL3RhYmxlcmFuZ2U6MDFkYTRiODYxMDU1NGJkOTlhMTQwNzlhODk3MGMwOWVfNC02LTEtMS02NjU1_ea957dca-47c0-42a7-94fb-f3c128fbe232"
      unitRef="usd">-280000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i4b6a8197ab2846cf8242cf259266a02c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjAxZGE0Yjg2MTA1NTRiZDk5YTE0MDc5YTg5NzBjMDllL3RhYmxlcmFuZ2U6MDFkYTRiODYxMDU1NGJkOTlhMTQwNzlhODk3MGMwOWVfNS00LTEtMS02NjU1_ba5e220b-715e-4462-bba2-37887ae2f6b2"
      unitRef="shares">64496</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i4b6a8197ab2846cf8242cf259266a02c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81NS9mcmFnOmM2MDY2MTkyMGFlNTQ0NTViMzViZGQ5MjU3NmM3N2RjL3RhYmxlOjAxZGE0Yjg2MTA1NTRiZDk5YTE0MDc5YTg5NzBjMDllL3RhYmxlcmFuZ2U6MDFkYTRiODYxMDU1NGJkOTlhMTQwNzlhODk3MGMwOWVfNS02LTEtMS02NjU1_777330a5-55b4-43e3-97bb-0d2ce454388d"
      unitRef="usd">5000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjU5Ng_61404128-5ddb-4c86-bec2-32776629cede">Stockholders&#x2019; Equity&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrecognized compensation cost related to non-vested stock options outstanding at September&#160;30, 2021, net of estimated forfeitures, was $10.1 million, which is expected to be recognized over a weighted-average remaining vesting period of 3.3 years.&#160;The weighted-average remaining contractual term of outstanding options as of September&#160;30, 2021 was &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximately 8.9 years. The total fair value of stock options vested during the nine months ended September 30, 2021 and 2020 were $1.2 million and $0.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity and changes in stock options outstanding is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,963,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,522,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,281,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,103,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,466,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,344,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 the Company's stockholders approved the 2021 Omnibus Equity Incentive Plan ("2021 Plan"). The number of authorized shares in the 2021 plan is equal to the sum of (i) 3,150,000 shares, plus (ii) the number of shares of Common Stock reserved, but unissued under the 2014 Plan; and (iii) the number of shares of Common Stock underlying forfeited awards under the 2014 Plan. As of September&#160;30, 2021, there were 2,289,902 shares available for issuance under the 2021 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the adoption of the 2021 Plan, no additional equity awards can be made under the terms of the 2014 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inducement Grants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company began issuing equity awards to certain new employees as inducement grants outside of its 2021 Plan. As of September&#160;30, 2021, an aggregate of 590,000 shares were issuable upon the exercise of inducement grant stock options approved by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Modification of Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 two of the Company's directors' terms ended. At the conclusion of their term, the Compensation Committee passed a resolution to extend the expiration date of the departing directors vested stock options, and to immediately accelerate the vesting of one of the directors unvested options. The Company recorded incremental stock compensation expenses of$0.6&#160;million during the nine months ended September 30, 2021, related to the modifications. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU activity is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of vested RSUs during the nine months ended September 30, 2021 and 2020 were $0.1 million and $0.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&#160;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,260,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(770,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our Company's classes of preferred stock is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares designated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation preference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjYwNg_4cd3c2f3-051b-41c8-86d3-9d9606918fcc">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i39e92eec12814d63b23dec15ee3a82e2_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfMy0xLTEtMS02NjU1_e3c1fd61-a8f7-4d36-be8e-b2f861a04da9"
      unitRef="usd">174000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i951a79658a174acdabb183cc6c576e38_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfMy0zLTEtMS02NjU1_2ded9470-3e4b-4795-97f1-49fb664550ee"
      unitRef="usd">104000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i44d179594bba4e1dad1a989df3916c06_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfMy01LTEtMS02NjU1_9c78f8fc-32b2-4942-bc76-4f01105eeb79"
      unitRef="usd">286000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7c42cef5a93d477d8d01cdeb0d9a6497_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfMy03LTEtMS02NjU1_12aa7d5b-7f94-4686-af93-22af47ef594b"
      unitRef="usd">251000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f4bdbe2cd9a4216b241d6c0f58f92af_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNC0xLTEtMS02NjU1_22ad757b-3bad-4347-a1be-d208c0e085b8"
      unitRef="usd">766000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9dd0cbb07f2c48e9809d2340ba480ed4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNC0zLTEtMS02NjU1_c95f7e0f-7fff-4ef7-b334-c8a7b842b91d"
      unitRef="usd">258000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iec5f94b33da24052af9749b10b28f208_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNC01LTEtMS02NjU1_5bab89b4-10db-4a50-bc07-edd37fecd355"
      unitRef="usd">1958000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i429dafc4192b4a51aac45b680a2ebe82_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNC03LTEtMS02NjU1_c3829237-9650-4070-9b42-6e044a34394f"
      unitRef="usd">570000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0dc4846745a44e46a049be06bcf71582_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNy0xLTEtMS02NjU1_1d99e203-68db-45ae-b348-3e02359eab80"
      unitRef="usd">940000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4aa978ac638d498b9de778d7b724f3ab_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNy0zLTEtMS02NjU1_2a9057cb-01ab-4510-b494-958d48a62646"
      unitRef="usd">362000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNy01LTEtMS02NjU1_ff78ba44-997b-4522-9361-af0633db6541"
      unitRef="usd">2244000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjIyYTQ2NmE5OGVmNzQyMjg5NWZkNGJmYzU0MTU2ZWZlL3RhYmxlcmFuZ2U6MjJhNDY2YTk4ZWY3NDIyODk1ZmQ0YmZjNTQxNTZlZmVfNy03LTEtMS02NjU1_287c9bef-329a-42ef-bb8a-5da615fce7ed"
      unitRef="usd">821000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMzA2_fe1a0405-793a-4d4c-9b52-f1fbf1110865"
      unitRef="usd">10100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMzk3_cedeb5cd-9c7e-484e-91cf-074438ed04ec">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfNDk5_4ccc26b7-16af-4824-9092-45696544c7ca">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfNTc0_d28be51e-9eba-4bf8-b0ab-6330de33f9f9"
      unitRef="usd">1200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i4f8f407668454ec8af231d99697dd1db_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfNTgx_e9c8f1e3-a334-4440-ab73-ff880199d06e"
      unitRef="usd">800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjYwMQ_6a2906b5-1e9f-4a77-86ad-2a2f56ee015b">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfMi0xLTEtMS02NjU1_b0293d5c-f545-4cf9-8456-07ecffd7de0a"
      unitRef="number">0.0095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i918a2f804e04472a831f145c622bff4c_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfMi0zLTEtMS02NjU1_a82c4ca7-9aca-4f45-9d91-a18bb097c85c"
      unitRef="number">0.0044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfMy0xLTEtMS02NjU1_2049c640-4ce8-4bbb-8f94-f8eff09fed27"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i918a2f804e04472a831f145c622bff4c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfMy0zLTEtMS02NjU1_024df8fc-a98d-468b-9822-a7f53b998570"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfNC0xLTEtMS02NjU1_2018cc4a-71c5-4da6-9c06-16583eb32b27"
      unitRef="number">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i918a2f804e04472a831f145c622bff4c_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfNC0zLTEtMS02NjU1_5d76c905-9a53-432f-acef-06fca11a1e5e"
      unitRef="number">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfNS0xLTEtMS02NjU1_2ea64ac4-3edb-4cbb-aa86-addbbbdf6bbe">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i918a2f804e04472a831f145c622bff4c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmFmYzU2ZjQ1N2UwMzQ3ZGI5OWYxOWQ5MDM5MzNlN2ZjL3RhYmxlcmFuZ2U6YWZjNTZmNDU3ZTAzNDdkYjk5ZjE5ZDkwMzkzM2U3ZmNfNS0zLTEtMS02NjU1_4992c90f-a42a-4e88-86d3-e6dc361259ac">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjYyMw_aa5ef558-a536-4b03-94d5-c68b0a6d2b5c">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity and changes in stock options outstanding is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,963,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,522,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,281,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,103,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,466,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,344,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7ec0a3e52eaa44bfbbe255b9105dd595_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfMS0xLTEtMS02NjU1_9932440b-de91-4bd1-89c3-adbd1d2575ca"
      unitRef="shares">1860507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7ec0a3e52eaa44bfbbe255b9105dd595_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfMS0zLTEtMS02NjU1_396ab57a-638c-4346-b72a-d560bde64ea1"
      unitRef="usdPerShare">7.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7ec0a3e52eaa44bfbbe255b9105dd595_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfMS01LTEtMS02NjU1_58e6a0f1-91df-43b0-a3d3-ab837204a234"
      unitRef="usd">27963363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfMi0xLTEtMS02NjU1_1f6ed4db-c6d6-4b42-b281-8f010df8f355"
      unitRef="shares">1721314</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfMi0zLTEtMS02NjU1_27cf51d6-bc19-4a38-8b4b-a2e71c85474c"
      unitRef="usdPerShare">7.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNC0xLTEtMS02NjU1_320030d2-b2f5-4957-b763-967b9c3836fc"
      unitRef="shares">10770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNC0zLTEtMS02NjU1_17301ae9-3bbd-4a57-9395-bc15686374b7"
      unitRef="usdPerShare">2.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
      contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNS0xLTEtMS02NjU1_4327f100-865a-4d78-a365-cc0d9d923906"
      unitRef="shares">4219</crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod>
    <crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNS0zLTEtMS02NjU1_0d73c83e-5684-454a-a360-8b9d52d63197"
      unitRef="usdPerShare">216.00</crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNi0xLTEtMS02NjU1_5fa80b68-203d-4e4c-85da-ea9623e51512"
      unitRef="shares">3566832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNi0zLTEtMS02NjU1_92a41d39-3e16-465b-b326-b67a0c8f0f75"
      unitRef="usdPerShare">7.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNi01LTEtMS02NjU1_8d58a5c5-f95f-493f-913c-a47342592060"
      unitRef="usd">7522769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNy0xLTEtMS02NjU1_ad3e411b-5b45-4d11-945c-d9c2938f166d"
      unitRef="shares">1281604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNy0zLTEtMS02NjU1_286ed7f5-f211-4a5c-a814-6636a0a23563"
      unitRef="usdPerShare">8.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfNy01LTEtMS02NjU1_42fce5f4-006a-4a1c-8e18-25fc9d2de7ac"
      unitRef="usd">5103890</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfOC0xLTEtMS02NjU1_792e5ad6-0f41-44a0-9a8b-7d85c7024dab"
      unitRef="shares">3466323</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfOC0zLTEtMS02NjU1_e758b079-9120-446d-9f5d-1ea2ba012a1b"
      unitRef="usdPerShare">7.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i1e25202af5cc42bb8a3716a17c2fb5da_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmI3YTZlY2E3MTkxNjRmZGVhODg5NDY0NjRhZGZhMDQ0L3RhYmxlcmFuZ2U6YjdhNmVjYTcxOTE2NGZkZWE4ODk0NjQ2NGFkZmEwNDRfOC01LTEtMS02NjU1_4fd5a3ed-4b16-4735-b395-c8a65504412b"
      unitRef="usd">7344075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMTEzMw_701b8214-d174-459c-a61b-5939753a108e"
      unitRef="shares">3150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia67d1806a46a419689781a32baf40aff_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMTM1Mg_4e9b1b8d-6720-4442-9e9f-08aa1f14b444"
      unitRef="shares">2289902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="idd65b030d4494709b2f9be0748ec2b5f_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMTY0OTI2NzQ0NTE3Mg_42222c72-4d62-4515-b353-d409efd29453"
      unitRef="shares">590000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="i3e1d4f2076ee4dce9307fbd38c110992_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMTk2OA_9490b704-550e-401f-b482-46a734713de9"
      unitRef="usd">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjYwNw_36475e94-2855-466a-8c3c-abdced58082c">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU activity is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i6cf797ce4852460992cc81f91f71ee21_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfMS0xLTEtMS02NjU1_09166e5c-4a01-4e35-a5e4-cf9f7c768712"
      unitRef="shares">491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6cf797ce4852460992cc81f91f71ee21_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfMS0zLTEtMS02NjU1_2fbb437c-475d-4e60-9724-cb97d23f77a7"
      unitRef="usdPerShare">147.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i6cf797ce4852460992cc81f91f71ee21_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfMS01LTEtMS02NjU1_e690e53e-f6a7-44d0-b11f-75c673e3de19"
      unitRef="usd">8833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i419dd88bc1ef4b699ca582afa2243156_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfMy0xLTEtMS02NjU1_7c40c8b4-9010-43df-99a8-43d111810d52"
      unitRef="shares">491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i419dd88bc1ef4b699ca582afa2243156_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfMy0zLTEtMS02NjU1_8845bf11-dd04-41e9-b396-48d29cf96038"
      unitRef="usdPerShare">147.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i967f68e7c70142858d962d262e96d5a5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfNS0xLTEtMS02NjU1_42be364f-919c-42ff-8728-86e7dc2e727c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i967f68e7c70142858d962d262e96d5a5_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfNS0zLTEtMS02NjU1_a9ca079f-1342-483a-b890-4c75eb1651b3"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i967f68e7c70142858d962d262e96d5a5_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmU5ZTVkNmI2OTNhMzQxMWI5YzRhNjFiZjNiMjdhMzQwL3RhYmxlcmFuZ2U6ZTllNWQ2YjY5M2EzNDExYjljNGE2MWJmM2IyN2EzNDBfNS01LTEtMS02NjU1_53e57d01-ebc6-47dc-ae62-2904f3d261f0"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i419dd88bc1ef4b699ca582afa2243156_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjE4Ng_6eb1dbf1-b536-4f1c-bba2-15460fcb7fd1"
      unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i53d86dcdd30e4e97a88db626c3ce171f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjE5Mw_c299618f-239f-428b-b124-23508fa62384"
      unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjYxNA_090baf66-53e8-4c2e-9f1f-83bded68a19b">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&#160;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,260,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(770,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfMS0xLTEtMS02NjU1_551f813b-9454-4f61-a550-afb91f36831d"
      unitRef="shares">5260992</us-gaap:ClassOfWarrantOrRightOutstanding>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="i8176bd16da194dae836e30659930f9a9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfMS0zLTEtMS02NjU1_8e4b3fb3-2722-4062-8035-6e3b4720d2df"
      unitRef="usdPerShare">5.19</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
      contextRef="i9e7dd4c9b04a4f348fa618cc15a91b23_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfMS01LTEtMS02NjU1_97186668-1239-4336-901c-cbba1048e4b0">P4Y1M6D</crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights>
    <crdf:ClassOfWarrantOrRightNumberExercised
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfMy0xLTEtMS02NjU1_0ed50ccb-5858-4ef2-b9cf-ce4252403ce5"
      unitRef="shares">770833</crdf:ClassOfWarrantOrRightNumberExercised>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfMy0zLTEtMS02NjU1_f9b9fce3-79dd-43f4-ba8a-eb0783f14a18"
      unitRef="usdPerShare">1.64</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfNS0xLTEtMS02NjU1_4061a1f5-09a9-46aa-9cf2-d6a867437551"
      unitRef="shares">4490159</us-gaap:ClassOfWarrantOrRightOutstanding>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="i5536a0b2fc2740479fff4987362a1f5e_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfNS0zLTEtMS02NjU1_c5c8e9ab-cb2a-4927-9ab3-f0b88e9c1baa"
      unitRef="usdPerShare">5.80</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOmYxMzNlMzBhNzMzMDRkYWQ5OGU5YTQxMmYzMDEwNDJhL3RhYmxlcmFuZ2U6ZjEzM2UzMGE3MzMwNGRhZDk4ZTlhNDEyZjMwMTA0MmFfNS01LTEtMS02NjU1_26bbacb0-f621-46b7-a847-8709a3f64b3a">P3Y2M12D</crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RleHRyZWdpb246NjllMGE2ZDg0ODViNGNjOGE1YmQ0ZjI5OWU0ZDczMTZfMjYwOQ_9a0a5c64-dbfb-4a8d-ab39-d11d2074b8dd">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our Company's classes of preferred stock is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares designated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation preference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7086b0baa05e4031aa8f4f411b551b42_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMi0yLTEtMS02NjU1_0a7a64df-59b1-4922-9c8e-044e89ed4712"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7086b0baa05e4031aa8f4f411b551b42_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMi00LTEtMS02NjU1_563b4e8e-3599-4b84-9839-88f0db64e3ed"
      unitRef="shares">277100</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="i7086b0baa05e4031aa8f4f411b551b42_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMi02LTEtMS02NjU1_b06714e9-daa5-4141-8de9-2b29857a13fa"
      unitRef="usd">606000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7086b0baa05e4031aa8f4f411b551b42_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMi04LTEtMS02NjU1_1b550391-d44d-4009-a8cf-19610c06366f"
      unitRef="shares">60600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id64a71bd7b9f42509949a24fc02bdde8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMi0xMC0xLTEtNjY1NQ_060fee95-da05-461f-9f9f-9bbc39011291"
      unitRef="shares">60600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id69610f358d94455a4cc69212cec3ba1_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMy0yLTEtMS02NjU1_9f2ef9df-c264-48fe-abe4-c0736ade02de"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id69610f358d94455a4cc69212cec3ba1_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMy00LTEtMS02NjU1_e707cf15-5462-48f4-bbca-326acaf0e73e"
      unitRef="shares">8860</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id69610f358d94455a4cc69212cec3ba1_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMy04LTEtMS02NjU1_2b6591bc-9f4d-4f06-b98d-d6e2ea0deb16"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8110c72e246c4d70b73aed2bc0bde2d2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfMy0xMC0xLTEtNjY1NQ_7c94dba8-48fb-4862-b7dc-7adedaab5491"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7451a3efe7274af285d44ebc3dd77d40_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNC0yLTEtMS02NjU1_993a26c0-17a9-4225-92e0-6c906c94a946"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7451a3efe7274af285d44ebc3dd77d40_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNC00LTEtMS02NjU1_8f325748-95be-487c-bdeb-919324249e53"
      unitRef="shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7451a3efe7274af285d44ebc3dd77d40_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNC04LTEtMS02NjU1_8d6daaa2-c9d7-4413-9d4a-d0f99454e9d1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9eff0db6959b461584bc397787961a0d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNC0xMC0xLTEtNjY1NQ_81cce1be-b840-446a-b140-5e266bc730a1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1e88f2da585d4200bcee660bbd23922a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNS0yLTEtMS02NjU1_492eaa64-6f44-4c3b-a2c6-3d8a46b72118"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1e88f2da585d4200bcee660bbd23922a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNS00LTEtMS02NjU1_796e7488-45fc-4926-8337-63e19f15ea00"
      unitRef="shares">154670</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1e88f2da585d4200bcee660bbd23922a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNS04LTEtMS02NjU1_ff8c1ad8-88ee-4aa2-89db-11edd91ec478"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i38a9fc7a1cf3406fa656608bfd2022aa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNS0xMC0xLTEtNjY1NQ_96badb5f-2c0d-462c-83fb-f1a1674413d1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i90efb04788c94a62b210da8a40d1537a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNi0yLTEtMS02NjU1_c945c500-fe34-4cc1-ab53-2d98deb11c86"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i90efb04788c94a62b210da8a40d1537a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNi00LTEtMS02NjU1_bb2b501c-96ea-4ad7-9983-62ae53b9efc2"
      unitRef="shares">865824</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i90efb04788c94a62b210da8a40d1537a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNi04LTEtMS02NjU1_8100e4d8-1ba6-4ccc-862a-2adb6f9699e4"
      unitRef="shares">655044</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9421b674007949588bce3135aff1f1ee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl81OC9mcmFnOjY5ZTBhNmQ4NDg1YjRjYzhhNWJkNGYyOTllNGQ3MzE2L3RhYmxlOjRhNjMwYjEwMzExYjRhOWU4YjBhYTlmYjczOGRkNWQ5L3RhYmxlcmFuZ2U6NGE2MzBiMTAzMTFiNGE5ZThiMGFhOWZiNzM4ZGQ1ZDlfNi0xMC0xLTEtNjY1NQ_841c7fd5-21e4-4513-89da-5cf87a72ef62"
      unitRef="shares">655044</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82MS9mcmFnOjg3NjA4NzhiYjQ5ODRhMDNhZGFmZmM4MjUyZGY5MDNiL3RleHRyZWdpb246ODc2MDg3OGJiNDk4NGEwM2FkYWZmYzgyNTJkZjkwM2JfMjE3Mw_f0092232-1933-4c05-8924-2e9ff22e0892">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Executive Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development and Clinical Trial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib. Onvansertib, an investigational drug, is an oral, and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK1. The Company is developing onvansertib in cancer indications with the greatest medical need for new treatment options. The Company was committed to order $1.0 million of future services provided by Nerviano, such as the cost to manufacture drug product, no later than June 30, 2019, and these services have been purchased. Terms of the agreement also provide for the Company to pay development milestones and royalties based on sales volume.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is a party of various agreements under which it licenses technology on an exclusive basis in the field of oncology therapeutics. These agreements include License fees, Royalties and Milestone payments. The company also has a legacy license agreement in the field of oncology diagnostics under which royalty payments are due. These royalty payments are calculated as a percent of revenue. For the three and nine months ended September&#160;30, 2021 and 2020, payments have not been material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company&#x2019;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#x2019;s business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="i6585aa9e614148a98914993084f4d834_I20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82MS9mcmFnOjg3NjA4NzhiYjQ5ODRhMDNhZGFmZmM4MjUyZGY5MDNiL3RleHRyZWdpb246ODc2MDg3OGJiNDk4NGEwM2FkYWZmYzgyNTJkZjkwM2JfNzY5_6f249ae2-85b9-49a3-9699-4ac8d70ab6f8"
      unitRef="usd">1000000</us-gaap:PurchaseObligation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMTM1OQ_eb627edf-5b3c-4aa8-8c0c-583f92f4262c">Related Party Transactions&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gary Pace Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company entered into a Securities Purchase Agreement with Gary W. Pace, one of the Company's directors. Dr. Pace purchased 447,761 shares of the Company's common stock at $1.34 per share for an aggregate purchase price of $600,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leucadia Life Sciences&lt;/span&gt;&lt;/div&gt;In November 2018, the Company entered into a Material Transfer Agreement (&#x201c;MTA&#x201d;) with Leucadia Life Sciences (&#x201c;Leucadia&#x201d;) pursuant to which Leucadia developed a PCR-based assay for onvansertib for Acute Myeloid Leukemia (&#x201c;AML&#x201d;). This assay was completed in December 2020. During the duration of the agreement, one of the Company's directors Dr. Thomas Adams (who is no longer a director as of June 2021), was a principal stockholder of Leucadia. In connection with the MTA, the Company entered into a consulting agreement with Tommy Adams, Co-Founder &amp;amp; Chief Operating Officer of Leucadia, who is the son of Dr. Adams. During the three months ended September&#160;30, 2021 and 2020 the Company incurred and recorded research and development expenses of approximately $0 and $0.3 million, respectively, for services performed by Leucadia and Tommy Adams. During the nine months ended September&#160;30, 2021 and 2020 the Company incurred and recorded research and development expenses of approximately $0 and $0.8&#160;million, respectively, for services performed by Leucadia and Tommy Adams.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ide58ed83af2b4d2ebaccb755576f716c_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMjE3_8f83b1ed-9818-4745-8380-a0cab34c3836"
      unitRef="shares">447761</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i18a95e66b28b495995cc5b43de061428_I20200531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMjYw_69b7baa1-4063-4413-a95e-9b1843446fdd"
      unitRef="usdPerShare">1.34</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ide58ed83af2b4d2ebaccb755576f716c_D20200501-20200531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMzA4_11bfc7e1-8440-4661-82ad-6bac11403f8c"
      unitRef="usd">600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i23b7b762231f4268ada27fef1b3fbde1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMTA4MQ_a33cb0e7-2f94-4457-b11e-3b96855707c4"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8d5c6bcbeb3143e6819f6adceffa7b49_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMTA4OA_b50734de-846c-4b6f-b2ca-73a09baeeeb2"
      unitRef="usd">300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7613ce60f5ae411799a4b34ca529c402_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMTI4MQ_7e30684d-ee2b-4220-9b30-bd44e5201a2e"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i16cbd98a78db40d8a92555d8d4608ec6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82NC9mcmFnOmFhOTU5YjU1ODI5YzRmNjg5MmY0ZWY5NmFmNjVlMzMwL3RleHRyZWdpb246YWE5NTliNTU4MjljNGY2ODkyZjRlZjk2YWY2NWUzMzBfMTI4OA_d506c801-e9c4-4f4a-9ea3-1bc3b3dc893e"
      unitRef="usd">800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock
      contextRef="i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl82Ny9mcmFnOjY1YThiNDA0YmZiNzRhOTI5MGZjM2M5MjVjNWZlOTJiL3RleHRyZWdpb246NjVhOGI0MDRiZmI3NGE5MjkwZmMzYzkyNWM1ZmU5MmJfMTc1Mg_0372f6b5-9422-4f6a-9804-86ade9a27073">COVID-19 The COVID-19 outbreak in the United States has caused significant business disruption. Thus far COVID-19 has not caused material disruptions to the Company's operational and financial performance. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance the development of its drugs and raise additional capital.</us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItNS0xLTEtNjY1NQ_7234ddc5-b679-4fc0-a393-e948e7d69e05"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItNS0xLTEtNjY1NQ_7234ddc5-b679-4fc0-a393-e948e7d69e05"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItMTctMS0xLTY2NTU_59530542-f04c-47ab-b223-2db7c69d1645"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItMTctMS0xLTY2NTU_59530542-f04c-47ab-b223-2db7c69d1645"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItOS0xLTEtNjY1NQ_1b881f8f-1dfb-4cc2-a134-d47449a4a1f3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItOS0xLTEtNjY1NQ_1b881f8f-1dfb-4cc2-a134-d47449a4a1f3"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk4_21f0155c-d8e7-41c8-8d42-1264084126c7" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk4_21f0155c-d8e7-41c8-8d42-1264084126c7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Net of expenses of $0.8&#160;million.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItNS0xLTEtNjY1NQ_7234ddc5-b679-4fc0-a393-e948e7d69e05"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk4_21f0155c-d8e7-41c8-8d42-1264084126c7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItMTctMS0xLTY2NTU_59530542-f04c-47ab-b223-2db7c69d1645"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk4_21f0155c-d8e7-41c8-8d42-1264084126c7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjUxMDNjYmMwMTllMjRjYmJiMzBkYWFiYjFlYmY0YTFlL3RhYmxlcmFuZ2U6NTEwM2NiYzAxOWUyNGNiYmIzMGRhYWJiMWViZjRhMWVfMTItOS0xLTEtNjY1NQ_1b881f8f-1dfb-4cc2-a134-d47449a4a1f3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk4_21f0155c-d8e7-41c8-8d42-1264084126c7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtNS0xLTEtNjY1NQ_c480c886-f66a-4315-9261-61b886b3ff94"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtNS0xLTEtNjY1NQ_c480c886-f66a-4315-9261-61b886b3ff94"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMy0xLTEtNjY1NQ_0c21b0be-0a08-4608-bbad-fb219c020305"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMy0xLTEtNjY1NQ_0c21b0be-0a08-4608-bbad-fb219c020305"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMS0xLTEtNjY1NQ_2cb15daf-5623-463f-b164-40c2c32e26af"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMS0xLTEtNjY1NQ_2cb15daf-5623-463f-b164-40c2c32e26af"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtOS0xLTEtNjY1NQ_bce4f6d3-de3c-4401-99d8-dad63b036878"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtOS0xLTEtNjY1NQ_bce4f6d3-de3c-4401-99d8-dad63b036878"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMTctMS0xLTY2NTU_250d4afb-d517-49b4-ae52-055936d7d7c9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMTctMS0xLTY2NTU_250d4afb-d517-49b4-ae52-055936d7d7c9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtNy0xLTEtNjY1NQ_f2aa8f4b-04f8-4b63-911b-932ff2860817"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtNy0xLTEtNjY1NQ_f2aa8f4b-04f8-4b63-911b-932ff2860817"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk3_c69ce9de-335f-478e-9ba5-d6131c0a2877" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk3_c69ce9de-335f-478e-9ba5-d6131c0a2877" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Net of expenses of $0.6&#160;million, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $0.4&#160;million.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtNS0xLTEtNjY1NQ_c480c886-f66a-4315-9261-61b886b3ff94"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk3_c69ce9de-335f-478e-9ba5-d6131c0a2877"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMy0xLTEtNjY1NQ_0c21b0be-0a08-4608-bbad-fb219c020305"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk3_c69ce9de-335f-478e-9ba5-d6131c0a2877"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMS0xLTEtNjY1NQ_2cb15daf-5623-463f-b164-40c2c32e26af"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk3_c69ce9de-335f-478e-9ba5-d6131c0a2877"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtOS0xLTEtNjY1NQ_bce4f6d3-de3c-4401-99d8-dad63b036878"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk3_c69ce9de-335f-478e-9ba5-d6131c0a2877"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtMTctMS0xLTY2NTU_250d4afb-d517-49b4-ae52-055936d7d7c9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk3_c69ce9de-335f-478e-9ba5-d6131c0a2877"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RhYmxlOjQyYWU1MzUyMTlkOTRhZDJhY2Y5NDY5NjM1ZmUyNzRmL3RhYmxlcmFuZ2U6NDJhZTUzNTIxOWQ5NGFkMmFjZjk0Njk2MzVmZTI3NGZfMTQtNy0xLTEtNjY1NQ_f2aa8f4b-04f8-4b63-911b-932ff2860817"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjNlZWUwZGExMTIzZjRjNmE4NTJhODU4YWViOWM2Y2E2L3NlYzozZWVlMGRhMTEyM2Y0YzZhODUyYTg1OGFlYjljNmNhNl8yNS9mcmFnOjJhOTY0ZjFhMWUyODQ3ZmRhMTVjOGI4MWFjNTAzMjE1L3RleHRyZWdpb246MmE5NjRmMWExZTI4NDdmZGExNWM4YjgxYWM1MDMyMTVfMzk3_c69ce9de-335f-478e-9ba5-d6131c0a2877"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435613676040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 29, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CARDIFF ONCOLOGY,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-2004382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11055 Flintkote Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-7570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRDF<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,552,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435610433752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,165<span></span>
</td>
<td class="nump">$ 130,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">120,882<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable and unbilled receivable</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,327<span></span>
</td>
<td class="nump">2,055<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">137,769<span></span>
</td>
<td class="nump">133,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,017<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">141,312<span></span>
</td>
<td class="nump">134,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,010<span></span>
</td>
<td class="nump">3,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,042<span></span>
</td>
<td class="nump">6,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments&#8212;warrants</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">2,691<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">7,768<span></span>
</td>
<td class="nump">6,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, 20,000 shares authorized; (Note 7)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 150,000 shares authorized; 39,552 and 36,781 shares issued and outstanding at September 30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">384,551<span></span>
</td>
<td class="nump">361,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ServiceReceivable', window );">Service receivables</a></td>
<td class="num">(666)<span></span>
</td>
<td class="num">(2,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(250,362)<span></span>
</td>
<td class="num">(231,495)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">133,544<span></span>
</td>
<td class="nump">128,158<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 141,312<span></span>
</td>
<td class="nump">$ 134,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ServiceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ServiceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435611176264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">39,552,000<span></span>
</td>
<td class="nump">36,781,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">39,552,000<span></span>
</td>
<td class="nump">36,781,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435612711320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalties</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">4,154<span></span>
</td>
<td class="nump">2,855<span></span>
</td>
<td class="nump">11,552<span></span>
</td>
<td class="nump">8,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,930<span></span>
</td>
<td class="nump">1,644<span></span>
</td>
<td class="nump">8,003<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,084<span></span>
</td>
<td class="nump">4,499<span></span>
</td>
<td class="nump">19,555<span></span>
</td>
<td class="nump">12,836<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(6,998)<span></span>
</td>
<td class="num">(4,363)<span></span>
</td>
<td class="num">(19,329)<span></span>
</td>
<td class="num">(12,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income, net</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) from change in fair value of derivative financial instruments&#8212;warrants</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,913)<span></span>
</td>
<td class="num">(4,497)<span></span>
</td>
<td class="num">(18,849)<span></span>
</td>
<td class="num">(12,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (6,919)<span></span>
</td>
<td class="num">$ (4,503)<span></span>
</td>
<td class="num">$ (18,867)<span></span>
</td>
<td class="num">$ (15,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (1.00)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (1.00)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding - basic (in shares)</a></td>
<td class="nump">39,552<span></span>
</td>
<td class="nump">23,341<span></span>
</td>
<td class="nump">38,501<span></span>
</td>
<td class="nump">15,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding - diluted (in shares)</a></td>
<td class="nump">39,552<span></span>
</td>
<td class="nump">23,341<span></span>
</td>
<td class="nump">38,501<span></span>
</td>
<td class="nump">15,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (602)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,665)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435613125096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,913)<span></span>
</td>
<td class="num">$ (4,497)<span></span>
</td>
<td class="num">$ (18,849)<span></span>
</td>
<td class="num">$ (12,710)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on securities available-for-sale</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">(6,887)<span></span>
</td>
<td class="num">(4,497)<span></span>
</td>
<td class="num">(18,833)<span></span>
</td>
<td class="num">(12,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic', window );">Comprehensive loss attributable to common stockholders</a></td>
<td class="num">(6,893)<span></span>
</td>
<td class="num">(4,503)<span></span>
</td>
<td class="num">(18,851)<span></span>
</td>
<td class="num">(15,995)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(602)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,665)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income (Loss) Available To Common Stockholders, Basic</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435528483528">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series&#160;E Convertible Preferred Stock</div>
</th>
<th class="th"><div>Service Receivable</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Series&#160;E Convertible Preferred Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,594,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,310<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (972)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (208,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_SaleOfStockCommonAndWarrantsNetShares', window );">Sale of common stock and warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_SaleOfStockValueCommonAndWarrantsNet', window );">Sale of common stock and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,141<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(679)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(212,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,594,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,310<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(972)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(208,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,521<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,404)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(224,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,141<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(679)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(212,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,473,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock', window );">Deemed dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 602<span></span>
</td>
<td class="nump">$ 2,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (602)<span></span>
</td>
<td class="num">$ (2,665)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,689,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,279<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(155,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,547,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,382<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,766)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(220,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,957,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,521<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,404)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(224,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,781,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">128,158<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,171)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(231,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,179)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,179)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,552,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">124,817<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,791)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="num">(236,680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,781,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">128,158<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,171)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(231,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,552,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">133,544<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(666)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(250,362)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,552,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">124,817<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,791)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="num">(236,680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,757)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,757)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of expenses (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">19,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,552,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">138,918<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,245)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(243,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,913)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,913)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,552,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 133,544<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (666)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="num">$ (250,362)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="14"></td></tr>
<tr><td colspan="14"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Net of expenses of $0.6&#160;million, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $0.4&#160;million.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Net of expenses of $0.8&#160;million.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ReleaseOfClinicalTrialFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Release Of Clinical Trial Funding Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ReleaseOfClinicalTrialFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_SaleOfStockCommonAndWarrantsNetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Common And Warrants, Net, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_SaleOfStockCommonAndWarrantsNetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_SaleOfStockValueCommonAndWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Value, Common And Warrants, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_SaleOfStockValueCommonAndWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Restricted Stock Units Released</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares issued during the period upon cash exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity impact during the period due to the cash exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435607127368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment', window );">Cost of issuance of common stock, preferred stock and warrants</a></td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_WarrantsFairValue', window );">Warrants, fair value</a></td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Of Issuance Of Common Stock, Preferred Stock And Warrants For Clinical Trial Funding Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_WarrantsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_WarrantsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435612939592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,849)<span></span>
</td>
<td class="num">$ (12,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,244<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums on short-term investments</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative financial instruments&#8212;warrants</a></td>
<td class="num">(280)<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived', window );">Release of clinical trial funding commitment</a></td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable and unbilled receivable</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other assets</a></td>
<td class="num">(741)<span></span>
</td>
<td class="num">(624)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">386<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(830)<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(645)<span></span>
</td>
<td class="num">(636)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,650)<span></span>
</td>
<td class="num">(11,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of short-term investments</a></td>
<td class="nump">15,101<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of short-term investments</a></td>
<td class="num">(146,632)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of short-term investments</a></td>
<td class="nump">8,975<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(122,654)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sales of common stock, preferred stock and warrants, net of expenses of $776 and $634, respectively</a></td>
<td class="nump">19,225<span></span>
</td>
<td class="nump">18,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Costs related to the clinical trial funding commitment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">18,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Borrowings under note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">20,488<span></span>
</td>
<td class="nump">37,555<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(117,816)<span></span>
</td>
<td class="nump">26,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;Beginning of period</a></td>
<td class="nump">130,981<span></span>
</td>
<td class="nump">10,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;End of period</a></td>
<td class="nump">13,165<span></span>
</td>
<td class="nump">36,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_PreferredStockDividendAccrued', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment', window );">Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PreferredStockDividendAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of preferred stock dividend accrued during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PreferredStockDividendAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Release Of Clinical Trial Funding Commitment For Services Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121593497&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435606929336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance expenses</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 776<span></span>
</td>
<td class="nump">$ 634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment', window );">Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount Of Issuance Of Common Stock, Preferred Stock And Warrants For Clinical Trial Funding Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435608400696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Organization and Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology, Inc. (&#8220;Cardiff Oncology&#8221; or the &#8220;Company&#8221;) headquartered in San Diego, California, is a clinical-stage oncology company with the mission of developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need, including KRAS-mutated metastatic colorectal cancer, metastatic pancreatic cancer and metastatic castration-resistant prostate cancer. The Company's common stock is listed on the Nasdaq Capital Market under the ticker symbol "CRDF".</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form&#160;10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules&#160;and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company&#8217;s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December&#160;31, 2020 included in the Company&#8217;s annual report on Form&#160;10-K filed with the SEC on February&#160;25, 2021.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since its inception and has negative operating cash flows. As of September&#160;30, 2021, the Company had $134.0&#160;million in cash, cash equivalents and short-term investments and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#8217;s stockholders may experience additional dilution. The economic effects of COVID-19 could also have an adverse effect on the Company's ability to raise additional capital. See Note 10 to the condensed financial statements for further information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435607014328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, there have been no changes to the Company&#8217;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, other than the addition of investment securities as described below.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Securities</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#8217;s ability to liquidate the investment for use in operations within the next 12 months.</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#8217;s investment holdings are in the form of debt securities or certificates of deposit, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,920,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,548,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,742,475&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,844,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncement Not Yet Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04 ("ASU 2021-04), Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435608370248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September&#160;30, 2021 and December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants (3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund (1)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,988&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,988&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants (3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value on a recurring basis</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;Included as a component of cash and cash equivalents on the accompanying condensed balance sheets. Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Included in short-term investments in the accompanying condensed balance sheets. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, all assets and liabilities for which the fair value </span></div>measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 6 to the condensed financial statements for further information.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435607039816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Supplementary Balance Sheet Information</a></td>
<td class="text">Supplementary Balance Sheet Information<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available for sale consist of the following: </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,866&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,628&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435606781224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently occupies 9,500 square feet of office and lab space in San Diego. During July 2021, the Company entered into an amended lease agreement to increase its occupied space to 12,300 square feet which commences on January 1, 2022 and expires on February 28, 2027. Under the current master facility lease, which expires on December 31, 2021, the Company leases 26,100 square feet of office and lab space. This includes 16,600 square feet of space that is subleased to third parties, all of which expires on December 31, 2021. The minimum monthly rent under the amended lease is $55,000 with an annual rent escalation of 3% per year beginning on January 1, 2022. Through December 31, 2021 rent payments are approximately $80,000 per month. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under three separate sublease agreements, which all expire on December 31, 2021. The Company as a sublessor is leasing approximately 16,600 square feet of space to third parties as of September 30, 2021.  </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,691&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div style="text-align:center;text-indent:33.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Sublease Income </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Operating Leases </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September 31, 2021)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,285&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently occupies 9,500 square feet of office and lab space in San Diego. During July 2021, the Company entered into an amended lease agreement to increase its occupied space to 12,300 square feet which commences on January 1, 2022 and expires on February 28, 2027. Under the current master facility lease, which expires on December 31, 2021, the Company leases 26,100 square feet of office and lab space. This includes 16,600 square feet of space that is subleased to third parties, all of which expires on December 31, 2021. The minimum monthly rent under the amended lease is $55,000 with an annual rent escalation of 3% per year beginning on January 1, 2022. Through December 31, 2021 rent payments are approximately $80,000 per month. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under three separate sublease agreements, which all expire on December 31, 2021. The Company as a sublessor is leasing approximately 16,600 square feet of space to third parties as of September 30, 2021.  </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,691&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div style="text-align:center;text-indent:33.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Sublease Income </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Operating Leases </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September 31, 2021)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,285&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph Note 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph Note 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888252<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435607101928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments - Warrants</a></td>
<td class="text">Derivative Financial Instruments &#8212; Warrants<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the Company&#8217;s analysis of the criteria contained in ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 815-40&#8221;) or ASC Topic 480-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 480-10&#8221;), Cardiff Oncology determined that certain warrants issued in connection with the execution of certain equity financings must be recorded as derivative liabilities.&#160;In accordance with ASC 815-40 and ASC 480-10, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company&#8217;s condensed statements of operations.&#160;The Company estimates the fair value of these warrants using the Black-Scholes option pricing model.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to determine the fair value of the warrants using the Black-Scholes option pricing model were:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.66&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.99&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility is based on historical volatility of Cardiff Oncology&#8217;s common stock.&#160;The warrants have a transferability provision, accordingly, Cardiff Oncology used the remaining contractual term as the expected term of the warrants.&#160;The risk-free rate is based on the U.S.&#160;Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of changes in the Company&#8217;s derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for number of warrants)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>Instrument<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants during the period recognized as a gain in the condensed statements of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435608449992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized compensation cost related to non-vested stock options outstanding at September&#160;30, 2021, net of estimated forfeitures, was $10.1 million, which is expected to be recognized over a weighted-average remaining vesting period of 3.3 years.&#160;The weighted-average remaining contractual term of outstanding options as of September&#160;30, 2021 was </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately 8.9 years. The total fair value of stock options vested during the nine months ended September 30, 2021 and 2020 were $1.2 million and $0.8 million, respectively.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and changes in stock options outstanding is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,963,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled / Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,522,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281,604&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,103,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,466,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,344,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Equity Incentive Plan</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the Company's stockholders approved the 2021 Omnibus Equity Incentive Plan ("2021 Plan"). The number of authorized shares in the 2021 plan is equal to the sum of (i) 3,150,000 shares, plus (ii) the number of shares of Common Stock reserved, but unissued under the 2014 Plan; and (iii) the number of shares of Common Stock underlying forfeited awards under the 2014 Plan. As of September&#160;30, 2021, there were 2,289,902 shares available for issuance under the 2021 Plan. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2014 Equity Incentive Plan</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the adoption of the 2021 Plan, no additional equity awards can be made under the terms of the 2014 Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inducement Grants</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company began issuing equity awards to certain new employees as inducement grants outside of its 2021 Plan. As of September&#160;30, 2021, an aggregate of 590,000 shares were issuable upon the exercise of inducement grant stock options approved by the Company.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Modification of Stock Options</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 two of the Company's directors' terms ended. At the conclusion of their term, the Compensation Committee passed a resolution to extend the expiration date of the departing directors vested stock options, and to immediately accelerate the vesting of one of the directors unvested options. The Company recorded incremental stock compensation expenses of$0.6&#160;million during the nine months ended September 30, 2021, related to the modifications. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity is presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair Value<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of vested RSUs during the nine months ended September 30, 2021 and 2020 were $0.1 million and $0.1 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining&#160;Contractual<br/>Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,260,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(770,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 years</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation preference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435608463640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development and Clinical Trial Agreements</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib. Onvansertib, an investigational drug, is an oral, and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK1. The Company is developing onvansertib in cancer indications with the greatest medical need for new treatment options. The Company was committed to order $1.0 million of future services provided by Nerviano, such as the cost to manufacture drug product, no later than June 30, 2019, and these services have been purchased. Terms of the agreement also provide for the Company to pay development milestones and royalties based on sales volume.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is a party of various agreements under which it licenses technology on an exclusive basis in the field of oncology therapeutics. These agreements include License fees, Royalties and Milestone payments. The company also has a legacy license agreement in the field of oncology diagnostics under which royalty payments are due. These royalty payments are calculated as a percent of revenue. For the three and nine months ended September&#160;30, 2021 and 2020, payments have not been material.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company&#8217;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#8217;s business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435609043288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gary Pace Securities Purchase Agreement</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company entered into a Securities Purchase Agreement with Gary W. Pace, one of the Company's directors. Dr. Pace purchased 447,761 shares of the Company's common stock at $1.34 per share for an aggregate purchase price of $600,000.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leucadia Life Sciences</span></div>In November 2018, the Company entered into a Material Transfer Agreement (&#8220;MTA&#8221;) with Leucadia Life Sciences (&#8220;Leucadia&#8221;) pursuant to which Leucadia developed a PCR-based assay for onvansertib for Acute Myeloid Leukemia (&#8220;AML&#8221;). This assay was completed in December 2020. During the duration of the agreement, one of the Company's directors Dr. Thomas Adams (who is no longer a director as of June 2021), was a principal stockholder of Leucadia. In connection with the MTA, the Company entered into a consulting agreement with Tommy Adams, Co-Founder &amp; Chief Operating Officer of Leucadia, who is the son of Dr. Adams. During the three months ended September&#160;30, 2021 and 2020 the Company incurred and recorded research and development expenses of approximately $0 and $0.3 million, respectively, for services performed by Leucadia and Tommy Adams. During the nine months ended September&#160;30, 2021 and 2020 the Company incurred and recorded research and development expenses of approximately $0 and $0.8&#160;million, respectively, for services performed by Leucadia and Tommy Adams.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435609313976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVID-19<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock', window );">COVID-19</a></td>
<td class="text">COVID-19 The COVID-19 outbreak in the United States has caused significant business disruption. Thus far COVID-19 has not caused material disruptions to the Company's operational and financial performance. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance the development of its drugs and raise additional capital.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=114868817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435611083496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Securities</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#8217;s ability to liquidate the investment for use in operations within the next 12 months.</span></div>Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#8217;s investment holdings are in the form of debt securities or certificates of deposit, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncement Not Yet Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04 ("ASU 2021-04), Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435608627336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,920,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,548,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,742,475&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,844,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435608587960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of the Company&#8217;s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September&#160;30, 2021 and December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments (2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants (3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund (1)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,988&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,988&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants (3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value on a recurring basis</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;Included as a component of cash and cash equivalents on the accompanying condensed balance sheets. Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Included in short-term investments in the accompanying condensed balance sheets. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, all assets and liabilities for which the fair value </span></div>measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 6 to the condensed financial statements for further information.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435607031448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Investments Available-for-sale</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available for sale consist of the following: </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,866&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Components of Property and Equipment</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,628&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435608472648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Expense and Supplemental Cash Flow Information</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,691&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div style="text-align:center;text-indent:33.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Sublease Income </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Operating Leases </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September 31, 2021)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,285&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435608706136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Warrants (Tables) - Black Scholes Option Pricing Method<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Assumptions Used to Determine the Fair Value of the Warrants</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to determine the fair value of the warrants using the Black-Scholes option pricing model were:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.66&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.99&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock', window );">Schedule of Components of Changes in the Company&#8217;s Derivative Financial Instruments Liability Balance</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of changes in the Company&#8217;s derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for number of warrants)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>Instrument<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants during the period recognized as a gain in the condensed statements of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of a concept from the beginning of a period to the end of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435606793976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions to Estimate Fair Value of Stock Option Awards</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity and of Changes in Stock Options Outstanding</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and changes in stock options outstanding is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,963,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled / Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,522,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281,604&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,103,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,466,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,344,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity is presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair Value<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity and Changes in Warrants Outstanding</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining&#160;Contractual<br/>Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,260,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(770,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Preferred Stock</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation preference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435606978360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 134.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435612696504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">10,742,475<span></span>
</td>
<td class="nump">12,844,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">3,566,832<span></span>
</td>
<td class="nump">1,920,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">4,490,159<span></span>
</td>
<td class="nump">7,373,351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series&#160;A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">2,684,607<span></span>
</td>
<td class="nump">3,548,459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435609649144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">$ 120,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments - warrants</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">2,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">77,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">12,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">27,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">12,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">120,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">133,532<span></span>
</td>
<td class="nump">129,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments - warrants</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value on a recurring basis</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">2,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">77,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">12,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">27,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">12,650<span></span>
</td>
<td class="nump">129,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">12,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">27,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">39,844<span></span>
</td>
<td class="nump">129,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments - warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">27,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">12,650<span></span>
</td>
<td class="nump">129,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">93,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">93,688<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments - warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">2,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">77,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">12,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments - warrants</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value on a recurring basis</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435609894792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Investments Available-for-sale (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 120,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">120,882<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">2,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">77,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">77,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">12,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">12,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">27,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">$ 27,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435613163192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,712<span></span>
</td>
<td class="nump">$ 3,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less&#8212;accumulated depreciation and amortization</a></td>
<td class="num">(3,329)<span></span>
</td>
<td class="num">(3,004)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">866<span></span>
</td>
<td class="nump">798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,962<span></span>
</td>
<td class="nump">1,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 884<span></span>
</td>
<td class="nump">$ 868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435645758408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">62 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2027 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LessorNumberOfSubleases', window );">Number of subleases | lease</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany', window );">Area of lease occupied by company</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseAreaOfLease', window );">Area of lease</a></td>
<td class="nump">26,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LessorAreaOfSublease', window );">Area of sublease</a></td>
<td class="nump">16,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseMonthlyRentPayment', window );">Monthly rent payments | $</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease', window );">Lease not yet commenced, area</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseMonthlyRentPayment', window );">Monthly rent payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage', window );">Annual rent increase, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Rent Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseAreaOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area Of Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseAreaOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area Of Lease Occupied By Company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Area Of Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseMonthlyRentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Rent Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseMonthlyRentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LessorAreaOfSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessor, Area Of Sublease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LessorAreaOfSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LessorNumberOfSubleases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessor, Number Of Subleases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LessorNumberOfSubleases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435605705288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 281<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Operating sublease income</a></td>
<td class="num">(101)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
<td class="num">(218)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net operating lease cost</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435609883048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets</a></td>
<td class="nump">$ 3,017<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">2,691<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 3,285<span></span>
</td>
<td class="nump">$ 869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term&#8211;operating leases</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate&#8211;operating leases</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435605676728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 726<span></span>
</td>
<td class="nump">$ 706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for lease liabilities</a></td>
<td class="nump">$ 3,061<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,061<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435610255608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (excluding the nine months ended September 31, 2021)</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">3,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(687)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">3,285<span></span>
</td>
<td class="nump">$ 869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract', window );"><strong>Sublease Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear', window );">2021 (excluding the nine months ended September 31, 2021)</a></td>
<td class="num">(101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total future minimum lease payments</a></td>
<td class="num">(101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract', window );"><strong>Net Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear', window );">2021 (excluding the nine months ended September 31, 2021)</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne', window );">2022</a></td>
<td class="nump">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo', window );">2023</a></td>
<td class="nump">737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree', window );">2024</a></td>
<td class="nump">754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour', window );">2025</a></td>
<td class="nump">775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue', window );">Total future minimum lease payments</a></td>
<td class="nump">$ 3,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Remainder Of Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessor, Operating Lease, Payment To Be Received, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435610486936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Warrants (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DerivativeFinancialInstrumentsLiabilityRollForward', window );"><strong>Changes in the Company's derivative financial instruments liability balance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,260,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares) | shares</a></td>
<td class="nump">4,490,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,490,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance of derivative financial instruments liability at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative financial instruments&#8212;warrants during the period recognized as a gain in the condensed statements of operations</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="num">$ (144)<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="num">$ (186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance of derivative financial instruments liability at the end of the period</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_EstimatedFairValueOfWarrant', window );">Estimated fair value of Cardiff Oncology common stock (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock | Black Scholes Option Pricing Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DerivativeFinancialInstrumentsLiabilityRollForward', window );"><strong>Changes in the Company's derivative financial instruments liability balance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares) | shares</a></td>
<td class="nump">64,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance of derivative financial instruments liability at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative financial instruments&#8212;warrants during the period recognized as a gain in the condensed statements of operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance of derivative financial instruments liability at the end of the period</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected warrant term | Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected warrant term</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility of Cardiff Oncology common stock | Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield | Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DerivativeFinancialInstrumentsLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DerivativeFinancialInstrumentsLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_EstimatedFairValueOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated fair value of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_EstimatedFairValueOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsQuantitativeInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsQuantitativeInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435612756952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td>
<td class="nump">$ 940<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">$ 2,244<span></span>
</td>
<td class="nump">$ 821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Options vested, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
<td class="nump">$ 570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining vesting period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435612935336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares under the plan (in shares)</a></td>
<td class="nump">3,150,000<span></span>
</td>
<td class="nump">3,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">0.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108.00%<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at the beginning of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,860,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,721,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled / Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,770)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod', window );">Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at the end of the period (in shares)</a></td>
<td class="nump">3,566,832<span></span>
</td>
<td class="nump">3,566,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">1,281,604<span></span>
</td>
<td class="nump">1,281,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at June 30, 2021 (in shares)</a></td>
<td class="nump">3,466,323<span></span>
</td>
<td class="nump">3,466,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance outstanding at the beginning of the period (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled / Forfeited (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice', window );">Expired (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance outstanding at the end of the period (in USD per share)</a></td>
<td class="nump">$ 7.22<span></span>
</td>
<td class="nump">7.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in USD per share)</a></td>
<td class="nump">8.96<span></span>
</td>
<td class="nump">8.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at June 30, 2021 (in USD per share)</a></td>
<td class="nump">$ 7.28<span></span>
</td>
<td class="nump">$ 7.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, intrinsic value</a></td>
<td class="nump">$ 7,522,769<span></span>
</td>
<td class="nump">$ 7,522,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,963,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end of the period, intrinsic value</a></td>
<td class="nump">5,103,890<span></span>
</td>
<td class="nump">5,103,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at March 31, 2021, intrinsic value</a></td>
<td class="nump">7,344,075<span></span>
</td>
<td class="nump">$ 7,344,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Accelerated compensation expense</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=crdf_InducementGrantStockOptionsMember', window );">Inducement Grant Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2021Member', window );">Equity Incentive Plan 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of remaining shares available for issuance (in shares)</a></td>
<td class="nump">2,289,902<span></span>
</td>
<td class="nump">2,289,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=crdf_InducementGrantStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=crdf_InducementGrantStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435613287736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock Units (Details) - Restricted Stock Units - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Total Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Non-vested at beginning of period (in shares)</a></td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(491)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Non-vested at end of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value Per&#160;Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, weighted average grant date fair value at end of period (in USD per share)</a></td>
<td class="nump">$ 147.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value (in USD per share)</a></td>
<td class="nump">147.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, weighted average grant date fair value at end of period (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Equity instruments other than options, aggregate intrinsic value, nonvested</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Equity instruments other than options, vested in period, fair value</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435612757576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_WarrantsAndRightsRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,490,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightNumberExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(770,833)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">5,260,992<span></span>
</td>
<td class="nump">5,260,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price of warrants at the beginning of the period (in USD per share)</a></td>
<td class="nump">$ 5.19<span></span>
</td>
<td class="nump">$ 5.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised', window );">Exercised (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price of warrants at the end of the period (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract', window );"><strong>Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights', window );">Weighted-Average Remaining&#160;Contractual Term</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightNumberExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightNumberExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period over which each class of warrants or rights outstanding may be exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of each class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No definition available</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of each class of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_WarrantsAndRightsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_WarrantsAndRightsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435610260296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">277,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference</a></td>
<td class="nump">$ 606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">60,600<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">8,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">154,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">865,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">655,044<span></span>
</td>
<td class="nump">655,044<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435608532168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=crdf_NorvianoMember', window );">Nerviano</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Other commitment</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=crdf_NorvianoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=crdf_NorvianoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140435612772520">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">447,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OtherAffiliatesMember', window );">Affiliated Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Net of expenses of $0.6&#160;million, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $0.4&#160;million.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OtherAffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OtherAffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( 'U_9%,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !]?V13*>"BK.\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>*$Z[0DWJR\9.+0Q6V-C-V&IK%L?&UDCZ]G.R-F5L#["CI=^?
M/H$:'83V$9^C#QC)8KH;7-LEH<.&G8B" $CZA$ZE,B>ZW#SXZ!3E9SQ"4/I#
M'1'JJEJ!0U)&D8(16(29R&1CM- 1%?EXP1L]X\-G;">8T8 M.NPH 2\Y,#E.
M#.>A;> &&&&$T:7O IJ9.%7_Q$X=8)?DD.R<ZON^[!=3+N_ X6VW?9G6+6R7
M2'4:\Z]D!9T#;MAU\NOBX7'_Q&1=U;S@O*B6>[X6]VNQ7+V/KC_\;L+.&WNP
M_]CX*B@;^'47\@M02P,$%     @ ?7]D4YE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !]?V13"!O!)Q8%  "\%   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)68;V_J-A3&7]]]"HM)TR:5)G9(*7<4B:;E#JVWI:7;=#?MA4D,1$UBKN-
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M7#,*#JX$P/,EY^KEHFR@_1!T\0]02P,$%     @ ?7]D4SIM0F@!!   M@X
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MY<42F +(]TM*Q?M ):BNJN-_ 5!+ P04    " !]?V13<TD3:.H,  #U4P
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M)/M=A!FR>!A6?(_=?.\)J9?B5KI:: ^IV"3[!#,@ZS-QF&).K8L$*UV W;H
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M"M,+VL-,Z32?#GW *Y>F\T!^P):>,(ZF^,^F''A[*8PM>6 2Y_-RPQ30G F
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M?%O+(W^!4. #V*\\PNQ?V,#X\\CY_P%02P,$%     @ ?7]D4PZ/^E$."0
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MQ/5\!?]=K6\4M).]QO(DRF*X:XT2KC48_.@MU0,OW+V"+L#Q= +WE#3NM:Q
MU(TAJKH\LG@Z8J?QGF]\<311\Q5C,BD(90)Y/,X8C2/FL:P]T<K+LJU;226M
M? \8I&KUYYIW/=<)KO(X9T02S6E:#)ZA* :%/O!\DM,X8@5\Z[0G%[<P=<@N
MO#66Z&V5ZR[D7MH_9\ON%O^JWKV%U-0[W_D2MV2:#L?7$9CN?>DV3C?A3M]H
M1R]$6.[I24;C%>C_5FMWWG@'_2._^!M02P,$%     @ ?7]D4Q .@9[-!@
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MS^O2\ *\7VKMUG]X@^X[\.U_ 5!+ P04    " !]?V13!S6K1UL%  "B#0
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MQ $H(,>%Q)X]X%.#4Q;YI/&C1SVD9 &;5Z@R:)FF@B@5<EO78B"82/37S@5
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M<>+MO$DT$V]T:N+]PK4O+ ?>VOK5DP/5MJ$ZL(1TKW8D^5QAB,TEG_L!T$T
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MP_XDZ3'MOZSZ!ZO6[FLF\MJJPMVN!,8D30>POU#*-@_$H/V\??-_4$L#!!0
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M(^5O6F2EFSK+9UWNX2:.8E82F2V(G&A:J!+MH<$%W1'W6;Z7G[31'_386'-
MA48[D!ZH(H/>4=?=P>^D3=S9?/QH5$-$B1UBXVU;TQ>%DW 8THYQ;+CGVCCN
M]=9Q2CO!FK1O%J2)5.4ZV?)AR9-"V3:R@!#6Y"G N$M#5K-OOU<YO@;9$*:*
MZNH9#X:+<? #XF_[MBR)XE3<#J28XO6>\3!T.E:J9Y4SB"1S=]-:JMU7FOR;
M^+21:_0(PSM@W^5U=S_G)*NBI3V'KZY#TJIEI6B1X328#UG/);I]0X[-7_4E
MY@:CS"]W6=V=C,0GH\"YEJ@N &9_N.6->,#K$#&KS/G4*:UF@6(8S9#+_:SX
M<NAHCZ1V-M8 $BLZ<:DY?YP]B^3)PEB3TY]7F1D$6LC"YD&.-HV80X4%>Q^C
MX<]Y8Z"/K<%F,EQUW*E4:.$0)GHX.I& X&N1<'=C=?/_PWE=0^\%H;8\FR#B
M39[=@UBMW,;6]$=;!QC8%.8(9M$ V$3:EQQ3 F=2V$$N;>C.J:+EF1CC0:H@
MXM@6?V%R,BZ,19P:*%WK^G.+\]$/6G2 QCG(*J"("QZ'0OH3CW.&W\4O/^?9
M@>,-E0SUF/0/WYVLED]_C"-D%\.HT#RR\S,@!FI\P$3"K,*M.$N[KV3/G3-/
MN6086LI*4W.# W],XXC3^R8?[+<8HB-&<I#40)?*DO/CW8/@N> E<N[X;.1#
M7AO.\.QK5Z7YZ'**TW2=K^ \YUN7NGOJ\'6XY5]TE]O[[=U/!%P UJ )490P
M7<R>/IYT)_+^)?DF7W4+GW!QSH\5?JE0X U8+[U/^Q<.,/SV.?\'4$L#!!0
M   ( 'U_9%/Z/%:^@ (  *P%   9    >&PO=V]R:W-H965T<R]S:&5E=#$X
M+GAM;*U4VV[;, S]%<(HL)<@=ASWLB()D+2[%&B!H-G6AV$/BDW;0FW)H^2E
M^?M1LN-EV-IAPUXL4>(Y/*1,SG::'DV):.&IKI29!Z6US648FK3$6IBQ;E#Q
M3:ZI%I9-*D+3$(K,@^HJC*/H+*R%5,%BYL_6M)CIUE92X9K M'4M:+_"2N_F
MP20X'-S+HK3N(%S,&E'@!NW'9DULA0-+)FM41FH%A/D\6$XN5XGS]PZ?).[,
MT1Y<)ENM'YUQD\V#R G""E/K& 0OW_ *J\H1L8RO/6<PA'3 X_V!_:W/G7/9
M"H-7NGJ0F2WGP44 &>:BK>R]WKW'/I]3QY?JRO@O[#K?*3NGK;&Z[L&LH):J
M6\537X<CP$7T#"#N ;'7W07R*J^%%8L9Z1V0\V8VM_&I>C2+D\H]RL82WTK&
MV<4]5L)B!FM!=@\?2"@C?+W,++3,[[S"M.=:=5SQ,UROX4XK6QIXHS+,?L:'
MK&L0%Q_$K>(7"3?8C&$:C2".XLD+?-,AV:GGF_YULO!YN366V/KR0IQDB)/X
M.,E_*>J_<L$[[B(^3Q$VF+8DK40#ZY;2DG]36!:$R.UCX4;!G=B[(G(I;8EP
MI>M&J#WP)1)S2V4UB#^P[*0MNY /8Q]U!%HAZ/R8\I6!3!)WG"8SAFOJ/*'I
MZ3)(DO/1^=D$3"F(X_R"3G5=<[/R?Y\^@K!P,AE/$VB0.@3P& +!S5RPKH(+
M,U!#0S+U<D[.HF@41=$8;K%-128%W,J<BY1*5"F:WSUP>-1!-5+AYX13TRK;
M-=-P.HRB9=>!/]R[.78GJ)#\.A7F#(W&YZ<!4#<;.L/JQO?C5EON;K\M>9PB
M.0>^S[6V!\,%& ;TXCM02P,$%     @ ?7]D4Q0!JLOC @  .08  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&ULG55-;]LP#/TKA"^[='&^NK5%$B!)
M-RR'8D6S=H=A!\6B;:&RY$ITTO[[47+B9,-:#+LD%,7WR,=0S&1GW:,O$0F>
M*VW\-"F)ZJLT]5F)E? ]6Z/AF]RZ2A ?79'ZVJ&0$53I=-CO?T@KH4PRFT3?
MK9M-;$-:&;QUX)NJ$NYE@=KNILD@.3CN5%%2<*2S22T*7"/=U[>.3VG'(E6%
MQBMKP&$^3>:#J\4XQ,> !X4[?V)#4+*Q]C$<5G*:]$-!J#&CP"#X:XM+U#H0
M<1E/>\ZD2QF I_:!_7/4SEHVPN/2ZN]*4CE-+A*0F(M&TYW=?<&]GO/ EUGM
MXR?LVM@Q!V>-)UOMP5Q!I4S[+9[W?3@!7/1? 0SW@&&LNTT4J[P6)&839W?@
M0C2S!2-*C6@N3IGPHZS)\:UB',V67Q]6U^\'EY.4F"WXTFR/7+3(X2O(2[BQ
MADH/GXQ$^3L^Y2JZ4H:'4A;#-PG76/=@U#^#87\X>(-OU$D;1;[1*WSWIO&-
MT& =K$SN\*E!0[ BK/Q9<"XLE?!COO'D>#9^OI%QW&4<QXSC_VCFOR'A6XG0
M'?@1;?BE/8(R0'QQ;Q2AA#4)0@^E\)")QK/'J\*H7&6"!6X:S^3>@U3>-768
M_1[3-AYRX8[< 6TL'1AXOM$I[M81Y8%L3+NT52W,RSL/O N<"'<<*(R$7!EA
ML@#CB[@A3(8]F$/MK+:F8.).0V8;+3GM%D$<TPFY1><1%*?("/B='CD=>GY;
M/F;J5'4EL)F?EG?&7<IT(Y4IHIM4%<P %ANE%;W\ 0CR,C8U$D*&CGB%0<:_
M#/=1 X7RVMP\)^@ <Q;(U81!4HZ5,9RK#XHCJ\0MK[BZ"D/&B12'2M<4+843
MBD4**=6^>YFH%0G=^]O4I2?/N4)7Q*7E0P,-M2^[\W9[<=ZN@V-XNU1OA"L4
MMTICSM!^[^-Y JY=5.V!;!V7P\82KYIHEKS;T84 OL^MI<,A).C^+6:_ %!+
M P04    " !]?V13>]I'\T@&  #=#P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R,"YX;6R]5VEO&S<0_2L#%2AL(+(.'W$3VX"L.(B!)C&BI$%1] .U.](2
MYBXW)->R_WW?D*O+L84F!?I%6AYSOWDDSQ;6W?J".=!]:2I_WBE"J%_U>CXK
MN%3^P-9<865F7:D"AF[>\[5CE4>ATO2&_?Y)KU2ZZER<Q;D;=W%FFV!TQ3>.
M?%.6RCU<LK&+\\Z@LYSXI.=%D(G>Q5FMYCSA\*6^<1CU5EIR77+EM:W(\>R\
M,QJ\NCR1_7'#'YH7?N.;))*IM;<RN,[/.WUQB UG030H_-WQF(T117#C6ZNS
MLS(I@IO?2^UO8^R(9:H\CZWYJO-0G'=..Y3S3#4F?+*+=]S&<RSZ,FM\_*5%
MVGM\U*&L\<&6K3 \*'65_M5]FX<-@=/^,P+#5F 8_4Z&HI=O5% 79\XNR,EN
M:)./&&J4AG.ZDJ),@L.JAERXF*1BD)W11,\K/=.9J@*-LLPV5=#5G&ZLT9EF
M3WO+K_VS7H!I4=#+6C.7R<SP&3._T7M;A<+3595SOBW?@\LKOX=+OR^'.Q5.
MN#Z@P_X+&O:'@QWZ#E=Y.(SZ#I_1]U3 ?XVF/CC@YN\=!HY6!HZB@:-G#%Q7
M=^P#X!QHPEGC=(")IQ+Y$VIH9 SIU8JG0MTQ39DKRHSR'E7EG)2G7W\Y'0[[
MK]6=TD9-#7?1U5VO#,>%P6M2%?8YIDPY%V4"S91V=*=,PZ(AY\ ..,2:-$-.
M38W>^M;8@&\@Z18\4CN=P2GKXI>DM+0Y&T^P1EZ7L(W_M?<P4K/3-B>N\@.Z
MW@ADH4-!&: C96B4@8FP%#/L/85"5308PD*$%U2% J$KHZJ,*?%:K@*GJ"S(
M)&<'5WUA7>A*+)N)^_?&I_Q@D2M;,3TPPA'URGC[*.$;9G(D,-CHWMB6M:H>
M).F#EZ_A]50;'1YDV>AOC8X.R\:U:S%WC9<I B,[)9R67,2,[*WX/JPS<; #
MLL<KR![OQ-H'Y.YWBR3?L*-)@1"?PNM.'7*FO/*UROB\@T/#L[OCSA.*:8>[
M)RMW3W:Z^XDS?D1=SE;XSCC5\X,-]"=,CW);A\<LE(+Y3Q8>&P"8:-3,0>+"
M4N J*=/;T>22M/<-UD>3+Y YB*O=_@GM=62F'77V7] ;G@;JIK^(QK$%(EP\
M$:55/T*CHX]U L/>I)D&6^N,CE[VN\/^?MSS!JUUI^3L\W'\CO.YN-X591':
M7D!UA8#"&I(?%Y@"%('*M=K3P7'W"&KW6A[9\+8ED/T#VI@D-NCV"FCVJ2VY
M8APP&JV4;0>2*5]LS:U3O,$=:4/08"ZX#&YNEET;4O,IC/-D:T-#%(4<KBBK
M=HXQ@SIX.VR+L#F%#68)B34:Y[#-/"QUHG*B,K+A.K=3SI0T*$Y27W,F)RE(
M+@23L%$[>Z<EMD@RI/)<2]5>;.4+L0IU@, !_5HAU*P1LGPF\)2Z[R*+GI?J
M 2ZU'N02;<RQ,+ T'.('!V6)+G-M&HGJZF8"-67=A$@O!_19$BDY3>8BTV@/
MSE]1*L]F'"]6,25U,\792=/&HW/0WS&[$H\LSK3/4'FA2\D60%A)==0,] B4
MHH>F^!@<IS.=]NSWLX<M#(0^1>VBL%0*Q4L4DZNQW,=T%1,;;S2E,@;2G[@&
M#8NQ\5(4S27)TZBFTV5[_FSPJ44E-QU^E MTL+ U$JS:7@^%L\V\(-:Q)Q7-
M&@/(. [."AYBCN!\6^+\T4K)L)F+TR@B3JF4_ROE!'9B0D*"T5I.WP"#R:'V
M))&5-4Q93FL5XXV'2"JTJ);B^8# E9.SBS2*BH3AK)2>Q$K@-; <&R61Y4B#
ML;X!:")TWP-94J&=?#;H]H_6?"8C9!SA2,DW>7_O<V26X4F_I;O8BL/7[V.:
MLO:8$W>N[B6B1OLBN;C-=L<B+]G >R$*M7HFP6:W6PM+DR\'IRT(GF'(5L//
MLN0KNI:LN-7FT38CC=N^W8X4"U?W&2XU<[E!S>BM8XX5$[%DJCM>7S&^.@%#
M16, ?7T.J'C30<"-3V5ORW15LHO<'SWS]%GY6\+C)N/]'^]UL?@?^OL%+&2F
MB7']8!?^WZ!_ZF[2VWAR25;CPQ+^2(73ZVLUNWJ[CM*3;;T]/7S?*RF*W&=G
M$.T?O,2-RJ7'9!H 5O$!-[4!S\'X6>#]S4XV8'UF<?MN!V)@]:*_^ =02P,$
M%     @ ?7]D4Y:I$=XR P  J 8  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&ULC57;;N,V$/V5@0H4+:"-KKZEM@$GFZ(%NML@WNT^%'V@J9%%A")5
MDHJS?]\A)6NS0&+TP3))S9DS9S@S6I^T>;0-HH/G5BJ[B1KGNNLDL;S!EMDK
MW:&B-[4V+7.T-<?$=@99%4"M3/(TG2<M$RK:KL/9O=FN=>^D4'AOP/9MR\S7
M&Y3ZM(FRZ'SP((Z-\P?)=MVQ(^[1?>[N#>V2R4LE6E16: 4&ZTVTRZYO2F\?
M#/X2>+(OUN"5'+1^])O?JTV4^H!0(G?> Z._)[Q%*;TC"N/?T6<T47K@R_79
M^Z]!.VDY,(NW6GX1E6LVT3*""FO62_>@3[_AJ&?F_7$M;7C":;1-(^"]=;H=
MP11!*]3PSY['//P?0#X"\A#W0!2B?,\<VZZ-/H'QUN3-+X+4@*;@A/*7LG>&
MW@K"N>U^N S0->S%48E:<*8<[#C7O7)"'>%>2\$%6OCI$SM(M#^O$T?$'I[P
MD>1F(,G?(%G!!ZU<8^%.55A]CT\HX"GJ_!SU37[1X1Z[*RC2&/(TSR[X*Z8L
M%,%?\8:_U^3^O3M89ZAJ_KE 4$X$92 HWPJ8FJGJ)?H\[XBH$K+WY0A[Y+T1
MSA/>/7/94WZ@-KH%UR#<,LE[R4+Y$O"]!]'[C]2K?VAKH4,#^X89?.U*+@;D
M>_W:=HSC)J)FMFB>,-I^(LY:2VI4GPGGKQLL.DN'QC4A).IKZYBJO$&G'9(6
M)N57F 39;X)<PQPTC X/B KPK$^HX(I_KZX:U2E2)\_JK%='<,YZBQXE#&!=
M4TO#B5F@4A7OSM37E,S.87L@W+DV_".%/SM/0@%IZ'K#&^IBN-5M2\1[I_DC
M%/%L/H^710Y9O,K3>)'.X0LSAOQ?0)5QN4KC;+:"15PLBKB89?" 5#2">R&#
MT6<ER,>//RSS+/\%5JN,HC0^.SMRII[0..'3?$_#"(V98,O%(OQ&X[N+QGD\
M7Y;Q/%UX(>4R+BFDC%24>5PN9I#E\;(LXV)9PFNEG+R8'BV:8YB1%D)'#(-D
M.IW&\&Z8/M_,AQG^@9FCH$1+K F:7BUF$9AA+@X;I[LPBP[:T60+RX8^)6B\
M ;VO-=74N/$$T\=I^Q]02P,$%     @ ?7]D4SM UGT9!0  7 X  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&ULW5=M;]LV$/XK!ZT8&L#SB^PDMIL8
M<)P5#="L6=-T'X9]H*2S180B59*RZ_WZ':D7RUZ<IACZ91_BD.+=<W</CW?D
MQ4;I1Y,B6OB:"6DN@]3:?-KKF3C%C)FNRE'2RE+IC%F:ZE7/Y!I9XI4RT0O[
M_;->QK@,9A?^VYV>7:C""B[Q3H,ILHSI[14*M;D,!D']X2-?I=9]Z,TN<K;"
M>[0/^9VF6:]!27B&TG E0>/R,I@/IE<C)^\%/G/<F-887"214H]N<I-<!GWG
M$ J,K4-@]&^-"Q3" 9$;7RK,H#'I%-OC&OVMCYUBB9C!A1)_\,2FE\$X@ 27
MK!#VH]J\PRJ>4X<7*V'\+VPJV7X <6&LRBIE\B#CLOS/OE8\O$0AK!1"[W=I
MR'MYS2R;76BU >VD"<T-?*A>FYSCTFW*O=6TRDG/SMXRKN$S$P7"+3)3:"3&
MK8'7GU@DT)Q<]"Q9<;*]N$*\*A'#(X@3N%72I@9^E0DF^_H]\JYQ,:Q=O J?
M!;S'O O#?@?"?CAX!F_8A#ST>,-OAWS-32R4B]K G_/(6$U9\M<S-D:-C9&W
M,3KF,QV>I! (:@DV15BH+&=R^_-/XW!P_L; W!@DEIE,X#UG$1?<<O+!ILP"
MT\U>)%[B(\9J)?G?;FJAY;[+:K=::,WE"JZ8X086@AG#EYRD'V@'M+<_SW.M
M<LV917B/:Q2U8RVT=QPUTW&Z?6K/GPW758ZIR5F,EP&5!H-ZC<'L$\$OE:!C
M[YRS+I_ K[K\>HH4MB-%/$5*UB9%[Y&R=&&L=Z3HAI3(DQ+O2"D:4EB+%-$F
MI866UJ20=VZ9DM%B%A%"G9'>FVN,JZ\#_[4_A6,GB[Q]S279484A57,"OQ?*
MDF-WFL<4+JW-?:F"6Z8?'2%4>N$F(64>,W$L=>XYL;$D"6GA P6AX4/D-L+3
M?B/SPN[+/$CUK_5/RC8&INX8XY9JC7,"ED0;O()!V#D[[=/ ;UKX9F]4+98H
M7,:BH +@XHF92;W#?H!?"D[DEF5F</)"U/F:<>&==708TB?D-1KK69W" K7U
ML5E_Z!+,E>&VP2&00?]@ME Z5]HI)!A9,"YG2C)KN?/SSJ2E5DTI;S/4,:<H
M<Y83T_4ZN3H:GAU.?Z.,?.C>=V&EUJBE\W>'. SWQE[.:I\OV[9'X7EG,!DU
MLDT@Y>>2<O8L1? Z=%Q7&J]@,NR<C<<'5/<[XW%8PY6)MCMUWSYFKV XZ8Q'
MQ^"'P\XI!=E*VRF='$W9X/-]R263GE8NJ107I=NU_H9IS7P<PY,CJ7+J_TKO
MVQ7D^T(XCOP_/-+U 9QT)@>[U4Z+<O4_I,7+#/RPQ C'I]7OCTB.';IC\Z8N
M?-0P&,34XXATVATJ2L?KH))E1XKCLB<ZD[&B3B4-(45,4/P(_IIGNK X5'?=
MD<0-I];FY+?M_@I60>0ZV2H56PJ=])*]PI 7U."8,[3A-@6E^8H(%Y0GMBX_
MOC%JI!Y<WNTH?>EV2'FL5>9M)57=K;&ZOMS<M)J 296VOUC4V9YQ_EV1NRV>
M/YD/S2VB[.0ND@KZR6Y.FQGYD"OFZ99"+NVN 8XW[HY0>?T@<=,Z:<3H 7*V
MJP==F%M %J>4/M1?K(N(N@1720>8$,>N.:XD;%).:@?03UU'>ZT;/_6BE7_7
MT#5'%=*6E__F:_-TFI<OAIUX^>ZBDD3;[7A;DFJ_>WX:@"[?,N7$JMR_'R)E
MZ37BARD]_U [ 5I?*JIUU<09:!Z4LW\ 4$L#!!0    ( 'U_9%,K$L$AX@,
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M@(6X6Z 0Y1ON^&QB] Z,/TW>_$-(-5A3<$+YIBR<H;>"[-QLT=2U1*JRHY;
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MU@'SOJS=$X(715,UDLA8>O8:))YU'QO>WI;]1S>/<T;MI3U-^STX7:(8%/K
M\U%.ZX#U3Y(@.9H1Q.UUF(26RMLHUXZ+3ML-VWD[8[X?;R<U7<>UO[,25V2:
M7@ZIVZ:=?JW@=!TFSE([FE_A<4-_&-#X _1^I;4["!Z@^PLR^Q=02P,$%
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M*+@43!-0AUHDQ+>.78B"8:74I5EM*8A[-Z8*L^(,&"RAJ0!!MQXI5K+%W^X
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M^G:&A3'0W[><J\/ +-#?]Q8_ 5!+ P04    " !]?V13(5F)!J((   N0@
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MW^M!&@%BD&F(0;J(T:]F"""#Z)'13JC1J9M&RRY1S-&J$K+[1LB*O$%D'YJ
MMY-4Y0BFU)-6::-)NMJ1* K#'F. 4T3/*4-Q1@!61 \K2WE&5&8]UF<=37H%
M&@&L$1/]DTHIAVUH566D6-(AGGHM 882O7IZQ!GT#QHL/RE EMJ**0J I-.(
M*:J*J7X-2H&M5*^E.OPX0I=2*6FSE5D4H$FG@295H:G1I1282?7,[/*EL5*E
M0#-JJ[HH@(Q.H[JHBB>-4J4 **H'E.K"8=J5 D"HK0AS@0_N-"+,5458KW9U
M@3#N( DF?#A"S;I $-=6G;E !W>:>SJN*LLT:M:5;NKH":.Z\GV>L:_H?5Q\
M81R]W2FWY$Z_"-#A>K9.!#ZX^OLPEA*W';U?XC:7]<YF_6+-!22Y>B2I/O]C
MEW.V_.$[[#L_WQ3)0LB6)&L.7]?WK=MXE,U[U4GS;BG,$UH@;9L=[[<VQR<W
M77]E>]:VPR]U$0"*N:%M-(%3KE[HV$8S&I*P>( \;QKD>8/R3@^@YQG)JF?)
M5SQ5:M$H=-W'MU#59KH5X %1/3U13>\E U8]/59M[R:K='U, VV3TUD#?#T3
M>?>,R8JGZC[%#EV34SND6_E#9>&W!-J8S,B#:XUGJT4] +\WC1;U5"W:%S,@
MN#=4AW[KF(W(PCRXJ'BVXM>'*X$_S97 5Z\$/6'SX2K@#Y6^WSQLQ@F?#]<#
MWU9A^W I\*=1V+XQX'T O#]477_C: W++7T@OF^KYGWIH:J)FA\1,%6?]P4,
M".W_GZ7YN$36!^;[MJK=!\#Z)JI]1-14N:Z1QP% .M!#^C^/W*"\.0#@!]@R
M9@%@-M#?"K7,M-K1G\J;.YOU9PT!D#W0DUT-\6URG]6Z+^/H=[YF!?K]KF3%
MOCXCWV7;'3\-%-%EOP%@/=!OA3&("9 T,'D,-3XFZA.E'@@& .1@&B '*I C
MZO?&7=H<8R2;GR7S#50I?3K']APV5MP!T#?0T]<PZ0T P8$>P99);Z"26%G*
MNB:G^Y, U*&)FG[&I#?4R>S&#FV34SL S.%0)3Z<1F-2UQ!P']JJZA#8&TZC
MJL..^]:]#_5"(' X5%B/<_Z('#0$M(>V(CD$)H?3,#E4F:QY$A@"D\.A0GED
M (RSR5#: FDK<T-@;#B-S V[[DKW/CZ,@)[14)D[RN_#\L((H!C9JM4(\!69
MJ-7AKH]4_=G[S#$" $;3B\]Q^5T$5(QL=6D$\(J,MD<-][ZQ((T ?I$>?L_D
M^T$96@0HC&PW;T> KLAD^]+H;"!2=R(]ED+:)J>SEO9Y#]VJ),?G4Y9K8T-U
M21EVY WAUCO"'6E+N&/RO&UT* [#&S@:.]+&<&<:*![&-9J.M*7<,9*%SY*:
M';Y+=_;JVSPR0]K-[CQ+;0MVI WISJ3U+8?A=?L.N]KT;CS$CK3IW3$1F\^8
MHAV^4&^-VD9CC;3MWK&1JD_3:4R2AAUI([YC*U>Q(^V\=Z81K(=Q35:67*2#
M;?2JF?/'E!&=U/[8:E8L5^X\4;HSOI3('-!RS0^VD:V&_C<O1I(KB+"M6,5R
M_<\3!4#CW6ZL5[%<-H1M%*N1VP>6-,EU2-A6L&*YCNB)0J+QGC=6HEBN/,+3
M:M%Q.1J6ZIDPL9:I4C42?J(<:;3[B;D^E0J9,!FZVWZP^P>E:5@JC,+$N@!2
MJF?"1@5-X_.#=GA?IW:U;9J9SZ5:_NJ7%(3?[H7,1"E;B3[.6?6 J&A^FZ Y
MX/FV+N^_RSG/-_7+-8N7K*@:B,]7><X/!]4O!AQ_(N+R7U!+ P04    " !]
M?V13W(@S21@$  !,$P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R]
MF%V/VC@4AO^*%?6BE3HDMB% !4@SC-H=J5N-RD[W8K47!@Y#-$F<M0VT^^MK
MATS,-+$+&L0-Q(G/>?WQYHGMT8Z+)[D&4.A[EN9R'*R5*CZ$H5RL(6.RPPO(
M]9,5%QE3NB@>0UD(8,LR*$M#$D5QF+$D#R:C\MZ]F(SX1J5)#O<"R4V6,?'C
M!E*^&P<X>+[Q-7E<*W,CG(P*]@@S4 _%O="EL,ZR3#+(9<)S)& U#J[QAQL:
MFX"RQK<$=O+@&IFNS#E_,H6[Y3B(3(L@A84R*9C^V\(4TM1DTNWXKTH:U)HF
M\/#Z.?O'LO.Z,W,F8<K3OY.E6H^#08"6L&*;5'WENS^@ZE#/Y%OP5):_:%?5
MC0*TV$C%LRI8MR!+\OT_^UX-Q$$ P8X 4@60LMU[H;*5MTRQR4CP'1*FMLYF
M+LJNEM&Z<4EN9F6FA'Z:Z#@UF6V*(@4]S$K/";IA*<L7@&:E(>[R_:R;T;O2
MI2U(96I*=+UE2<KF*5SI&E>2I8#>WH+2-^4[] 8E.?IKS3>2Y4LY"I5NIA$+
M%U63;O9-(JXF0=%!-'J/2$3PP^P6O7WS[F664'>R[BFI>TK*M-21]A;F"LU@
ML1&)2D"^;^O$/Y]U$+I3D,E_/9*TEJ2E9-<A>9UQH9+_88FF7*JVD=C'QV6\
M>8&V$TRB01R/PFV+;K?6[7IU/PDN)7K(]6N:EO*?].O9.A/[/+T#?=)KU^[5
MVKW3M#_K,K2*]QKB5\-V\;@6C[WB'UDBT)],/&GW?F/I!MIDXX:L&?,!:9?N
MU])]K_04]%2OD@53@/A*@Z'@,E$>$PWJQ(-+^7982PY?Z=MATS=QY)@\'%D6
M16?R;97HQ20ZU ](B,_EW"K3H7SDD+=XPN3UWJURO!QX[-*VG,)^4$VY*+@P
MUET:M\G:;1XS84LCW+V4@['%$/9SZ/<>QDW^]/O#R.4CRR#LA] )+FY!D0._
MV'((^T%TBHW[30([/CW8X@H/SN#C0=O8.XULP87]Y)KR+ .Q2%B*"E: \*T;
M+)9(="G_$DLCXJ?1[_U+FA#"I$N[[6-(#M9)?A =[U_2I)%+W:*(^%%T@GVK
M3"_LZ_B*$PLKXE\['65?TEPWF:%WO#O$0HOXH?5%K[0?.K,.>N1;$+E9;/O,
M9)%$XHLYV(*(^$%TA(.;_.E3UPQ: !$_@$[P;Y-"#@(12R#B)] I_FVNHASR
MU+**^I=01]F7-E=/SG&GEEC43ZS2N$KW6V[T5O*H-02U4**7V[T=;-]>O7]K
M(HCT\= UC99"]%P[.-I$D6,)02V&Z-GV<+1E$^=805&+*WJ&;5R5(_YEZ'_]
M (4'9R/FG$FG?=1#B5)8Z;BHT]=-%_NCFWU!\:(\+IESI7A67JZ!+4&8"OKY
MBG/U7# G,/4!VN0G4$L#!!0    ( 'U_9%.='B8."@,  )T*   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;+U6;6_:,!#^*U963:W4-F\00@=(*UVU
M2IN$RKI]-LE!K#IQ:CO0[M?/=D*@$-)VJOH%;.>>N^<>7RXW6#%^+Q( B1Y3
MFHFAE4B97]BVB!)(L3AG.63JR9SQ%$NUY0M;Y!QP;$ IM3W'">P4D\P:#<S9
MA(\&K)"49##A2!1IBOG3)5"V&EJNM3ZX)8M$Z@-[-,CQ J8@[_()5SN[]A*3
M%#)!6(8XS(?65_=B['8TP%C\)K 26VND4YDQ=J\W-_'0<C0CH!!)[0*KOR6,
M@5+M2?%XJ)Q:=4P-W%ZOO5^;Y%4R,RQ@S.@?$LMD:(46BF&."RIOV>H[5 EU
MM;^(46%^T:JR=2P4%4*RM (K!BG)RG_\6 FQ!5")-@.\"N"]%N!7 -\D6C(S
M:5UAB4<#SE:(:VOE32^,-@:MLB&9OL:IY.HI43@YFA9Y3D'=BU27B"XQQ5D$
M:&HJZ"8KRT3+?88F7-4.ET\(9S'Z]E"07*/0\15(3*@X429WTRMT?'2"CA#)
MT*^$%4+9BH$M%5$=SHXJ4I<E*>\0*<C/D>^<(L_QW ;XN!U^!9&"NP;N/(?;
M2IY:(Z_6R#/^_ /^UIF?(JC3UB+$H-Z<B)0"Z0.<,B[)7W/0$M>OX_HF;N>%
MN,9W'?H4+3@3C:J6[@+C3K^_RY'?<[V!O=S6KL$H\,+:Z!G33LVTT\KT!PCQ
M^5/HN=X7'$5%6E LX4T"E0F44;I;W,Y\W^OO9-!DY3B=YA2Z=0K=_Q([ ]G$
MM+O'P0_]'9[[-H%W@&50LPQ:65X7/".RX&!HLOF<J+>U9MM2<[TZ0.]#:SVL
MXX;O6^OAGKAA$.Q<P+Y-KW^@TOLUS_X+E:Z^&0FC,2)ISMG2M$[1(H#K;#JQ
M\Z'2NUO? /=]Q:_\;2OK]H/=3O.2U7.VFV[L>NU7@&>,8\G4]^HUE>]NVJWK
M?^P%;-JGV]X_WWX!G;TN'H:=7?T;C(+=^K>W9@<]N/W$?$$R@2C,%<HY[ZGK
MX^4L5&XDR\TX,6-2#2=FF:CY$;@V4,_GC,GU1D\H]40Z^@=02P,$%     @
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M;:IIE;:U:MKU8MJ% R?!JK&9;9+VW\\VE*4)0>INP(;SOCSG8',8;[AXE#F
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M+VA1][9ZHGAIV\."*]UL[##7OP,@3("^O^1<O4Q,QVE_,*9_ 5!+ P04
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M%M)@,W7+' <J*&N ]YF49K.Q#IH1'?\%4$L#!!0    ( 'U_9%/_DM<LK@,
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MN,%?+->)LE8"_F7 IQ9KQ:/7A*<Q%?(WM/I9,O6.;I$YOM41B-&29Y"6DIC
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MUCPG))A1YJH:6YK3YLGRU0SJG?,'?+_$/>>A?N*8*?HHOGH??2-BR\ A*=V
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M-B3X_9TQ> K"A>I_!_E?4$L#!!0    ( 'U_9%/N^MX-U@,  $H-   9
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MLP-";\#UA'/U/-$&ZM^G\;]02P,$%     @ ?7]D4RH_M[ K P  &!,   T
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M!W?=##JKX2FX5+J.[2*XO]/F\3U@/0.!7(A68(\XPWA84F.8EK=V4C]<&U]
M03-^6)568:[IJMOKDXU#?;-!IDJG3+=ANF1M&@\%RT".YOD<[D:5(8#&J,(.
M4DYS)6FM8>W1#"SMC EQ#Z_=CVR'>YEMU;4#597MT IJAH[&38!_F\UQ;]/V
M7L4;E/Q)F<\+FXZLY] M[$ZSC"_K^3)K!6#L79R=EJ58?1(\EP5SR1\=<#RD
M:[]@KC1_MM&@56;6P#0)GI@V?+9M^:5I^<"69MU.RPS7W#M#S7]WG7,FF:9B
M6[3M_5->Y5<KCJ[_E>3ZO\J^8*_&9B\]=9']<Q 9GX/(,^C)*#E]C<VIZ>1$
MALW^O75(V#DBM-8 CF(C\AT.?F(3-)@NN#!<-K,Y3U,F7YP4++VA4WOLW^&W
MSZ<LHPMA'EIP1#;C;RSEBR)IG[J#A6B>VHR_0GK=N#T'VEA<IFS)TDDSU?FT
M'@9V8*,V%SCL([?UY4<P'X?Y$<"P.)@"S,=Y87'^IWP&:#X.P[0-O,@ ]1F@
M/L[+ATSJ#Q;'[Y/8RY]IDD11'&,K.IEX%4RP=8MC^/K9,&W@@<6!2'^VUGBU
M\0XYW =830]U")8IWHE8IOA: ^)?-_!($G^UL3C@@54!ZQV([X\#/>7WB2*H
M*J8->X-Q)$DP!'K1WZ-QC*Q.#!]_?;"W)(J2Q(\ YE<011@";R..8 I  X9$
M4;T/[NU'X7J?"C>_A8U_ U!+ P04    " !]?V13EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( 'U_9%.#$6T;#@0
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M) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M
M(:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$
M(6N"0M8$A:P)"ED3%+(F_TG6=ZU7?_UWI5WC6I7-T9]UO[#FGU!+ 0(4 Q0
M   ( 'U_9%,'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ ?7]D4RG@HJSO    *P(  !$
M     ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ?7]D4YE<
MG",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX
M;6Q02P$"% ,4    " !]?V13"!O!)Q8%  "\%   &               @($.
M"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ?7]D4Q (
ME';P!0  :1<  !@              ("!6@T  'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;%!+ 0(4 Q0    ( 'U_9%,?_3)XG@(  (P'   8
M  " @8 3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !]
M?V13/M\QQC$&   4&@  &               @(%4%@  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ ?7]D4SIM0F@!!   M@X  !@
M         ("!NQP  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( 'U_9%-S21-HZ@P  /53   8              " @?(@  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !]?V13!)&[3G "   I!0
M&               @($2+@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ ?7]D4]:ZG>WR!P  :R(  !@              ("!N#   'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( 'U_9%/ZK&W4M0(
M .H&   8              " @> X  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " !]?V13OIMS*PX'   J$0  &0              @('+
M.P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( 'U_9%,.
MC_I1#@D  -46   9              " @1!#  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ ?7]D4]W*<W3I!   Q0T  !D
M     ("!54P  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'U_9%.'Q+?NPP4   <-   9              "
M@=IJ  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ ?7]D
M4_H\5KZ  @  K 4  !D              ("!U'   'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " !]?V13% &JR^,"   Y!@  &0
M        @(&+<P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( 'U_9%-[VD?S2 8  -T/   9              " @:5V  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ ?7]D4Y:I$=XR P  J 8
M !D              ("!)'T  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " !]?V13.T#6?1D%  !<#@  &0              @(&-@
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( 'U_9%,K$L$A
MX@,  (X(   9              " @=V%  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ ?7]D4W]"[_.\!   5@P  !D
M ("!]HD  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !]
M?V13ZAKP?^\#  #L"0  &0              @('IC@  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( 'U_9%/W&C4"C 8  $,2   9
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M970S,"YX;6Q02P$"% ,4    " !]?V13G1XF#@H#  "="@  &0
M    @($$K0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M 'U_9%.YD7$;0 ,  #H*   9              " @46P  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ ?7]D4W&H<7"^ @  8P@  !D
M             ("!O+,  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " !]?V138<_:[MT"  !L"   &0              @(&QM@  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( 'U_9%.08JUKN0(
M *X'   9              " @<6Y  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ ?7]D4_^2URRN P  A \  !D              ("!
MM;P  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !]?V13
M*(47.HD%  !"&@  &0              @(&:P   >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( 'U_9%.":!<QZ@,   0.   9
M      " @5K&  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ ?7]D4Q2E\NY#!@  GQL  !D              ("!>\H  'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !]?V136K'N UL#  #D"@
M&0              @('UT   >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( 'U_9%-LA4M;2P,  '\*   9              " @8?4  !X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ ?7]D4_-BVRRJ
M P  K!$  !D              ("!"=@  'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " !]?V1399LMI?$!   :!   &0
M@('JVP  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( 'U_
M9%/N^MX-U@,  $H-   9              " @1+>  !X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ ?7]D4RH_M[ K P  &!,   T
M         ( !'^(  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !]?V13EXJ[
M',     3 @  "P              @ %UY0  7W)E;',O+G)E;'-02P$"% ,4
M    " !]?V13@Q%M&PX$  "^'0  #P              @ %>Y@  >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ ?7]D4T<<8+FD 0  FQH  !H
M     ( !F>H  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ ?7]D4R[2^,"N 0  RAH  !,              ( !=>P  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     #0 -  C#@  5.X

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>216</ContextCount>
  <ElementCount>326</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1008009 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Supplementary Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation</Role>
      <ShortName>Supplementary Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Derivative Financial Instruments - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants</Role>
      <ShortName>Derivative Financial Instruments - Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131108 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2135110 - Disclosure - COVID-19</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/COVID19</Role>
      <ShortName>COVID-19</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2311303 - Disclosure - Supplementary Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables</Role>
      <ShortName>Supplementary Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Derivative Financial Instruments - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables</Role>
      <ShortName>Derivative Financial Instruments - Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2325306 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/StockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Investments Available-for-sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Derivative Financial Instruments - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails</Role>
      <ShortName>Derivative Financial Instruments - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Stockholders' Equity - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Stockholders' Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/CommitmentsandContingencies</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="crdf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/RelatedPartyTransactions</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="crdf-20210930.htm">crdf-20210930.htm</File>
    <File>crdf-093021exhibit311.htm</File>
    <File>crdf-093021exhibit312.htm</File>
    <File>crdf-093021exhibit321.htm</File>
    <File>crdf-093021exhibit322.htm</File>
    <File>crdf-20210930.xsd</File>
    <File>crdf-20210930_cal.xml</File>
    <File>crdf-20210930_def.xml</File>
    <File>crdf-20210930_lab.xml</File>
    <File>crdf-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>61
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "crdf-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 216,
   "dts": {
    "calculationLink": {
     "local": [
      "crdf-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "crdf-20210930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "crdf-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "crdf-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crdf-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "crdf-20210930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 406,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 43,
   "keyStandard": 283,
   "memberCustom": 11,
   "memberStandard": 30,
   "nsprefix": "crdf",
   "nsuri": "http://www.cardiffoncology.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cardiffoncology.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Fair Value Measurements",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Supplementary Balance Sheet Information",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation",
     "shortName": "Supplementary Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Leases",
     "role": "http://www.cardiffoncology.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Derivative Financial Instruments - Warrants",
     "role": "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants",
     "shortName": "Derivative Financial Instruments - Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Stockholders' Equity",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131108 - Disclosure - Commitments and Contingencies",
     "role": "http://www.cardiffoncology.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - Related Party Transactions",
     "role": "http://www.cardiffoncology.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135110 - Disclosure - COVID-19",
     "role": "http://www.cardiffoncology.com/role/COVID19",
     "shortName": "COVID-19",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED BALANCE SHEETS",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311303 - Disclosure - Supplementary Balance Sheet Information (Tables)",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables",
     "shortName": "Supplementary Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Leases (Tables)",
     "role": "http://www.cardiffoncology.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i2c7f42dfef2c4958ba29b2e28bb9b35d_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Derivative Financial Instruments - Warrants (Tables)",
     "role": "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables",
     "shortName": "Derivative Financial Instruments - Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i2c7f42dfef2c4958ba29b2e28bb9b35d_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325306 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Basis of Presentation (Details)",
     "role": "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities (Details)",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Fair Value of Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "ie508430c486f4b33b819c76634f5166c_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale (Details)",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails",
     "shortName": "Supplementary Balance Sheet Information - Investments Available-for-sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails",
     "shortName": "Supplementary Balance Sheet Information - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "crdf:LessorNumberOfSubleases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "crdf:LessorNumberOfSubleases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i0dc4846745a44e46a049be06bcf71582_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i0dc4846745a44e46a049be06bcf71582_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "crdf:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "crdf:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i0dc4846745a44e46a049be06bcf71582_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Leases - Supplemental Cash Flow Information (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails",
     "shortName": "Leases - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i0dc4846745a44e46a049be06bcf71582_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Leases - Future Minimum Lease Payments (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i8176bd16da194dae836e30659930f9a9_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Derivative Financial Instruments - Warrants (Details)",
     "role": "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
     "shortName": "Derivative Financial Instruments - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i81c4317e30404c12b737872399063ecb_I20201231",
      "decimals": "2",
      "lang": "en-US",
      "name": "crdf:EstimatedFairValueOfWarrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i0dc4846745a44e46a049be06bcf71582_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i0dc4846745a44e46a049be06bcf71582_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
     "shortName": "Stockholders' Equity - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i0ffabb17df04402db39c47e6b173b15b_D20210101-20210930",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i0dc4846745a44e46a049be06bcf71582_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i0dc4846745a44e46a049be06bcf71582_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i6cf797ce4852460992cc81f91f71ee21_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Stockholders' Equity - Restricted Stock Units (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails",
     "shortName": "Stockholders' Equity - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i6cf797ce4852460992cc81f91f71ee21_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Stockholders' Equity - Warrants (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails",
     "shortName": "Stockholders' Equity - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "crdf:ClassOfWarrantOrRightNumberExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5536a0b2fc2740479fff4987362a1f5e_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Stockholders' Equity - Preferred Stock (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
     "shortName": "Stockholders' Equity - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i7086b0baa05e4031aa8f4f411b551b42_I20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i6585aa9e614148a98914993084f4d834_I20170331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i6585aa9e614148a98914993084f4d834_I20170331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "ide58ed83af2b4d2ebaccb755576f716c_D20200501-20200531",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i0dc4846745a44e46a049be06bcf71582_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i0dc4846745a44e46a049be06bcf71582_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "ib94e5739ad98459497e72c9a6bc0ad84_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "ic0199d9546ff4b8b895eea651dea4467_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "crdf:CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "ia7185a76f9f745d6bcb925948e49ec36_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "crdf:CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i5cc1d42f01aa47548e5fee9780827616_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i41602febb1074927adedec6da8eb37fe_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008009 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20210930.htm",
      "contextRef": "i41602febb1074927adedec6da8eb37fe_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 45,
   "tag": {
    "crdf_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock",
        "label": "Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock",
        "terseLabel": "Deemed dividend"
       }
      }
     },
     "localname": "BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_BlackScholesOptionPricingMethodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Black-Scholes option pricing method which is used for valuation of derivative instruments.",
        "label": "Black Scholes Option Pricing Method [Member]",
        "terseLabel": "Black Scholes Option Pricing Method"
       }
      }
     },
     "localname": "BlackScholesOptionPricingMethodMember",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ClassOfWarrantOrRightNumberExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants or rights exercised during the period.",
        "label": "Class of Warrant or Right Number Exercised",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberExercised",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period over which each class of warrants or rights outstanding may be exercised.",
        "label": "Class of Warrant or Right Term of Outstanding Warrants or Rights",
        "terseLabel": "Weighted-Average Remaining\u00a0Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right Term of Warrants or Rights [Abstract]",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average exercise price of each class of warrants or rights outstanding.",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights",
        "periodEndLabel": "Weighted average exercise price of warrants at the end of the period (in USD per share)",
        "periodStartLabel": "Weighted average exercise price of warrants at the beginning of the period (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average exercise price of each class of warrants or rights exercised during the period.",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Exercised",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment",
        "label": "Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment",
        "terseLabel": "Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment"
       }
      }
     },
     "localname": "Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comprehensive Income (Loss) Available To Common Stockholders, Basic",
        "label": "Comprehensive Income (Loss) Available To Common Stockholders, Basic",
        "totalLabel": "Comprehensive loss attributable to common stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Issuance Of Common Stock, Preferred Stock And Warrants For Clinical Trial Funding Commitment",
        "label": "Cost Of Issuance Of Common Stock, Preferred Stock And Warrants For Clinical Trial Funding Commitment",
        "terseLabel": "Cost of issuance of common stock, preferred stock and warrants"
       }
      }
     },
     "localname": "CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      },
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance",
        "label": "Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock",
        "negatedTerseLabel": "Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance",
        "terseLabel": "Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance"
       }
      }
     },
     "localname": "DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DerivativeFinancialInstrumentsLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments Liability [Roll Forward]",
        "terseLabel": "Changes in the Company's derivative financial instruments liability balance"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilityRollForward",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount Of Issuance Of Common Stock, Preferred Stock And Warrants For Clinical Trial Funding Commitment",
        "label": "Discount Of Issuance Of Common Stock, Preferred Stock And Warrants For Clinical Trial Funding Commitment",
        "terseLabel": "Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment"
       }
      }
     },
     "localname": "DiscountOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_EquityIncentivePlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2021",
        "label": "Equity Incentive Plan 2021 [Member]",
        "terseLabel": "Equity Incentive Plan 2021"
       }
      }
     },
     "localname": "EquityIncentivePlan2021Member",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_EstimatedFairValueOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the estimated fair value of warrant.",
        "label": "Estimated Fair Value of Warrant",
        "terseLabel": "Estimated fair value of Cardiff Oncology common stock (in dollars per share)"
       }
      }
     },
     "localname": "EstimatedFairValueOfWarrant",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to furniture and office equipment.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Liability",
        "label": "Increase (Decrease) In Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_InducementGrantStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Grant Stock Options",
        "label": "Inducement Grant Stock Options [Member]",
        "terseLabel": "Inducement Grant Stock Options"
       }
      }
     },
     "localname": "InducementGrantStockOptionsMember",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Annual Rent Increase, Percentage",
        "label": "Lessee, Operating Lease, Annual Rent Increase, Percentage",
        "terseLabel": "Annual rent increase, percentage"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualRentIncreasePercentage",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "crdf_LesseeOperatingLeaseAreaOfLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area Of Lease",
        "label": "Lessee, Operating Lease, Area Of Lease",
        "terseLabel": "Area of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaOfLease",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "crdf_LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area Of Lease Occupied By Company",
        "label": "Lessee, Operating Lease, Area Of Lease Occupied By Company",
        "terseLabel": "Area of lease occupied by company"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "crdf_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Area Of Lease",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Area Of Lease",
        "terseLabel": "Lease not yet commenced, area"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAreaOfLease",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 6.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due After Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due After Year Four",
        "totalLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Four",
        "totalLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year One",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year One",
        "totalLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three",
        "totalLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two",
        "totalLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Remainder Of Fiscal Year",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Remainder Of Fiscal Year",
        "totalLabel": "2021 (excluding the nine months ended September 31, 2021)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Net Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseMonthlyRentPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Monthly Rent Payment",
        "label": "Lessee, Operating Lease, Monthly Rent Payment",
        "terseLabel": "Monthly rent payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyRentPayment",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LessorAreaOfSublease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Area Of Sublease",
        "label": "Lessor, Area Of Sublease",
        "terseLabel": "Area of sublease"
       }
      }
     },
     "localname": "LessorAreaOfSublease",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "crdf_LessorNumberOfSubleases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Number Of Subleases",
        "label": "Lessor, Number Of Subleases",
        "terseLabel": "Number of subleases"
       }
      }
     },
     "localname": "LessorNumberOfSubleases",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "crdf_LessorOperatingLeasePaymentToBeReceivedAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Operating Lease, Payment To Be Received, After Year Four",
        "label": "Lessor, Operating Lease, Payment To Be Received, After Year Four",
        "negatedTerseLabel": "Thereafter"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentToBeReceivedAfterYearFour",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_NorvianoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nerviano [Member]",
        "label": "Norviano [Member]",
        "terseLabel": "Nerviano"
       }
      }
     },
     "localname": "NorvianoMember",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_PreferredStockDividendAccrued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of preferred stock dividend accrued during the reporting period.",
        "label": "Preferred Stock Dividend Accrued",
        "terseLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockDividendAccrued",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ReleaseOfClinicalTrialFundingCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Release Of Clinical Trial Funding Commitment",
        "label": "Release Of Clinical Trial Funding Commitment",
        "terseLabel": "Release of clinical trial funding commitment"
       }
      }
     },
     "localname": "ReleaseOfClinicalTrialFundingCommitment",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ReleaseOfClinicalTrialFundingCommitmentForServicesReceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Release Of Clinical Trial Funding Commitment For Services Received",
        "label": "Release Of Clinical Trial Funding Commitment For Services Received",
        "terseLabel": "Release of clinical trial funding commitment"
       }
      }
     },
     "localname": "ReleaseOfClinicalTrialFundingCommitmentForServicesReceived",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_SaleOfStockCommonAndWarrantsNetShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Common And Warrants, Net, Shares",
        "label": "Sale Of Stock, Common And Warrants, Net, Shares",
        "negatedLabel": "Sale of common stock and warrants (in shares)"
       }
      }
     },
     "localname": "SaleOfStockCommonAndWarrantsNetShares",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_SaleOfStockValueCommonAndWarrantsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Value, Common And Warrants, Net",
        "label": "Sale Of Stock, Value, Common And Warrants, Net",
        "negatedLabel": "Sale of common stock and warrants"
       }
      }
     },
     "localname": "SaleOfStockValueCommonAndWarrantsNet",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of a concept from the beginning of a period to the end of the period.",
        "label": "Schedule of Components of Changes in Derivative Financial Liability [Table Text Block]",
        "terseLabel": "Schedule of Components of Changes in the Company\u2019s Derivative Financial Instruments Liability Balance"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "crdf_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Convertible Preferred Stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Convertible Preferred Stock",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares at the owner's option.",
        "label": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesDConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D Convertible Preferred Stock",
        "label": "Series D Convertible Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesEConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series E Convertible Preferred Stock",
        "label": "Series E Convertible Preferred Stock [Member]",
        "terseLabel": "Series\u00a0E Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesEConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ServiceReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants",
        "label": "Service Receivable",
        "negatedTerseLabel": "Service receivables"
       }
      }
     },
     "localname": "ServiceReceivable",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ServiceReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Receivable",
        "label": "Service Receivable [Member]",
        "terseLabel": "Service Receivable"
       }
      }
     },
     "localname": "ServiceReceivableMember",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expired in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Restricted Stock Units Released",
        "label": "Stock Issued During Period Restricted Stock Units Released",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodRestrictedStockUnitsReleased",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares issued during the period upon cash exercise of warrants.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity impact during the period due to the cash exercise of warrants.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_WarrantsAndRightsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights [Roll Forward]",
        "terseLabel": "Number of Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsRollForward",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_WarrantsFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Fair Value",
        "label": "Warrants, Fair Value",
        "terseLabel": "Warrants, fair value"
       }
      }
     },
     "localname": "WarrantsFairValue",
     "nsuri": "http://www.cardiffoncology.com/20210930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r38",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r173",
      "r201",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r16",
      "r137",
      "r138"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable and unbilled receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premiums on short-term investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r25",
      "r165"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less\u2014accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r42",
      "r43",
      "r44",
      "r369",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r41",
      "r44",
      "r45",
      "r87",
      "r88",
      "r89",
      "r246",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r236"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r202",
      "r204",
      "r239",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r204",
      "r229",
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r82",
      "r122",
      "r125",
      "r131",
      "r150",
      "r244",
      "r247",
      "r273",
      "r353",
      "r368"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r36",
      "r82",
      "r150",
      "r244",
      "r247",
      "r273"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r142",
      "r157"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r140",
      "r143",
      "r157",
      "r357"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Total available for sale investments",
        "verboseLabel": "Fair Market Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r205",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r23",
      "r76"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total included in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r70",
      "r76",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents\u2014End of period",
        "periodStartLabel": "Cash and cash equivalents\u2014Beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r70",
      "r274"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r80",
      "r82",
      "r103",
      "r104",
      "r105",
      "r108",
      "r110",
      "r116",
      "r117",
      "r118",
      "r150",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Balance of warrants outstanding at the end of the period (in shares)",
        "periodStartLabel": "Balance of warrants outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r32",
      "r172",
      "r358",
      "r373"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value, 150,000 shares authorized; 39,552 and 36,781 shares issued and outstanding at September 30, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r56",
      "r361",
      "r376"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r192",
      "r200",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Investments Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r74",
      "r121"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r255",
      "r256",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments - Warrants"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "periodEndLabel": "Balance of derivative financial instruments liability at the end of the period",
        "periodStartLabel": "Balance of derivative financial instruments liability at the beginning of the period",
        "terseLabel": "Derivative financial instruments - warrants",
        "verboseLabel": "Derivative financial instruments\u2014warrants"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r187",
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock",
        "negatedTerseLabel": "Preferred stock dividend"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r57",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r100",
      "r103",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r362",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r57",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r103",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r362",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average remaining vesting period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails",
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r115",
      "r151",
      "r180",
      "r187",
      "r233",
      "r234",
      "r235",
      "r242",
      "r243",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r379",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtraordinaryAndUnusualItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unusual or Infrequent Items, or Both [Abstract]",
        "terseLabel": "Unusual or Infrequent Items, or Both [Abstract]"
       }
      }
     },
     "localname": "ExtraordinaryAndUnusualItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine the Fair Value of the Warrants"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r265",
      "r313",
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r264",
      "r265",
      "r268",
      "r269",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r192",
      "r193",
      "r198",
      "r200",
      "r265",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0Prices in\u00a0Active Markets\u00a0for Identical\u00a0Assets and\u00a0Liabilities (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r192",
      "r193",
      "r198",
      "r200",
      "r265",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r265",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsQuantitativeInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]",
        "terseLabel": "Range of assumptions used to determine the fair value of warrants"
       }
      }
     },
     "localname": "FairValueInputsQuantitativeInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of the Company\u2019s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r313",
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r192",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Non U.S. government"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Loss on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r71",
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable and unbilled receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r149",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment Securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r295",
      "r297"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Net operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Expense and Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (excluding the nine months ended September 31, 2021)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Sublease Income"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "negatedTotalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Four",
        "negatedTerseLabel": "2025"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "negatedTerseLabel": "2022"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year",
        "negatedTerseLabel": "2021 (excluding the nine months ended September 31, 2021)"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "negatedTerseLabel": "2024"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "negatedTerseLabel": "2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r82",
      "r126",
      "r150",
      "r245",
      "r247",
      "r248",
      "r273"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r82",
      "r150",
      "r273",
      "r354",
      "r371"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r82",
      "r150",
      "r245",
      "r247",
      "r248",
      "r273"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected warrant term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected volatility of Cardiff Oncology common stock"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r70",
      "r72",
      "r75"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r46",
      "r49",
      "r54",
      "r75",
      "r82",
      "r90",
      "r92",
      "r93",
      "r94",
      "r95",
      "r98",
      "r99",
      "r106",
      "r122",
      "r124",
      "r127",
      "r130",
      "r132",
      "r150",
      "r273",
      "r359",
      "r374"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r100",
      "r101",
      "r107",
      "r110",
      "r122",
      "r124",
      "r127",
      "r130",
      "r132"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r122",
      "r124",
      "r127",
      "r130",
      "r132"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r289",
      "r297"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment loss"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r287",
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r294",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate\u2013operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r293",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term\u2013operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "auth_ref": [
      "r282",
      "r283",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessor's operating leases.",
        "label": "Lessor, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAffiliatesMember": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A category that identifies other affiliates.",
        "label": "Other Affiliates [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "OtherAffiliatesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r39",
      "r40",
      "r42"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain on securities available-for-sale"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r47",
      "r50",
      "r52",
      "r55",
      "r180",
      "r275",
      "r280",
      "r281",
      "r360",
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r29"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r62",
      "r64",
      "r141"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r205",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      },
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "crdf_ComprehensiveIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "negatedLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock",
        "negatedTerseLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "terseLabel": "Liquidation preference"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "verboseLabel": "Shares designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, 20,000 shares authorized; (Note 7)"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r162",
      "r163"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sales of common stock, preferred stock and warrants, net of expenses of $776 and $634, respectively"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Borrowings under note payable"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r62",
      "r63",
      "r141"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r68",
      "r69",
      "r85"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Costs related to the clinical trial funding commitment"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r62",
      "r63",
      "r141"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Sales of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r66",
      "r232"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r25",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Supplementary Balance Sheet Information"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r24",
      "r164"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, equipment and depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r166",
      "r372"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Components of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Other commitment"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r199",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r199",
      "r303",
      "r306",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r301",
      "r302",
      "r304",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r241",
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails",
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r187",
      "r236",
      "r370",
      "r382",
      "r384"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r151",
      "r233",
      "r234",
      "r235",
      "r242",
      "r243",
      "r379",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r119",
      "r120",
      "r123",
      "r128",
      "r129",
      "r133",
      "r134",
      "r135",
      "r190",
      "r191",
      "r340"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r53",
      "r82",
      "r119",
      "r120",
      "r123",
      "r128",
      "r129",
      "r133",
      "r134",
      "r135",
      "r150",
      "r273",
      "r363"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r292",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r204",
      "r228",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r204",
      "r228",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r25",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r83",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r205",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r209",
      "r218",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Summary of Stock Option Activity and of Changes in Stock Options Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions to Estimate Fair Value of Stock Option Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r33",
      "r80",
      "r116",
      "r117",
      "r176",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Preferred Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r188",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Warrant Activity and Changes in Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series\u00a0A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.",
        "label": "Share-based Payment Arrangement, Accelerated Cost",
        "terseLabel": "Accelerated compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Total Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested, weighted average grant date fair value at end of period (in USD per share)",
        "periodStartLabel": "Nonvested, weighted average grant date fair value at end of period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value Per\u00a0Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Equity instruments other than options, vested in period, fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, weighted average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r210",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Non-vested at end of period (in shares)",
        "periodStartLabel": "Non-vested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Authorized shares under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of remaining shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at the end of the period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled / Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r211",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance outstanding at the end of the period (in shares)",
        "periodStartLabel": "Balance outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance outstanding at the end of the period (in USD per share)",
        "periodStartLabel": "Balance outstanding at the beginning of the period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest at March 31, 2021, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at June 30, 2021 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at June 30, 2021 (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r203",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled / Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Equity instruments other than options, aggregate intrinsic value, nonvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r223",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at the end of the period, intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Options vested, fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance, ending (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r12",
      "r355",
      "r356",
      "r367"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r80",
      "r82",
      "r103",
      "r104",
      "r105",
      "r108",
      "r110",
      "r116",
      "r117",
      "r118",
      "r150",
      "r180",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r35",
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r115",
      "r151",
      "r180",
      "r187",
      "r233",
      "r234",
      "r235",
      "r242",
      "r243",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r379",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r115",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r34",
      "r180",
      "r181",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r180",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of common stock, net of expenses (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r180",
      "r187",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r180",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of common stock, net of expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of common stock, preferred stock and warrants for clinical trial funding commitment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r180",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r20",
      "r21",
      "r82",
      "r139",
      "r150",
      "r273"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r187",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r290",
      "r297"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Operating sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosure of cash flow activity:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r192",
      "r200",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "negatedLabel": "Change in fair value of derivative financial instruments\u2014warrants",
        "terseLabel": "Gain (loss) from change in fair value of derivative financial instruments\u2014warrants",
        "verboseLabel": "Change in fair value of derivative financial instruments\u2014warrants during the period recognized as a gain in the condensed statements of operations"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Items, or Both, Disclosure [Text Block]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/COVID19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase Common Stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expected warrant term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r102",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r100",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "Note 1",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "Note 3",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121593497&loc=SL77918431-209957"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919396-209981"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888252"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(1)(a)(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611322-123010"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r391": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r392": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r393": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r394": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r395": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/subtopic&trid=114868817"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>62
<FILENAME>0001628280-21-021747-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-021747-xbrl.zip
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MQ_N#]BJ5/P3[SEEP _.[Y\^=H8_A,I6"$,VMSCF5#&XQ&H@ $\QI]U5!#H-
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M%7(,<:XX,]0Y%=-J!0G3=!N;ABFB +4/2^*B;\8K[/[QBIC13@DL$(G!6HS
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MI9)9SX5<(25:>#/DF;DDAX+@!IB?D,P!=IBE5B:*!R^D,F)E()MS,^19X1,
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MMA.GHOH^#/9:9A#^OKC[!M<%O=H][?0O0LC9U\YINM4S1SKX_FTH9GC(!K>
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M&CP3#;XOP+/38!29]3:0?+&38&$)PQY4-W(5-3%QU7SP7NAT@)QMA5X8F [
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M%?ECID%_%(O,*YHWD\42T>4#*C6+?-L_2]U)3LU@='%C';?>'WQNFU[_.7'
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M#1C]92O6+M#YNT9U5-M#I'Z\CS\9H5BTG&5:$YXQBU2FF$991 PK['# *7.
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MWLU4WG+>ZD05H6"@=K'+Q.HHB ^<"1,MY]2N;6@]6]-GY@ R!@]642SOU3)
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M*J@54E +[B,A,]TW,TWM"-'L5.+2DF"KBA(V$<C2$*ZHC)1:6P&ZBXIZL(6
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MY1YQ^/?V#_?MI1Z9?ZP_4"'7?6Q<T_A*6S0677G48S@=II>7+WZ^-""ZO6;
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M7WL3CQ.D8_=3-Z9>Q'QHW"9%G! GQ EQ0IP0)\0)<4*<$*<V!P>DY=DE[BT
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MQLJR"6S26,D%V^AD)"[%3*2QGC@:#4DN:FE2#)R:M0V)W(7<]4RY*R@A=*3
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MYIU^[H2+WN:=46UNWLEG37?SFI%WT=X<,_%PDP=A0I@0)H0)84*8$*8E)B"
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MI"V7>2[+%PQ)H#21@M9J?]J0;)17PCN:C2\.*K7KULV&X=">0[);<;*;IW!
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MM,^N>1;YRM^/-W]*PU%YE'IQ4%X.NJ'V-[MX0Y%CS&;&34[$"7%:G>#SCTV
M-U=$U[SA;:6Y-^DX 1H"<QH"TXU2-#=,9ZU(8M83Z4 3:T$1\+Q8?M1%YMC:
MQL)'EE"*D6T1)\0)<4*<$"?$"7%"G##%\.LL_SI(.0T&5X&<V/W4C:D7,9$0
M-Q 0)\0)<4*<$"?$"7%"G! GQ.FA<9JGYTV,/##*,_?:2A624TI3[T3R8 75
M8N["=UL7SM#PRDMJ=H%PXV>>C9_N3&\;):6.P4N24V)$!NJ(USP0%ICF-D1%
M,UW;F,W^N'U7&Y33-LOIT@M4HIPN24XG,[64]YYF+DAR3-4,=$8LT$A8-*E(
M:0PY^=;(Z;-(T+I(/6CRL\K5.J[.:- M/W-YLIJ<5=.VNDVMUJ>2C<7H:H2+
MGWE8'V%"F! FA EA0IA6%*9Y6DX69X5:QKPHSJP/P3$>D\\<;(K)*I@O^?3"
MK-O/FQ=&W6&UZ5Z/3;K-*XL._9EY_)GBR^Q.QAVLD3F'H @$$$1F10EX&@A7
M23$7J-+)K&UP)S#I=,4D%PD684*8'D$/+BV4AWKP'O7@5%Q/&) \.TILL)Q(
MR2EQ219EJ(HQ(XRCD%S;]."S2,;;2Z/.<7_X9*KXW:M:P#T>A EA0I@0)H0)
M84*8$":$"6%:"DP/G'0W3UN RY2?XBKM]$+_)/V[^$L8$)@C(+"_.9.0!]XK
MJH(BPK) I-:&6/"<!*VCUD[;8&%M0ZY3Z]J1[(-BW,*</!3C!Q?CJ;B>5XEK
M(XFF@1(I8B;_/WOOVM1&LJP+_Q4%9^UX9T=0GKI?/">(8 #/9IT!QC:>V?87
M1UV-;"&Q=+&-?_V;U2T)28"-C( 65*Q8C*QN=5=55C[U9%96IN$\(L&,BQ0[
MXGALE!H_B9B]WVTGYU3;;!W8OC]I,;+9RAITF_ \U^N'V$?#WMGS//2#7J<=
M6KDKC4*INTG[1'W0,EFBA6+<1.44TY(X28VM<C^]W[]9S'!=.:#.^%2 9QG@
M&7.'BW(!0C*%&4?!4( =2RURTG/D/0W)YNJ(7&]L2;*BW82;3?X'WB&\0PUN
M'L+]ZVY$N(3HFH5;E]G5SX/6+)=*[:\QH&^QW[L$9OFXPTFO Z,ZV/O/J#T\
M+Y"V'*1]F\^];YEPTA*DM *#"*N(=-(!22\CL]2Q%-G4F_&4<*VPE)NQ%&Z\
MC@PSK;G@$1-'%&&),8\9B9K8FRG\#XRG0F%^7M_GDU$FQRD!0,XCK1'75B%'
MB$4  3SCM%6);VP1LHE)H3&%QCQ5&O/SJ%;HRFKAB\W!%XLI>!' [DH8X$L!
MAFD;#9+<*2U=\)*FC2U=D*L@UQ-%+F\]]=A+S+#G2F*-?0A>&QTL3<'%U?"Q
M FNWA+7Y"FA"^."3)L@S01 7E"(KJ$#!>&4-MTH0@#5*S*;&HH!; ;?'!&Y+
M;=[9Z#PW%G.).8[41!&YD"(%@['S[GITF^[9%21;L8M\\>R9<(0J(Q&L.0EQ
MHPUR-F'D(B&:*&%Q%!M;4MUF9ZY 6(&P)G5["023S-JDK5:&.HZ9</F$BG9,
M<1>$5#?D9\5!?I> -A]L0#,#XS0@[2( 6LPN,Z,8HD(ZZ4QR-A<)?X(N\H)L
MCQ_9EB%GW.,HA:4A2L4]8!SA@7NF10Q2:2MO0,Z*#7J?0+<0'!FL)9IS@\#>
MI(A;S9'F3"/JO5%"@R4J<M8 0C?-%2<F"WLK&+>>&+<$Q$6 -R^E8LXQGGRR
M0-^(4TECKCE1JGC7&H)L\Q3.IHB]2!SQ0 GBE &9LR8A@;%30DFA%"";W"1\
M/38]U_J,^ UCNBLM0"[7G\RY'L]B=V"S0,J1\7("H8BIB*F(J8BIB&E=TB<1
M@IUQ26A)*&?,."#+@E-@SU1S8,_C4U=\<NI*,OS]R)KM\'$TJ)(D#8Y[VS!T
MN06V\Y=MA_WNCCUK#VVG"ANL&,3.#(%X%8%3#]K#^#KV/[=]G-2_]KT/W>HI
M?]O.*!;*O03E/CC>'A[-.Q,P9U93+A%)G"%NF$;&48H,BUACE=,RA8TMJNEM
M"7?1^@+.14Q%3$5,14R-H#I6$2VLDLDDQ460SCM#A>$Z<A,]DX7JK#O5.3CV
MPSKJY2T]/'[SWFHK(K4):4<2XM8)9!G.A,=GW[!1A/NF<9VU/I%^0Z7-!X;R
MB?2JBDSO]+276]#SGS9;9PO%H&TWM+[8?M^"CF57?2DZ<ZM#840[')FF$6/-
M4Z3&,TJMH%8&DYS$2T-@Y0RNSW_MCOHP=C62U>?"CH8GL5] ;"D0VQLNANVY
MX(/%$<E\P)U3SG/R>(NP4O MD4[K?#!,K"K\N$%[O(]<=4LN\K40TY+)070(
M1$B6@VPY"\9QZ90,7BG@FDG'@K /C[ +X37$.,*D$<A10Q W-B<MP@8%[I+F
M5N:X@8TM@-^"L&NFN@5AUT),][M=L6S SV7LK8SS KT_ [T+FQ'&,IHH=8@%
MA1'7D2&KB48R&>PT4SI1!P;Z)C6W-M&+5C<X]R/G)M#$HM,!<T.3QH(Z9ZEV
MDCHEP@W4^J=#E8M^K])XG1JPM0=.<R&4M (1#8R**U!US<"8=5II3)U11.9"
M+YL,X]L'+A?=+L2JB*F(:=W$M,Q*N8)-K.^=N"Z+X4H7P_GMJ 3VBL->(^6E
M1IS)'.T.:Z.P@07BA4DQ7I4DYT$6PJ<0RKX;XVD,K=#^W ZQ&UK]>@/V&WP'
M6NAB-Z:VS]M,H(+0[D'6S13M<-2'-O12ZS6\%C[MMG:JZ\.VZ\367],MK$JC
M6NWQ9E>)CR_Q$T5,14Q%3$5,14SKXG#V&F=BIF44B5M.M%1 W"C5DEEAO+KQ
M?EY57OCW*:78F3**%S6A>-'K3\)BCM(,GYC2B8I-% Z^% ??7W0X4VI<%#0@
M&XQ#8#+E["$R)PZAW"0FDPXR[_4U*2*LZ'2!WB*F(J:FNJ2H9#)(0S2UG#L?
MK0\Z1FZHD=923I=W296U\D'6RH/C-W/^*A&349%HA+E,B#N5D,N'QF)4"KN\
M_V[MU8ME*<G76,U^< !^"@'N*W(L[MV=8W%]=TO*IE814Q%3$5,14Q%3T\2T
MA-7DC'"<8FM,PMRK:'40SFN& XO$.KN:2-9B23V )76PZ'44+!D7&4/:"H-X
M<@19;#PB02>)L= ^G^&BFU*64USKIO(%F8N8BI@>Q.^(!>,JZB2XY@936#2-
M!*2U0>B4Y$U6T&6"QLM2^B!+Z:)3$@M",%<21<DEX@%K9*5UR+ D$[ HK>HC
M(U>MI26BO+&*_^#X?-_QCJ']^8'R]P+\+)=X8R*.E;96WB@)^&]GO4&5$.=Y
M/W;LL/TY_I93-R-6_7IQ;.T@Y@? ,D(O5+T:Z"?BW'_H;" PM8Y2M<X=CDY=
M[,,_9BI$[W>/83X-ZK:5A7"IA?#E8EX0ZAT1P28D)&6( _%!CDB../84Y!BI
MM+GBJI0EDN6Q*/$5QZ'O4(.!P@[:(?;'"<M\!/ -1T6%;Z/"\]4/0%.)PRXB
M;'/19 E_G+,!)4>)\2 OAL7&UJTK'Q0%;HH"WU7&F&6./)<E^N[T>R&QC.<:
M>ZTE2E):Q!D1R%!)D"0.OG4L)<,WMOBFU)=K;A8=7U,=O\)/M?*44&61ODLE
MGE^D$[46Y.80Y@D6:2<9,H1D?Q--B6I8M(DJB_2C5N![3CI4M/L.M7MA9];Y
MR),,#(3!/.)9A,8$C8(-DCG,I%8:M%MM4J6*BJ^9BC]XJ&L14Q%3$5,14T-Y
MS0IRR11>TQ!>LYAKA@H<N$T.!4$4XF!T(AL%15@(PV1007DS)C9-<CX\A<,A
MUU4_:(W.X&/\&ON^/:BN+F[ EEB $K)1Q%3$M/:[$54LW7<SV_\SAKZ],1R&
MP@B68@1O%C<C1#(LL$ 1@6F!.)88N1 3TE*[*EPR.K^QQ3:Y*GGNUTW%"Q*O
MA9@:YW+^'@Q7>3\+"M\6A1?\S<H1G*P-2,9<?1?;B*PW%H$=[J/F,@D3JRUA
M7$X"K9MZ%Q0N8BIB*F)Z4F)JG+NY<)H[YS2+OF;G%,/*,!2U-H@;[Y$!(2.I
MJ?"1^8B3:!ZI>0H)SK_O:OX<!T/H2;[8AX_]MA].S_]D/?XYO_/Z;IV5'<XB
MIB*FM?4[_WC]?S5%N>J&-QGC7L5.M(4%+,L"WB[ZES$A6L=H49#"(ZZM1$9S
MBF0**C@28L!D8ZOD55XW-2YH6\14Q%3$5,14Q%3$5,2TCF(J484S>:9O6+?N
MB<4<7I]X[&IS-6F*4]))>LH#%ODP;V",F82#3]ZLO QG'15UD71L+L78Z^CA
MUF$[-[-8L4M8L7XQJPK#@4C*$_+:1\0)94@KP5$D+FAIB/ I;FP147*+K9%N
MEZW$M1#3DLFKHHHFF"!=4%PH;'20V$E!@L,!<'C%AU<**M\G*B_X%DE>8(FR
MB'@7$ ?I(J,313+(  (C%#,&J+PI^*T/Z1:M+^!<Q%3$5,14Q%3$5,14Q%3$
M5$+)8)#_6D@0/:UM=V;/;?8?@L4V]BMNK]RO6'S?98NBB*F(J8BIB*F(J8BI
MB*F(J8BIB.F.*XQ%ITS0P5-F \=<64*48=A((;A5S"^=N7EW;#0-2E&P6^P/
M?;A4%,Q*R;5)#FGJ*>(V*.2"T@A'I0/#//E<#.5R*92;;]H7/6VPGJ[@9&G1
MT[O1T_F3HM)@+[RSB*9H$*?*(2>"0"Q)DGP2(@3>&#U]"E&#X]-/5= @7,W-
M:@W[;?B;H&/Y<&B.)6P/3V-W^,0B A_<JUR<_T5,14Q%3$5,14Q%3.LHIB5,
M&,Y-H(E%IP/FAB:-!77.4NTD=4J$Y<Z_CVG=4=H9D[KCS.E>U)1N9\KHBCVS
ME#WS">R9O3E[)GB0!(\::0>F#(]>().(0%$ZG$@2/B:\L45)2:FZ;JI;$+:(
MJ8AI/;/$E87P'A;"><=>KB?"L,BE3HE%7,&2:)*7R/'D>.! 8)JW$#Z%J+W#
M.&QU>H.2R:WL\10Q%3$5,14Q%3$5,14Q%3$5,14Q-3*:9P51=]/<.DND> !3
M:;_K>Z?Q3["7BD-@&8? Q^U+$7D$*QN\Q4ACQ1#GCB&KG4&.&ZT]<8'&*B<\
MH;P9T3Y%CQL8E5?T^/[U>-ZQ9Q,3PMF$I J@QTDDY+21*$5JF)%:)NP:I<=/
M(6KO=]O)J?XV6_\>=6.+X<U65J#;Q.>Y7C_$/AKVSI[G@1_T.NW0RAUI%$B9
M9^(.,DFY9%T*6EKG-?= /1BC5@4I*(7)C<7[_9L%#=?)H.HD405WEL*=O<4\
M?")8ZJR+*+)D$ ]:(<>\0-[0& W301"]L67HJO(]W6S^/_ FX1TJ\?U!W$UU
M^%]W(\(E1-<LZ+K,KU:&6_EHPTFO Z,WV/O/J#T\+^BU+'J=SZ&7-(99GRB*
MCB7$)8G(V!B0DKF0*PW!,KZQ19X2=A4R<C,R@H.Q3@<92&)<$6N#Q<1)^%9I
MH.+A>J5>)IME82H_K^L+N2D9"=$H9Y%U$G2=DH"T!%WW4H*ARY-+,>;(ATU&
M5U7];BT4OI"50E96@FN%K*P:P.;)2O":^" ]L). $1<\(DT909@&9W+Y>1$-
MF%H%NPIV/5'LBBE0#Y1>*XZY2-A@1A1)-@5II6)J-9RL -MM@>UHGIEY+@6+
MB2&C%$4\ KI9RA@BP5!*=,)*!&!F7&T*J@N\%7A[3/"VS$8=IHY0+45T1')/
M@*99JZA1Q,7DF?R.(^EG]N<*T-W>W;1P#(W)0 -P-12Q<8B;X) 122*2HN$T
M"Y-:0+I-)6^36J- 7(&X)G5["80#!6!))Q&Y4UP =?,R&BM8$@2,4*)OQN!2
M^VL,Z%OL]PJFW0&F'<QA&E8Z>IH"P@P#IED.F.8-1<(DPWS41G$[#?\K[*U
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MX[A+*;#HC2,J8K]<H:HQK3M*.V-2=YPYW8N:TNU,&5T) %DJ ,0/#W+^P3H
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M@3)J$\\U]'+AY=M@4?%4-%B+'^XD2-'B6VCQ/*,PB5+M@4PH[@+BTC#DP !
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M3-4V6_TX.(MY,8N=\^E*5H%Q\>(V9ZMFHFQ'::=:ERH-+$JWK-(M%(S4,3A
M8R03 3 V%!1(>0KRL!*,&\)!,&#AF$U*R^;,(U;K%6_.%+6^;[5>"%E5S @K
M$W)19H[%'=)2*D1CE(8(F.08@UKK3:I,@]2ZG"MNVA92Q6R!('7L$ R_8:\U
M/(DM#_?EUK6&_3;\3="_[ _(YF*["G5Y8E&W#T>?;K8)/K%:7O3Z50ZXJ0NG
M>(I_$G _+?(HGQ050@<DF7>(6^K \G :*:X#TTI$Y1L9DU>";M=GWZ>H]!VK
M]$*F(VV<S65CC) "\2@$,CYA1 3%A#OCO18;6PW),_#H8VOG7=3Q:^S[]B!F
M-W/O+ ][B:YM%N>HS+BC6C1[8VF% DE+0-+A[J7<)TEBK7(Y*Z6" ;-.6^2<
M22@$P:R.!,?8R$B[XJYIGKNFJ.X=J^X"FU F$,\2& A&(DYX0!8GB2(1D4@9
MN79J8TLU2&D?O6_C>DHQV=8N?HSF;0/]4\MF DS%S%D.F"[E-%'61<,%02(9
MBCCF' P>@5$PEAN-N4D$. 79I)(5O\7C5>B'VP J"GU;A9YG&HER8U/BB.A$
M$,\;0(9I#YP#X#DJG#0+U=Z/49=/_C?V=/ CV/M9-Y?+[[U^O_<%FCH X BQ
MW^KVAG%28[RX6QKE;KG81?^SU_UP'/NGY63CTE!ZZ>1R2E+A[&K!%H/1QH E
M&:+K&EU**1F8Q\7?\@1T^D[]+45W5Z.[\S2(!6M)/JR#$\&@N](A)Y1&/!$9
ME5/&8K:QQ7"3PMH>&P<J#2X11C<^I'XV/L_8<N>M=,4AHW)0O0ET].>.IY?P
MA-NN;Y<BMX.C-"JA$..4(JZ91R:"U8\-YB)83:M"3!1O<GTY1N'GS/QR1/U1
M(</]NOP*,MP=,BR46<!).^H-(E& U0HHCPQ(#X@P2Y*E%'QTP'S5IA"W)K_W
M?'K]H=E8\0[.\[83V_T0<V:ABL'EXYG5A_B?4?LSJ/ MDQX^-FQ>@_1"&:+S
M__<N)/@J#H;]MA_&D"]L=\/\%S-W_@7#T@N7"X_[SBB+:N]K/5]>V6'<2RGZ
MXN-8#NDO19T;8:SWDB,#.H1XL@P9[P321CMO"#!$GH_Y$+6IR>7CU,VKQEF*
M]3Y>_E>0I=G(,L\A@V5>2YJ02%(C+C5#&O.$".,.5A_F'>=@7<I-6'I6Y$!]
M: ZY_JZTG>M(V'B'ZO?XH=WM9J]:+[7.*I4J$6[7H:,F2KI 9+#$\&"C9C(R
M+(4!&$S&FO?[&10)0.9#@6+!N&4P[OA2-#T7WE(2(I)1Y$JB1"$+(D?6:Q>D
M88G$G."1X4VC;UW.J\2^-5?5N<>1^F@C!<*L';<XNH"MI3A9B;W,JDY,4?5U
M4O4%.D,DT<%;A'6.A/-)(YM40 Q'9AA<])2!JN--8E;E$BNG^E; 6/;@TK5<
MY6Y-NZL&ZD$![5]WU_]'@^1",&FQH\E3Q3%7!C21&ZV8I)8D$2O2=ML]SH+D
M]X?DEXXKL, XK-8.,9)=7I(I9 0/R"1MG.:2PPJ>2=LFD:N*[%D7MU?!PX*'
MB\R6>"<4CUX"LPW)@*I(A6WTSH4@E*^-V(*'ZX2'"Z<],!%4BH"XMCF!GTK(
M.N;!IB7*:BVIHF9CB\E-OK)(Q_5(5;["S- S'6;0I= ;N4Y<3:[RAVWE([(O
MKDY6_GIT=M:).5..[9^W0GO@.[W!J%\=\JU,CM3I?9G$&)[_7!KS%::;O[-G
MK,CU76FS>J9$,V3^'9ORS (FP1K6&MJOET-';^WN6F,R=%47'PW?67D:^?VN
M[YW&XSR)_H(I5=C*4FSE4DTES[VQQ  ]H2'75/(1.1L,TD(DSJCC)&?I?H3.
M]H(XCQ1Q5GXRK"#.+1%GP3XR),1 )%(\N'P,C"&;3$"4,A!=8(0PT2S$*:&N
M36.4,U9$9\&(@'% E2$Q4UJS&ZX\O_1DK8NUF[&EP:MI\*_#G"EB:UQ+!?XL
M>'0X?I8MR;/>H)TQ]WF59KS].?[VI1V&)Y.U>.9W-5 ^QQ<_L6[0ZXR&U_]D
M!E0\*'#LWS^&T-PFLU!89N;OR=33=68_ "'N1_L)%BEHZW/;^6+/!QN_SG7I
MM-U%\R.XV/EKNYC2'<$D^Z\:OH'9]/JV$DV5,R3?!6VRC6E+ZZ2?>=O_:;,8
M(PZ6$,H2]])J0>'_VD9GO/16OE<;6\=Y_F:8W\F4KSK-8+>N$N2L=&S_ P@H
MN^'&#LOJ(=,97#GI8!@Z]FP0GT\^_#91HG:WZDSUH]_&SQI/^RSIQ34Q][.^
M/)X$QCS3@N5Y,(:+\8O'4^19-446Z$Q]3=%GTM!K+^-GY-IKWWLL(<\D4S_U
MV.]?$^R.&FMN]-@?0/(/%UMSZ=8K>% -6?=C&^D;>50/X9O6 =QV,FCM=?-Q
M[=?Q;!A/7>RW&-Z<XSBW':(9/E*KS5@1+N\Z++,ET>SQS6ZIFQ#%555/?4H#
MBY>9G8_*)_[70NU.6*_:(8*A,L[FU>IU08_[8*6TMO-B5S4\?W_QPRHK<'&D
M/Q&WULH<Z;X?TO/I+*HFT>YX\FU[WQ^5S-++>;@^7@ICMPHS'$U$RA*).+9@
M0G""$<:66F6\I;[*]]@@%U=QJA?TN1>G>D&?U://O'^=8(XU3Q1I'@F@#R7(
M>B416-%.Y<!;YE/#T&<]G6F/J,%+Y=!K.K7>C?$4Z/&44?>C[WWHP@/J^!,7
MNS&U?:Z3Z"M>/<C8EZ(=COK0B%Z:\.[=[_'N5GN<(_(V60D?VQ)X51<?S1(8
MB0'B1I)*V'%EB-:.BR 3R_N87I-;9Q&NEL9Z\DZ6Q%=UF<_CWN_32;LSG;,O
MZBE[E.:7T[)^+K5^7DHQ[#%15GI8,(.+B'-BD-7"(VJ#2 F8/2/N$:<8+OCU
M2/'+,A&(L"8D)[E,WJ7D4W+.!$TE=60Y"E]PZOYQ:O$$;12:>8ZT3AYQIQER
M@%9(<(EEC#I93C:V)+YU28GF5;!Z4C1T;[4TM'ABUAO&G4^.2U!PDSAG2CD>
M-59.JZ!("M(6&KJ6\'XI,#NJ"/8%9LAPEC/))0<TE&%D7&)&V* #65VEB^))
M+OAU3_C%/+%<44JT(MR%"#8UE9$F^)_SV*K5Y+@K(/9 (+80ZRTMMP!@* 5L
M<I87BHSU!(40%1$@9&?UQA;=E+=/#5#<T?<4[ST363?^/<HW/Y<5'W^H(X:]
MT]->MXZEV+R9 S='A4_*RE8T&J[DO,F];C?6*/:E/3QI>7A9'H/6L)^Y>H)1
MS%'D'E[8'N8(],U6-PXS7\]QZ##(U>=_W:]C<1;TQJTX2A=5C.K1J;H]CV_;
MW3 N]CAXT>OOC+MZG'OZHN[HSK2?4RS$!0MO@(5OAP<[,UCXVN!W_WN"_>G?
M7?N/&1U]_'!^> JCMOM)',*[CHY??7QW_/?)V^.]+] F>O#'/G][NH</C__^
M]+_?]KX<'7^"]NW1@X\>[O_T7FE/0C028>H"L$/!D<EET:RTU)F4@K9F8^MR
M(M!JUB\S.5?L-;KSR5D6ZGN?G)6UDJ)5N82ZT/"' Z-#6I"(3%)*,>$%,71C
MZZK")YNM?AR<9<3]'#OG"Z'<Q2?]N'W2][.G5B-,Q0W.)@A3_0O <,( :@+0
M[EXL_WGUGRS^U=H_7OI] 9V?!IV%9/DZ&2P)1H(#5'"LP3H(.J"DC.** &1P
M57;:"JHUHF_WRYENZN(HT-84:)MW?&ABO*1 A7P$:LZE34@S3Q VFB>')>?4
M9L<'PZM*UE\<'Z7!I<&EP0]UDOQA#G$O8.7BT=_+Y]^J;]K= /]ZKMDS^B N
MRZKIKV-L60]++KS[/+L4N[TA/'W8:PU/(M +.PKM8<Q2R:T=Q&D."]N!IMIA
ME?YB\.S:OC_!(_T$7W^F/S>W8C(_/&;.U,8J$@&4- #-2@-P_Y/TTK'7:I+N
M;+_:W7_QHG5TN'/TY]$?;S=K#-L_W)GJ\CH@Z0.-WN'1\=[KUO%1:^?H<'?O
M\/7>;NO%_N'VX<[^]I^MU\?;QWL'>X?'KQO?CU_>3 #^OR^UM5D3X&:@F<L:
MWE\/KAY3\JPUMM(/1Z?P"+^"$[3SJ>".^A]LM_VMPBZ GNKP??6/[6[XJQ\'
M.2%5_N=1>C%9JU]/E^K=:9ZJ8VC3[YTJON AC6M\L#,VKC^"07W\0;S]!Z[_
M\_>G@V^OP&B&Y]-]?$ /OKX[WL?OCC^PH]VWV;CNQ/]Y=?[NGW#F*)?9H#[:
M[9S [T[>_?/RV^$?__[T[OCD8S;0WWY[T3GX^*ISM.OYX<>3=/!M[^OAA_<^
M26=LDBB:&!&GV>]GJ426*DNHTY&KL4NEW1W%L)W]((X9B5TB/C'-A506_F 5
M:7#>.^M 4G'@[5G6\/X(5K99256;7K_;0;L*JYR5T\3V'L^7A24$KHT;43^F
MDM4/&](\%;ZSQE1/?-X> I[Z&S3O]]$ OAL,6I>$<_0Y]C^WXY>&0^'L&C*V
M(1A[H+"'FDO8?FBGU#KJYC=^.-]L[7?]L]8OV6=.\6^+EZNOR6^MG(49;(S)
M7;4),K[XWZV3:,-_1K8/BV,=$O$:.K;;CA]ZFZT=$'7J];MMN]D"=;+3\ B8
M"\"06[WQFUICNZ:.H<@O.VT/J@CG'"@1/\=.[ZRR>6 <SOK1MZMKIS&T?4YG
M,P2B7?DA6[VS/$D&5<BTSQO&_=89S)M8!6V 2G;A%[:^9?JJ#_G7<3 $(^HT
M#NNG@M'4C3% JR<E2EO_[]7V:W0ZRO@<X*:AS595M6B \*+/J07K-V[.7H5>
MY5JGU8UU>_($GOTY?*C9+0*D:<.WT(VS?J^RV<:_>=8ZAG:.!_[_&U31))/P
ME3RN'?@9- J^ROTYM(-@_P-C?Y95K75@^Y]B[AQ0Y^HZO/43?!R<G[I>I[6Q
M\VKWQ<9EN[!1JM082+IZ56CRT#4/A?)<GO-D7#@OVIEBMT]_X,2H++D%K&J=
MV,^QY6+L9H XLV,LRN_IAZQ$M;[G?X^Z59K/LS[H=ONL QW[$+NQ;SN=\WP]
M9\.J?IMUY4VW:E?%RJKW;E<KOYUBYA_;VW]-H3"K=OY5?P1/K>5AJZ,<'T:=
M,>K (_(=KZ,?]:NLHM6/)O6/6U6(2HU\DS>\WMN9OJ!?!Z5FKX]MC4$76@T=
M[O6'6?]?]/JG]8L)1B^?M79B?V@KX*NWB"8K:'8>S61"'< 7<#F/0 UXX]'K
M I?I7"V#[XUR'I09@5Q($U"Y=]H>YBZ<C?HYI&=8>[!Z@^^-6HU_2T^3?DP=
M .86]*MEP\?18%A_#S_+0#NNHUOW/)^W&?7[5<;7F5N_G+3]R>9D-N1%:+PH
M@1;  E8'],$PP&KA@:KD(A5YZ;&M9-O]B[9,Q#ZS=A+UVV"FV1/OV<4<BH-1
MIY[K[?R?L]@?3Z%IN;U<^Z)>ZO(/ZAI[E6 R-,6P.&H7H^5LIQ+6X"3"RF"'
MK5UH?<X 5X\^(YNMO-,((AS4$H2EH_TY#W._=UJ];/+,*\<='C@\@3\AKV!N
ME$N95#-L.)E<E43&0[(X,V<G93\7%,QSS)W7<ZH:V^LG9=WC\5"!)"=C.!V2
ML2 '/S&9*B%#%R:";E>Z4M.)SW'2F\D;J_Z?VG,8OE;\FN.5QN>X,LE)HQP\
M/A%8U>B?:='@I#?JA/P&(!B38-2/H^Y,-.J/136>;6-G\@EP.-#'R90ZC[;?
MBE62P&MFR"Q:7#7!Q\*Z!J#^'S2J S^>MA6PKKHINCZ VWE](Q75R\CUONOK
MU[:M_^OZOVXUED_\V88)#N(YOZ:%US2_F6OZ6/85:L"\&%7!TSG8&=1Y *\"
M:PXPIUTQ\;S*3C0^W]^-'\9Z-%7>"XA[UMH>GW <)ZH<3T)<SXO-V9D'3ULN
M8O4G*TZ*VU98V^Z&UR>@%,>Q?[I?Y1X_G2NG)I^:L^?C/CG\\EX9K".6'C'B
M->(IY$*_PB/GO*>:P!^O<GE(_NRZ2 B8W9W*_=*MIM#FI=*TU:0;Y+%'@+.G
MX\SO%WCH8J<-)B=,TV$U-P>CE,__Y&6\>A0 Y&E>-_-,GL3WCU>J^B$5SL.T
MCV#:U>@*LZU%: N,MIQV-?4Z,*WSSZH%<!S:7"^7]3H"R\'5ZUMK=1C8/!!Y
M,5YV8/Q@!&*U:5.OE?,J7B^HU=[GQ.N7/U>8,P&;FD%60FGE4)<\02H+O3:*
M\R(WZN?U#JY^MA-@6CB] 6;XA[X]'<^8T5FUB%5LK/KE!2>;,]"ST9Z9 BS,
M?DR_*SHPTXS)M/D"<S7?9S_;=F>2Q[.V0:I_Y?DYV&S5\PE($[RGWN\%F>7Y
M6#UW./_J5M^V!W'Q;8/,H?)4RZ_-XS(\;PVF1LCFE8MWY5\XZ76 _0TJ,I,'
MO@^*X.<>']J=4?Y8#T($D0#']ZV84B6E;*P=_;V_BX@!<67& @C:J\T#:"T,
M/SP^CF^?^# N?!W6M3NYL2"Q2QT;2_-9*V^.'V:3AN#)CO@/R%/6T<D,F*&@
M"QSCUP6?[BTU[H9[(^SA]T;HG>^-O&Y_Z+8!5\$$W)X:Y7_U.AEI!XW9\3B?
M+(*_MP_I/CGX^'OG\-L>.]Q]!<\*[7?_[.%WNV_PP3^'GW)XX=MOV_C2(OA'
M#O][<W[PQQMV<.SQX1]_?SRD_^Z\/7[UZ?#XY=>W]"6TN_/Q8/=5.MQ]>7ZP
M_5Y[[:DD 6'M%.+<8:1-$$AS28-UP23F%G<\C""6Y3/@SBNNG#5:&LT2PUQR
M$Z)<W/%X/3H]S>9JYE47HFA=R*(U$<9/['K\N#'SC:=46^V9<<P8SF5RR1&,
M$TPJQ8S6MH&[),U;/G='_0FGZ&:O^)AMQ,M)WB]H,ZR.%WZ:+JRGE1MJ&E9T
M:468F2FSKK3Q3&D!6PHPS?IM5YN$>:W<KDW 5W,F8*NV_B8+?CN3WA^;FYOC
MA1>6O7J9F*P%E9=D2N-F%K;Y%@&SZWU9E1EYM_!X81)4:GC^I!'QPWME\]$P
MCU%,)"$ 1(Z<H10E827E5C)MZ*4]8)BSFFD<N%5< [C8%$32/$F?84DL(F*3
M' ,7XI]Q%:^[DV ;R.ZLL37C(>[8P0" !704%';L^)Z28@0X@09@O$TV)#,=
MS_XX;_O]ZC?#VM\*!AZ8 I7*9^8,#<B^SLP!1V< $O\9]:J]NWI#[ S4-OOT
M^]6G#&.GO1 [-34<M*'_@$:S2#(<>^PR1#UKS=CLXY/?T/]LB6:P.\WI(>J?
M=?(.=@58%P;@F+3/NV$K\Z_J579/AVHW]6HK]>8O=_$<:#" [MB7EQ]?L>_Y
M 9]Y3:AMJ2M]>1=,O%/YK7*#:Q?N=++FL1L-\E>S'NO<Q+&#<-X4OH)NSQ&-
MJ^CWC2;];%3ETXAE)=?'LI:PU#4/2[V28]^,,S=O%;@F3NI'B_76JPAJEM/A
M?;#M\2[8V-=3.?NN)'_].+=# 1 (S/C#8+J 3/:U<J11S9SSV?+,<%LY"="P
MXKK#.M9D>-*KMW FB\OD)[XWJ#;X9EX,H!'F?4*5D[LWS%LU=2_RE[-TNNY5
MKS_3J;SD5?Z3RROA-1T.M0F0GSW>D+IB5W![4.V_707Q,T_-?I]ZK*I!G#CF
M3NN('#?WVAQLDP^*5:-5-SG$"D,W6Z-N_UK!U6ZQ2@[3]1I6%Y<=7Z=@+F3[
M%%[=K9(M53?6&TGUJF6KJ"%8V^K]5;!'1J>C>G^\-A/RY7X\B;"<?JXF0N\T
M0O>S&S]/RVFO+JA#?DQWZA@[KPV&6L!56]N96E1Y&F<-D6E;)[M_>4L\FU+]
M#]5B.C?M*N_=(+OWVH.3R=ZPK2*;JO>X*L1D8AE-6I*7_!Q@-1B.^Y&;,I,B
M\@OTLGI/-;-"OCH[\6?D6O]\LQK ?KU^VU,8TTE\';3F;-2'QL,J#J-WVAZ-
M_9\POOUXZ99)%IOKM?#9%<OXS8GLW5I9>V/)_!7[KT%<\<G;6E^/MM]S3[SG
M3".F:43<:HDT/ DQ,,5QQ!I;2Q9M+>Q)8L%K%I+CA!/+0Y+2)PMF-YANO,FV
MUB&0[S\!D%HP"UK5-&AP1-<B15ZC)?Z'<Z0*K_/C*)#,NB^VC_,Z-@U[/*F6
MI'DK[[S.G%L'B8Y_8\_.8 ;4&RF]N:#)R:8&_"P#8-V9&! 8I/T<ESK[)D"V
MT3"'958/#Q=.MGII?3:3*6R2O/<R\[AHTW#8;[O1\'NM&J]+>?D:#:>H["X-
MSG1=R8-3M?4*K+V\8_A08/O:G\0PZL2CM WMJW>-/L<+]\;>UWJ\7O1[ISL7
M?3]*BRC]I/'YY?O@(L]6!<JEE1 P?XLLQ0)9CHT)44=VV=O?3)PXKCCE=#.\
MKK,;Z]VY<430K.Z=];*5U*["%"?39Y:&5A3MPJD4O\[')GG;\>.(PCK_WA40
M4V.+B]YF+P;\"JCA>&?R2V9,\'HT>?7S!B\3I9YQJ6?\-.H9WV/UXL=11/<!
MJA,_CH&[9?7AVR31?8@,5D?CHU1 4J?6_CAO[I6EA*>#0'\\"#>>%U<F,ENC
M;%^U!;$0<DJ4]9Q+1@,WG ML-,76,"."TEY0\X,TAGBIT--;<NWMT^S=:4HR
MWY^EW'5^K].W!"CU^='N'CWXMOWE:/?EEX/=WT\.H(UOO_EO!_#O=__\^]/!
M\5NRF-_KW<<WY'!WG\,UN&^;'^YN?SGX8^_\\(_#CX??#KX<[O[>>7OZ\NOA
MQ[_30;O.[77P&M-#^-U[%07E1!$4E6:(<Q:0=DP@'$3"V"E'C=C88IM"RDW-
M5E6 9QGL?<B\A@4W;HH;0CA"2= &2\F5%M;(1*T+4@>E.+,_2!18<*/QN/%M
M#C=BU)QBKY$RQN7$!QRY)!)2S%(G&',RR(TMLFDHWE18K@MNK*BJ5W.9TR0-
M^6JITTTKV:P[RG&E=!)<QIS\DIJD;1!1><M=!-KDKO8T%I1;&Y0[7V!'026A
M91!(1!\05R8@9PU!%DLO+4!=$'QCBV]R@S>), TJ_+*BVE5%^V>T7_G K8TL
M)4ZY#$GS&'QF.3Q8[JDK'&?=M7^>XSBJF+0*(\<,1ES$A(PS#$FB!",<^VC9
MQI;:9(IM,D$:I/V/W@'T*@Z&_;8?3DL@Y608@]NX?1X]>@F;7&"&D40(=UH;
M@"Y@Z21Y6-*"^5&!"ORC^A0%N!X*N YW%ITZE$>JF478*H*X"PEI20T"6UQZ
MIKP)-#SB:A1%[>=,%FH) W7FB7+%DV.4:&N<=!X+P_V/24M1[P=7[WE>@J4&
MP0F/2&3 2UPBR 1,$55.<F&P#SD/@3&W9B3-*Y?>7$92%VJL!WC[>]4:BX/E
M.VB5N."Y!"#50O&8N"8PF5T@AG%CDM0_)BD%K1X8K5XOD!%+%5!,+9!@2B).
M/,GU8Q(*#%,)<X93B3>VM%(-LI^*]V3UJLV<5Z#4@E+A.$D!.(@R$6.OK=->
MZ$)$UD"UYXE(B))SF M(*R(0E\X@PR5&-$@-X.T%"+9IJKV>-6H>LR]GECGM
MK9PY/14[CY+$M/&,>>JX=]A(XX(QF! 'JV]P96MJO;%W<6N*\62)(4"F2*X\
MD, 2M#(IE%1*U"E-A->Y+)_4?%/B6R-P\?(T6ONC8B[Z(%T.OY$IV8 U-3@(
M+''@\@;DJFA_L[5_GGD1[Z)6FB-+>0+F!4:5C=P@[QR-1)OH!:["]KC>Y+??
MF&Z0(^@V-M8X?&A\1(2=Y>S/HTPT)NI\;7S1XT>0GSI$5Q!D71#D:'&/B$BP
MSXB1"$QQCCCF$6D)3,)+Y[0$XYQCDLL0;BI.-V%"K,B$6Y$*KI%CIX#.=S:G
MDDX<*PDD-1\8U3911L!JD4:%0$*)J%E[T%F(&JYD33URG#'$32#(T201B\;)
M2 G1+D<-TTW-^2;3_'& SA55AF^:*D$^8)I'0(29[+?]7A<^^CI%<9V+I&0D
M.7CYWG#LC;4$2:(IXDPXY!BA.4$)-Y8J'$VCLSF^BOE XUQNW5E1Y]35K;<1
M;@B]7'QH!7D>Y8.=Z=_OMK9''T:#X3AC:SYY_V+[]>]5\O$86MNOWT!_GU57
M$9:M7S;R-^-_;?SW9FLW)Y="]7^JW(:UMW(P+?Y795Z:G$[\Y?7( :2 :G*%
M0<WJ(DR[.:]7E>NOSEWT/S%\R,..JE1K&>BJ+!M[((SA1?:KHR_P59T:_>*Q
M.GO=X;&3<DPSK9V497K6FOFR%3OMTW;7CNNIM%SLQEP^(*<KG^](54Q@]KN+
MZ3&3B=+/^&K;W0%,[DD.R&&=RA'P)&<<&8ZK:HV?D,8YN6Q=%N:BSS CXGRW
M>]#M<4;X:4*NJGI'=UA7Q,K/G)2O&=0YT\9C.TF4D+.?31*G#>)PV*GG]5F_
M][DJU5>EK)QFZ]V<&R_H:TY$.6B=]+ZTSFS&^%%.O7E-Q^NAN]2SV8([=0O"
MI )$3D\VSN32/CV#NZNQFJ1_V/OK]6RFE3IK6S6FIY.J@<.3]J U.ILFZ*P3
M0N3D$WE(SF"5@VZ[2;7*:G1S?ZH4\Q>9C?-HP22LTL95R1>G28Y;9%SAIO5+
M[_*W;#P-<J:V_-@O)^/Z$Y.".0'F5W>:!OEU+N,%OZ[S+>>7[4Q^"LI5Y08;
MEQ>:I(:;9N?L#>92,0\6QB*GW*FSL]D:I^ GP 0^G+1BNZZDT$JC3E6.;-CO
MY?E05W3I3T0<%JZ,<^KE3'5]0)QV/?[ "?.T"W4IQ_S2LYSE9SBM:#5)J0=7
M+J9IS G<ZL(Q54K26M!5$KQVKF0 ';?]JD1B5;;CNEI(DP)K,U6H;I@O^OLL
MHI$X?0#J<E% YQJ0)@CS"Y#._X)I-.'M%RFS6K\<5W!))1YC^#CT\:"2_:3H
M9EWL+HMI-$Y_MPCA(O\^BSAV!]6/QL^I0Y!G+TQ>J8@>S^QK8'_\A)^%_N>M
M_3PJ_>G-V_,P.ZFQ-]]3N#"IZE<E1'S1CW&:R:9^%=JYR,+[3S_/\&ZNF-JY
M6-QLE0P8.CR:5@ZLQ+0';+1:T*J6#5K'=O IYU7W\;^7![#\QEN UFR-U"6A
MY6$U^4;9AF]=7N?I92*FUV<B7J((BIP602GIB]<\??&#5;%AS\:^C+LUXE_8
M=O_OG#]V]P)KFF*Q'[:G%OO)X<>3D\/=O7.X5[P[?@F6^CX_^.< _GMR>O#M
M'3P;+')X]F6+?8\>_;&'H7W0KDX'K/U/!Q\_?'W[[=6GHS_>?CL\!0O^V'^%
M=B5HTY>#+^]U"HK",I,#$A/B01BDE0/;W4>FG:(B.K^80U3(",.+M1'><FNQ
MQ=1[[:QP(G!+]**%GX>]58U[ZR#:/.JG]2Q<NES-C]\\WU(E:%)6:)$"YLIR
M[1TA.DKFE8;^T::5J[FGZ?]GNRX1 #QB+)!PU'TUJ:M;U<Y^RFIQN/V>:BF]
MT1S4PFG@EHDCJYQ%T?.H/,PD+B]--A9U(HQI;@/C0A/G89[!Y+2)8*GIE:EU
MUR/5XS@G^>#J:A.#*A-DE2W\8EY=>"A.QS-L3/:FF;#G:X%DM\I,:><ZN?9,
M\8MJZ:M])V=G_=Y9OYTY<B=^CM,"Q3-/.VG'ONW[D_/L![F^(.G8%KFJ@E')
M&7F3G)' U9[AFJ\MFS22BV>:WBQAXK)Y&,G//?9'22.O?VEI;!,;2_F]I..D
M9#WS<68V4*-+Q0GJC[/\K/[&#BNS^7)9NI])X7G#\.N'')9?:C?("!X1!O^]
MJA2<:S$C7E9EMVJQ_U47W6IWQX?X:B_40561:SPSL@=JORJ^ LT?WS;E O6_
M9XAF-8M^^3,OV..R\BL;W">5WW2V!NAXA\W!DSY7Z_Y^]VPTO#S4M SU;8?Z
M3;?WPV%F99A_9IB/>T/;>5HI>VN<?'Z3Z7*K['\WF4<_?=2@-++1C5Q1DH$Z
MTA(W69L.>MUX/JD6FJ!'MSE*>65HZ?V1U!MV^5^WZN*:1LV.!N%2G#ZGA#$6
M3,[ ZH-AFDENE;&,JXC)^_VKPO,16RI4=L<.3K:[(?\G;P=_MIUL'5VQES -
MAV7KZ32MPV$_?OIV=/P)'WS\P ]._SXY.GYU>OC/BY.WQV_PX1]OZ='Q2PZ?
MR<'IV_/%<-BCXP-Q5(72?CA_]\^>@/O)6_CM87[OQ[?B<!?:<OSF_-W'?U^1
M7I(Z;G2DR"GL$+=!(I/SS9$@N(N!$1%H%0XK!6[0$>H5!=$7B'JD$&6Y5B0&
MB1.6,+^UYC((QHSC/B;'U,T@ZOH,<P6=[@B=YH/UN0BPL&B+A"$VHY- &F2(
MJ)>*:1<T2W9E6>0*/!5XNB=X4M:19 B5U%IN)'')4J4X=X**Q(@M\-10>")S
M\*2)9EB'@(C'$G%A"7(X$D2L$"HECRUQ!9X*/#6B;TO!DZ&<&)P$\9Q9Z51@
M5.$4HF 4H*H8>$W&*#:?I 7D&#5-2&#%<W4EB30L,2CHY )8[X)(TT #;^UR
M9*W+G2OR\J^!@[+:X9@K,UT==YJ>+8L7J-/ZY?*^Z$_[AA_UNK=<YQ_-BHB3
M9BJ'%'H>N7%2D\BU<U((%C!SKJR(C5T1+V6#=8H;0:E"/%4AURPBQZ5%!F@[
M\2H0:\FJ5L2EU.6!LYD5P"N -P4\YREV)*H4? (]X4X8'RF5+A(3I)+%0]%0
MK%O(TV\]CCX ^Q=1(!Z)1U8S@WRR@A*".2%DU64X"M@5L&M KY< .^:MEXPY
MDX+@B5IC4N3$2).$3L+P G8-!;MY=VR*2@MJ'/(L&,1#,DA+0I 7TF"J.;.8
M%K K8/>TP2X*#*H AJR6B3M /4W,_\_>FS:UL21MPW^E@_N9-^:.H)C:%Y\G
MB. 8VX]/C,38QL<!7QRU&F$MC"2,X=>_62VQ2(#-(J %=18;M'175U5>N51F
M7EY)R7@21$I?7-DF(]YL<)<XCZF7"5'B<P=N*U'F.D&"&4](4%9XME2N[#0Z
M.=<=@DRK[!;<.?,&U_C]T][GZF6$2SG"18;0>9,CZ!L_;*=;UU[DJJ.1K5N-
M_8BC<5VI=J]$^J9D>)=KW. :+R>I/3>KFG2IJENWA%@W&"I\>=<9DY0JJI4(
M)$K,L7/.<^\X44K$Y+$7]_6<SQ#H[6#X"?#GO&ER[J%V_ELQ(V]A1EYJQ"Z=
MB=0DABB8C8@;SY$F/"%KN!!2*)H,>\9Y3$6<SZ/^-KC L/(*<YVP-LY*!D(=
M,0Z&L(7XAD6F'T:F9R/_7KED2$I(YA;GW!B%G#$)>2JM),I;*UQ-SD2:E/93
M)'K1A1".<!=3-+1F.M5&RT@LX<0(99,*14$W4YCG(MN&^>B(1-+GQEA>>Q!F
MGKMCF>!!:0<<0U'0+T"<34I!,!=2X($+X[53F&'"+*<A<QD7!=U@F9Z-W5IB
MP:ZF$D7*%.+,)N0L,2A0,+@$L5$JW3P%_7+21U\/A@>Y!6P$07+C:G2V[0L'
M[+7&AJ&.4IJ"I(F+1)UFFFN2A)?,:*R+L=%$8)K/C[14AP1XA&#'YBZ<3B!-
M8P)C(Y"HB#%"ZT4?HS?HL+R(\ZDX)TX",<DSD[M<*V]4=,KY8)4VU@13C(T&
MR_1L-, QE[23#IG((N+6,.0$"PA,1J(UH5X)L;*NU*JYO[511+JY(AV4238Z
MGH0*=3]KCFVDFC@!)F<B-TS^*!KZL:69S+5%D);XX)#$%N<R!@T:&CMDG< \
MF 16U^+B]46<FRO.T5./':%&1[#87-!6^B0Y%8H(9^@-#>ZBH9]$IF?# > M
M495L[KP4 N*&@4PK+$%-2Z:Q(([))FKH!:4&-#<,,)G:RW^^'O1Z<5A3*QW8
M@S@L.0+7@927ACFE&&:><INSZQW5G 8E@Z*4W[!=7+$Y'K>/P/9&QJ8Z,M#>
MWR'M#U^Q,IP(PY%*U".N,/@0@4HD0M8W1+N$53F$> $"#>X"]M*'3'K%C;=9
MHJ/(P6SNM(R+:0]2I/JAI/IX1JH==][HP!"16B+N*4&&@7Q;!_M"L!@)%W4*
M.6>R"/4S%FIKM-!12.DMYX)8,$@#-R21%'RP)5&@J?+<GM728%<19;U$@,H"
M<6("<I(XQ%,T*L-T(+AHZ1<@T%@*342FW*.!>^&=L3H&$KUR)/&PF)8E1:H?
M2JIGM72,S%"%(W(11)LS8T%+BX0(32Z$I)7"J8%:^N5D"[1!&#^O?5JKO@U@
M3/U<(%/R!*X]A0A),.(\H0QS\"8M6!@N]Q[G7*L@BJW13%1Z,Q\1$$DD*H-!
M*0F#."82:6$MF!Y$1!=),'1Q:8GE'**Y LU]Q)PKT%*.\J0<^!%>,DDQ3A8+
M^0N!+H+[.(([Y_3'[.)IC[ !".4J$*13Q$B1!-:BD<QPO;*N&"U"^WR%%F.A
MM*(X!(MY$E%CEG0('$?!O,2X:.&&"O.<QZ]H$%0JC3@X XAS0S*9"T:)""$]
M5YG\HFCA%R#0"<26"S"[G*=<4&M9@'^C9)9BH^PO//XBN(\CN+-:V$CE/;$&
MR8 %XC(R9)S+=7K1DQ@MBTDV30N_G%8 M3<_'M;4S,?W3?]_$1%'9S"X\5Y(
M+7.?>>*H$9R 5A+11/#X2\2QN>#T?MZWYX8EKQ2X]3Y;%2Y:I!71B!+IDW?)
M69?KA]4J,;Q!$<=RC+!HUSYI3*,2WNC(L75&&1*BE9QQ[*,J-3V-E>=98X-B
M3[BF.>7?*,2%#RB?!R%-F:0A4>S2XJIZBD W5Z -<3B3^_"4(O>&&*T98UA*
MC0WUYH;G@D6@'UV@Y]Q^H1F5+D7D<.X)@)E!%@O8RR'RJ(WQQ)=TO)<@T-Y2
ML,6DLT(R[A)U"?[41@;E#15Z,0U=BU0_E%3/JFEBG?:!""0QR>0D1B 3G$')
MQ"""4([)V$"S>Z$'_:;)88$)JY3]96?,ZI^TT$F5'MQ/3"=5(/M!(+LU'RG1
MAD1-C$1,6H.X41Y9P3!*D3+.<:0XID5!=F$=*(C7G*=^=#ZI@GA/A'ASV:CY
MU"I(BP1C#G'K"7(A$F1$E)Y3&ZEE*^N&K4JM"^(5Q'N1B/?0I%(%[!X([.;B
M;#%*PC#5B(%!ASA/$EGB"-*:8R>#\2055JF"=B\<[1Z%5:I WD-!WJQ]IX**
MQCN':!06[#L9D9;:(LN2EIZP8*/)U49X5>M%)2<57JFEYD0J(VP,KU3C8^>C
M41R/JEZ=61=#9<=5LIUA]2,S U:@9FPUS% ^A&>JG!UU+J7<%<NC6!Z/'$NO
M]VSAK[ROJ?%Y/G@>57".<@?N5#8UP(="-@J"L,>6:L,4YWAEG9E5S4OPO$#<
MRX2XQPF>%XA;%,3->E/,<ZRBX"AZE3L[)H X"S@'KK&Q3 @"_Y5H>8&X%PUQ
M#QXM+^BV('2;"X\[$HQ(GB")HP$#3F8:FVB1Q3KZI!@%C57"XP7>7C:\/4YX
MO&#<HC!NUH+SB7CIJ45&<[#@- 5W53J*-%?42)6(,V%EG3"V*A96K/LH\?#G
MV[;[WQWK.MWZ-.AN//670[@,YCH,#G/2;U.CS&6(CS;$1PW6A\Z/TPM/OX_R
MAU^9>CQ/(5^;\+4?=MSY$:O4Z=M^W0B_TQ^-AX=U"ORIS#W0V.HKONJ,89+\
MC9KX3\W/!QW4+X=P9(=#6]<&L//: %C7N[5O>*9FX?,T_A9S0G&];WLNBQ>T
M7GO0SV=H((O%^KN5]><O\1X(S*/7$FP^SQ%8[PEIC"7" EX5 E.EQ3/NKU1@
MZ9G"TF).%0HL/1HLS2?A.^Y-4D@HRQ"WSB 3%$=:42FL)$J;Y]Q\M<#2,X6E
MNY\$%/AY2/B9B_O#.MN8,DM=/MKDRF!D ]<H4IQ+@'RR'JPB48"G ,^2 ,_=
M8_0%>!X4>.;2*9C QK <@L]-YTURR-J<4Y&2CK!X@6/2+.!Y]L'V25YO]WRW
M/TAR[VR@=C+%\[':_)S7GIP\][/5Q4_0L\'VAP[!74#Z<OYZ7\C_-A^!4Y1P
MXB5%*FB1>Q<"VC/E4="8.,^YJ.D*%MOJ;'%2],2-T@J>%CQ=NMAAP=/%XNFL
M"2U9",$)C9C0"7$L)3(F4.2#%: =/?CUKN!IP=."I\L6]"RXN5#<G(MY$LL3
MN LZYP&"'1J,1(Y9A0A1,@CM$W%J :&'@I@%,0MB/E*TMB#F8A%SUM),+%HN
M543*$(\X];DP)& DHA&*&1^2?U:(68=Z_S7./6I.T_LNY&[V[/!;IU_?7IQE
M;J[_7S?\U_IL2N =OP.35/<D/IVGR=/"''7MP2B^.OWAC] 9'73M\:M.OQ;!
M^DM_3&\TG3RXUZ7X<IZ)R=M_''7">"\+[1J>".XTO#V]\_3MM?JMN=6;O,?%
MFJ;FVK?Q&KGVO5]=EI U2>YVV5^_)]CU-RV#;>)@*;_197]S./-[^@%RZ;-7
MV" ^@NH:/HZNU7.J5EVI:K.RFZ!LK?(F/[8FQS9U!O?D%3NNH68S^MAS<5@Q
MLEJ!8L4ST'S#.7Q2V^QFL_+/3K\:[PT.X1)A=*F'^U7&\"TT2K,WQ(?#P3B&
MR:K_9]CQ<.%.?_+KAJ\3_5MV^#V>;HS<]_Y]@*?(PY]^;-+8!Z9N\OL%TZK>
M1/_\=_P1IY\E"YO<FQ1]/)M%^@0#Z"083']<;8WW0""W'%SI1ZWVW_</#L>7
MI_HR%T&9ZEM.]>?^X+?3S,HTWV6:Z]R!VVB3Y6^#-L')NY4E_JXZ]+;[Z,YL
MRV60C1[D[4RR):#C;0WZ\;CJU29(E6"*JG]>MB&N>+KE#@D^S]B=3,D[)R7#
M,7#.HJ41:^TX8\X;'R>G'9A01N[1#>&U'>UM]$/^Z\U_#SL_;#=[-<\WQK?;
M@['1K<TWK/WE[[W=S8_=UOY>IWW2[FYM[^YO;?[U?6O[SUZK]YG/Q_C:O=WN
M[O8.;VU[LOOE[??VN\_'6^_>LQ;]+-J]%F_U/HC6NYWCW>V]='J2W/J$:7O_
M,_G*@Z/<BH@DC03QH ERR3I$69*:L  OI-PKV*R:V[:W>K@CC-^<5!3\:#9^
M $Q0J9(RGEJNC='&2N6#IS@PR[R\&7Y<GWU2H..!H.-D!CJ29-8G)Q#56"(>
M.4:.JX"BBM@EEH16=ZU@*]!1H.-*Z"!11BJ)=\9@[JVU(5HCC8Y6$"ML*M#1
M4.@@,]#!4A"*1XDPM11QP3QR5!$D#"$N$]]JBPMT%.A8: T!I=1&10$;$@>S
MUR05 #>H-LZJJ'#Q6IJ,'VP&/WS0PG$/;HK#&G$C)7)"2V0P<]DW#5S3)_1:
M?A.].3V_AS'%7T-.^>3L)\O$EHE=KD\^^].0)R>%F3\R6V[;:P'/_VPL-BT"
M^'LZ2*,\CPG;E*0CROF A=&!+<1B>^Y==Q_'0FO/QY69]])Q[9&GX&IS:P32
MEAI$!!9,@=.N";FCA79_$6EX"Y("=2\.ZA)X,Y%PF01GW'%NF16>4$6]D00[
M>]^X5D&Y!:'<; B<!AN4P!0ES\$/Q88@0VQ"C&"E(PFIIK]Z)/:$@G(%Y9J-
M<EH2RJ,)S$>1._]H'I4+WE@=711!%Y1K",K-1NNC-"1@R<""LPIQ#WBG >%0
M8!A[KISQU!24*RA74&Z"<H1194)*42A.?7!2,VM#(LQ+X<0-4:ZXK8\#=;,'
M"S996+/@$2:.($XS54SFB['2.T=82MS(I7-;%UO?LSRD,-=2@ER;=GO'(K)R
MSQO<LS"N%,:5PKA26OD^6N#_I5,;/(X)M?5I+O*?F&,6:XLX]@;!\FGD% .+
MBFMA9;!"A\*W4D"I&<_6H!!] :6%@M)<H!Z4"64X(NH(^'4Z6&0-S:>3R6L<
MB<>RL*T44&K&LSU*1+V SP."SVS\7&%I1!08.2<<XF  (8,!?*R+40C!I%1@
M$5'=)-*# CP%>!XFR%V YP&!9S::+2)VL"]=;G.JP15S$1D=.2*)$H$#]3'Y
MI@'/<PE6/PBI2NFTNNAY>#Z _, QLQ?1:/61RIFV-^8I4@+EA&#'D3*9I#BW
M7-7<)20=CBKF.FMM[^J?/GE7U3N54Q:L*UCW5*&X@G6+Q;K9IM(Z<WEE0G;0
M5@GQ8 4R# =D2;2&B,!8*EA7L*Y@W4(C? 73%HII<]0B-EB)$R'(R(@1=U0C
M$W5$4<:(E=($\W 73[O@6<&S9X9G"PH<%CQ;+)[-VFA82L:D"CGEWR'.,DLS
MLQ%)P8+B8+P)Z982SZYF^%A_;.8-L\8YOPOQAM%K!M^,<6$:23W]P%1@60W8
MO\SJG#[);5K57LN94C][IY\[S;]B;$V)ITC I#4W /G?R=Y\W_?=PY#CL*/*
MPC3T#@9]&%XU2)6WH[W< '_R0SSOX).CM..]6%F?/V_[QSE4"[@&SS6"*SG;
MM7T/^V<OQO%HK7H]_W4[C/GCHP[,;_[\<7VUUY-K5>-!Y6*U!X/M'E?=#GPO
M5)W^CS@:UZFAU<'AT._9?*.CSGBO&L ^[_1MMP)7]G X"2[#X,=[PQBK'DS$
M'OP^K+IQ-*K2<-"K[Q7L..9/G5YK[5K*FNN7[#=<-PU::_J_U=DR=^#V>X/A
M&(WCL#<SKYU;+>H5?#W+-2GL?ZN-*Y./:U];_3&"+?,C=NM--IV:"^<4>YTX
MM+!WCJO.*)]2P Q-A:([.((IG7X9MEC>TIW<91_>M>/\\=&%9ORPV>>NW#NG
M+5FK-L95M'ZO&L8#6+.\(@?PN(.P6MGN69^1+*(7CU8RF\717@>^-G?IN<3A
MB:YJPT,/.W[R>S9..OU#6RNOBPLWG3N> ?U@,.KD#[P:QFY]6'G.H/2/V6SS
M*7;B\Z]8!R!Z.+[^*Y?Z^S_1_B!L;K8N_+DW/#?]OT7DAM%^1S;!8%_9[I$]
M'JW\:Y;V"A3BQ0F<?_9KGS"E!S)3V3\FE@+8E(-AO=JO#D$JA_E3,";;F+%4
M .-@*/]/AT7P'8,E8 LG[J75@L+_VD9GO/16?E4KZ]NUV0(R]SK;V'49@5V_
M:AE_-></NJO^[YR,3<QQ)6A25FB1 N;*<NT=(3I*YI6.+#=ON_I[+&KP%)CF
M-C N-'$>OJ*=M8E@J2E?6;\ )C- =1&"#B_R@=1(52O,"]48$^0:#VW('TA#
MT.7P,FCGC#R9N"4"Y  FVA\ ?YWQ."_"L.H/JH-,O9._V(?)'L:^/Y[H_BX@
M%]Q^8G74M",56ZL^@<)N#T QRU-8/%<_YT ]&H/NG@PK UTZ'-;4,3"N.IH-
MD[-V!91=\<K"%/YT+7ZS/[E9><3M=XF?I-Y^'/3V#.K/>J/">Q(X39A8RY7@
M.HH4HU$::ZHDD5\W:QI*^!>=\U'..J+_&0Y 0XV/_P/6PGBC'W+?QX.\6N?>
MZ#;<[\_NP']_8F=TZ].I,_J&M4[ #=S>H3O[WW#[Y -MG83.+CB<6]MA;V?_
MSWT8!X'W,3B6W?C_/A[O?@D'CG()#N4)W.=G>W^WL[7Y@;4W=T[:]*]>N[<C
MVO1MI_4.GF'[,[S_$1Q+__,KSOX^]1(1[17BF7K72J:1Q=1$YF,4UD]B!+!3
M8]C(IS,8:^>)BY3SP#V33N7?-2-:F$ #K$$$__X@[]WA(<#WI\.#@VXM(G9X
M7/TY-=P^9<,-[, S,;EL -S8HKL2C7X[S/4'WGN;T8T_Y=21V@S:^&$[W8QI
M;P?#3^!XU,KAY>Z]'?I52QZY41P1G\,8(C*DC8V(@=Z@QEA#7)K?2\TTWM]?
M<%OLZ3K7ZF $*SWQ+4?CB1N87^^"49Y=]<M>RYU1_]&#)(6>M RVJ8,M]*2_
MI(7;J"-2G^+!>,H[BE=K4,F*K'"/7JJA7W(2P(U>#M6<@-/R>C :%Q[%.TSA
MN^%@-*H^]X<1QI)G\IT%=[1,Y2*F\M_P>RQS>5>:Z2EQ<%4?L;XLJL_7>2 Y
M:#0Y.PFQCNJ6UM6E!]CO>(JLRMPB(F"9>*+<D@CNIHM84<; Y:^S'*8N_=U[
M@,WY^W/1@%.EG'7RG[FJI#%)$7>,!4R3(K[3K7?YYQ;>VFP=M;8_[N^<_+VW
M<](ZVMWN=K<V-_#.?HNW]O_NS"=%;&WO\-UW;SL[)Q]XZV3C9_M=>[_]Y>U^
MZ^3/[M:7S[RU^;'3.OEVW/[R5VIUYOI:2(<U(=*@F$A"7'B++ \$\62)\M$%
MB?7*.EV5V"Q+8[#2 ['@7]/P[U80Y_UA[[ +VCG41M^YS9>MYS_K,YIM^[/@
MWNUP[V2.(=9(:1F@'381<>YS'UBND>:&&:>E"AQPCQ3,*YA7,._^-M\ONEO?
M$0NS^UNP\(Y8.-O)P_HD E<1B8@Y8"&)@(4I(B)<#)YCZ\.=2Y<*(A9$+(AX
M?R_X'!)G ;(@W^V0;[:5"!?6&L5Q[NHH$&>:(6,H0TEX1Y4T6M!4>[\$+PON
MW3IZF>I_EBAZ.1@>Y/S"",+E8 ;/1.':4#B]W=-?B=1+C5B2>F:QEU)2QH4D
MH,B)%9H30[VETI:X7>.1:YZ)#@>)O18"2:8EXBI09')E4Q)1)8^-8EBLK"NU
M:O"]G=BK$>)!K;*Y6UZ?25!$^ZZB74)23R[2LR$II9(BFC/D! ,WC!&#P/\R
MB!I86.-I )]L99W<NZU9$>='%N=_+I$\E[#*/>1Y-JP2J!92!X\4-KDC#.?(
M4$>1E48ZHS$3!IP+>4F<+V59%4ENBB0WW>8N48+%"/)LE !'*40R,8MO ,4L
M%7*&8,2"X-H%JX-($UO[_F&"!8KT\\]C&O1Z<5@7DQW8@SB\4P#@IBV;EQJ,
M',6)"<JP\Y%[89RVA#IA03]AV,JB! ":#DKMU_.).Q04C*,<@:?O<K\Y@S1U
M'F&=O%:6)B%<YO1;Y8PWJ!'R@HYEBFC?7[1+ .#)17HV . 5-XZ'A*Q-#'&3
MLJ] !))*<A4Y8=+'E?4BS<LFS;?Q_Y]:G(O_?P]QGO7_I>0D<>Z0@K_ ;6 4
MF40BLA2;'+P/PN.5=7H/_[](\G/4R\7_?W)!GO7_%6-&>V514EQDFC6%#,NM
M'Y)3&@?.A:134_MR-*^QG"/+GPG0!@G\O/9IK?HV@#'U<QN!D@-P'1XQHB1S
M21A"%??2.89%-"XE <_.PJ)RUXN7?R_HF:>=98 N7"6%HF7@$I!\.F@Y1=@;
MK1C1Q$IP"12[;$640\$BN@^<@EU<_WO(^:SK+W52GON A $W@1,7D0L2' 9G
M%/&:!1H6Q^1:9+W(>HD+/**LS\8%#(X>QT@0(23+NF%()QJ1Y5A&KIUE:7%4
M\D76GZ.LERC 8X@MFXO.2Q45*&:;8D)<:HV<)Q99JVV4FG'.=--,\6>? E"[
M_^-AW1WW^+ZU "\B+FDB=]Y@%T*PG'AKB:;6,2IA#V.?0DD%:#PRS??PX)1(
MPVV&HN@1]T8BS3U&PC$+?U.K<BT 5:O$+*J,J1PY/"O1+O& )Q?IDSF.<PD;
MEAH40LX=YD8AQS5'40ACF#<FV;"RWB2&\R+-BTX%>&IQ+B[_/<1YKL,"8\K1
M"$*<<G@/-#+2CAADE>%4Q$1H$%=UFRFI (V5Y*:;W"4(L!A!G@L"$*N$$@+1
M(!GH9>F15H(@PKQ*3GLA+)F:VDW*TUM0*L!$,EF3 P+;@W'FELG,:-4\,]IM
M(S"_Y'6\OI/#LV[[LLBI>38 +P23%CN:/%4<<V5@BG@^H)?4DB1BB:DT'N@O
M]5?0F. 0$P(+C2,.JXB,502!%O<D,.]@<7/.%U[5\MY)7PL4JB<^W"F06B#U
MB2&UQ+*>'$IG8UG,&1-HBHA*9A&7DB 37$)"8D(4M3HZ!3;SHOI:%!0M*/JL
M4?0V,<2GAM$20[P'C,ZE#24A&=,!V<04XBYZY'@*2.MHF=>,6Q)6UB]WZ;]U
M.Y$"H 5 GS6 -MVS+Z';Q>#G;.A6$RX%<0SE!46<BIPE012*4C*=@E0DQJE'
MKQ>5P_644%K'?/]5\Y2>TIW.$P7?CS?UD46W)HR=6X93$N.G(,)^P13$[*LP
M3 8K!")2&\0#%<AX@Q'+F<R82"<56PX*XM/UK6P_5/%T<:^G'FZP(%R8WRDQ
M<8:6R=0N#<FQU&OF(4B.V9I8'BI>&"REBZ3B?8Y,LTM%.7ECZN [4BHO];1L
M1C^=%7(V*_AE<7*^/1R"%W(XC+4>&J34\?%<'15NSL)*\KLD(TF9CH8KS2E/
MR6@6HV5@B3$G ]?^II&^:^W=.K+W/%S0'EQY\_-):_NO3OM="X,+VH.QB-TO
M.VP7W,_6_E][N^]V.^ VTGD7='>__;V]W?K9ZKV'\7T %W1'[)QTN[O[X7MK
M\\-QJ_?V^V[O/6UO[Z;6?#4_IT;@I 5B)E?^!<R1#8P@'J7EVB@2<@AO 0?*
MA62IP-ERPQD1U# ?%:8V\$2,X4E$K"-17G"<7 UGF%!&"IP]'IS-'NQB&Y5+
MSB%JG$><6XPTCPS!"@43C2$R$Q8HHY<%SIY]QZ1_1SN*>X-NJ#J]@^'@1[PR
M+[)4:)^BD"8A"1D(YR%P&Y.VEG#-O?,Q*&86D[E=(&IQ$#5?&BFH5$18B51(
M8'%)PI#E4B$LDG:YWZI/F>9W%:SG!I5METX+"Y;C"-O @27!5)1<,.I" N."
M6$<5U=Z(ZZV)(L=/),>SI@:)1 3M'3).:<2]]\@9%Q"\BIVBEF!-FB?'SSYJ
M]6_K,A7C8'A\?:RJU(&=UX'EK'*PC9D,W%!A/).4&N^MY%:K5$(TCP\T\WG_
M#/. A<H^32*(,YJ02S8AXC5VC'!!K5U9U[I)U5VE8'/!@LH]]6 Q*(&MYY8D
M[6D@5'FOO)/"\!)\> I!G;4( B/:&,H1$Q0C'H-#FE&!8.4,>&TR",)S+'51
MP8<FQ!?N8^#?+X:ZU.+\*$E\1=87)NN7N(Z(E#)X%I$FS*'<$!E9:W'NBT(,
M*.QD35A99ZN*+#AQ[^E/3@H"+":.IZ0+1 9+# \V:B8CPS+WTL')6%/\_\8A
MP-Q1 V7>Y;8I4CD)VAX+Y(2B*'"7L$DN1:PR DAZ;WW_6 CP_(,#<32:=K&U
MYP5"(%\'0Q @6\ML3G:QD]+U^H47%CQXG%*NVY0BG"_4YH5U@I^[,?\ L+9Q
M8;FNA;R"=K=!N_D\$1&-8IHG),#CS-DA-6DT00XL'^V%3\S9C':,WJ?<JT0@
M&BSMCV*Q%&E_&FF?M6UHDLZR&%!(F2=.< -^CG(H..*<X"$&H[.T8WPYZ/@D
MTO[LTR2NK@E9K?KQYIFX-ZD P[\J GONN6V+GZ!FH_\35.U?"]CM6##[5IA]
MJ>4VCX8;SU$$FPQQ*P@R(C)$(M;,1(.5R)BMV6,4DMY*2I:Y,K_@9<'+Q1K+
M!2\?"B_G^,V\4M@'L&PQUHA39L&C#0II9KFVFC*=>0PEO?>Q>F/P\@;E]_GW
MO(\[_</:OVI@.7&]TUF,$8-L@0 E[J75@L+_VD9GO/16?A5TY1$+HB]5$M9/
M(-:J!^X$L 78 .O4_U9G48^V4@YP#H:;G9'O#D:'P]B0C@"DU3E%B,]'[=XN
M? ^0@7[LMD%*M[;_!(38H*W-#0:2V]OMO1&M+^W>?$> ]O8&W>W!&#?A3N\^
MX_;F>]%Z]U>OM;ESU-H,O3:\N[/]_><.W4VM[<\_6]^^8D.X8L0@D.8$-I&1
MR$C+$7BW*0@B0=3I!+AAP\>PD6,4B1DFF3*4)\R9D(YCS>%+.##*F9&7>@@\
M[!+G%8UQ;J%?\+*>M#Y\92QY3FA"5D@P=7/G/IT"19Y0+BQ @_-Z?EE-(,;[
MY(BFG)-$-"Q$4IQZ1X67-,POZV2BKP3(F=^OZ79PN^8E<Z@[6=3?;\39)PR!
M&O#$!%4T\$BBL_"S#,:9'+4):N6:^_Q^9F;O0V, %X.%*!7GVB23I">9,] #
M(D=&F]I68Z)0-D:5K;JU4*W6?31>#WHPF./Z6$C],:K\X7"8VVUTZPU0=?J^
M>QABU1F/JIX=C>.P2M9WNIWQ\>0C=42FT^M9>*MCNQ<:=DRNL%K9;C>7E!_M
M=?Q>98=QTLD#='T,U>!4L*>?!I6QF"W5R"78/I_OZI\VK\0HFT!99_TO3--H
M,/F]GOB#'.6%B<I3ER?_;-;' UBWSC!4!W:8>U"!&0YS65UKG-?7FP]GW 68
MS^WT]^VW,U%MF ^?(]M'8,*-8O\4P_TPI%<3E0R X>)P*WTZ?;XSXQV_- S?
MWZ%?N6".TJ@1E=8A[HE#UCJ-A /PTA0GRLG*^GAO&.,E\[L:15AY$+?SS;)6
M;4QD# 1Z=.'U:L_^B)6+L0^+EWOOPXX,>0.Y>$GR)@>_N=N!]V"^YW-A6.&S
MFW6/JS0<]&K(V(LV3+ZU2'%],)&LK_BJ,P:?P-] 2%L3E'M[*F^U)GPIJ#1%
M?UCM@?>'!QE>K@66T7_3>+&X@F]T5G8&*_-VX<8PVNP#P(];D]&'/X^G3_9R
M\69[0VQE=V![YZ1]TB*MHZ]1)X$C2\BKD#OI$XFLT1;AJ ,'LXLD ^AC5@6^
M3$Y8C?Y[F%$"EK5NQ37MBY+!HVM=!?L7?NOTJT^PCS<[\=M@K=H\'&:8^>L0
M=E5>]1F[HZH;X #8=/J 2_ E6&(0BG!J7'P#"*RM"7@7;)%A_6K6A]/]&::W
MA+=OLU&C4QH 6+JH#8]8&>EU@N>/UJM(C:TW*CW=J I^U@O<J/4?[<%X)XYA
M&N#Q/-B6YYNW[-7)7J7@ZR0=+'4JHKP:F4G3(\.#0<II[37UA.2D<D)7V>\V
MZ\3^]-/YA@W4K_ZRX D,CRO8DGFY)X>+/P\ZP\G;;Z,;UN]377] K56?:ULK
M[]]3._E*HWAU>K<+%[O84>D*,9@JX:4$V[)?I_NU_>&KR3PD@7J$F01LQ3#Y
MAG.+HN2!4NF2)N!=4[E*[@BN:]7V7N?,+VORCAD,)WODU.8OVV2Z3;8V<CZ9
M5=1;E"))L$T81:"/!")4,YJ\C90K@#6Y*F^P3:8:<,^.*]@9I]9_N.0ISKGB
MOP*GO,MB!?Y"IW?8JWJPB?9 >]> =W@&@;.J&F[]?VYQ0A0B!_RV,NCDN178
M,<^$L(%+)Z1D?E8#TSOF55T+7ZW)(WV$)_J//9Y)F7IYVW,';VV_I^V3#[B]
M_8;#]HP\80DK@@S.G>VYXLBF7.8=, Y@+.7CH95U(5;Q5=OSJ#/>JTVY/JC7
M[F37Y.AB=Q)U@PUX[3[IUW&"Q1IK=;3B=]JL'FK>#>^G1N9_XC W9[3?SG$+
MT1>],]X?M[]]50P\A>@)$MH&Q*7AR!G.X \EDHA>Q"16UB\G6?RC@OFNCJ,=
M5BY^Z_3[V26X;()EW!D.#K_M78:DR3XZF CK:!*J.#@8#GYV>I/XQ&W0YYZ:
ML*#/PO98>__-R=?(-/Q'-*)1P:XBQB+-$T7!)64(2<HSO[*N\=5XDW=6K:*>
M8SCJ+ YU%CI]SK&H^G@"C)+#;FW9^,'P8%#'.N&U\?#0C^M80C9_JX-A_-$9
M'(YJ4!G->E,_K*\K6^QI&/U2%#W;U'MVQEJ"[Y_%$DJ$?7D1!<9TU/KVU1 A
MM(M@4Z>0"U-3RB8V0<RGF$\4#4GIYC'V\TC4Z-2YS\;TQ(;^A0E]NB-G3WNR
ML9POFY7@K!(K[MP2[*]SJVAK\_T)[#47301+.2)!<\& = ;IQ 1B/"\'_"N3
MO:T[-P]"]G*_\ND^F]-ZEY.8KDQKNK?6F (WS_P#!X-1)U_YU3!F*_]'/*<=
M^,?L@?@T 0R??\6ZT:![.+[^*Y?ZI3^1<B)\;J(O_+DW/._V_BTB!Z+R'7PF
M&.PKVSVRQZ.5?\W2073ZZ.($SC_[M4^8T@-E>+)_3/+I0/ZSRLTK4^N]_"D8
MDVW,6"J ;("___E]%IQ:6=^N639 <%YGY*Q;:]KUJY;QRMR0N^:4W"!'Y*'3
MI@"A,_%T_?PO.%_JN+7Q-7ACI 1W%4<C$'>&(A<M038JK@+! @LUG^43HS(!
M?%WOJ>$N$IAY[6V4-%A*)([+0:63+1 /%LB@7_O,( 838P;,EMB'OX]B]J)'
M4S*=T554.DM#4\/%FGX(FAJR)I>'IJ8,]@$'2_DB"8"N+;4VRTD<LYT]J:J.
M;(VJ-_7!P"RYS@(X=99T:MKPRDUGY@731]VF J39"WY##JD;/? -"*:>U<3A
M10#%#>9FZ2;F7CMJ(=MIZ:;L22C+GK1&<VLVK1>><U2XR@JYS^_.0W'P7'.I
MN+"<1RXMYL9%+)U/B@A-IR$']8OST%^5YN5(1%/*=>\:A9B6Z[9^MC?_S$6[
M>^W>VSWXSM$.;8G='GS_I$5W-^%>)QLGNYMO\'RY[L[)&]QZMYN?A>Y\>8/A
M.OL[)]W>[KO/K'6R^[WUY>_]UF;[>VO[XV7:#*D$5EH:I"5UB <=D=7>(RJ3
MCB'2X*D!R--D69A]"E%9P;('ZA5NK5':>LETX$8[$Z)2.BBG*$_,NAK+\"F6
MX8)E#X]E<ZT'J'5,NH2D-H!E-FI -4Y1;M&B--/*XKBR;BYWTBM05J#L14'9
M M+4"I0M%LK(#)1IL+NTU!)A,)H1-Q(C4#<:B22Q)MSE&O:5=;XPSH."907+
MFO3@MS'+DDX<*RDU%SQZ;1-E)!@CC0J!A%.SC!2S[-&PC,U@62+6!' RD<[$
M#CQ1B9R*$6$G7&0I&AIS:C<7RX)ERW"4<NNPWEE"8J?O![UX;4R87OF<S[ O
M\\)#5Z<)CN_K"2Z8<AM,F2=O\]$D@9E#+'J,N,0,6>8H@H5RE@7KN<IU;OAR
MV.JZ/LH/9^3<H@?Z,Q>IA4=0BDC=1Z3FHB>8RF@Y02!:N7L#H\AX9A'#+EF=
MDO.1KZRKRR581:*>D"IDT8Y\D:C[2-2L$V])\MQ1A[2KVR0RC9S X,DK[%TR
M+ KCP?#%1:2:)%(+]R>+2-U'I&9]21Q!29E 4 )T0SP8CUP*&C&;7S8>NT!7
MUBFY'!=[2)%Z"0D@[5Q$M+@DD-+V_1$FJ-F@_)2^> GMW06.+]&U1F,#DYPA
M@9-''%.!3, !.66P3R+IF+L2$7VY./%>H;TE(,=8S#E&0<F"DD\87BDH>4>4
MG(VLJ( -CSHB)8S-E+9@M()SD>D>A4R8$Y^;<E%90+* 9 ')94M]*2!Y1Y"<
M#98)+RTAW" &/R"NL0(KDA- 2L6\$HDK4W<N7/ I<4')@I(%)1\^"%I0\HXH
M.1O_] F64E*99STA3IU!#BN&'$E9DV&&<XHSH>K9H.0-V-7NPP_T +U2ZLY6
M&Z-1'(\V^N'?'>MR:[A.'$TZ-I;.*4=?K8O$6'"&B+ L]V44R)CH<@X'O(H)
MN*MI.3JA?#H\..C6_=MLMW*V:_L^5J.]W'*KTY^T0<M06[>OFK1.GG9D/[*C
M7W9(^563JJ7IG2+UFGF(WBEL32Q/AP\8+*6+[/#Q''LT+%4%^,;EEGFU=KEA
M,?TM2N:7<%HN-JP\G952+_]QZS/ ?;8)2M5\*6GX78Q*,&FQH\E3Q3%7)J7$
MC59,4DN2B#7+]5V;AU]=YO QCW0K?1[%VG)])EX:>%3O_MK?Z>WN9X]K9S_S
M9K_M[/;^WMO=_*NW^^5MS9O=WOY.+G%@;_NCG5X;/MLZVH6_VV#<MK[4W_G>
M@G'L?('GWOY,MK;_3N"=S1Z+$H.U2<(A0;  +XT[I*6RB'.A&-8DXMPBF*UB
MLF _[;D$JPK8O1RPTT1)%X@,EA@>;-1,1H:E, !O"9S$&NSP53PM!<\>#,]F
M#S!YH"QXB1&)R@&>184,D0EQYQ(F,>:"U%S!=3F1M:%H-K5 3P=RNG4G881%
MM@:[(F)V!^O_8>[Y$LSPUU,VO?G,Q>YY5.ZVF_,%:*'GJ6CN;E7_2M&<QG>/
MIUNM:)K;:)KYNK[ N,**)Q2\88@'PG/5<$(V).]%H)[FA$)A^((TS1*9Q@5W
MFO1L3V[@%MRY'^[,6KBP* D;3)'6U"/N?4!6"(F82HQSB8.B<F5=RT4E,I<V
M!+/%)8,^\K<WU9Y'<5JS X-G. -KY O4W!IJ+M5,>(H%@#_)V)(I>J5#6EF%
M E6,!$J8BG9EG:Y*<\N>FZ4X=-E5>1&QNXK8R7SA-0<8Q"@&F\N2I$8&5@I1
MG:PTSB@C<R/(QQ>O!85<)G+%UT3#U?KV(&?%+##V4HX'7MSQP%.:/ 6%;X/"
M\Z>@E*4@33*(6BD05SXBXY5'$E;4I$ ,S88.6Z5Z:3J_E5/0 G-+:5D6)+L=
MDLW:DUIH8Q6F*%B7&XL[ BX;.&\N<A$#3I8$EJ-#2]-9O)Q_OI#SSR_U+S$@
M"Z.RWS+??<]V^N?&^#@.>__?_VA*R!]S=OKUT;;[S5%C8?KJ.I!;F)\7#$X8
MBG\5#H?'T0Y_#=&G*[0Q6:"/I^M3O[D-JT,*8O\>L>?/$;&)SE /VS)$AKAD
M$3D)OSK)@Q?<4"[TRKI88_/%1%5>L85L_9N UK,7G]N8-45\GE!\YA*^6.!<
M<XZB3Q1QQQ/2L&Q(<Q\Q\8[8D%;6R1J^4GR6CG?TKLHT=$8>I'=<P8:,M]6B
MSS-FWC_,M1\+B>'\QK>9D_S-Z5I\A*7X3QSZBT%T1 L(_!8$MN8/JK2)  )4
M(LR]0)Q0BPP!':J$Y2P*+1DV*^MJ[99GXO?T7YYBM_]C$45=+TC>[Q;,*/+^
MV/(^UP \"FRD9RC2*,%F%@H9*25B"0<P 5QP'FQFN7;+:.W2R_O-.A#\LLM
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M_;B][>G.B6>[[]J9T?BX_>VKHBKHY!VB(4?Y<QLJ$S%%3+NH<U=:+M7$Z +
MC6$CFTR<<D8"<TY'S+77%KY&J* ^THB)\_,,R.>K4KWM]&W?=VRWNK! U31/
MJ_IBAT-;;]]Y-7!Q*\\I@,FR_79,C[+YK\;A.7OE2L;C1I!"_PGV;:@.#P;]
MF@OO]: '@SBN5T?],:ILWW:/1YW1*=6S'W8 ^CNVWAX6KI9C;]7&I]?5]N
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MS?7N?*C==9\,D_L5+#<OFGSM@<HHE^R.YFL!+$V>4THT]YP9Y5+0*429X(?
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MW,V 7%/9RRCY(9,0-OLGB6_)*#_X8W(6=)3(=0!.O_O"-PS#1XHFZ;]SUWN
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M4KTN#4.$3YK<N7D\\!!@GJ"%@&IHP#P=[26<*QL)(AC/'T1P'SV(<$&9G/F
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MA^857B<B 9.75Z$(E+"33U"/YSSA^*>HLQP_RECXJ/K%5?2!K]Z)X_H;<_6
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MIO6F^_K%<G4F])$' I>=[07'48_WG@-1F6/S+% IL=L/[R#7!]8-Q\>U,!Y
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M5F=PO6,MGY1'()?.W6&E 4UL]@.LA[Z.6Q%3*1W!Z%SS(D0 H+@YS6%?$(D
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M"A[KM]@NL%%4B24\)8R''_FZ+$<B8A3(U-NZO*^%[WA***C@(.-0RT'?$.5
M6VBT/T]WYD5A=;#34%OC*DTU5>-#&7K\-,!PUI_KQ=M!D[L&&UFX"YB/@4^[
MDV,:\G%);^J$(*O.LY$!R]^TGLN;#EN8A(UJM!E+N+HX_T=63(,KT1]83S;5
M^T/#C)1$!@*CL=1'CYXL<;_*5$G@,GSZY/S]R>G%*8\EUYCAJX/.#2AT4?)(
M'G9S*:C,=;#+.KM[H8<=0R/&,Q[FP=N#U[L'->DY 58:9?,MF''FPESC"*R?
MJ@,VNA&X1Q:]'*QW_U"RI^DB1Z6U9-RL6KE]V99DZ=/EH7269ADL@X6W&06M
MF\U%..36RR&CLA:S5;MDE J>.?ES+KWJ9-&O-"$MJ1LE"<W3(6^?< + C ("
MBLV_L2=ACD723"2!T"A3#\I'G";I#9$N_1X60O/E3T$EB8;8?HP-0>I<7)U.
M/OG-8J]"PXT?S(T/+XY.9$51Z]QX#BM>FQ,G) %K:H#A#%0_:KJQJ#@X!VP9
M!73W6,OS,^2R*@Y3H L_!=4R2DK%M&:8\#8H2[$@YA:YF^U8R[$=5H"KOGD*
MIE+["5[HC'I@VO\@4Y>Q5>]B/XLSL1LNLRF=3W\L+E.SRP$3*?/-O?HZPLD9
M#6-9'8M>B]I%&B11CC"=]9"BO_-N1J'/9Q2R]!>%!4[SC,"Y'U'BIZS^:9JJ
MC\#$E4](AN'I:5KE3*Z+34C]7I'3(6SK'<7<W5CZWS0O&WMLA96Z?(M>9K?.
M*(&[GA>^T-R[F\HG=6=Y-=UYF<#"<CG."PW)QHY<G[N\:.<C*CR#+.KC%(NJ
MV+\:CL1QG=<> #K%!4N [S$/(@4L[T<LVL""&KP(X=7!T?NK_("SY#[Y&?6+
M/OP>LW+8@-T'UW2OCN 2%KQFHT]9^6TI9\4U%Q\T=M$#W"<E^;XN2Q2J<B4V
M*;4J>:UY-T&*X&NQ^584(_8X_>[A>]!>/A:5C;[*$96 -5,\,ZI-H.0=H'_0
M4=GJ&E/Y:KTL6*P)66(,XI=P'S8/EI3GE +30[Z':=6#X8Q;NBU=SJ[!!XF)
M2!Z93KT/*,_0\"-:E9?1B82VX6V*E1\4)[N1@)$%R\D(@-/WQFFX9+P4-H'E
MM6?CON& #WR1<G8<#[Q//!YM3C[U#"#%LE>8N.!M$N@@P@58[DD\'/<WRVJ1
MN3)RSR* .)<^\5,QX[36P9SM@^6(L!'"5$2 )ZIS0/[4\D\P/I5Y*<NP1#$V
MWA>+SK-2R+(R*::3$.*DPC-BQODT: T5.5_L-HH#&4/^@"P8=RQ30=AILL-G
M1;WB!$5F0OT,\81X&[7)U,<BJ0(4O. J&Z?ML%8L; 2GN&(JAE4"JUI[J@1@
M#CNH>0Y$R'[F$E,^^815 ?T!G(?H ".XR.MZ\*M">[;(M'XPE1($5E]OLO*+
M!=3JL;1Z\S] RQ(:HJPI2V]9L6IU.@PX8OY@D\5893&J31;C%NQE9QO#S<<J
M5G1$XGK>S1.7M4S.87V6>H&%@KTJF*PE*M;8&DL0!V%]@[4!\:@VZ4.H@:46
M J^4QE%0II!C%3KS"^B(&^;84BN3H\#*8D%S417;(]6MW)DS*0;?2-I\3HWL
M6>6NB2K?B__THE7#(S(D9;D]5_VJ%OJ2PQOHM-#_0I@RB,7!*'50O<+)T10%
M6=8:CVA'43X8#W"E53+@8*&I#B!?VMZ>DQ.Z%+P;%^N*+E:'-]237AG:[Z_'
M-,=\)I@+C)7SH+FFL$>IZDJQHJVHFE+_^H_^LY6GW>GU,)R[W![:<[)@-L;G
MEK(N/FCSE_VD9OH"D/I(93"GBB$P[G#<@P=K#;-A5.?=KPX^7!R\;DO_6_4Z
MQ-;W8\]#=6'&>E:_.CB_N. G:\JJ_GLM/ZQ*-F>,OVRV5U;7#](!IBA7>;]P
MW83+C"<(X83Y'@@1GE T6M1DXRF)OX,\ZV'R>]M(7F\S"*@: EW7I%>Z4Z?Y
M222;0JX2L1"O&-LO,[W0ID3B%^V4:CCWX:(YQ\<\1PQ]P$YJ99ERB,Z<LMT'
MRU<_P8X-M;,JCU4>G_:X,THNN6VCG+.#>E+9;'Y$AR6Q\[9!S"N#QWZ7H$!I
M,,UA<$>(3_\7Y(]LMNWR:94NV;"3'4/#JRGGCVA',ZT$#.(B+_TJ?]0]LY'(
M>:V<TSL:@F-)$+L>=IN?U[/!_!WD*LSCMF*6VUIU.FV)5U)%&;8:$RP$BT50
M8C$.4TU\?-E%: B%NZ-*FXW"+$[?.D]&:$ V = U J M3CFL8+[*W&)]T!?$
MNV?S+Y NF%G!]/>0-TID],'OO:9]'S@>5H3(53]KE*$\-%)A3.6BQX!DDJ58
MLS Q*<^H.7"$^I%'/T4R1SD6!S.^IH:_L'#43F1^[9Z88EC$4G!V74S-3PQ;
M74PUN5YK^R9>U9+G9A*_YM85+U$L*RU1+/NBO;3+IX&(FD0>'!<E?JNF/$X>
M&EQ2>I8P/R-+61T:5PQXP+HZ$QR7B*%+5ON*9:FO#CY<=@XP7NK'HIH0W?51
MV0Q(8G$W2=5 UZ<_N+OJ#C&%)UWY_2G!_KH8+67W[6>-](+,CGD)'3C !;O9
M1WF_[&Z=X@EUSSNSOEG$@88+KLT%RX[196Y E5@RSG]@&1)%/EN5CFB?4;F2
M6JA399$8*C*9V,"R /)Z]Q% 4M[]]A6VZ@"*>(T$RMJ9(,VP=B:BD575PH&G
MC91;OJ/?98,4#T**R<2.LME77K4^$^<B>G/42\\7X0H8LIUJ!B&ZT:9S=WB/
M<IX?F/2JV89UFZUJ(8#; Z@!EK F-V \\X9K]W>L>-$<E@5(N;/[[P+.3:N"
MHKGH^R87@W*T9C 332UGDDBJ6HNFL@DH;#0JO-!EZI<UT55]\7G9Y_H=30 ]
ML&,>+L*-C5RZ'+%.MD6_*GSJ7!Z>R^\^53.TJHALO6!\RHQ?Q72O"U2I@[UR
M.]*KY%^JS96\O_"#IO /A](K5>?=2V #FOM[2S*4W[F/Q_B]KO--SUCF88+2
MZBLU'IH$@S3BVN*,*C*LM =NB[(,-Y%(BET(IXKI<0W8/NP17<N\F<B<UGN9
M"&'7C-5R9^4.)A09; 4B8P"D+1W7 %Y!>*+-9UVQ&6?K=2XFL@5KSGD=6$,?
M7L\?8M/!:D8"UNH3--3+%B8^MZ%+IE<VP2[;+>4+7NCRJ Y%Z0:>5%U511&0
M+= 088L]F^I [U8)AE7W9FRW*SKXSRAQ\#06NP0%$O!^[*JO=UH$1,$WS>B
M1,S)W\.\+-XE'1L1\-Q!WK*][.&88QEJF3&8SLBM.JY/B;E)J<H<TG5U&/%D
M,D%/4%#]@*:PK&E%N(DD/FT2%DT27Y/$]_!6'N6T:-ZX8]%LT>WUUM5?8@/^
M.NL9^\ESA4JM-"H<=)8D*8[]X[8(J*\H]ZL)G/\FZ'9&T?:^+5T489B@W[;;
M/FHS=>P0)%I8^6O/D>,+A^W?!#=^W);>H\BCXXM/JGD_XG(V#(-Q/2:HT960
M2+0_B--1G_>/GYAGT,VJ-=.I]V$/9A<=9=5N\:I.<5V GF^T%D68=DQ#QOD<
MQ/>+LND@+Y085I4154*A&-RG"/B "O.;9BJ86A#%,0IB,3DR9:DD#!]8/.*:
M%6.RW$!0C_LL7^F&)H5(JN=!!S'B!/<R'LL>I^BF8F/V^ @O*2PREBN/Z@F;
M0,$[08]['XJR@XB6T]&63P38-=,&#X[E--??'Q2E-!.ST[@R#"J8\+7A"![1
M>6X\2JU/?@#%B$FO^5B_RH?5&$(^$9'-N,%'SGD:&S0UQ)58&1A/#6[5[N==
M^ *)]($_#+G#3^  G]4:E#983K@$2HMR+$<UD)0/6,1<$/X$X>- <2!FR90#
M(T#9Y0,0Q>OT\9K)>:11<I/&0IV?&D+$@ K@"2(F8WB/K>P''4[W[8]3-"B*
MK'*WC&,5"%'LPLI>J?2K3@RB8TW-!RQD#7]@S#L7XS=!4X5[64_#R=A'F8J#
M14H_Q3S;JJG[B,?J,$5(M *+X%V82I[SB:&B71F;G4.P^*E&:CYAA=)\PZ!8
M%QE7Y,79<0_M?))# @;U6V"6&!&"$"JG]2"X>4VXN$T42F77)*G:RO.$G[G%
M,_!DV+Z_M%K^+$)Q"X>)A:'\%XD9MEWV*!V"Y<S:OS93V=?K(XBU"0G8I@!7
M3\ U9W E-;@*9],"J=E,O9N7GH03X9'+=7P?Q0-RB@]IC.6:#9JNI\V58!P(
M,,ZV7S^].NY*=EOJ=LXZ[XZ[QV=7K$N/_>92.CJ]//QT>7EZ?B9USH[@G\[[
M+Y>GE]+YB71R>M8Y.SSMO)<.S\^.3J_*:RZ.+S^]OV*7G'\XONC@#Y>E&+]O
M6#2G&-:J:-6QT=6<O\OCPWMG2/,NU^,<=Z!E-A^:BWC<J5]BXCP0YA%2_/S]
MK)@V(D7!OPZ6L,BM@V<GSKDGN]U4^3R NN))3CSQ^9CA[K@6J[*:$,L181:9
MC2\=A L])0NP3U@)VPVM[1,#5^FP;F<SE_UOCM6"IX[3>!C"BDQ]NA!A<SZL
M->,FVF^J/KG*((O@+XQQIT%;NJ@L>W@@&\&$;!5MNEQD'L+%1<Z<ONQCEHY(
MS PRM*"8;8\#H6)LT%QPDP?6!J-%3)$$*Z-(:B9C+5!0/9W5LH$A49\GPI\S
MPNDA\*IYF5-1,TVKN:J$S;VJ_ CE"F(#=-Z<R*W"QNVAW9K!>%0S&(^%P;C=
M8-P^HKZXSP)G8\=Q6D)0(FTUJGU1B^LM [9HKX@I(1S.O#J\BH9E <UDV&M,
M!CG]L_SC31#E@YB,_HP2]D1VTYO95HU3Z27L9/G/(J+DNFW'1 _]_QEF\$]0
M/EC$F]HLWO3',)C]S7#:IJXO_%EIJPM_NVM9+.BUK+66O?LW4]?V?+-88[S<
MAOY@R, 1 KUO@+K_.M /IAS)?RJ2RE"V7*^Z5#5GKM4&/_'J-S/!VID4*(:>
MFV8XSKVQMF4TVHJ*5P#2G!='!_PVO?8K7@8)6@HH"J\G7G+^NPFVQ":C#H:B
M_T6YS9TZ<=3X-O7""\GAA0).:0"W!N!.R\RM5T=BGNOK5=B*1_P?UQG.3I/%
MAGV?TC"\"PCS^ U \NF5.@: 2Q+C4!4>"\V') QY\&T:F^Y[X:510I&>E0<O
M"9;?'N_]Z^^=X2.WZL5-39W2D3<- /QU14#<Q8KNH\!I=M8@\GX@LJ%J#2(W
MB+S[B*PJ[I8B\LK*4<C^MT/*T3#U?PA/,4LL27*6+K)0U=96>_FYE+>%&&@;
M*V+@_(-^5&XY]<B%5LP+/2*E.:(M/R);>;X3>O%F;%7ZQC(56<+AD(T@Q:*I
MR"^S V/B27DQ&,3UU)Y5T&\.7'8$_?36ZCQB/A8\I]+[P@]):ZGFFO9W<TA/
M=4BNJ3_?$=W#R<M(9)*R.K [3G67KVR L _6UPE.C.0Y,"Q!!K-S]LSRTDVS
M4>NW^XA4QVF.:,N/R+)WWO1BS[99^M?V<NPR[7-^GMB:_DN10*4##(*TP'2L
M\D4:#_?& +3=!&R 6;2F[;HY&.U&N*>AEKVG%JWEK*PV-M324,M^4HO:TMR'
M!5B?D5J8<OD'RS??]M3Z7:IC&/<%\T;2;VI;+WN,K%B\5*]<XLTE^E34*F$-
M+*O<'+>7*"N ZMWD[NUZP'K#\59W "DI*$0/C)R5@D\U22N#)*)=A?"K3$9*
MQ+W\1?$ERQELD\T@9AIGU#<G"F]QSMM4-XO69,54S<7#'SN&O'@3@C/!6 L(
M6!!KL0BKBHWQHK:T*'NQMLX,;,8_]6!_K,ZV[-OG%UG&!L*(<K*FFUK534UO
MNJEMP5X>N9O:UO0MFU_1=TGCF'6U><=:.O%&,YT VSKQ-K,WM"GN6W.C%6RO
M:[ ED[!MZOR:.K]M*)W;J<TV=7Y-G5]3Y]?4^35U?DV=7U/G]U+\HCOO]K3L
MILZO0>07@,BFMFI>?8/(#2)O(2*OG?G]W'5^VY<:VZ3;-L6.:Y=I65:3S[G=
M1Z293<KMEA^1J3SC$;UX8_Y\JKA1#-U-0YRUQN8IA'3O"AQ=M2EOW/(C,E:N
ME6B.Z*F/2%M5_6F*&Y_4T-B^#3= :$S.IL)S74797C7YN+%EGOB(=+LQ-[?\
MB#1E5=]I8VZN6M:9WY\AV%1X-E4XZ]:LN?K#XGA-S5I#+?M"+6K+,IIZZ(9:
M&FI9LL+36=.I]?S4TE1X/G8QR_,4>]9&3;,[TX1-[Q7U-%4)*)N<-]W+4N1P
MS@_7MZ6K^@)1LO!*G%8^4QV) \C9#5(Z8!==9P0W%N5YP=^-]@=Q.J)B&T&4
M47^89OGL<^=N>R9*-7<7XS.)DAL*^\EXN2D;U8UWM7#(7E9$K!B4?\'Z>]+K
M<MFI\E0X;D H,9$/:TD'9,A*/=-L& +5IFUI<;GG8LS>\HJY0S9?%@_CA$29
M] ^)"U81> 0/N.%T<!(E)/%QO/MI L11\"G2Y1L]+O7.WS0;!*R]>>P]K C*
MSVS*=C.X?-6-?A8CCP4#N15@!*(D0S:F4\PZIGS\,LFE8(R<<40\X2$6O+-S
MUWCSEJA$K^X/*^2.QLB]!;C]-%N8?R#5"=2 R^5,1F^00?!!JR:.644VFQ<Q
MX[+ 1&"S=09_4[*3WU2-#V7%B:M_%PF=/A9OJA2_&(@!J&%<X*!5+HX2/JV5
M21^XUJ>(#;<@R_&__&3'#V=356F?@$S'?@!12$OA6;Y@3=K6;^2[9CN ^^';
M O\#H@#P<0%>L28+.-4U0]D/?Q/I&A[,WY<U#JCX;(A\M@),@XK+H6+9?R%%
MCH6HD@]!/%>])'C;!Y#]*\XYWQ;9<4:'TOLT;V3'BAM%N,4 -ZXY@K*=]YC$
MZ*/ $$R+Y*+Z/)^M/;_[C9Z\YMM6[#5KOG7U<6J^'?=1RJCW?;-6VS*66[:I
M^=[?FN\6&*4^O/0L9VNJP==]X;TJ:FZJP9MJ\/5<XJ5BU51_/];[;W=(Y)75
M<E5]1LQL[/5W(S;8H/&NH['1,ER[0>/I]]AK'-XE!-9:AOJPT/0][_]D.8UW
MY%/:VZP)?<AH2+.,BH"J%$0W44"38,_2T%]9RW/1)KNY.9SF<,K#$6&4)OW\
MT8U5B0R'6>05W&_/NISW^VG"(<_\9[TT!IFX.:NVT:-V1(]B]JR[.4.@L0(:
M['U2,]94-NB-:;"WP=[&ABT5HW(7Y:8-'OS?L'+;K+&9-?9'F\6H+]=@1?"W
MS'OU2![Y(KD:A\/,^")6@<4+Y9P[Q!]?*6UU=1_U#HGP!MVVZ=T0W5:WA!IT
M:]!M7713M&=!MZ9%4*/C[N8:+U['_<P^8*D$CK2\IES!S5E%X)#P>8Y+:[M+
MQ0]VM^&>[K9,4VO:(F[W*6EZ2S?6[,_>G-)3G9)JM33U&4^I44E>6L>"A8+]
MJ=X JQ>?LT3O-ZUME T1YNWCV0$T49&:W!TJENI1XJG)V;R>%(M=L>2P7NDZ
MKD $M:5J&[&X.<1S'M?BRNBM/+Q[>F;@5W!" .D1)1GO,/$;&IP3!;U)W:/*
M7:EXM!$L[0]Y6X_A5&L*KG3>+J&FCNN?QZA2E?UB33M)?(8B9##(TI]PR9#"
M):I>ZR-2+AM6:,A2S5#GG?B"_J>(;DC,&C"P9YS[PQ0+HE1VB KB6EI<]Q8=
M\AT#RU?N8"%%P;\.[A\S[6@'3\CD%U37PC=WE)+Q"FX$-H/A;E807] ;FA3-
M6.N5Q2=K79D)Z/&*X=\TS>+M"@0+3Q"![FOO0_*)#C^_:88]L0CG4YQWM:7R
MO%B'"T;+K+4!$'<N.O' Q44.3$=\S-(1B5DK!FQ1@XV0@4\!*XDI]D>(L6\.
MK#T<28 O3 "UI"*I];A)DQL $RJG7O5TUK+@.HF&HNT-$W'L.2-@H"#' O8T
M)L6B/O(XUH49F6$<\\U*P$*C&]XC0JP@-D#S.>QF*[%17&M@F?8@S1DX_N3M
MA&ZHJ,[F]D/]+E';K8QO(5Z>HH=BX2TS-6_/A/2:,0F+^K][E:]PP) /1.(/
MF82PV3])?$M&^<$?DY/2HT2N W#ZW1>^81@^DJ&G_\ZML@#[<;"V$'^" D,S
MO KV1+9F+Q)HAN&_#O[K?BEJ Z-BFBJ0V"$\D+<&(6_G'>-6":4<U#*_Q]C&
M$?"<.!VPGAW'0DG>#?ZP/=)J J!!#:"5U>&G21[ER/,%-^:]+]!QL1O %ITS
M,.7GF;IP.*:^9A>.QVIL85F/TMA"V_/-6FW#7FY#^]J%XQ[+:1^:<#2M-M9]
MX;WJ&-&TVFA:;:PY5I?$)"LG'.5#$J(7,!\VK3?VM&>!VE)<<TL'?3]WS4>#
MRCN&RIJUK3/K&U1N4'F5-%;56J'(_JF0^,4/@+Q<,)I@S[IOK#Z?I&GS\-1'
M9#[CA,'FB);*I%U5K6Z:<"P/W$/X"C<B#;.(Q'EK9KJ+&,!"/"DO!H,XHC,6
M[@M//G5;IKKF",,M4GA?^"&9+5?7FT/:[D/26Z9M-UG<SY_%W0#AA=M?)\0O
M)P"QU"_,.]LSV\M:V875*/9/+;3=YHBV_(CL537?[;.]>*]:EOZUO0R[S&>>
MGR?VC". 7[1[>P]F)*OK5R$__Y#DIPWV-.2R]^3BM!1]9T>*-]324,M3^W,>
MV"'R&:GE196S/]5&[R]D&$]X]T;2;WK;K*IE5ZK*NZ> &-,V:V. R]*V>BGP
M(EUZO-7).G$QH9[E\$DDSU,_8C5XM]&P)_EEE&20I=<9Z0NWRF2H1-S+WQ.+
MQ]/D.L7J.W\RQC(]PKZ^.3'$/J8$-IT5<"_6*P=P>6NR%'!1^F%501W,OEM
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M/[&D4::*ELS%-"9BZW]<X@,PU@*C:WP%,$H/Z)4XX)-T6A;AD%K!W.D</R,
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M,)D@]NXY?3*BQ $C1/VF97D!]0D=/7DNL0@NRF5.4/5LK)DR8;- 9 0LF$M
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M*QZC9$P-B:/;%&?,8LYI4;LH_8'S.=:>"7D>Q[5^7J7ZOY)HO*O;4V("Y$*
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ML]PZBK+/#DZ8CLMW4"9)A@N7Y%EE0;9-I*W(<TW[A(PLL5SOQ.W4E& SH/?
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M9FJW:8<6G!%%8BT'%]T=M\%%5.\E&[>7ZYK'ZN>OUR^!'ORWO_Q_4$L#!!0
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M-$<7A1 E#:)B<HPJFJ##[F/'I5"?,?.V-]T2MO635+TBA%F.V&>6L+L%&;F
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MLK,;V>S^HJ,/4?ANRL[F0)&+*P*BZ5+7E $?4P2F%7VJ.,NBR6)P\&5G>V;
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MVP5RNZZUDV?V36LX4)PLXCPF"0E &D(?H-#7!^$$ 2PFA"9)PA-L%?;X$6K
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M<%=>*]X@B1H[J@^4DM&-\ES)%SM:GDBSV+UR:O7XWNN2Z[H6T/E":3@(E:/
M!1#JOP'R8PHHH@3$?AK"B$6483IK3MM_6I!R848L4U#-YD/=57"X;W8EOW%1
M/K+P= =<Y?&W10^F6Z7/XKV+.20^)!B(6/$"$B0"*4<$))0+&OM$RJA[[][D
M_+_S6]>I]_^_<T._<V93_A1$G9"3,5X]R(W7]+]/(4A[FT\BW<JE7C]&PM8
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M:)@B=F?&?J::=6:('"]19WA_3\>B:3FFJXT6\TQ[*JLYT\<08H%3$!&DG(Q
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M?A5U4&.G:YWM$<9=D1S4;F_=</BJGMZ]7CIL)/<T>\<4RS1B00PX(S% 82J
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M(7+=;^/<L*/WW3#$X5#_#=-;^Q&2?E;-B7>"W>?9/Y?B=:'/F<P898Q)3H%
M?@H0)Q2D,"4 HI0D4O$1%]"&A8X--#7J6<GI73\^E@5A]W6I^974WA^-W);U
M 8[B;$8W+M ;F&,N!\Z:8<ZAXI)6CHXU*I><TWB70,Y>?UG]D,=2W"NG*OLJ
MU@VOWXO%K;PCWS\49>UK+19E1I<+[4+=%8K%M(>UJL@/"8M8DN@6(2% 3'DY
MA,82U.EX-$E$@EB?BB,7RC4U3FH*<+!-O=IR0W_I5Z7D4KL9!M_&M\;0(;NN
M$LJ&(=K4XA=:JY_5<E1O1TB=::P<K48Y;U,[O=??Z#=(/P''F ]1>N52T9ZE
M6(LC/(^5=W'U^ OH?*.S^7N%35N.,&4B8B)A *M%J7(#60Q(!&, (S\4'.$H
M]KDU0Q\<:IJD.U^+VH-J#V-JP9X7(S4*(6Y(63?P9:Y+/9['PCE1'1YM?.XY
MJ?5!.CE]AQU#L)++65=YFJGG*(;2;9MTW9#?ZS(B,Q22R(]##"(1Q\J'BP-
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M/ 0HE3[ D@O@HTB2!&$>$KM6#P,+/+59I][,:SF*;6ACV3QB:#.;S3U3,M[
M<]#UAYM75X=GF/4W?Z7]\K).0=>%-W0&L;>AD\/>%R,![[2+QM RC]N/8R0+
M['7V&&O<'H&BU^J)7XE>.;W-<I*SC,PW^I6MSL%]+.;SMT6I)\-9D&*"$EV
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MDTHM MHS>;?E1UVY[4Z4#[?R=KFH%J1NY-<=V6O_7LUB1A(=4@&<JO]"+"4
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MMAQ!;+E4L4'K] +$Z$DC+BML--M>+%C=V;>KD$Y/;4HG";I0(S2E)C?FBZX
M*DI%%*4Z32J*%*5#J3SZ* R B)(T]6.&!++LU&HZ]-0<] W)K[QZMTQS>EM#
M=<OYZU>)UL(H9C[X,% /S/4.4>[1J<@6,+=MBXQ''[F'D2TJ^PV-K)_0LWC;
M5IFXZE;JZG%%>>AT7Y3$4@:8 !PB'Z PY8 &-%#D)A+BXX!$$EE5=#,>>FJ\
MU@AL6>#-'&@SKAH&OH&YJI%QKQAE-=#!27N,G!:+,Q]]W IRUJCLE96S?T+_
M*KI%N3U<5\+RKG@I/@HFU*J=WWTK=#G+:B82+D(:"&63F -$A024I0SXF(0I
ME#A%*+38@.TKQT0W6?LU8[,R@!EY#8+GLU+8U6H+M"FFVVDP5#^V/NBYKJ9K
M)</HQ73[('2HEFZOY_0LV[>YDLVKC-?C%GDWS&V^<49]%J$HE@'Q00Q)!!!)
M(: Q3$$@,8[B%%*86&T=68T^-9_L0UDP(7CEZ9?!J]J 8AU)M"S>9V4#,[H;
M#-DQPHC%1HQK0_85PWGJYPWQ'=;TZX.:T]I^5@*,6^.O#S9[M?YZ/:0?M;T6
MCZ5@6=.75SS.1;VAG_/K!YU+\E]-H)A /TJ8"  A:0(0)QR0* Q!2H*(4T@3
M$EIU53$9=&I$MBFS'7,906Q&6*Z!&YBG-L75,;!6X*9=W(;([KC)!B"7E&0T
M[JA,9(/$+@%9W=MC#[9QW][7:6Z*Z):T/H!=S4@:^)1$/D@$)0#YD .JG =
M()8\2/V88*.JY:<&F1JOO%\G^W4B6FS['4/28._4 3XC+>E:B/2FGD.(+/9"
M'4 UTNYG'\CL=CK/8'%R;_/8O>/M9IZ1?FO_\MRU/4-G;<N73+V"(2,"HQCI
M+4G2M)92_XP!"N-4\ !#$4*;$J4;S[:BN='JE&X(:!GOVD#-,)35#XNA*<T
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M7<^#,^--F1\_J%=;E&776JTO]1W&V9;D+D9O1#IK.M$IXJJE;0G+&^3XOB%
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MON0VQ5SGO L*OBW*5^IY&2/SNS(C\[?+NL*MOC6K>XG.%#MPPB4&,6$)0'X
M 64D M G4<03PI,D,-_P&D+$J?&+5E('KK)6S?HDPE8!V\?5K%W_HDX*_-:J
M:[.+,HC!37;&GMN,@X<EJ[J.3J>A_GF[@NZ.WU6GTZXVQY2J7J>K5ROKM=IZ
M:W6?W<XV^V;/;>^1=M">U>Z6VW%#FN3TQMP@(X^X13<D<MN;=8..9+\.^"@>
MU9=R3RIQ_:44==SD5;'4]5X>2;EX>J^^C-:;Q6F","0!"!GF $$4 HIP#,*
M()2$29J8=:6U&G5Z\_A:2D^+V6/!8 [Y^07$($ ./I-:8VBULK#&Y-*5AOF
MHZT\K#'87(G8W]PS0MI6GKLKKMD_EUDICM:JGF$81U&:2I!&<0!0RCF@/(Y
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MKE.4EX:IS+3":Q+1U=K8!H+:QF1O9*]\\FZ '6/T4+!%IAQOQ/Q#9Q<D@H;
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M/0[YU1\V,.@G?M:WX^_Y_$5^'Z]82GWAE.>]$,N-DA.,48ZTR(',M#:3^8(
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M/\5L(Y5\9URPI+=9-R?OWK*E/<:U,C16<5Y=(ISE6I4(I0##PI;V4QI04:1
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M%H[GBB_<'.98T.?IZI_OELHF/RCS*JX_L_4VD-8\IYQ@!3 Q\S6H) %FSJ9
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MY_%*?C&VKGZ-D +FA$M(BNEN<%!F<?+]F%#<;@J1SF5W&">\$(RQE .29PC
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M:F]8+0\'ST^T/%SNZ9N$9&C^O33/FNJIJ!8Q/VZJ ZIIP0N*4PPHAH8]H*2
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MHNYM^YE$44\0#:R+>OK\'M.7+VII#Y]='"6:4EN2L@P3R0$O2P:@EA(07D!
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MS]O^5$P\)F+[1OS1ZMUEW;MJ]^W*S7);J>FYVCL()6$0HU,ZQ\R@#0XWLL;
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MW=?]I'ZL^EE5BTZ?V'+]XZMY]U8VM#'/W\4A4.>(8H) R@L%("T(X%HR()'
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M+]*1,?'L"\YSS5=]-0L$9A3*<V.@QF5KBJ( QP,"9L.09U%B+@-@X<9+=\-
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M64DA)^]\$U1M)Z<;1!VE[#MBAT=(O@_\+$_IK3_(:!(ECXHE"UG3(E,QDH?
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M@6=_OY[_>"W\?C&;O5HL?P_+/"EHO161]!R+I&40: 4(<AH,:BPY%]I5F]R
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MEQ&$L8 ZM%X[@^WVN40J> RL9COD&&K> QGA2'\(C9H;JUGP;686/$19E_&
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ME$0KZ/]/=LL\D_2S&Y+>L@+I%]XNYLN;"W(36-",*\5=@5+W !6C)<=&USV
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MV/)>X)*LA]J([!I_),$J/U+/A"DG0S :HL+:]38;",)&<)YIE:QE*38)5SY
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MT46ODF3HFZ1Y_'>I>SP*A(-IK@L8;JNF4QFY\E@@2EE+ZDJ"4%2L\0GDN>3
M0IO65G_RNL?C8'>LICJ VV[5<IN9M-HA"$VR4B+F.B\1(23-7>+<HVHS'^&_
M6=WC,7 <7I,=P/.>&CIEG6%:UO%U*H *(D.P9&W4=$ O DJKFV#ROT7=XS%
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MKR'4EV(<+1U5=84X;S.X8B@.NFXSW0=]^[X ;*/C#D*0V_:<Y05V-H;2%Q'
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M2-(F+;/.LLVEWB"^:?!T>V3?M(\R1K^6>MET-@TLOONWB]4_OG^V[)$5M$6
M-CZ#0C00E(@@M&045'@2@#C<B1U&U,@7/8VBK[&T-O:^H0'XOJC.VAKG2.C+
M3;T42<3"/4@LSH7@HK6[K1$:@)@1 [C1(#0PCO?2YZOQN?=AC<LB\UC?U4EG
MZIQ1 ^0\&"#S3&?F*-C9+8<=DJH1(\S7@NO#-/P:''3,4E$@YB"@+K6V*B!F
M'\ F.BNU4C[;(W*A!@ZZ313[6H"\ESZ[3=@IH_M]@X!M20(3*D GD0+_G$G
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M+3 Y,S R,65X:&EB:70S,3$N:'1M4$L! A0#%     @ ?7]D4]K_CY,B"
MK"D  !D              ( !8P@  &-R9&8M,#DS,#(Q97AH:6)I=#,Q,BYH
M=&U02P$"% ,4    " !]?V13_ #]3P4%  #:%P  &0              @ &\
M$   8W)D9BTP.3,P,C%E>&AI8FET,S(Q+FAT;5!+ 0(4 Q0    ( 'U_9%,L
M,.K[  4  +P7   9              "  ?@5  !C<F1F+3 Y,S R,65X:&EB
M:70S,C(N:'1M4$L! A0#%     @ ?7]D4[\I[I[&D $ MU\5 !$
M     ( !+QL  &-R9&8M,C R,3 Y,S N:'1M4$L! A0#%     @ ?7]D4\^^
M8O\P#@  ])8  !$              ( !)*P! &-R9&8M,C R,3 Y,S N>'-D
M4$L! A0#%     @ ?7]D4R13@L;_'@  X3P! !4              ( !@[H!
M &-R9&8M,C R,3 Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( 'U_9%,'(3'%F4D
M 'M  P 5              "  ;79 0!C<F1F+3(P,C$P.3,P7V1E9BYX;6Q0
M2P$"% ,4    " !]?V13Z2:AO1["  !)+ @ %0              @ &!(P(
M8W)D9BTR,#(Q,#DS,%]L86(N>&UL4$L! A0#%     @ ?7]D4QA4X@J^;
M?1 % !4              ( !TN4" &-R9&8M,C R,3 Y,S!?<')E+GAM;%!+
4!08     "@ * *8"  ##4@,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
